-DOCSTART- -X- O O

Independent NNP O
prognostic JJ O
information NN O
provided VBN O
by IN O
sphygmomanometrically RB B-INTV
determined VBN I-INTV
pulse JJ I-INTV
pressure NN I-INTV
and CC I-INTV
mean JJ I-INTV
arterial JJ I-INTV
pressure NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

OBJECTIVES CC O
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
relationship NN O
of IN O
baseline NN O
pulse JJ O
pressure NN O
and CC O
mean JJ O
arterial JJ O
pressure NN O
to TO O
mortality NN O
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

BACKGROUND NNP O
Increased VBD O
conduit NN O
vessel NN O
stiffness NN O
increases VBZ O
pulse JJ O
pressure NN O
and CC O
pulsatile NN O
load NN O
, , O
potentially RB O
contributing VBG O
to TO O
adverse VB O
outcomes NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

METHODS NNP O
Pulse NNP O
and CC O
mean VB O
arterial JJ O
pressure NN O
were VBD O
analyzed VBN O
for IN O
their PRP$ O
effect NN O
on IN O
mortality NN B-OC
, , O
adjusting VBG O
for IN O
other JJ O
modifiers NNS O
of IN O
risk NN O
, , O
using VBG O
Cox NNP O
proportional JJ O
hazards NNS O
regression NN O
analysis NN O
of IN O
data NNS O
collected VBN O
from IN O
6,781 CD B-POPU
patients NNS I-POPU
randomized VBN I-POPU
into IN I-POPU
the DT I-POPU
Studies NNPS I-POPU
of IN I-POPU
Left NNP I-POPU
Ventricular NNP I-POPU
Dysfunction NNP I-POPU
trials NNS I-POPU
. . O

RESULTS NNP O
Pulse NNP B-OC
and CC I-OC
mean VB I-OC
arterial JJ I-OC
pressure NN I-OC
were VBD O
related VBN O
positively RB O
to TO O
each DT O
other JJ O
, , O
age NN O
, , O
ejection NN O
fraction NN O
and CC O
prevalence NN O
of IN O
diabetes NNS O
and CC O
hypertension NN O
and CC O
inversely RB O
to TO O
prior VB O
myocardial JJ O
infarction NN O
and CC O
beta-adrenergic JJ O
blocking NN O
agent NN O
use NN O
. . O

Higher JJR B-OC
pulse JJ I-OC
pressure NN I-OC
was VBD O
associated VBN O
with IN O
increased JJ O
prevalence NN O
of IN O
female JJ O
gender NN O
, , O
greater JJR O
calcium NN B-INTV
channel NN I-INTV
blocking VBG I-INTV
agent NN I-INTV
, , I-INTV
digoxin NN I-INTV
and CC O
diuretic JJ B-INTV
use NN O
, , O
lower JJR O
heart NN O
rate NN O
and CC O
a DT O
higher JJR O
rate NN O
of IN O
reported VBN O
smoking NN O
history NN O
. . O

Higher JJR B-OC
mean JJ I-OC
arterial JJ I-OC
pressure NN I-OC
was VBD O
associated VBN O
with IN O
higher JJR O
heart NN O
rate NN O
, , O
lower JJR O
calcium NN B-INTV
channel NN I-INTV
blocker NN I-INTV
and CC O
digoxin NN B-INTV
use NN O
and CC O
lower JJR O
New NNP O
York NNP O
Heart NNP O
Association NNP O
functional JJ O
class NN O
. . O

Over IN O
a DT O
61-month JJ O
follow-up JJ O
1,582 CD O
deaths NNS B-OC
( ( O
1,397 CD O
cardiovascular NN O
) ) O
occurred VBD O
. . O

In IN O
a DT O
multivariate NN O
analysis NN O
adjusting VBG O
for IN O
the DT O
above JJ O
covariates NNS O
and CC O
treatment NN O
assignment NN O
, , O
higher JJR O
pulse JJ B-OC
pressure NN I-OC
remained VBD O
an DT O
independent JJ O
predictor NN O
of IN O
total JJ B-OC
and CC I-OC
cardiovascular JJ I-OC
mortality NN I-OC
( ( O
total JJ O
mortality NN O
relative NN O
risk NN O
, , O
1.05 CD O
per IN O
10 CD O
mm NN O
Hg NNP O
increment NN O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
1.01 CD O
to TO O
1.10 CD O
; : O
p NN O
= VBZ O
0.02 CD O
) ) O
. . O

Mean JJ B-OC
arterial JJ I-OC
pressure NN I-OC
was VBD O
inversely RB O
related VBN O
to TO O
total JJ B-OC
and CC I-OC
cardiovascular JJ I-OC
mortality NN I-OC
( ( O
total JJ O
mortality NN O
relative NN O
risk NN O
, , O
0.89 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0.85 CD O
to TO O
0.94 CD O
; : O
p NN O
< VBZ O
0.0001 CD O
) ) O
. . O

CONCLUSIONS NNP O
One CD O
noninvasive JJ B-INTV
blood NN I-INTV
pressure NN I-INTV
measurement NN I-INTV
provides VBZ O
two CD O
independent JJ O
prognostic JJ O
factors NNS O
for IN O
survival NN B-OC
. . O

Increased VBD B-OC
conduit NN I-OC
vessel NN I-OC
stiffness NN I-OC
, , O
as IN O
assessed VBN O
by IN O
pulse JJ O
pressure NN O
, , O
may MD O
contribute VB O
to TO O
increased VBN O
mortality NN B-OC
in IN O
patients NNS O
with IN O
left JJ O
ventricular JJ O
dysfunction NN O
, , O
independent JJ O
of IN O
mean JJ O
arterial JJ O
pressure NN O
. . O

-DOCSTART- -X- O O

Treatment NN O
with IN O
metformin NN B-INTV
of IN O
non-diabetic JJ B-POPU
men NNS I-POPU
with IN I-POPU
hypertension NN I-POPU
, , I-POPU
hypertriglyceridaemia NN I-POPU
and CC I-POPU
central JJ I-POPU
fat JJ I-POPU
distribution NN I-POPU
: : I-POPU
the DT O
BIGPRO NNP O
1.2 CD O
trial NN O
. . O

BACKGROUND NNP O
In IN O
the DT O
BIGPRO NNP O
1 CD O
trial NN O
, , O
one CD O
year NN O
of IN O
treatment NN O
with IN O
metformin NN B-INTV
in IN O
non-diabetic JJ B-POPU
obese JJ I-POPU
subjects NNS I-POPU
with IN I-POPU
a DT I-POPU
central JJ I-POPU
fat JJ I-POPU
distribution NN I-POPU
had VBD O
no DT O
significant JJ O
effect NN O
on IN O
fasting VBG O
plasma JJ O
triglyceride JJ O
concentration NN O
or CC O
on IN O
blood NN O
pressure NN O
despite IN O
a DT O
decrease NN O
in IN O
weight NN O
, , O
fasting VBG O
plasma JJ O
insulin NN O
and CC O
glucose JJ O
concentrations NNS O
. . O

To TO O
re-evaluate VB O
the DT O
effect NN O
of IN O
metformin NN B-INTV
on IN O
fasting VBG O
triglyceride JJ O
concentration NN O
and CC O
on IN O
blood NN O
pressure NN O
, , O
the DT O
BIGPRO NNP O
1.2 CD O
trial NN O
included VBD O
non-diabetic JJ B-POPU
men NNS I-POPU
( ( I-POPU
n=168 NN I-POPU
) ) I-POPU
with IN I-POPU
a DT I-POPU
fasting VBG I-POPU
plasma NN I-POPU
triglyceride JJ I-POPU
concentration NN I-POPU
> NN I-POPU
or CC I-POPU
=1.7 NN I-POPU
and CC I-POPU
< NN I-POPU
or CC I-POPU
=6.5 NN I-POPU
mmol/l NN I-POPU
, , I-POPU
high JJ I-POPU
blood NN I-POPU
pressure NN I-POPU
( ( I-POPU
systolic JJ I-POPU
> NN I-POPU
or CC I-POPU
=140 NN I-POPU
and CC I-POPU
< NN I-POPU
or CC I-POPU
=180 VB I-POPU
and/or JJ I-POPU
diastolic JJ I-POPU
> NN I-POPU
or CC I-POPU
=90 NN I-POPU
and CC I-POPU
< NN I-POPU
or CC I-POPU
=105 NN I-POPU
mmHg NN I-POPU
, , I-POPU
or CC I-POPU
treatment NN I-POPU
for IN I-POPU
hypertension NN I-POPU
) ) I-POPU
and CC I-POPU
a DT I-POPU
waist-to-hip JJ I-POPU
ratio NN I-POPU
> NN I-POPU
or CC I-POPU
=0.95 NN I-POPU
. . O

METHODS NNP O
A DT O
randomised JJ O
double-blind JJ O
trial NN O
comparing VBG O
metformin NN B-INTV
treatment NN I-INTV
( ( I-INTV
850 CD I-INTV
mg RB I-INTV
bid NN I-INTV
) ) I-INTV
with IN I-INTV
placebo NN I-INTV
. . O

RESULTS NNP O
Metformin NNP B-INTV
had VBD O
no DT O
significant JJ O
effect NN O
either DT O
on IN O
blood NN B-OC
pressure NN I-OC
or CC I-OC
plasma NN I-OC
triglyceride JJ I-OC
concentration NN I-OC
. . O

In IN O
comparison NN O
with IN O
the DT O
placebo NN B-INTV
group NN O
, , O
fasting VBG B-OC
plasma JJ I-OC
insulin NN I-OC
( ( O
p JJ O
< NNP O
0.04 CD O
) ) O
, , O
total JJ B-OC
cholesterol NN I-OC
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
and CC O
Apo NNP B-OC
B NNP I-OC
( ( O
p JJ O
< NNP O
0.008 CD O
) ) O
concentrations NNS B-OC
decreased VBD O
more RBR O
in IN O
the DT O
metformin NN O
group NN O
in IN O
the DT O
BIGPRO NNP O
1 CD O
. . O

2 CD O
trial NN O
, , O
confirming VBG O
most JJS O
of IN O
the DT O
previous JJ O
results NNS O
of IN O
the DT O
BIGPRO NNP O
1 CD O
trial NN O
. . O

Tissue NNP B-OC
plasminogen NN I-OC
activator NN I-OC
antigen NN I-OC
concentration NN I-OC
decreased VBN O
significantly RB O
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
only RB O
in IN O
the DT O
metformin NN B-INTV
group NN O
, , O
but CC O
this DT O
was VBD O
not RB O
significantly RB O
different JJ O
from IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
p JJ O
< NNP O
0.12 CD O
) ) O
; : O
further RB O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
change NN O
in IN O
plasminogen NN O
activator NN O
inhibitor NN O
1 CD O
. . O

CONCLUSIONS VB O
The DT O
consistency NN O
of IN O
the DT O
two CD O
BIGPRO NNP O
trials NNS O
supports VBZ O
the DT O
conclusion NN O
that IN O
metformin VBZ B-INTV
affects NNS O
several JJ O
cardiovascular JJ O
risk NN O
factors NNS O
favourably RB O
in IN O
non-diabetic JJ B-POPU
subjects NNS I-POPU
with IN I-POPU
a DT I-POPU
central JJ I-POPU
fat JJ I-POPU
distribution NN I-POPU
. . O

-DOCSTART- -X- O O

Growth NNP B-OC
hormone NN I-OC
( ( I-OC
GH NNP I-OC
) ) I-OC
responses VBZ I-OC
to TO O
GH-releasing NNP B-INTV
hormone NN I-INTV
alone RB I-INTV
or CC O
combined VBN B-INTV
with IN I-INTV
arginine NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
adrenal JJ I-POPU
incidentaloma NN I-POPU
: : I-POPU
evidence NN O
for IN O
enhanced JJ O
somatostatinergic JJ O
tone NN O
. . O

Spontaneous JJ O
and CC O
stimulated VBD O
GH NNP O
secretion NN O
is VBZ O
blunted VBN O
in IN O
hypercortisolemic JJ O
states NNS O
due JJ O
to TO O
increased VBN O
hypothalamic JJ O
somatostatinergic NN O
tone NN O
. . O

However RB O
, , O
no DT O
data NNS O
are VBP O
available JJ O
on IN O
the DT O
characteristics NNS O
of IN O
GH NNP O
secretion NN O
in IN O
patients NNS B-POPU
with IN I-POPU
incidentally RB I-POPU
discovered VBN I-POPU
adrenal JJ I-POPU
adenomas NN I-POPU
. . O

They PRP O
represent VBP O
an DT O
interesting JJ O
model NN O
for IN O
studying VBG O
GH NNP O
secretion NN O
, , O
as IN O
a DT O
slight JJ O
degree NN O
of IN O
cortisol NN O
excess NN O
may MD O
frequently RB O
be VB O
observed VBN O
in IN O
such JJ O
patients NNS B-POPU
who WP I-POPU
do VBP I-POPU
not RB I-POPU
present VB I-POPU
with IN I-POPU
any DT I-POPU
clear JJ I-POPU
Cushingoid NNP I-POPU
sign NN I-POPU
. . O

In IN O
the DT O
present JJ O
study NN O
, , O
10 CD B-POPU
patients NNS I-POPU
( ( I-POPU
3 CD I-POPU
men NNS I-POPU
and CC I-POPU
7 CD I-POPU
women NNS I-POPU
, , I-POPU
aged VBD I-POPU
48-63 JJ I-POPU
yr NN I-POPU
) ) I-POPU
with IN I-POPU
an DT I-POPU
adrenal JJ I-POPU
mass NN I-POPU
discovered VBD I-POPU
serendipitously RB I-POPU
underwent JJ O
, , O
on IN O
separate JJ O
occasions NNS O
, , O
a DT O
GHRH NNP B-INTV
injection NN I-INTV
alone RB I-INTV
or CC O
combined VBN B-INTV
with IN I-INTV
an DT I-INTV
infusion NN I-INTV
of IN I-INTV
the DT I-INTV
functional JJ I-INTV
somatostatin NN I-INTV
antagonist NN I-INTV
, , I-INTV
arginine NN I-INTV
. . O

Thirteen JJ B-POPU
age-matched JJ I-POPU
healthy JJ I-POPU
volunteers NNS I-POPU
served VBD I-POPU
as IN I-POPU
controls NNS I-POPU
. . O

Briefly NNP O
, , O
arginine NN B-INTV
( ( I-INTV
30 CD I-INTV
g NN I-INTV
) ) I-INTV
was VBD I-INTV
infused VBN I-INTV
from IN I-INTV
-30 NN I-INTV
to TO I-INTV
0 CD I-INTV
min NN I-INTV
, , I-INTV
and CC I-INTV
GHRH NNP I-INTV
( ( I-INTV
100 CD I-INTV
microg NN I-INTV
) ) I-INTV
was VBD I-INTV
injected VBN I-INTV
as IN I-INTV
a DT I-INTV
bolus NN I-INTV
at IN I-INTV
0 CD I-INTV
min NNS I-INTV
, , O
with IN O
measurement NN O
of IN O
serum NN B-INTV
GH NNP I-INTV
[ NNP I-INTV
immunoradiometric JJ I-INTV
assay NN I-INTV
( ( I-INTV
IRMA NNP I-INTV
) ) I-INTV
] VBP I-INTV
every DT O
15 CD O
min NN O
for IN O
150 CD O
min NN O
. . O

Plasma NNP B-INTV
IGF-I NNP I-INTV
( ( I-INTV
RIA NNP I-INTV
after IN I-INTV
acid-ethanol JJ I-INTV
extraction NN I-INTV
) ) I-INTV
was VBD O
measured VBN O
in IN O
a DT O
morning NN O
sample NN O
. . O

The DT O
diagnosis NN O
of IN O
cortical JJ O
adenoma NN O
was VBD O
based VBN O
on IN O
computed JJ O
tomography NN O
features NNS O
and CC O
pattern NN O
of IN O
uptake NN O
on IN O
adrenal JJ O
scintigraphy NN O
. . O

Patients NNS B-POPU
with IN I-POPU
obesity NN I-POPU
and/or NN I-POPU
diabetes NNS I-POPU
were VBD I-POPU
excluded VBN I-POPU
. . O

The DT O
study NN O
design NN O
included VBD O
also RB O
an DT O
endocrine JJ O
work-up NN O
aimed VBN O
to TO O
study VB O
the DT O
hypothalamic-pituitary-adrenal JJ B-OC
axis NN I-OC
[ NNP I-OC
urinary JJ I-OC
free JJ I-OC
cortisol NN I-OC
( ( I-OC
UFC NNP I-OC
) ) I-OC
excretion NN I-OC
, , I-OC
serum NN I-OC
cortisol NN I-OC
at IN I-OC
0800 CD I-OC
h NN I-OC
, , I-OC
plasma JJ I-OC
ACTH NNP I-OC
at IN I-OC
0800 CD I-OC
h NN I-OC
, , I-OC
morning NN I-OC
cortisol NN I-OC
after IN I-OC
overnight JJ I-OC
1 CD I-OC
mg NN I-OC
dexamethasone NN I-OC
] NN I-OC
. . O

Five CD O
of IN O
10 CD O
patients NNS O
showed VBD O
abnormalities NNS B-OC
of IN I-OC
the DT I-OC
hypothalamic-pituitary-adrenal JJ I-OC
axis NN I-OC
, , O
including VBG O
borderline NN B-OC
or CC I-OC
increased VBN I-OC
UFC JJ I-OC
excretion NN I-OC
in IN O
4 CD O
of IN O
them PRP O
accompanied VBN O
by IN O
blunted JJ O
ACTH NNP O
in IN O
2 CD O
cases NNS O
and CC O
failure NN O
of IN O
cortisol NN O
to TO O
suppress VB O
after IN O
dexamethasone NN O
in IN O
1 CD O
; : O
the DT O
fifth JJ O
patient NN O
displayed VBD O
low JJ O
ACTH NNP O
and CC O
resistance NN O
to TO O
dexamethasone VB O
suppression NN O
. . O

However RB O
, , O
all DT O
patients NNS O
had VBD O
a DT O
unilateral JJ O
uptake NN O
of IN O
the DT O
tracer NN O
on IN O
the DT O
side NN O
of IN O
the DT O
mass NN O
with IN O
suppression NN O
of IN O
the DT O
contralateral JJ O
normal JJ O
adrenal JJ O
gland NN O
. . O

As IN O
a DT O
group NN O
, , O
the DT O
patients NNS O
displayed VBD O
greater JJR O
UFC NNP B-OC
excretion NN I-OC
and CC I-OC
lower JJR I-OC
ACTH NNP I-OC
concentrations NNS I-OC
than IN O
the DT O
controls NNS O
. . O

GH NNP B-OC
release NN I-OC
after IN I-OC
GHRH NNP B-INTV
treatment NN I-INTV
was VBD O
blunted VBN O
in IN O
patients NNS B-POPU
bearing VBG I-POPU
adrenal JJ I-POPU
incidentaloma NNS I-POPU
compared VBN O
with IN O
controls NNS O
( ( O
GH NNP O
peak NN O
, , O
5.7 CD O
+/- JJ O
5.2 CD O
vs. FW O
18.0 CD O
+/- JJ O
7.0 CD O
microg/L NN O
; : O
P NNP O
< NNP O
0.0001 CD O
) ) O
, , O
whereas JJ O
GHRH NNP B-INTV
plus CC I-INTV
arginine NN I-INTV
was VBD O
able JJ O
to TO O
elicit VB O
a DT O
comparable JJ O
response NN O
in IN O
the DT O
2 CD O
groups NNS O
( ( O
GH NNP O
peak NN O
, , O
33.5 CD O
+/- JJ O
20.3 CD O
vs. FW O
33.7 CD O
+/- JJ O
17.5 CD O
microg/L NN O
; : O
P NNP O
= NNP O
NS NNP O
) ) O
. . O

The DT O
ratio NN O
between IN O
GH NNP B-OC
peaks NNS I-OC
after IN I-OC
GHRH NNP B-INTV
plus CC I-INTV
arginine NN I-INTV
and CC B-OC
after IN I-OC
GHRH NNP B-INTV
plus CC I-INTV
saline NN I-INTV
was VBD O
significantly RB O
greater JJR O
in IN O
patients NNS O
than IN O
in IN O
controls NNS O
( ( O
751 CD O
+/- JJ O
531 CD O
% NN O
vs. FW O
81 CD O
+/- JJ O
45 CD O
% NN O
; : O
P NNP O
= NNP O
0.0001 CD O
) ) O
. . O

Similar JJ O
data NNS O
were VBD O
obtained VBN O
when WRB O
comparing VBG O
GH NNP O
area NN O
under IN O
the DT O
curve NN O
after IN O
GHRH NNP O
plus CC O
saline NN O
or CC O
GHRH NNP O
plus CC O
arginine NN O
between IN O
the DT O
2 CD O
groups NNS O
. . O

In IN O
summary JJ O
, , O
the DT O
present JJ O
data NNS O
suggest VBP O
that IN O
in IN O
patients NNS B-POPU
with IN I-POPU
incidental JJ I-POPU
adrenal JJ I-POPU
adenomas IN I-POPU
the DT O
GH NNP B-OC
response NN I-OC
to TO O
GHRH NNP O
is VBZ O
blunted VBN O
due JJ O
to TO O
increased VBN O
somatostatinergic NN B-OC
tone NN I-OC
, , O
as IN O
it PRP O
can MD O
be VB O
restored VBN O
to TO O
normal JJ O
by IN O
pretreatment NN O
with IN O
the DT O
functional JJ O
somatostatin NN O
antagonist JJ O
arginine NN O
. . O

The DT O
blunted JJ O
GH NNP O
release NN O
to TO O
GHRH NNP O
may MD O
be VB O
an DT O
early JJ O
and CC O
long JJ O
lasting JJ O
sign NN O
of IN O
autonomous JJ O
cortisol NNS O
secretion NN O
by IN O
the DT O
adrenal JJ O
adenoma NN O
. . O

-DOCSTART- -X- O O

The DT O
Finnish JJ B-POPU
Diabetes NNP I-POPU
Prevention NNP O
Study NNP O
. . O

The DT O
aim NN O
of IN O
the DT O
Finnish NNP B-POPU
Diabetes NNP I-POPU
Prevention NNP O
Study NNP O
is VBZ O
to TO O
assess VB O
the DT O
efficacy NN B-OC
of IN O
an DT O
intensive JJ B-INTV
diet-exercise NN I-INTV
programme NN I-INTV
in IN O
preventing VBG O
or CC O
delaying VBG O
type JJ B-POPU
2 CD I-POPU
diabetes NNS I-POPU
in IN I-POPU
individuals NNS I-POPU
with IN I-POPU
impaired JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
( ( I-POPU
IGT NNP I-POPU
) ) I-POPU
and CC O
to TO O
evaluate VB O
the DT O
effect NN O
of IN O
the DT O
programme NN O
on IN O
the DT O
risk NN O
factors NNS O
of IN O
atherosclerotic JJ O
vascular NN O
diseases NNS O
and CC O
the DT O
incidence NN O
of IN O
cardiovascular JJ O
events NNS O
. . O

In IN O
this DT O
ongoing JJ O
study NN O
, , O
a DT B-POPU
total NN I-POPU
of IN I-POPU
523 CD I-POPU
overweight JJ I-POPU
subjects NNS I-POPU
with IN I-POPU
IGT NNP I-POPU
based VBN I-POPU
on IN I-POPU
two CD I-POPU
oral JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
tests NNS I-POPU
were VBD O
randomized VBN O
to TO O
either DT O
an DT O
intervention NN B-POPU
group NN I-POPU
or CC O
a DT O
control NN B-POPU
group NN I-POPU
. . O

The DT O
main JJ O
measure NN O
in IN O
the DT O
intervention NN O
group NN O
is VBZ O
individual JJ B-INTV
dietary JJ I-INTV
advice NN I-INTV
aimed VBN O
at IN O
reducing VBG B-INTV
weight NN I-INTV
and CC I-INTV
intake NN I-INTV
of IN I-INTV
saturated JJ I-INTV
fat NN I-INTV
and CC I-INTV
increasing VBG I-INTV
intake NN I-INTV
of IN I-INTV
dietary JJ I-INTV
fibre NN I-INTV
. . O

The DT O
intervention NN O
subjects NNS O
are VBP O
individually RB O
guided VBN O
to TO O
increase VB B-INTV
their PRP$ I-INTV
level NN I-INTV
of IN I-INTV
physical JJ I-INTV
activity NN I-INTV
. . O

The DT O
control NN B-INTV
group NN I-INTV
receives VBZ I-INTV
general JJ I-INTV
information NN I-INTV
about IN I-INTV
the DT I-INTV
benefits NNS I-INTV
of IN I-INTV
weight NN I-INTV
reduction NN I-INTV
, , I-INTV
physical JJ I-INTV
activity NN I-INTV
and CC I-INTV
healthy JJ I-INTV
diet NN I-INTV
in IN I-INTV
the DT I-INTV
prevention NN I-INTV
of IN I-INTV
diabetes NNS I-INTV
. . O

A DT O
pilot NN O
study NN O
began VBD O
in IN O
1993 CD O
, , O
and CC O
recruitment NN O
ended VBN O
in IN O
1998 CD O
. . O

By IN O
the DT O
end NN O
of IN O
April NNP O
1999 CD O
there EX O
were VBD O
65 CD O
new JJ O
cases NNS O
of IN O
diabetes NNS O
, , O
34 CD O
drop-outs NNS O
and CC O
one CD O
death NN B-OC
. . O

The DT O
weight NN B-OC
reduction NN I-OC
was VBD O
greater JJR O
( ( O
-4.6 NNP O
kg NN O
) ) O
at IN O
1 CD O
year NN O
in IN O
the DT O
intervention NN O
group NN O
( ( O
n JJ O
= NNP O
152 CD O
) ) O
than IN O
in IN O
the DT O
control NN O
group NN O
( ( O
n JJ O
= NN O
143 CD O
, , O
-0.9 NNP O
kg NNP O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
, , O
and CC O
this DT O
difference NN O
was VBD O
sustained VBN O
in IN O
the DT O
second JJ O
year NN O
of IN O
follow-up NN O
. . O

At IN O
1 CD O
year NN O
43.4 CD O
% NN O
and CC O
at IN O
2 CD O
years NNS O
41.8 CD O
% NN O
of IN O
the DT O
intervention NN O
subjects NNS O
had VBD O
achieved VBN O
a DT O
weight JJ B-OC
reduction NN I-OC
of IN O
at IN O
least JJS O
5 CD O
kg NNS O
, , O
while IN O
the DT O
corresponding JJ O
figures NNS O
for IN O
the DT O
control NN O
subjects VBZ O
were VBD O
14.0 CD O
and CC O
12.0 CD O
% NN O
( ( O
P NNP O
< VBZ O
0.001 CD O
between IN O
the DT O
groups NNS O
) ) O
. . O

At IN O
1 CD O
year NN O
the DT O
intervention NN O
group NN O
showed VBD O
significantly RB O
greater JJR B-OC
reductions NNS I-OC
in IN O
2 CD B-OC
h NN I-OC
glucose NN I-OC
, , I-OC
fasting VBG I-OC
and CC I-OC
2 CD I-OC
h NN I-OC
insulin NN I-OC
, , I-OC
systolic JJ I-OC
and CC I-OC
diastolic JJ I-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
and CC I-OC
serum NN I-OC
triglycerides NNS I-OC
. . O

Most JJS O
of IN O
the DT O
beneficial JJ O
changes NNS O
in IN O
cardiovascular JJ B-OC
risk NN I-OC
factors NNS I-OC
were VBD O
sustained VBN O
for IN O
2 CD O
years NNS O
. . O

These DT O
interim JJ O
results NNS O
of IN O
the DT O
ongoing JJ O
Finnish JJ O
Diabetes NNP O
Prevention NNP O
Study NNP O
demonstrate VB O
the DT O
efficacy NN B-OC
and CC I-OC
feasibility NN I-OC
of IN O
the DT O
lifestyle JJ O
intervention NN O
programme NN O
. . O

-DOCSTART- -X- O O

Efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
recombinant JJ B-INTV
human JJ I-INTV
nerve NN I-INTV
growth NN I-INTV
factor NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
diabetic JJ I-POPU
polyneuropathy NN I-POPU
: : I-POPU
A DT O
randomized NN O
controlled VBN O
trial NN O
. . O

rhNGF VB O
Clinical NNP O
Investigator NNP O
Group NNP O
. . O

CONTEXT NNP O
Nerve NNP O
growth NN O
factor NN O
is VBZ O
a DT O
neurotrophic JJ O
factor NN O
that WDT O
promotes VBZ O
the DT O
survival NN O
of IN O
small JJ O
fiber NNP O
sensory JJ O
neurons NNS O
and CC O
sympathetic JJ O
neurons NNS O
in IN O
the DT O
peripheral JJ O
nervous JJ O
system NN O
. . O

Recombinant JJ B-INTV
human JJ I-INTV
nerve NN I-INTV
growth NN I-INTV
factor NN I-INTV
( ( I-INTV
rhNGF NN I-INTV
) ) I-INTV
has VBZ O
demonstrated VBN O
efficacy NN O
as IN O
treatment NN O
for IN O
peripheral JJ O
neuropathy NN O
in IN O
experimental JJ O
models NNS O
and CC O
phase VB O
2 CD O
clinical JJ O
trials NNS O
. . O

OBJECTIVE NNP O
To TO O
evaluate VB O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
a DT O
12-month JJ O
regimen NN O
of IN O
rhNGF NN O
in IN O
patients NNS B-POPU
with IN I-POPU
diabetic JJ I-POPU
polyneuropathy NN I-POPU
. . O

DESIGN NNP O
Randomized NNP O
, , O
double-blind NN O
, , O
placebo-controlled JJ B-INTV
phase NN O
3 CD O
trial NN O
conducted VBN O
from IN O
July NNP O
1997 CD O
through IN O
May NNP O
1999 CD O
. . O

SETTING VB O
Eighty-four JJ B-POPU
outpatient NN I-POPU
centers NNS I-POPU
throughout IN I-POPU
the DT I-POPU
United NNP I-POPU
States NNPS I-POPU
. . O

PATIENTS VB O
A DT B-POPU
total NN I-POPU
of IN I-POPU
1019 CD I-POPU
men NNS I-POPU
and CC I-POPU
women NNS I-POPU
aged VBD I-POPU
18 CD I-POPU
to TO I-POPU
74 CD I-POPU
years NNS I-POPU
with IN I-POPU
either DT I-POPU
type NN I-POPU
1 CD I-POPU
or CC I-POPU
type VB I-POPU
2 CD I-POPU
diabetes NNS I-POPU
and CC I-POPU
a DT I-POPU
sensory JJ I-POPU
polyneuropathy NN I-POPU
attributable JJ I-POPU
to TO I-POPU
diabetes NNS I-POPU
. . O

INTERVENTIONS JJ O
Patients NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
either DT O
rhNGF NN B-INTV
, , O
0.1 CD O
microg/kg NN O
( ( O
n JJ O
= NNP O
504 CD O
) ) O
, , O
or CC O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
515 CD O
) ) O
by IN O
subcutaneous JJ O
injection NN O
3 CD O
times NNS O
per IN O
week NN O
for IN O
48 CD O
weeks NNS O
. . O

Patients NNS O
were VBD O
assessed VBN O
at IN O
baseline NN O
, , O
12 CD O
weeks NNS O
, , O
24 CD O
weeks NNS O
, , O
and CC O
48 CD O
weeks NNS O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
The DT O
primary JJ O
outcome NN O
measure NN O
was VBD O
a DT O
change NN B-OC
in IN I-OC
neuropathy JJ I-OC
between IN I-OC
baseline NN I-OC
and CC I-OC
week NN I-OC
48 CD I-OC
, , I-OC
demonstrated VBN I-OC
by IN I-OC
the DT I-OC
Neuropathy NNP I-OC
Impairment NNP I-OC
Score NNP I-OC
for IN O
the DT O
Lower NNP O
Limbs NNP O
, , O
compared VBN O
between IN O
the DT O
2 CD O
groups NNS O
. . O

Secondary JJ O
outcome NN O
measures NNS O
included VBD O
quantitative JJ B-OC
sensory NN I-OC
tests NNS I-OC
using VBG I-OC
the DT I-OC
CASE NNP I-OC
IV NNP I-OC
System NNP I-OC
, , I-OC
the DT I-OC
Neuropathy NNP I-OC
Symptom NNP I-OC
and CC I-OC
Change NNP I-OC
questionnaire NN I-OC
, , I-OC
the DT I-OC
Patient NNP I-OC
Benefit NNP I-OC
Questionnaire NNP I-OC
( ( I-OC
PBQ NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
a DT I-OC
global JJ I-OC
symptom NN I-OC
assessment NN I-OC
, , I-OC
as RB I-OC
well RB I-OC
as IN I-OC
nerve NN I-OC
conduction NN I-OC
studies NNS I-OC
and CC I-OC
occurrence NN I-OC
of IN I-OC
new JJ I-OC
plantar JJ I-OC
foot NN I-OC
ulcers NNS I-OC
. . O

Patients NNS O
also RB O
were VBD O
evaluated VBN O
for IN O
presence NN O
of IN O
adverse JJ B-OC
events NNS I-OC
. . O

RESULTS NNP O
Among IN O
patients NNS O
who WP O
received VBD O
rhNGF NN B-INTV
, , O
418 CD O
( ( O
83 CD O
% NN O
) ) O
completed VBD O
the DT O
regimen NNS O
compared VBN O
with IN O
461 CD O
( ( O
90 CD O
% NN O
) ) O
who WP O
received VBD O
placebo NN B-INTV
. . O

Administration NNP O
of IN O
rhNGF NN B-INTV
was VBD O
safe JJ O
, , O
with IN O
few JJ O
adverse JJ B-OC
events NNS I-OC
attributed VBD O
to TO O
treatment NN O
apart RB O
from IN O
injection NN O
site NN B-OC
pain/hyperalgesia NN I-OC
and CC I-OC
other JJ I-OC
pain NN I-OC
syndromes NNS I-OC
. . O

However RB O
, , O
neither CC O
the DT O
primary JJ O
end NN O
point NN O
( ( O
P NNP O
=.25 NNP O
) ) O
nor CC O
most JJS O
of IN O
the DT O
secondary JJ O
end NN O
points NNS O
demonstrated VBD O
a DT O
significant JJ O
benefit NN O
of IN O
rhNGF NN B-INTV
. . O

Exceptions NNS O
were VBD O
the DT O
global JJ B-OC
symptom NN I-OC
assessment NN I-OC
( ( O
P NNP O
=.03 NNP O
) ) O
and CC O
2 CD O
of IN O
32 CD O
comparisons NNS O
within IN O
the DT O
PBQ NNP O
, , O
which WDT O
showed VBD O
a DT O
modest JJ O
but CC O
significant JJ O
benefit NN O
of IN O
rhNGF NN B-INTV
( ( O
P NNP O
=.05 NNP O
for IN O
severity NN O
of IN O
pain NN O
in IN O
the DT O
legs NN O
and CC O
P NNP O
=.003 NNP O
for IN O
6-month JJ O
symptoms NNS O
in IN O
the DT O
feet NNS O
and CC O
legs NNS O
) ) O
. . O

CONCLUSION NNP O
Unlike IN O
previous JJ O
phase NN O
2 CD O
trials NNS O
, , O
this DT O
phase NN O
3 CD O
clinical JJ O
trial NN O
failed VBD O
to TO O
demonstrate VB O
a DT O
significant JJ O
beneficial JJ O
effect NN O
of IN O
rhNGF NN O
on IN O
diabetic JJ O
polyneuropathy NN O
. . O

JAMA NNP O
. . O

2000 CD O
; : O
284:2215-2221 JJ O
. . O

-DOCSTART- -X- O O

A DT B-POPU
randomized JJ I-POPU
trial NN I-POPU
in IN I-POPU
simultaneous JJ I-POPU
pancreas-kidney JJ I-POPU
transplantation NN I-POPU
: : I-POPU
portal JJ B-INTV
versus NN I-INTV
systemic JJ I-INTV
venous JJ I-INTV
drainage NN I-INTV
of IN I-INTV
the DT I-INTV
pancreas NN I-INTV
allograft NN I-INTV
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
the DT O
efficacy NN O
of IN O
fluoxetine NN B-INTV
alone RB I-INTV
vs. FW I-INTV
fluoxetine JJ I-INTV
plus CC I-INTV
local JJ I-INTV
lidocaine NN I-INTV
ointment NN I-INTV
in IN O
the DT O
treatment NN O
of IN O
premature JJ B-POPU
ejaculation NN I-POPU
. . O

OBJECTIVE CC O
The DT O
present JJ O
study NN O
compares VBZ O
the DT O
efficacy NN O
and CC O
side JJ O
effects NNS O
of IN O
fluoxetine NN B-INTV
alone RB I-INTV
vs. FW I-INTV
fluoxetine JJ I-INTV
plus CC I-INTV
local JJ I-INTV
lidocaine NN I-INTV
ointment NN I-INTV
in IN O
the DT O
treatment NN O
of IN O
premature JJ B-POPU
ejaculation NN I-POPU
. . O

METHODS NNP O
Forty-three JJ B-POPU
patients NNS I-POPU
suffering VBG I-POPU
from IN I-POPU
premature JJ I-POPU
ejaculation NN I-POPU
were VBD O
studied VBN O
. . O

The DT B-POPU
exclusion NN I-POPU
criteria NNS I-POPU
were VBD I-POPU
erectile JJ I-POPU
dysfunction NN I-POPU
, , I-POPU
loss NN I-POPU
of IN I-POPU
libido NN I-POPU
, , I-POPU
alcohol NN I-POPU
and CC I-POPU
substance NN I-POPU
abuse NN I-POPU
, , I-POPU
mental JJ I-POPU
retardation NN I-POPU
, , I-POPU
diabetes VBZ I-POPU
mellitus NN I-POPU
, , I-POPU
thyroid JJ I-POPU
disease NN I-POPU
, , I-POPU
hypotension NN I-POPU
, , I-POPU
previous JJ I-POPU
use NN I-POPU
of IN I-POPU
these DT I-POPU
drugs NNS I-POPU
and CC I-POPU
urogenital JJ I-POPU
infections NNS I-POPU
. . O

The DT B-POPU
patients NNS I-POPU
' POS I-POPU
ages NNS I-POPU
ranged VBD I-POPU
from IN I-POPU
19 CD I-POPU
to TO I-POPU
48 CD I-POPU
years NNS I-POPU
( ( I-POPU
mean JJ I-POPU
age NN I-POPU
28 CD I-POPU
+/- JJ I-POPU
1.6 CD I-POPU
) ) I-POPU
. . O

They PRP B-POPU
had VBD I-POPU
regular JJ I-POPU
sexual JJ I-POPU
lives NNS I-POPU
. . O

They PRP B-POPU
had VBD I-POPU
normal JJ I-POPU
psychiatric JJ I-POPU
consultation NN I-POPU
and CC I-POPU
the DT I-POPU
Glombock NNP I-POPU
Rast NNP I-POPU
Sexual NNP I-POPU
Satisfactory NNP I-POPU
Test NNP I-POPU
( ( I-POPU
GRISS NNP I-POPU
) ) I-POPU
psychiatric JJ I-POPU
test NN I-POPU
were VBD I-POPU
in IN I-POPU
accordance NN I-POPU
with IN I-POPU
premature JJ I-POPU
ejaculation NN I-POPU
. . O

RESULTS VB O
The DT O
patients NNS O
were VBD O
assigned VBN O
to TO O
two CD O
groups NNS O
. . O

Twenty-six JJ O
patients NNS O
, , O
aged VBD O
21 CD O
to TO O
36 CD O
years NNS O
( ( O
mean JJ O
age NN O
27 CD O
) ) O
, , O
received VBD O
only RB O
fluoxetine JJ B-INTV
20 CD O
mg/day NN O
( ( O
1 CD O
capsule NN O
) ) O
for IN O
a DT O
week NN O
which WDT O
was VBD O
later RBR O
increased VBN O
to TO O
40 CD O
mg/day NN O
( ( O
2 CD O
capsules NNS O
) ) O
. . O

Seventeen JJ O
patients NNS O
, , O
aged VBD O
19 CD O
to TO O
48 CD O
years NNS O
( ( O
mean JJ O
age NN O
31 CD O
) ) O
, , O
were VBD O
given VBN O
fluoxetine JJ B-INTV
20 CD O
mg/day JJ O
plus CC O
local JJ O
application NN O
of IN O
lidocaine JJ B-INTV
ointment NN I-INTV
. . O

The DT O
patients NNS O
and CC O
partners NNS O
were VBD O
re-evaluated JJ O
8 CD O
weeks NNS O
after IN O
the DT O
treatment NN O
. . O

The DT O
results NNS O
were VBD O
classified VBN O
as IN O
unsuccessful JJ B-OC
, , I-OC
improvement NN I-OC
and CC I-OC
cure NN I-OC
. . O

The DT O
chi-square JJ B-OC
test NN I-OC
was VBD O
used VBN O
for IN O
statistical JJ O
analysis NN O
. . O

In IN O
the DT O
fluoxetine NN O
group NN O
, , O
8 CD O
( ( O
30.8 CD O
% NN O
) ) O
patients NNS O
cured VBD B-OC
, , O
11 CD O
( ( O
42.2 CD O
% NN O
) ) O
showed VBD O
improvement NN B-OC
and CC O
there EX O
were VBD O
7 CD O
failures NNS B-OC
( ( O
26.9 CD O
% NN O
) ) O
. . O

In IN O
the DT O
combination NN O
treatment NN O
group NN O
, , O
9 CD O
( ( O
52.9 CD O
% NN O
) ) O
patients NNS O
cured VBN O
, , O
improvement NN B-OC
was VBD O
observed VBN O
in IN O
5 CD O
( ( O
29.4 CD O
% NN O
) ) O
and CC O
failure NN O
in IN O
3 CD O
( ( O
17.6 CD O
% NN O
) ) O
. . O

Side JJ O
effects NNS O
in IN O
group NN O
I PRP O
were VBD O
observed VBN O
in IN O
6 CD O
patients NNS O
( ( O
23 CD O
% NN O
) ) O
and CC O
in IN O
5 CD O
( ( O
29.4 CD O
% NN O
) ) O
in IN O
group NN O
II NNP O
. . O

There EX O
were VBD O
no DT O
statistical JJ O
differences NNS O
between IN O
the DT O
two CD O
groups NNS O
according VBG O
to TO O
the DT O
side NN O
effects NNS O
( ( O
p JJ O
> NNP O
0.01 CD O
) ) O
. . O

No UH B-POPU
patients NNS I-POPU
were VBD I-POPU
excluded VBN I-POPU
from IN I-POPU
the DT I-POPU
study NN I-POPU
due JJ I-POPU
to TO I-POPU
side VB I-POPU
effects NNS I-POPU
. . O

CONCLUSION VB O
The DT O
combination NN O
of IN O
fluoxetine JJ B-INTV
plus CC O
local JJ O
application NN O
of IN O
lidocaine JJ B-INTV
ointment NN O
was VBD O
found VBN O
to TO O
be VB O
more RBR O
effective JJ O
than IN O
fluoxetine VB B-INTV
alone RB O
in IN O
the DT O
treatment NN O
of IN O
premature JJ B-POPU
ejaculation NN I-POPU
. . O

However RB O
, , O
the DT O
results NNS O
should MD O
be VB O
confirmed VBN O
in IN O
further JJ O
studies NNS O
with IN O
a DT O
placebo NN O
group NN O
to TO O
rule VB O
out IN O
the DT O
placebo NN O
effect NN O
. . O

-DOCSTART- -X- O O

Beneficial JJ O
effects NNS O
of IN O
a DT O
soy-based JJ B-INTV
dietary JJ I-INTV
supplement NN I-INTV
on IN O
lipid JJ B-OC
levels NNS I-OC
and CC I-OC
cardiovascular JJ I-OC
risk NN I-OC
markers NNS I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
. . O

OBJECTIVE NNP O
Consumption NNP O
of IN O
soy NN O
protein NN O
has VBZ O
recently RB O
been VBN O
shown VBN O
to TO O
improve VB O
the DT O
blood NN B-OC
lipid JJ I-OC
levels NNS I-OC
in IN O
nondiabetic JJ O
subjects NNS O
. . O

The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
if IN O
a DT O
dietary JJ O
supplement NN O
of IN O
soy NN B-INTV
protein NN I-INTV
, , I-INTV
isoflavones NNS I-INTV
, , I-INTV
and CC I-INTV
cotyledon VB I-INTV
fiber NN I-INTV
( ( I-INTV
Abalon NNP I-INTV
) ) I-INTV
affects VBZ O
cardiovascular JJ B-OC
risk NN I-OC
markers NNS I-OC
, , I-OC
blood NN I-OC
glucose NN I-OC
, , I-OC
and CC I-OC
insulin NN I-OC
levels NNS I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
Twenty NNP B-POPU
type NN I-POPU
2 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
participated VBN I-POPU
in IN I-POPU
a DT I-POPU
crossover NN I-POPU
trial NN I-POPU
. . O

They PRP O
were VBD O
randomized VBN O
to TO O
double-blind JJ O
supplementation NN O
for IN O
6 CD B-INTV
weeks NNS I-INTV
with IN I-INTV
Abalon NNP I-INTV
( ( I-INTV
soy JJ I-INTV
protein NN I-INTV
[ VBD O
50 CD O
g/day JJ O
] NNP O
with IN O
high JJ O
levels NNS O
of IN O
isoflavones NNS B-INTV
[ NNP O
minimum VBD O
165 CD O
mg/day NN O
] NNP O
and CC O
cotyledon VB B-INTV
fiber NN I-INTV
[ $ O
20 CD O
g/day JJ O
] NNPS O
) ) O
or CC O
placebo NN B-INTV
( ( O
casein JJ O
[ VBZ O
50 CD O
g/day NN O
] NNP O
and CC O
cellulose VB O
[ JJ O
20 CD O
g/day JJ O
] NNP O
) ) O
, , O
separated VBN O
by IN O
a DT O
3-week JJ O
wash-out JJ O
period NN O
. . O

RESULTS VB O
The DT O
results NNS O
are VBP O
expressed VBN O
as IN O
means NNS O
+/- JJ O
SD NNP O
. . O

The DT O
percentage NN O
mean JJ O
treatment NN O
difference NN O
between IN O
Abalon NNP B-INTV
and CC O
placebo NN B-INTV
demonstrated VBD O
significantly RB O
lower JJR O
mean NN O
values NNS O
after IN O
Abalon NNP B-INTV
for IN O
LDL NNP B-OC
cholesterol NN I-OC
( ( O
10 CD O
+/- JJ O
15 CD O
% NN O
, , O
P NNP O
< NNP O
0.05 CD O
) ) O
, , O
LDL/UHDL NNP B-OC
ratio NN I-OC
( ( O
12 CD O
+/- JJ O
18 CD O
% NN O
, , O
P NNP O
< NNP O
0.05 CD O
) ) O
, , O
apolipoprotein RB B-OC
( ( O
apo NN O
) ) O
B100 NNP O
( ( O
30 CD O
+/- JJ O
38 CD O
% NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
triglycerides NNS B-OC
( ( O
22 CD O
+/- JJ O
10 CD O
% NN O
, , O
P NNP O
< NNP O
0.05 CD O
) ) O
, , O
and CC O
homocysteine NN B-OC
( ( O
14 CD O
+/- JJ O
21 CD O
% NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
whereas VBD O
the DT O
total JJ B-OC
cholesterol NN I-OC
value NN I-OC
tended VBD O
to TO O
be VB O
less RBR O
significant JJ O
but CC O
still RB O
lower JJR O
( ( O
8 CD O
+/- JJ O
15 CD O
% NN O
, , O
P NNP O
< NNP O
0.08 CD O
) ) O
. . O

No UH O
change NN O
occurred VBD O
in IN O
HDL NNP B-OC
cholesterol NN I-OC
, , I-OC
apo JJ I-OC
B100/apo NNP I-OC
A1 NNP I-OC
ratio NN I-OC
, , I-OC
plasminogen NN I-OC
activator NN I-OC
inhibitor NN I-OC
1 CD I-OC
, , I-OC
factor NN I-OC
VIIc NNP I-OC
, , I-OC
von NNP I-OC
Willebrand NNP I-OC
factor NN I-OC
, , I-OC
fibrinogen NN I-OC
, , I-OC
lipoprotein NN I-OC
( ( I-OC
a DT I-OC
) ) I-OC
, , I-OC
glucose JJ I-OC
, , I-OC
HbA1c NNP I-OC
, , I-OC
or CC I-OC
24-h JJ I-OC
blood NN I-OC
pressure NN I-OC
. . O

CONCLUSIONS NNP O
These DT O
results NNS O
indicate VBP O
beneficial JJ O
effects NNS O
of IN O
dietary JJ O
supplementation NN O
with IN O
Abalon NNP B-INTV
on IN O
cardiovascular JJ B-OC
risk NN I-OC
markers NNS I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
. . O

This DT O
improvement NN O
is VBZ O
seen VBN O
even RB O
in IN O
individuals NNS O
with IN O
near-normal JJ O
lipid JJ O
values NNS O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
acarbose NN B-INTV
on IN O
additional JJ O
insulin NN B-INTV
therapy NN I-INTV
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
late JJ I-POPU
failure NN I-POPU
of IN I-POPU
sulphonylurea JJ I-POPU
therapy NN I-POPU
. . O

AIM VB O
The DT O
present JJ O
study NN O
investigated VBD O
the DT O
effect NN O
of IN O
acarbose NN B-INTV
on IN O
insulin NN B-OC
requirements NNS I-OC
and CC O
glycaemic JJ B-OC
control NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
receiving VBG I-POPU
exogenous JJ I-POPU
insulin NN I-POPU
due JJ I-POPU
to TO I-POPU
secondary JJ I-POPU
failure NN I-POPU
of IN I-POPU
maximum NN I-POPU
dose JJ I-POPU
sulphonylurea JJ I-POPU
therapy NN I-POPU
. . O

METHODS VB O
A DT O
single-centre JJ O
, , O
double-blind JJ O
, , O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
study NN O
was VBD O
performed VBN O
in IN O
48 CD B-POPU
type NN I-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
late-term JJ I-POPU
failure NN I-POPU
following VBG I-POPU
at IN I-POPU
least JJS I-POPU
3 CD I-POPU
years NNS I-POPU
of IN I-POPU
sulphonylurea JJ I-POPU
therapy NN I-POPU
requiring VBG I-POPU
additional JJ I-POPU
insulin NN I-POPU
therapy NN I-POPU
to TO I-POPU
determine VB I-POPU
the DT I-POPU
impact NN I-POPU
of IN I-POPU
acarbose NN I-POPU
on IN I-POPU
glycaemic JJ I-POPU
control NN I-POPU
and CC I-POPU
insulin NN I-POPU
requirements NNS I-POPU
. . O

The DT O
primary JJ O
end NN O
points NNS O
were VBD O
glycaemic JJ B-OC
response NN I-OC
rate NN I-OC
( ( O
responders NNS O
being VBG O
predefined VBN O
as IN O
patients NNS O
who WP O
achieve VBP O
a DT O
decrease NN O
in IN O
HbA1c NNP O
to TO O
less JJR O
than IN O
8 CD O
% NN O
or CC O
a DT O
reduction NN O
by IN O
at IN O
least JJS O
15 CD O
% NN O
as IN O
compared VBN O
to TO O
the DT O
baseline NN O
values NNS O
) ) O
and CC O
the DT O
daily JJ B-OC
insulin NN B-INTV
dose NN B-OC
at IN O
6 CD O
months NNS O
. . O

Secondary JJ O
parameters NNS O
assessed VBD O
included VBN O
postprandial JJ B-OC
changes NNS I-OC
in IN I-OC
blood NN I-OC
glucose NN I-OC
, , I-OC
serum JJ I-OC
insulin NN B-INTV
and CC B-OC
C-peptide NNP I-OC
during IN O
the DT O
treatment NN O
period NN O
. . O

RESULTS CC O
There EX O
were VBD O
significantly RB O
more JJR O
responders NNS O
in IN O
the DT O
acarbose-treated JJ O
group NN O
compared VBN O
with IN O
the DT O
placebo NN O
group NN O
( ( O
20/24 CD O
patients NNS O
vs. FW O
10/19 CD O
patients NNS O
; : O
p VB O
< $ O
0.05 CD O
) ) O
. . O

The DT O
mean JJ B-OC
daily JJ I-OC
insulin NN B-INTV
dose NN B-OC
after IN O
24 CD O
weeks NNS O
of IN O
treatment NN O
was VBD O
16.4 CD O
+/- JJ O
10.1 CD O
IU NNP O
in IN O
the DT O
acarbose JJ B-INTV
group NN O
and CC O
22.4 CD O
+/- JJ O
12.2 CD O
IU NNP O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
mean JJ O
+/- JJ O
s.d NN O
. . O

; : O
p JJ O
< NNP O
0.07 CD O
) ) O
. . O

Postprandial JJ B-OC
increases NNS I-OC
in IN I-OC
blood NN I-OC
glucose NN I-OC
, , I-OC
insulin NN I-OC
and CC I-OC
C-peptide NNP I-OC
were VBD O
consistently RB O
lower JJR O
in IN O
the DT O
acarbose-treated JJ O
group NN O
than IN O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

For IN O
example NN O
, , O
the DT O
mean JJ B-OC
increase NN I-OC
in IN I-OC
2-h JJ I-OC
postprandial JJ I-OC
serum NN I-OC
insulin NN B-INTV
remained VBD O
almost RB O
unchanged JJ O
in IN O
the DT O
acarbose JJ O
group NN O
at IN O
the DT O
end NN O
of IN O
24 CD O
weeks NNS O
of IN O
treatment NN O
compared VBN O
to TO O
an DT O
increase NN O
to TO O
43 CD O
+/- JJ O
29 CD O
microU/ml NN O
( ( O
mean JJ O
+/- JJ O
s.d NN O
. . O

) ) O
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
period NN O
for IN O
the DT O
placebo NN B-INTV
group NN O
. . O

CONCLUSIONS VB O
The DT O
findings NNS O
of IN O
this DT O
study NN O
suggest VBP O
that IN O
the DT O
addition NN O
of IN O
acarbose NN B-INTV
to TO O
sulphonylurea/insulin VB B-INTV
combination NN I-INTV
therapy NN I-INTV
can MD O
improve VB O
glycaemic JJ B-OC
control NN I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
. . O

Acarbose NNP B-INTV
may MD O
also RB O
reduce VB O
insulin NN B-OC
resistance NN I-OC
and CC I-OC
hyperinsulinaemia NN I-OC
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
protein NN B-INTV
ingestion NN I-INTV
on IN O
the DT O
glucose JJ B-OC
appearance NN I-OC
rate NN I-OC
in IN O
people NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

Amino NNP O
acids NNS O
derived VBD O
from IN O
ingested VBN O
protein NN O
are VBP O
potential JJ O
substrates NNS O
for IN O
gluconeogenesis NN O
. . O

However RB O
, , O
several JJ O
laboratories NNS O
have VBP O
reported VBN O
that IN O
protein JJ O
ingestion NN O
does VBZ O
not RB O
result VB O
in IN O
an DT O
increase NN O
in IN O
the DT O
circulating NN B-OC
glucose JJ I-OC
concentration NN I-OC
in IN O
people NNS O
with IN O
or CC O
without IN O
type JJ B-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

The DT O
reason NN O
for IN O
this DT O
has VBZ O
remained VBN O
unclear JJ O
. . O

In IN O
people NNS O
without IN O
diabetes NNS O
it PRP O
seems VBZ O
to TO O
be VB O
due JJ O
to TO O
less RBR O
glucose JJ O
being VBG O
produced VBN O
and CC O
entering VBG O
the DT O
circulation NN O
than IN O
the DT O
calculated JJ O
theoretical JJ O
amount NN O
. . O

Therefore RB O
, , O
we PRP O
were VBD O
interested JJ O
in IN O
determining VBG O
whether IN O
this DT O
also RB O
was VBD O
the DT O
case NN O
in IN O
people NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

Ten CD B-POPU
male JJ I-POPU
subjects NNS I-POPU
with IN I-POPU
untreated JJ I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
were VBD O
given VBN O
, , O
in IN O
random JJ O
sequence NN O
, , O
50 CD B-INTV
g NN I-INTV
protein NN I-INTV
in IN I-INTV
the DT I-INTV
form NN I-INTV
of IN I-INTV
very RB I-INTV
lean JJ I-INTV
beef NN I-INTV
or CC I-INTV
only RB I-INTV
water NN I-INTV
at IN I-INTV
0800 CD I-INTV
h NN I-INTV
and CC I-INTV
studied VBN I-INTV
over IN I-INTV
the DT I-INTV
subsequent JJ I-INTV
8 CD I-INTV
h. NN I-INTV
Protein NNP I-INTV
ingestion NN O
resulted VBD O
in IN O
an DT O
increase NN O
in IN O
circulating VBG B-OC
insulin NN I-OC
, , I-OC
C-peptide NNP I-OC
, , I-OC
glucagon NN I-OC
, , I-OC
alpha NN I-OC
amino NN I-OC
and CC I-OC
urea JJ I-OC
nitrogen NN I-OC
, , I-OC
and CC I-OC
triglycerides NNS I-OC
; : I-OC
a DT I-OC
decrease NN I-OC
in IN I-OC
nonesterified JJ I-OC
fatty JJ I-OC
acids NNS I-OC
; : I-OC
and CC I-OC
a DT I-OC
modest JJ I-OC
increase NN I-OC
in IN I-OC
respiratory JJ I-OC
quotient NN I-OC
. . O

The DT O
total JJ O
amount NN O
of IN O
protein NN B-OC
deaminated VBN I-OC
and CC I-OC
the DT I-OC
amino NN I-OC
groups NNS I-OC
incorporated VBD I-OC
into IN I-OC
urea NN I-OC
was VBD O
calculated VBN O
to TO O
be VB O
approximately RB O
20-23 JJ O
g. VBP O
The DT O
net JJ O
amount NN O
of IN O
glucose NN B-OC
estimated VBN O
to TO O
be VB O
produced VBN O
, , O
based VBN O
on IN O
the DT O
quantity NN B-OC
of IN I-OC
amino JJ I-OC
acids NNS I-OC
deaminated VBD I-OC
, , O
was VBD O
approximately RB O
11-13 JJ O
g. NN O
However RB O
, , O
the DT O
amount NN B-OC
of IN I-OC
glucose JJ I-OC
appearing VBG I-OC
in IN I-OC
the DT I-OC
circulation NN I-OC
was VBD O
only RB O
approximately RB O
2 CD O
g. VBD O
The DT O
peripheral JJ B-OC
plasma NN I-OC
glucose JJ I-OC
concentration NN I-OC
decreased VBN O
by IN O
approximately RB O
1 CD O
mM NNS O
after IN O
ingestion NN O
of IN O
either DT O
protein NN O
or CC O
water NN O
, , O
confirming VBG O
that IN O
ingested JJ O
protein NN O
does VBZ O
not RB O
result VB O
in IN O
a DT O
net JJ O
increase NN O
in IN O
glucose JJ B-OC
concentration NN I-OC
, , O
and CC O
results NNS O
in IN O
only RB O
a DT O
modest JJ O
increase NN O
in IN O
the DT O
rate NN B-OC
of IN I-OC
glucose JJ I-OC
disappearance NN I-OC
. . O

-DOCSTART- -X- O O

Physiologic NNP O
modeling NN O
of IN O
the DT O
intravenous JJ B-OC
glucose JJ I-OC
tolerance NN I-OC
test NN I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetes NNS I-POPU
: : I-POPU
a DT O
new JJ O
approach NN O
to TO O
the DT O
insulin NN O
compartment NN O
. . O

The DT O
minimal JJ O
model NN O
of IN O
Bergman NNP O
et FW O
al NN O
has VBZ O
been VBN O
used VBN O
to TO O
yield VB O
estimates NNS O
of IN O
insulin NN B-OC
sensitivity NN I-OC
( ( I-OC
Si NNP I-OC
) ) I-OC
and CC I-OC
glucose JJ I-OC
effectiveness NN I-OC
( ( I-OC
Sg NNP I-OC
) ) I-OC
in IN O
type NN O
2 CD O
diabetes NNS O
by IN O
incorporating VBG O
exogenous JJ B-INTV
insulin NN I-INTV
protocols NNS I-INTV
into IN O
the DT O
regular JJ O
intravenous JJ O
glucose NN O
tolerance NN O
test NN O
( ( O
IVGTT NNP O
) ) O
. . O

These DT O
estimates NNS O
, , O
however RB O
, , O
are VBP O
influenced VBN O
by IN O
the DT O
degree NN O
to TO O
which WDT O
the DT O
dose NN O
of IN O
exogenous JJ B-INTV
insulin NN I-INTV
is VBZ O
greater JJR O
than IN O
the DT O
physiologic JJ O
response NN O
to TO O
a DT O
glucose JJ O
load NN O
. . O

Moreover RB O
, , O
most JJS O
studies NNS O
have VBP O
related VBN O
to TO O
type VB B-POPU
2 CD I-POPU
diabetes NNS I-POPU
subjects NNS I-POPU
whose WP$ O
diabetes NNS O
was VBD O
relatively RB O
mild JJ O
in IN O
terms NNS O
of IN O
therapeutic JJ O
requirements NNS O
. . O

To TO O
develop VB O
a DT O
" NN O
minimal JJ O
disturbance NN O
" NNP O
approach NN O
in IN O
estimating VBG O
Si NNP B-OC
and CC I-OC
Sg NNP I-OC
in IN O
type NN O
2 CD O
diabetes NNS O
, , O
we PRP O
have VBP O
used VBN O
a DT O
reduced JJ B-INTV
glucose JJ I-INTV
load NN I-INTV
( ( O
200 CD O
mg/kg NN O
) ) O
and CC B-INTV
a DT I-INTV
" JJ I-INTV
physiologic NN I-INTV
" NNP I-INTV
insulin NN I-INTV
infusion NN I-INTV
throughout IN O
the DT O
IVGTT NNP O
in IN O
a DT O
series NN O
of IN O
8 CD B-POPU
patients NNS I-POPU
, , I-POPU
5 CD I-POPU
of IN I-POPU
whom WP I-POPU
were VBD I-POPU
insulin-requiring JJ I-POPU
. . O

Data NNS O
from IN O
this DT O
approach NN O
were VBD O
analyzed VBN O
using VBG O
the DT O
modelling VBG O
program NN O
CONSAM NNP O
to TO O
apply VB O
the DT O
Bergman NNP O
model NN O
, , O
either RB O
unmodified JJ O
( ( O
BMM NNP O
) ) O
, , O
or CC O
incorporating VBG O
an DT O
additional JJ O
delay NN O
element NN O
between IN O
the DT O
plasma NN O
and CC O
" JJ O
remote NN O
" NNP O
insulin NN O
compartments NNS O
( ( O
MMD NNP O
) ) O
. . O

Application NN O
of IN O
the DT O
MMD NNP O
and CC O
extension NN O
of IN O
the DT O
IVGTT NNP O
from IN O
3 CD O
to TO O
5 CD O
hours NNS O
improved VBN O
successful JJ O
resolution NN B-OC
of IN I-OC
Si NNP I-OC
and CC I-OC
Sg NNP I-OC
from IN O
37.5 CD O
% NN O
( ( O
BMM NNP O
, , O
3-hour JJ O
IVGTT NNP O
) ) O
to TO O
100 CD O
% NN O
( ( O
MMD NNP O
, , O
5-hour JJ O
IVGTT NNP O
) ) O
. . O

Si NNP B-OC
was VBD O
reduced VBN O
in IN O
these DT O
type NN O
2 CD O
diabetes VBZ O
patients NNS O
compared VBN O
with IN O
normal JJ O
subjects NNS O
( ( O
1.86 CD O
+/- JJ O
0.60 CD O
v. JJ O
8.65 CD O
+/- JJ O
2.27 CD O
min NN O
( ( O
-1 NNP O
) ) O
x VBP O
microU NN O
( ( O
-1 NNP O
) ) O
x VBP O
mL JJ O
x $ O
10 CD O
( ( O
4 CD O
) ) O
P NNP O
< NNP O
.01 NNP O
) ) O
. . O

The DT O
results NNS O
were VBD O
validated VBN O
in IN O
the DT O
type NN B-POPU
2 CD I-POPU
diabetes NNS I-POPU
group NN I-POPU
using VBG O
a DT O
2-stage JJ O
euglycemic JJ O
clamp NN O
( ( O
( ( O
Si NNP O
) ) O
CLAMP NNP O
= $ O
2.02 CD O
+/- JJ O
0.42 CD O
min NN O
( ( O
-1 NNP O
) ) O
x VBP O
microU NN O
( ( O
-1 NNP O
) ) O
x VBP O
mL JJ O
x $ O
10 CD O
( ( O
4 CD O
) ) O
P NNP O
> NNP O
.4 NNP O
) ) O
. . O

Sg NNP B-OC
was VBD O
not RB O
significantly RB O
reduced VBN O
( ( O
2.00 CD O
+/- JJ O
0.25 CD O
type NN O
2 CD O
diabetes NNS O
v. JJ O
1.55 CD O
+/- JJ O
0.26 CD O
normal JJ O
min NN O
( ( O
-1 NNP O
) ) O
x VBZ O
10 CD O
( ( O
2 CD O
) ) O
) ) O
. . O

Data NNS O
from IN O
a DT O
group NN O
of IN O
normal JJ B-POPU
nondiabetic JJ I-POPU
subjects NNS I-POPU
was VBD O
then RB O
analyzed VBN O
using VBG O
the DT O
MMD NNP O
, , O
but CC O
this DT O
approach NN O
did VBD O
not RB O
enhance VB O
the DT O
fit NN O
of IN O
the DT O
model NN O
compared VBN O
with IN O
the DT O
BMM NNP O
. . O

This DT O
result NN O
indicates VBZ O
that IN O
the DT O
delay NN O
in IN O
insulin JJ O
action NN O
in IN O
type NN O
2 CD O
diabetes VBZ O
represents VBZ O
an DT O
abnormality NN O
whereby WRB O
the DT O
onset NN O
of IN O
insulin JJ O
action NN O
can MD O
not RB O
be VB O
described VBN O
as IN O
a DT O
single JJ O
phase NN O
in IN O
the DT O
transfer NN O
of IN O
insulin NN O
from IN O
plasma NN O
to TO O
the DT O
remote JJ O
compartment NN O
. . O

It PRP O
is VBZ O
postulated VBN O
that IN O
the DT O
physiologic JJ O
basis NN O
for IN O
this DT O
delayed JJ O
action NN O
may MD O
relate VB O
to TO O
transcapillary JJ O
endothelial JJ O
transfer NN O
of IN O
insulin NN O
, , O
this DT O
process NN O
limiting VBG O
the DT O
rate NN O
of IN O
onset NN O
of IN O
insulin JJ O
action NN O
. . O

-DOCSTART- -X- O O

Nicotine NNP B-INTV
infusion NN O
acutely RB O
impairs JJ O
insulin NN O
sensitivity NN O
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
but CC O
not RB O
in IN O
healthy JJ O
subjects NNS O
. . O

OBJECTIVES IN O
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
examine VB O
if IN O
an DT O
acute JJ O
nicotine NN B-INTV
infusion NN O
alters NNS O
insulin VBP O
sensitivity NN O
to TO O
a DT O
similar JJ O
degree NN O
in IN O
type NN O
2 CD O
diabetic JJ O
patients NNS O
as IN O
in IN O
healthy JJ O
control NN O
subjects NNS O
. . O

DESIGN NNP O
. . O

Double-blind NNP O
, , O
cross-over NN O
, , O
placebo-controlled JJ B-INTV
, , O
randomized JJ O
experimental NN O
study NN O
. . O

Nicotine NNP B-INTV
0.3 CD O
microg NN O
kg-1 JJ O
min NN O
( ( O
-1 JJ O
) ) O
or CC B-INTV
NaCl NNP I-INTV
was VBD I-INTV
infused VBN I-INTV
( ( O
2 CD O
h NN O
) ) O
during IN O
a DT O
euglycaemic JJ O
hyperinsulinaemic NN O
clamp NN O
( ( O
4 CD O
h NN O
) ) O
to TO O
assess VB O
insulin JJ O
sensitivity NN O
. . O

SETTING NNP O
University NNP O
research NN O
laboratory NN O
. . O

SUBJECTS NNP O
Six NNP B-POPU
male NN I-POPU
and CC I-POPU
female JJ I-POPU
type NN I-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
[ JJ I-POPU
DM2 NNP I-POPU
; : I-POPU
age NN I-POPU
54 CD I-POPU
+/- JJ I-POPU
10 CD I-POPU
( ( I-POPU
mean JJ I-POPU
+/- NNP I-POPU
SD NNP I-POPU
) ) I-POPU
years NNS I-POPU
; : I-POPU
body NN I-POPU
mass NN I-POPU
index NN I-POPU
( ( I-POPU
BMI NNP I-POPU
) ) I-POPU
25.6 CD I-POPU
+/- JJ I-POPU
2.9 CD I-POPU
kg NN I-POPU
m NN I-POPU
( ( I-POPU
-2 NNP I-POPU
) ) I-POPU
] NN I-POPU
treated VBN I-POPU
with IN I-POPU
diet JJ I-POPU
or CC I-POPU
one CD I-POPU
oral JJ I-POPU
hypoglycaemic JJ I-POPU
agent NN I-POPU
and CC I-POPU
six CD I-POPU
age- JJ I-POPU
and CC I-POPU
BMI-matched JJ I-POPU
control NN I-POPU
subjects NNS I-POPU
( ( I-POPU
Ctr NNP I-POPU
) ) I-POPU
. . O

MAIN NNP O
OUTCOME NNP O
MEASURE NNP O
Insulin NNP B-OC
sensitivity NN I-OC
( ( I-OC
rate NN I-OC
of IN I-OC
glucose JJ I-OC
infusion NN I-OC
per IN I-OC
kg NN I-OC
fat JJ I-OC
free JJ I-OC
body NN I-OC
mass NN I-OC
and CC I-OC
minute NN I-OC
) ) I-OC
, , I-OC
nicotine JJ I-OC
and CC I-OC
free JJ I-OC
fatty NN I-OC
acid NN I-OC
( ( I-OC
FFA NNP I-OC
) ) I-OC
levels NNS I-OC
, , I-OC
pulse NN I-OC
rate NN I-OC
and CC I-OC
blood NN I-OC
pressure NN I-OC
. . O

RESULTS VB O
The DT O
infusions NNS O
produced VBD O
similar JJ O
nicotine NN O
levels NNS O
in IN O
both DT O
groups NNS O
. . O

In IN O
the DT O
absence NN O
of IN O
nicotine NN B-INTV
, , O
DM2 NNP O
were VBD O
more JJR O
insulin NN B-OC
resistant NN I-OC
than IN O
Ctr NNP O
( ( O
6.7 CD O
+/- JJ O
0.4 CD O
vs. FW O
10.9 CD O
+/- JJ O
0.3 CD O
mg JJ O
kg-1 JJ O
LBM NNP O
min NN O
( ( O
-1 NNP O
) ) O
, , O
respectively RB O
; : O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

This DT O
insulin NN B-OC
resistance NN I-OC
was VBD O
further RBR O
aggravated VBN O
by IN O
the DT O
nicotine JJ O
infusion NN O
in IN O
DM2 NNP O
but CC O
not RB O
in IN O
Ctr NNP O
( ( O
4.6 CD O
+/- JJ O
0.3 CD O
vs. FW O
10.9 CD O
+/- JJ O
0.3 CD O
mg NN O
kg NN O
( ( O
-1 NNP O
) ) O
LBM NNP O
min NN O
( ( O
-1 NNP O
) ) O
; : O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

Only RB O
minor JJ O
differences NNS O
were VBD O
seen VBN O
in IN O
FFA NNP B-OC
levels NNS I-OC
, , I-OC
pulse NN I-OC
rates NNS I-OC
and CC I-OC
blood NN I-OC
pressure NN I-OC
. . O

CONCLUSIONS NN O
At IN O
this DT O
low JJ O
infusion NN O
rate NN O
, , O
nicotine NN B-INTV
aggravated VBD O
the DT O
insulin NN B-OC
resistance NN I-OC
in IN O
DM2 NNP O
but CC O
not RB O
in IN O
Ctr NNP O
. . O

This DT O
finding NN O
may MD O
be VB O
because IN O
of IN O
the DT O
( ( O
dysmetabolic JJ O
) ) O
diabetic JJ O
state NN O
per IN O
se NN O
or CC O
to TO O
an DT O
increased VBN O
sensitivity NN O
to TO O
environmental JJ O
factors NNS O
associated VBN O
with IN O
a DT O
genetic JJ O
predisposition NN O
for IN O
type NN O
2 CD O
diabetes NNS O
. . O

These DT O
results NNS O
show VBP O
that IN O
diabetic JJ O
subjects NNS O
are VBP O
particularly RB O
susceptible JJ O
to TO O
the DT O
detrimental JJ O
effects NNS O
of IN O
nicotine NN B-INTV
. . O

-DOCSTART- -X- O O

Induction NNP B-INTV
versus NN O
noninduction NN B-INTV
in IN O
renal JJ B-POPU
transplant NN I-POPU
recipients NNS I-POPU
with IN I-POPU
tacrolimus-based JJ I-POPU
immunosuppression NN I-POPU
. . O

BACKGROUND IN O
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
induction NN O
treatment NN O
with IN O
antithymocyte NN B-INTV
globulins NNS I-INTV
( ( I-INTV
ATG NNP I-INTV
) ) I-INTV
followed VBN O
by IN O
tacrolimus JJ B-INTV
therapy NN O
with IN O
immediate JJ O
tacrolimus NNS O
therapy NN O
in IN O
renal JJ B-POPU
transplant NN I-POPU
recipients NNS I-POPU
. . O

METHODS NNP O
This DT O
12-month JJ O
, , O
open JJ O
, , O
prospective JJ O
study NN O
was VBD O
conducted VBN O
in IN O
15 CD B-POPU
centers NNS I-POPU
in IN I-POPU
France NNP I-POPU
and CC I-POPU
1 CD I-POPU
center NN I-POPU
in IN I-POPU
Belgium NNP I-POPU
; : I-POPU
309 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
receive VB I-POPU
either DT I-POPU
induction NN I-POPU
therapy NN I-POPU
with IN I-POPU
ATG NNP I-POPU
( ( I-POPU
n=151 NN I-POPU
) ) I-POPU
followed VBN I-POPU
by IN I-POPU
initiation NN I-POPU
of IN I-POPU
tacrolimus NN I-POPU
on IN I-POPU
day NN I-POPU
9 CD I-POPU
or CC I-POPU
immediate JJ I-POPU
tacrolimus-based JJ I-POPU
triple NN I-POPU
therapy NN I-POPU
( ( I-POPU
n=158 JJ I-POPU
) ) I-POPU
. . O

In IN O
both DT O
study NN O
arms NNS O
, , O
the DT O
initial JJ O
daily JJ O
tacrolimus NN B-INTV
dose NN O
was VBD O
0.2 CD O
mg/kg NN O
. . O

Steroid JJ B-INTV
boluses NNS I-INTV
were VBD O
given VBN O
in IN O
the DT O
first JJ O
2 CD O
days NNS O
and CC O
tapered JJ O
thereafter NN O
from IN O
20 CD O
mg/day NN O
to TO O
5 CD O
mg/day NN O
. . O

Azathioprine NNP B-INTV
was VBD O
administered VBN O
at IN O
1-2 JJ O
mg/kg NNS O
per IN O
day NN O
. . O

RESULTS NNP O
At IN O
month NN O
12 CD O
, , O
biopsy-confirmed JJ B-OC
acute NN I-OC
rejections NNS I-OC
were VBD O
reported VBN O
for IN O
15.2 CD O
% NN O
( ( O
induction NN O
) ) O
and CC O
30.4 CD O
% NN O
( ( O
noninduction NN O
) ) O
of IN O
patients NNS O
( ( O
P=0.001 NNP O
) ) O
. . O

The DT O
incidence NN B-OC
of IN I-OC
steroid-sensitive JJ I-OC
acute JJ I-OC
rejections NNS I-OC
was VBD O
7.9 CD O
% NN O
( ( O
induction NN O
) ) O
and CC O
22.2 CD O
% NN O
( ( O
noninduction NN O
) ) O
( ( O
P=0.001 NNP O
) ) O
. . O

Steroid-resistant JJ B-OC
acute JJ I-OC
rejections NNS I-OC
were VBD O
reported VBN O
for IN O
8.6 CD O
% NN O
( ( O
induction NN O
) ) O
and CC O
8.9 CD O
% NN O
( ( O
noninduction NN O
) ) O
of IN O
patients NNS O
. . O

A DT O
total NN O
of IN O
nine CD O
patients NNS O
died VBD B-OC
. . O

Patient NNP B-OC
survival NN I-OC
and CC I-OC
graft NN I-OC
survival NN I-OC
at IN O
month NN O
12 CD O
was VBD O
similar JJ O
in IN O
both DT O
treatment NN O
groups NNS O
( ( O
97.4 CD O
% NN O
vs. FW O
96.8 CD O
% NN O
and CC O
92.1 CD O
% NN O
vs. FW O
91.1 CD O
% NN O
, , O
respectively RB O
) ) O
. . O

Statistically NNP O
significant JJ O
differences NNS O
in IN O
the DT O
incidence NN B-OC
of IN I-OC
adverse JJ I-OC
events NNS I-OC
were VBD O
found VBN O
for IN O
cytomegalovirus NN B-OC
( ( I-OC
CMV NNP I-OC
) ) I-OC
infection NN I-OC
( ( O
induction NN O
, , O
32.5 CD O
% NN O
vs. FW O
noninduction NN O
, , O
19.0 CD O
% NN O
, , O
P=0.009 NNP O
) ) O
, , O
leukopenia NN B-OC
( ( O
37.3 CD O
% NN O
vs. FW O
9.5 CD O
% NN O
, , O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
fever RB B-OC
( ( O
25.2 CD O
% NN O
vs. FW O
10.1 CD O
% NN O
, , O
P=0.001 NNP O
) ) O
, , O
herpes VBZ B-OC
simplex JJ I-OC
( ( O
17.9 CD O
% NN O
vs. FW O
5.7 CD O
% NN O
, , O
P=0.001 NNP O
) ) O
, , O
and CC O
thrombocytopenia NN B-OC
( ( O
11.3 CD O
% NN O
vs. FW O
3.2 CD O
% NN O
, , O
P=0.007 NNP O
) ) O
. . O

In IN O
the DT O
induction NN O
group NN O
, , O
serum NN B-OC
sickness NN I-OC
was VBD O
observed VBN O
in IN O
10.6 CD O
% NN O
of IN O
patients NNS O
. . O

The DT O
incidence NN O
of IN O
new JJ B-OC
onset NN I-OC
diabetes NNS I-OC
mellitus NN I-OC
was VBD O
3.4 CD O
% NN O
( ( O
induction NN O
) ) O
and CC O
4.5 CD O
% NN O
( ( O
noninduction NN O
) ) O
. . O

CONCLUSION NNP O
Low NNP O
incidences NNS O
of IN O
acute JJ B-OC
rejection NN I-OC
were VBD O
found VBN O
in IN O
both DT O
treatment NN O
arms NNS O
. . O

Induction NNP O
treatment NN O
with IN O
ATG NNP B-INTV
has VBZ O
the DT O
advantage NN O
of IN O
a DT O
lower JJR O
incidence NN O
of IN O
acute JJ O
rejection NN O
, , O
but CC O
it PRP O
significantly RB O
increases VBZ O
adverse JJ B-OC
events NNS I-OC
, , O
particularly RB O
CMV NNP B-OC
infection NN I-OC
. . O

-DOCSTART- -X- O O

Glibenclamide NNP B-INTV
vs NN I-INTV
gliclazide NN I-INTV
in IN O
reducing VBG O
oxidative JJ B-OC
stress NN I-OC
in IN O
patients NNS B-POPU
of IN I-POPU
noninsulin JJ I-POPU
dependent JJ I-POPU
diabetes VBZ I-POPU
mellitus NN I-POPU
-- : I-POPU
a DT I-POPU
double JJ O
blind NN O
randomized VBN O
study NN O
. . O

OBJECTIVE NNP O
Parameters NNPS O
of IN O
oxidative JJ B-OC
stress NN I-OC
were VBD O
quantitated VBN O
in IN O
50 CD B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus VBP I-POPU
in IN I-POPU
uncontrolled JJ I-POPU
state NN I-POPU
and CC O
after IN O
control NN O
using VBG O
oral JJ O
glibenclamide NN B-INTV
or CC I-INTV
gliclazide NN I-INTV
. . O

The DT O
estimates NNS O
were VBD O
further RB O
compared VBN O
between IN O
the DT O
two CD O
groups NNS O
irrespective JJ O
of IN O
drug NN O
used VBN O
to TO O
evaluate VB O
the DT O
difference NN O
, , O
if IN O
any DT O
. . O

METHODS NNP O
The DT O
study NN O
was VBD O
a DT O
double JJ O
blind NN O
, , O
uncontrolled JJ O
, , O
noncrossover RB O
and CC O
randomized JJ O
trial NN O
. . O

Fifty JJ B-POPU
patients NNS I-POPU
of IN I-POPU
uncontrolled JJ I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
were VBD O
divided VBN O
in IN O
to TO O
two CD O
groups NNS O
. . O

Group NNP O
I PRP O
( ( O
25 CD O
patients NNS O
) ) O
received VBD O
capsule NN B-INTV
A NNP I-INTV
( ( I-INTV
glibenclamide NN I-INTV
) ) I-INTV
while IN O
Group NNP O
II NNP O
( ( O
25 CD O
patients NNS O
) ) O
received VBD O
capsule NN B-INTV
B NNP I-INTV
( ( I-INTV
gliclazide NN I-INTV
) ) I-INTV
. . O

The DT O
parameters NNS O
studied VBN O
were VBD O
Superoxide NNP B-OC
dismutase NN I-OC
( ( I-OC
SOD NNP I-OC
) ) I-OC
, , I-OC
malonyl-dialdehyde JJ I-OC
( ( I-OC
MDA NNP I-OC
) ) I-OC
and CC I-OC
reduced VBN I-OC
glutathione NN I-OC
( ( I-OC
GSH NNP I-OC
) ) I-OC
. . O

They PRP O
were VBD O
done VBN O
at IN O
( ( O
a DT O
) ) O
uncontrolled JJ O
stage NN O
( ( O
FBS NNP O
-- : O
165 CD O
+/- JJ O
16.7 CD O
mg/dl NN O
, , O
PP NNP O
-- : O
240 CD O
+/- JJ O
30.1 CD O
mg/dl NN O
and CC O
HbA1 NNP O
-- : O
10.5 CD O
+/- JJ O
0.9 CD O
% NN O
in IN O
group NN O
I PRP O
and CC O
FBS NNP O
-- : O
150 CD O
+/- JJ O
15.8 CD O
mg/dl NN O
, , O
PP NNP O
-- : O
246 CD O
+/- JJ O
29.1 CD O
mg/dl NN O
HbA1 NNP O
10.6 CD O
+/- JJ O
0.8 CD O
% NN O
in IN O
group NN O
II NNP O
) ) O
and CC O
during IN O
controlled VBN O
stage NN O
at IN O
12 CD O
weeks NNS O
( ( O
FBS NNP O
-- : O
120 CD O
+/- JJ O
18.5 CD O
mg/dl NN O
, , O
PP NNP O
-- : O
180 CD O
+/- JJ O
19.1 CD O
mg/dl NN O
and CC O
HbA1 NNP O
-- : O
8.4 CD O
+/- JJ O
0.29 CD O
% NN O
in IN O
group NN O
I PRP O
and CC O
FBS NNP O
-- : O
118 CD O
+/- JJ O
17.6 CD O
mg/dl NN O
, , O
PP NNP O
-- : O
176 CD O
+/- JJ O
20.1 CD O
mg/dl NN O
and CC O
HbA1 NNP O
-- : O
8.5 CD O
+/- JJ O
0.39 CD O
% NN O
in IN O
group NN O
II NNP O
patients NNS O
) ) O
. . O

RESULTS VB O
The DT O
significantly RB O
raised VBN O
levels NNS B-OC
of IN I-OC
MDA NNP I-OC
and CC I-OC
SOD NNP I-OC
, , O
and CC O
decreased JJ O
levels NNS B-OC
of IN I-OC
reduced VBN I-OC
glutathione NN I-OC
( ( I-OC
GSH NNP I-OC
) ) I-OC
during IN O
uncontrolled JJ O
stage NN O
of IN O
diabetes NNS O
indicated VBD O
free JJ O
radical JJ O
stress NN O
induced VBD O
lipid JJ O
peroxidation NN O
. . O

The DT O
significant JJ O
fall NN B-OC
of IN I-OC
MDA NNP I-OC
and CC I-OC
SOD NNP I-OC
and CC I-OC
increased VBD I-OC
levels NNS I-OC
of IN I-OC
GSH NNP I-OC
in IN I-OC
blood NN I-OC
in IN O
both DT O
groups NNS O
after IN O
control NN O
revealed VBD O
beneficial JJ O
effects NNS O
of IN O
glycemic JJ O
control NN O
on IN O
oxidative JJ B-OC
stress NN I-OC
. . O

The DT O
levels NNS O
were VBD O
not RB O
normalized VBN O
and CC O
stayed VBD O
higher JJR O
than IN O
those DT O
in IN O
controls NNS O
. . O

On IN O
intergroup JJ O
comparison NN O
; : O
the DT O
control NN O
of IN O
diabetes NNS O
with IN O
gliclazide NN B-INTV
( ( O
group NN O
II NNP O
) ) O
showed VBD O
improvement NN O
in IN O
oxidative JJ B-OC
stress NN I-OC
( ( I-OC
MDA NNP I-OC
, , I-OC
GSH NNP I-OC
) ) I-OC
better JJR O
( ( O
p JJ O
< NNP O
0.001 CD O
) ) O
than IN O
glibenclamide NN B-INTV
( ( O
group NN O
I PRP O
) ) O
. . O

CONCLUSION NNP O
Oxidative NNP B-OC
stress NN I-OC
in IN O
uncontrolled JJ O
diabetes NNS O
is VBZ O
decreased VBN O
with IN O
glycemic JJ O
control NN O
. . O

The DT O
control NN O
of IN O
diabetes NNS O
with IN O
gliclazide NN B-INTV
reduced VBN O
oxidative JJ B-OC
stress NN I-OC
more JJR O
than IN O
glibenclamide NN B-INTV
, , O
indicating VBG O
higher JJR O
antioxidant JJ O
properties NNS O
of IN O
gliclazide NN O
. . O

Normalization NN O
of IN O
oxidative JJ B-OC
stress NN I-OC
was VBD O
not RB O
achieved VBN O
. . O

Further JJ O
studies NNS O
are VBP O
required VBN O
to TO O
see VB O
long-term JJ O
effect NN O
of IN O
drug NN O
therapy NN O
in IN O
combating VBG O
oxidative JJ B-OC
stress NN I-OC
after IN O
achieving VBG O
acceptable JJ O
control NN O
of IN O
diabetes NNS O
. . O

-DOCSTART- -X- O O

Diet NNP B-INTV
and CC O
tobacco NN O
use NN O
: : O
analysis NN O
of IN O
data NNS O
from IN O
the DT O
diabetic JJ O
control NN O
and CC O
complications NNS O
trial NN O
, , O
a DT O
randomized VBN O
study NN O
. . O

CONTEXT NNP O
The DT O
Diabetic NNP O
Control NNP O
and CC O
Complications NNP O
Trial NNP O
( ( O
DCCT NNP O
) ) O
researchers NNS O
kept VBD O
careful JJ O
records NNS O
of IN O
the DT O
food NN O
consumption NN O
and CC O
tobacco NN O
using VBG O
habits NNS O
of IN B-POPU
type NN I-POPU
1 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
. . O

However RB O
, , O
they PRP O
did VBD O
not RB O
report VB O
the DT O
relationship NN O
of IN O
tobacco NN B-OC
using VBG I-OC
habits NNS I-OC
with IN O
dietary JJ B-OC
intake NN I-OC
. . O

OBJECTIVE NNP O
Analyze NNP O
the DT O
relationship NN B-OC
between IN I-OC
tobacco NN I-OC
smoking NN I-OC
and CC I-OC
intake NN B-INTV
of IN I-INTV
macro NN I-INTV
and CC I-INTV
micronutrients NNS I-INTV
. . O

DESIGN NNP O
Randomized NNP O
controlled VBD O
trial NN O
. . O

SETTING NNP O
Referral JJ B-POPU
clinics NNS I-POPU
in IN I-POPU
27 CD I-POPU
academic JJ I-POPU
centers NNS I-POPU
. . O

PATIENTS NNP B-POPU
Type NNP I-POPU
1 CD I-POPU
diabetics NNS I-POPU
. . O

INTERVENTION NNP O
Using VBG O
the DT O
data NNS B-INTV
sets NNS I-INTV
of IN I-INTV
the DT I-INTV
DCCT NNP I-INTV
, , O
this DT O
study NN O
analyzed VBD O
the DT O
strengths NNS O
of IN O
the DT O
associations NNS B-OC
between IN I-OC
smoking NN I-OC
and CC I-OC
macronutrient NN B-INTV
consumption NN I-INTV
, , B-OC
hemoglobin NN I-OC
A1c NNP I-OC
( ( I-OC
HbA1c NNP I-OC
) ) I-OC
, , I-OC
body JJ I-OC
mass NN I-OC
index NN I-OC
( ( I-OC
BMI NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
serum VB I-OC
lipid JJ I-OC
levels NNS I-OC
at IN O
the DT O
study NN O
baseline NN O
, , O
2 CD O
years NNS O
, , O
and CC O
4 CD O
years NNS O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Statistically NNP B-OC
significant JJ I-OC
correlations NNS I-OC
between IN I-OC
smoking NN I-OC
and CC I-OC
nutrient JJ I-OC
intake NN I-OC
, , I-OC
HbA1c NNP I-OC
, , I-OC
and CC I-OC
serum VB I-OC
lipid JJ I-OC
levels NNS I-OC
. . O

RESULTS NNP O
Cigarette NNP B-OC
, , I-OC
cigar NN I-OC
, , I-OC
or CC I-OC
pipe NN I-OC
use NN I-OC
at IN O
each DT O
time NN O
interval NN O
correlated VBD O
with IN O
significantly RB O
increased VBN O
caloric JJ B-OC
intake NN I-OC
in IN O
males NNS O
but CC O
not RB O
in IN O
females NNS O
. . O

In IN O
both DT O
males NNS B-POPU
and CC I-POPU
females NNS I-POPU
, , I-POPU
tobacco NN I-POPU
users NNS I-POPU
consumed VBD B-OC
more RBR I-OC
fat JJ I-OC
, , I-OC
cholesterol NN I-OC
, , I-OC
and CC I-OC
alcohol NN I-OC
. . O

Female JJ B-POPU
smokers NNS I-POPU
had VBD O
higher JJR O
serum JJ B-OC
low-density NN I-OC
lipoprotein NN I-OC
( ( I-OC
LDL NNP I-OC
) ) I-OC
/high-density NN I-OC
lipoprotein NN I-OC
( ( I-OC
HDL NNP I-OC
) ) I-OC
ratios NNS I-OC
and CC I-OC
triglycerides NNS I-OC
. . O

Serum NNP B-OC
cholesterols NNS I-OC
, , I-OC
LDL/HDL NNP I-OC
ratios NNS I-OC
, , I-OC
LDL NNP I-OC
cholesterols VBZ I-OC
, , I-OC
and CC I-OC
triglyceride JJ I-OC
determinations NNS I-OC
in IN O
male JJ B-POPU
tobacco NN I-POPU
users NNS I-POPU
significantly RB O
exceeded VBD O
those DT O
in IN O
nonsmoking JJ O
males NNS O
. . O

HDL NNP B-OC
cholesterols NNS I-OC
were VBD O
lower JJR O
in IN O
both DT O
female JJ B-POPU
and CC I-POPU
male JJ I-POPU
tobacco NN I-POPU
users NNS I-POPU
. . O

Nutrient NNP B-OC
intake NN I-OC
of IN O
former JJ B-POPU
tobacco NN I-POPU
users NNS I-POPU
resembled VBD O
that IN O
of IN O
nonusers NNS O
rather RB O
than IN O
current JJ O
users NNS O
. . O

CONCLUSIONS VB O
A NNP O
significant JJ O
association NN O
exists NNS O
between IN O
smoking NN O
and CC O
a DT O
diet JJ B-OC
with IN I-OC
higher JJR I-OC
risks NNS I-OC
of IN I-OC
atherosclerosis NN I-OC
, , I-OC
cancer NN I-OC
, , I-OC
and CC I-OC
other JJ I-OC
degenerative JJ I-OC
diseases NNS I-OC
. . O

The DT O
strong JJ O
association NN O
of IN O
tobacco NN O
with IN O
heart NN O
disease NN O
, , O
stroke NN O
, , O
vasculopathies NNS O
, , O
and CC O
various JJ O
malignancies NNS O
may MD O
be VB O
in IN O
part NN O
due JJ O
to TO O
its PRP$ O
association NN O
with IN O
a DT O
higher JJR O
fat JJ B-OC
diet NN O
. . O

The DT O
higher JJR O
fat JJ O
diet NNS O
of IN O
tobacco NN O
users NNS O
probably RB O
accounts NNS O
in IN O
part NN O
for IN O
their PRP$ O
higher JJR O
risk NN O
of IN O
developing VBG O
type JJ O
2 CD O
diabetes NNS O
and CC O
hyperlipidemia NN O
. . O

Tobacco NN O
users NNS O
should MD O
be VB O
informed VBN O
about IN O
the DT O
diet JJ B-OC
and CC I-OC
tobacco NN I-OC
use NN I-OC
association NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
intensive JJ B-INTV
therapy NN I-INTV
on IN O
the DT O
microvascular JJ B-POPU
complications NNS I-POPU
of IN I-POPU
type NN I-POPU
1 CD I-POPU
diabetes NNS I-POPU
mellitus RB I-POPU
. . O

The DT O
purpose NN O
of IN O
this DT O
report NN O
is VBZ O
to TO O
summarize VB O
and CC O
integrate VB O
the DT O
findings NNS O
of IN O
the DT O
Diabetes NNP O
Control NNP O
and CC O
Complications NNP O
Trial NNP O
( ( O
DCCT NNP O
) ) O
, , O
a DT O
randomized VBN O
controlled JJ O
clinical JJ O
trial NN O
, , O
and CC O
the DT O
succeeding JJ O
observational JJ O
follow-up NN O
of IN O
the DT O
DCCT NNP O
cohort NN O
in IN O
the DT O
Epidemiology NNP O
of IN O
Diabetes NNP O
Interventions NNP O
and CC O
Complications NNP O
( ( O
EDIC NNP O
) ) O
study NN O
, , O
regarding VBG O
the DT O
effects NNS O
of IN O
intensive JJ B-INTV
treatment NN I-INTV
on IN O
the DT O
microvascular JJ B-POPU
complications NNS I-POPU
of IN I-POPU
type NN I-POPU
1 CD I-POPU
diabetes NNS I-POPU
mellitus RB I-POPU
. . O

The DT O
DCCT NNP O
proved VBD O
that IN O
intensive JJ B-INTV
treatment NN I-INTV
reduced VBD O
the DT O
risks NNS O
of IN O
retinopathy NN B-OC
, , I-OC
nephropathy JJ I-OC
, , I-OC
and CC I-OC
neuropathy JJ I-OC
by IN O
35 CD O
% NN O
to TO O
90 CD O
% NN O
compared VBN O
with IN O
conventional JJ O
treatment NN O
. . O

The DT O
absolute JJ O
risks NNS O
of IN O
retinopathy NN B-OC
and CC O
nephropathy JJ B-OC
were VBD O
proportional JJ O
to TO O
the DT O
mean NN B-OC
glycosylated VBD I-OC
hemoglobin NN I-OC
( ( I-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
) ) I-OC
level NN I-OC
over IN O
the DT O
follow-up JJ O
period NN O
preceding VBG O
each DT O
event NN O
. . O

Intensive JJ B-INTV
treatment NN I-INTV
was VBD O
most RBS O
effective JJ O
when WRB O
begun VBN O
early RB O
, , O
before IN O
complications NNS O
were VBD O
detectable JJ O
. . O

These DT O
risk NN O
reductions NNS O
, , O
achieved VBN O
at IN O
a DT O
median JJ B-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
level NN I-OC
difference NN O
of IN O
9.1 CD O
% NN O
for IN O
conventional JJ O
treatment NN O
vs RB O
7.3 CD O
% NN O
for IN O
intensive JJ B-INTV
treatment NN I-INTV
have VBP O
been VBN O
maintained VBN O
through IN O
7 CD O
years NNS O
of IN O
EDIC NNP O
, , O
even RB O
though IN O
the DT O
difference NN B-OC
in IN I-OC
mean JJ I-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
levels NNS I-OC
of IN O
the DT O
2 CD O
former JJ O
randomized VBN O
treatment NN O
groups NNS O
was VBD O
only RB O
0.4 CD O
% NN O
at IN O
1 CD O
year NN O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
( ( O
8.3 CD O
% NN O
in IN O
the DT O
former JJ O
conventional JJ O
treatment NN O
group NN O
vs VBD O
7.9 CD O
% NN O
in IN O
the DT O
former JJ O
intensive JJ B-INTV
treatment NN I-INTV
group NN O
) ) O
, , O
continued VBD O
to TO O
narrow VB O
, , O
and CC O
became VBD O
statistically RB O
nonsignificant JJ O
by IN O
5 CD O
years NNS O
( ( O
8.1 CD O
% NN O
vs JJ O
8.2 CD O
% NN O
, , O
P NNP O
=.09 NNP O
) ) O
. . O

The DT O
further JJ O
rate NN B-OC
of IN I-OC
progression NN I-OC
of IN I-OC
complications NNS I-OC
from IN O
their PRP$ O
levels NNS O
at IN O
the DT O
end NN O
of IN O
the DT O
DCCT NNP O
remains VBZ O
less RBR O
in IN O
the DT O
former JJ O
intensive JJ B-INTV
treatment NN I-INTV
group NN O
. . O

Thus RB O
, , O
the DT O
benefits NNS O
of IN O
6.5 CD O
years NNS O
of IN O
intensive JJ B-INTV
treatment NN I-INTV
extend VBP O
well RB O
beyond IN O
the DT O
period NN O
of IN O
its PRP$ O
most RBS O
intensive JJ O
implementation NN O
. . O

Intensive JJ B-INTV
treatment NN I-INTV
should MD O
be VB O
started VBN O
as RB O
soon RB O
as IN O
is VBZ O
safely RB O
possible JJ O
after IN O
the DT O
onset NN O
of IN O
type NN B-POPU
1 CD I-POPU
diabetes NNS I-POPU
mellitus NN I-POPU
and CC O
maintained VBD O
thereafter RB O
, , O
aiming VBG O
for IN O
a DT O
practicable JJ O
target NN B-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
level NN I-OC
of IN O
7.0 CD O
% NN O
or CC O
less JJR O
. . O

-DOCSTART- -X- O O

Do VB O
colonic JJ O
short-chain NN O
fatty JJ O
acids NNS O
contribute NN O
to TO O
the DT O
long-term JJ B-OC
adaptation NN I-OC
of IN I-OC
blood NN I-OC
lipids NNS I-OC
in IN O
subjects NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
consuming VBG I-POPU
a DT I-POPU
high-fiber JJ I-POPU
diet NN I-POPU
? . O
BACKGROUND NNP O
We PRP O
recently RB O
obtained VBD O
evidence NN O
of IN O
long-term JJ B-OC
adaptation NN I-OC
of IN I-OC
blood NN I-OC
lipids NNS I-OC
to TO O
changes NNS O
in IN O
intakes NNS O
of IN O
carbohydrate NN B-INTV
and CC I-INTV
fiber NN I-INTV
in IN O
subjects NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

OBJECTIVE IN O
We PRP O
determined VBD O
the DT O
effect NN O
of IN O
increased JJ B-INTV
carbohydrate NN I-INTV
and CC I-INTV
fiber NN I-INTV
intakes NNS I-INTV
on IN O
serum JJ B-OC
short-chain JJ I-OC
fatty JJ I-OC
acids NNS I-OC
( ( I-OC
SCFAs NNP I-OC
) ) I-OC
and CC O
the DT O
relation NN B-OC
between IN I-OC
changes NNS I-OC
in IN I-OC
serum NN I-OC
acetate NN I-OC
and CC I-OC
changes NNS I-OC
in IN I-OC
blood NN I-OC
lipids NNS I-OC
. . O

DESIGN NNP O
Subjects VBZ B-POPU
with IN I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
62 CD I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
approximately RB O
10 CD O
% NN O
of IN O
energy NN B-INTV
from IN I-INTV
low-fiber JJ I-INTV
breakfast NN I-INTV
cereal NN I-INTV
( ( I-INTV
LF NNP I-INTV
diet NN I-INTV
) ) I-INTV
, , I-INTV
high-fiber JJ I-INTV
breakfast NN I-INTV
cereal NN I-INTV
( ( I-INTV
HF NNP I-INTV
diet NN I-INTV
) ) I-INTV
, , I-INTV
or CC I-INTV
monounsaturated VBN I-INTV
fatty JJ I-INTV
acids NNS I-INTV
( ( I-INTV
MUFA NNP I-INTV
diet NN I-INTV
) ) I-INTV
for IN O
6 CD O
mo NNS O
. . O

RESULTS NNP O
Carbohydrate NNP B-OC
intakes NNS I-OC
were VBD O
higher JJR O
in IN O
the DT O
LF NNP O
and CC O
HF NNP O
groups NNS O
than IN O
in IN O
the DT O
MUFA NNP O
group NN O
( ( O
54 CD O
% NN O
compared VBN O
with IN O
43 CD O
% NN O
) ) O
, , O
and CC O
more JJR O
fiber NN O
was VBD O
consumed VBN O
by IN O
the DT O
HF NNP O
group NN O
( ( O
approximately RB O
50 CD O
g/d NNS O
) ) O
than IN O
by IN O
the DT O
LF NNP O
or CC O
MUFA NNP O
group NN O
( ( O
approximately RB O
23 CD O
g/d NN O
) ) O
. . O

Fasting VBG B-OC
serum JJ I-OC
SCFAs NNP I-OC
did VBD O
not RB O
change VB O
significantly RB O
over IN O
the DT O
first JJ O
3 CD O
mo NN O
. . O

Between CC O
3 CD O
and CC O
6 CD O
mo NN O
, , O
serum JJ B-OC
acetate NN I-OC
tended VBD O
( ( O
NS NNP O
) ) O
to TO O
decrease VB O
in IN O
the DT O
LF NNP O
group NN O
( ( O
from IN O
69 CD O
+/- JJ O
4 CD O
to TO O
59 CD O
+/- JJ O
5 CD O
micromol/L NN O
) ) O
and CC O
increase VB O
in IN O
the DT O
HF NNP O
group NN O
( ( O
from IN O
100 CD O
+/- JJ O
18 CD O
to TO O
107 CD O
+/- JJ O
17 CD O
micromol/L NN O
) ) O
, , O
with IN O
no DT O
significant JJ O
change NN O
in IN O
the DT O
MUFA NNP O
group NN O
. . O

Serum NNP B-OC
butyrate NN I-OC
did VBD O
not RB O
change VB O
significantly RB O
in IN O
the DT O
LF NNP O
or CC O
MUFA NNP O
group NN O
but CC O
increased VBD O
in IN O
the DT O
HF NNP O
group NN O
( ( O
from IN O
2.5 CD O
+/- JJ O
0.5 CD O
to TO O
3.1 CD O
+/- JJ O
0.6 CD O
micromol/L NN O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

Changes NNS B-OC
in IN I-OC
serum NN I-OC
acetate NN I-OC
from IN O
0 CD O
to TO O
3 CD O
mo NNS O
were VBD O
not RB O
related VBN O
to TO O
changes NNS B-OC
in IN I-OC
lipids NNS I-OC
. . O

However RB O
, , O
changes NNS B-OC
in IN I-OC
serum NN I-OC
acetate NN I-OC
from IN O
3 CD O
to TO O
6 CD O
mo NNS O
were VBD O
positively RB O
related VBN O
to TO O
changes NNS B-OC
in IN I-OC
the DT I-OC
ratio NN I-OC
of IN I-OC
total JJ I-OC
to TO I-OC
HDL NNP I-OC
cholesterol NN I-OC
( ( O
P NNP O
= NNP O
0.041 CD O
) ) O
and CC O
in IN O
fasting NN O
( ( O
P NNP O
= NNP O
0.013 CD O
) ) O
and CC O
postprandial JJ B-OC
( ( I-OC
P NNP I-OC
= NNP I-OC
0.016 CD I-OC
) ) I-OC
triacylglycerols NNS I-OC
. . O

CONCLUSIONS NNP O
In IN O
subjects NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
, , O
changes NNS O
in IN O
serum NN B-OC
SCFAs NNP I-OC
in IN O
response NN O
to TO O
changes NNS O
in IN O
carbohydrate NN B-OC
and CC I-OC
fiber NN I-OC
intakes NNS I-OC
took VBD O
many JJ O
months NNS O
to TO O
occur VB O
, , O
and CC O
the DT O
changes NNS O
in IN O
serum NN B-OC
acetate NN I-OC
were VBD O
significantly RB O
related VBN O
to TO O
the DT O
long-term JJ B-OC
adaptive JJ I-OC
changes NNS I-OC
in IN I-OC
blood NN I-OC
lipids NNS I-OC
. . O

-DOCSTART- -X- O O

Impact NN O
of IN O
different JJ O
platelet NN O
glycoprotein NN O
IIb/IIIa NNP O
receptor NN O
inhibitors NNS O
among IN O
diabetic JJ B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
: : I-POPU
: : O
Do VB O
Tirofiban NNP O
and CC O
ReoPro NNP O
Give NNP O
Similar NNP O
Efficacy NNP O
Outcomes NNP O
Trial NNP O
( ( O
TARGET NNP O
) ) O
1-year JJ O
follow-up NN O
. . O

BACKGROUND IN O
The DT O
platelet NN O
glycoprotein NN O
IIb/IIIa NNP O
receptor NN O
inhibitor NN O
abciximab NN O
, , O
a DT O
monoclonal JJ O
antibody NN O
, , O
has VBZ O
been VBN O
shown VBN O
to TO O
improve VB O
early JJ O
and CC O
late JJ O
outcomes NNS O
among IN O
diabetic JJ B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

It PRP O
is VBZ O
unknown JJ O
whether IN O
small-molecule JJ O
agents NNS O
confer VBP O
similar JJ O
benefits NNS O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
In IN B-POPU
18 CD I-POPU
countries NNS I-POPU
, , I-POPU
4809 CD I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
PCI NNP I-POPU
with IN I-POPU
stent JJ I-POPU
implantation NN I-POPU
were VBD O
randomized VBN O
to TO O
tirofiban VB B-INTV
or CC I-INTV
abciximab VB I-INTV
. . O

At IN O
the DT O
time NN O
of IN O
enrollment NN O
, , O
patients NNS O
were VBD O
stratified VBN O
according VBG O
to TO O
diabetes NNS O
status NN O
. . O

As IN O
compared VBN O
with IN O
non-diabetic JJ O
patients NNS O
, , O
patients NNS O
with IN O
diabetes NNS O
( ( O
n=1117 NN O
) ) O
showed VBD O
similar JJ O
30-day JJ O
ischemic JJ O
outcomes NNS O
, , O
an DT O
increased JJ O
incidence NN B-OC
of IN I-OC
any DT I-OC
target NN I-OC
vessel NN I-OC
revascularization NN I-OC
( ( I-OC
TVR NNP I-OC
) ) I-OC
at IN O
6 CD O
months NNS O
( ( O
10.3 CD O
% NN O
versus IN O
7.8 CD O
% NN O
; : O
P= NNP O
0.008 CD O
) ) O
, , O
and CC O
a DT O
trend NN O
toward IN O
higher JJR B-OC
1-year JJ I-OC
mortality NN I-OC
( ( O
2.5 CD O
% NN O
versus IN O
1.6 CD O
% NN O
; : O
P=0.056 NNP O
) ) O
. . O

Among IN O
diabetic JJ O
patients NNS O
randomized VBN O
to TO O
tirofiban VB O
( ( O
n=560 NN O
) ) O
, , O
the DT O
incidence NN B-OC
of IN I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
MI NNP I-OC
) ) I-OC
, , I-OC
or CC I-OC
urgent JJ I-OC
TVR NNP I-OC
at IN O
30 CD O
days NNS O
was VBD O
6.2 CD O
% NN O
, , O
and CC O
among IN O
those DT O
randomized VBN O
to TO O
abciximab VB O
( ( O
n=557 NN O
) ) O
it PRP O
was VBD O
5.4 CD O
% NN O
( ( O
hazard JJ O
ratio NN O
[ NNP O
HR NNP O
] NNP O
1.16 CD O
; : O
P=0.540 NNP O
) ) O
. . O

At IN O
6 CD O
months NNS O
, , O
the DT O
composite NN O
of IN O
death NN B-OC
, , I-OC
MI NNP I-OC
, , I-OC
or CC I-OC
any DT I-OC
TVR NNP I-OC
occurred VBD O
in IN O
15.7 CD O
% NN O
and CC O
in IN O
16.9 CD O
% NN O
of IN O
tirofiban NN O
and CC O
abciximab NN O
patients NNS O
, , O
respectively RB O
( ( O
HR NNP O
0.93 CD O
; : O
P=0.610 NNP O
) ) O
. . O

Any DT O
TVR NNP B-OC
occurred VBD O
in IN O
9.5 CD O
% NN O
and CC O
11.1 CD O
% NN O
, , O
respectively RB O
( ( O
HR NNP O
0.84 CD O
; : O
P= NNP O
0.366 CD O
) ) O
. . O

The DT O
1-year JJ B-OC
mortality NN I-OC
was VBD O
2.1 CD O
% NN O
in IN O
the DT O
tirofiban NN O
group NN O
and CC O
2.9 CD O
% NN O
in IN O
the DT O
abciximab NN O
group NN O
( ( O
HR NNP O
0.74 CD O
; : O
P= NNP O
0.436 CD O
) ) O
. . O

CONCLUSIONS NNP O
Among IN O
diabetic JJ B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
PCI NNP I-POPU
, , O
tirofiban NN O
and CC O
abciximab NN O
were VBD O
associated VBN O
with IN O
comparable JJ O
event NN O
rates NNS O
, , O
including VBG O
similar JJ O
rates NNS O
of IN O
6-month JJ O
TVR NNP O
and CC O
1-year JJ O
mortality NN O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
the DT O
non-glycoprotein JJ O
IIb/IIIa NNP O
properties NNS O
of IN O
abciximab NNS O
do VBP O
not RB O
translate VB O
into IN O
a DT O
discernible JJ O
long-term JJ O
clinical JJ O
benefit NN O
among IN O
diabetic JJ B-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Double-blind JJ O
placebo-controlled JJ B-INTV
trial NN O
of IN O
aprindine NN B-INTV
and CC I-INTV
digoxin NN I-INTV
for IN O
the DT O
prevention NN B-OC
of IN I-OC
symptomatic JJ B-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
. . O

A DT O
multicenter NN O
, , O
placebo-controlled JJ B-INTV
, , O
randomized VBN O
, , O
double-blind JJ O
trial NN O
compared VBN O
the DT O
preventive JJ B-OC
effect NN I-OC
of IN O
aprindine NN B-INTV
and CC I-INTV
digoxin NN I-INTV
on IN O
the DT O
recurrence NN B-OC
of IN I-OC
atrial JJ B-POPU
fibrillation NN I-POPU
( ( I-POPU
AF NNP I-POPU
) ) I-POPU
with IN O
placebo NN B-INTV
, , O
and CC O
also RB O
compare VBP O
the DT O
effectiveness NN B-OC
of IN O
these DT O
2 CD O
drugs NNS O
in IN O
the DT O
prevention NN B-OC
of IN I-OC
AF NNP I-OC
. . O

Patients NNS B-POPU
with IN I-POPU
symptomatic JJ I-POPU
paroxysmal NN I-POPU
or CC I-POPU
persistent JJ I-POPU
AF NNP I-POPU
who WP I-POPU
had VBD I-POPU
converted VBN I-POPU
to TO I-POPU
sinus VB I-POPU
rhythm NN I-POPU
( ( I-POPU
SR NNP I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
aprindine NN B-INTV
( ( O
40 CD O
mg/day NN O
) ) O
, , O
digoxin NN B-INTV
( ( O
0.25 CD O
mg/day NN O
) ) O
or CC B-INTV
placebo NN I-INTV
and CC O
followed VBD O
up RP O
on IN O
an DT O
outpatient JJ O
basis NN O
every DT O
2 CD O
weeks NNS O
for IN O
6 CD O
months NNS O
. . O

Of IN B-POPU
the DT I-POPU
141 CD I-POPU
patients NNS I-POPU
from IN I-POPU
36 CD I-POPU
participating VBG I-POPU
centers NNS I-POPU
, , I-POPU
47 CD I-POPU
were VBD I-POPU
given VBN I-POPU
aprindine NN I-POPU
, , I-POPU
47 CD I-POPU
digoxin NN I-POPU
, , I-POPU
and CC I-POPU
47 CD I-POPU
were VBD I-POPU
on IN I-POPU
placebo NN I-POPU
. . O

After IN O
the DT O
6-month JJ O
follow-up NN O
, , O
the DT O
Kaplan-Meier NNP B-OC
estimates NNS O
of IN O
the DT O
percentage NN O
of IN O
patients NNS O
remaining VBG O
free JJ O
of IN O
recurrent JJ B-OC
symptomatic JJ I-OC
AF NNP I-OC
on IN O
aprindine NN B-INTV
, , I-INTV
digoxin NN I-INTV
and CC O
placebo NN B-INTV
were VBD O
33.3 CD O
% NN O
, , O
29.2 CD O
% NN O
and CC O
21.5 CD O
% NN O
, , O
respectively RB O
. . O

In IN O
patients NNS O
remaining VBG O
in IN O
SR NNP O
for IN O
15 CD O
days NNS O
after IN O
from IN O
the DT O
start NN O
of IN O
follow-up NN O
, , O
freedom NN B-OC
from IN I-OC
recurrence NN I-OC
was VBD O
significantly RB O
more RBR O
prevalent JJ B-OC
in IN O
the DT O
aprindine NN O
group NN O
than IN O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
p=0.0414 NN O
) ) O
, , O
but CC O
there EX O
was VBD O
no DT O
significant JJ B-OC
difference NN I-OC
between IN O
the DT O
digoxin NN O
and CC O
placebo NN O
groups NNS O
. . O

The DT O
rate NN B-OC
of IN I-OC
adverse JJ I-OC
events NNS I-OC
was VBD O
similar JJ O
in IN O
the DT O
3 CD O
groups NNS O
. . O

In IN O
conclusion NN O
, , O
neither CC O
aprindine JJ O
nor CC O
digoxin NN B-INTV
had VBD O
a DT O
significant JJ B-OC
effect NN I-OC
on IN O
preventing VBG B-OC
relapse NN I-OC
of IN I-OC
symptomatic JJ I-OC
AF NNP I-OC
; : I-OC
however RB O
, , O
recurrence NN B-OC
of IN I-OC
AF NNP I-OC
occurred VBD O
later RBR B-OC
with IN O
aprindine NN B-INTV
than IN O
with IN O
placebo NN B-INTV
or CC O
digoxin NN B-INTV
. . O

-DOCSTART- -X- O O

Multifaceted VBN B-INTV
support NN I-INTV
to TO O
improve VB O
clinical JJ O
decision NN O
making NN O
in IN O
diabetes NNS O
care NN O
: : O
a DT O
randomized NN O
controlled VBN O
trial NN O
in IN O
general JJ O
practice NN O
. . O

AIMS NNP O
To TO O
evaluate VB O
the DT O
effectiveness NN O
of IN O
a DT O
multifaceted VBN B-INTV
intervention NN I-INTV
to TO O
improve VB O
the DT O
clinical JJ O
decision NN O
making NN O
of IN O
general JJ B-POPU
practitioners NNS I-POPU
( ( I-POPU
GPs NNP I-POPU
) ) I-POPU
for IN I-POPU
patients NNS I-POPU
with IN I-POPU
diabetes NNS I-POPU
. . O

To TO O
identify VB O
practice NN O
characteristics NNS O
which WDT O
predict VBP O
success NN O
. . O

METHODS NNP O
Cluster NNP B-POPU
randomized VBD I-POPU
controlled VBN I-POPU
trial NN I-POPU
with IN I-POPU
124 CD I-POPU
practices NNS I-POPU
and CC I-POPU
185 CD I-POPU
GPs NNP I-POPU
in IN I-POPU
The DT I-POPU
Netherlands NNP I-POPU
. . O

The DT B-INTV
intervention NN I-INTV
group NN I-INTV
received VBD I-INTV
feedback JJ I-INTV
reports NNS I-INTV
and CC I-INTV
support NN I-INTV
from IN I-INTV
a DT I-INTV
facilitator NN I-INTV
; : I-INTV
the DT I-INTV
control NN I-INTV
group NN I-INTV
received VBD I-INTV
no DT I-INTV
special JJ I-INTV
attention NN I-INTV
. . O

Outcome JJ B-INTV
measures NNS I-INTV
were VBD I-INTV
the DT I-INTV
compliance NN I-INTV
rates NNS I-INTV
with IN I-INTV
evidence-based JJ I-INTV
recommendations NNS I-INTV
pertaining VBG I-INTV
to TO I-INTV
discussion NN I-INTV
of IN I-INTV
body NN I-INTV
weight NN I-INTV
control NN I-INTV
, , I-INTV
discussion NN I-INTV
of IN I-INTV
problems NNS I-INTV
with IN I-INTV
medication NN I-INTV
, , I-INTV
blood NN I-INTV
pressure NN I-INTV
measurement NN I-INTV
, , I-INTV
foot NN I-INTV
examination NN I-INTV
, , I-INTV
eye NN I-INTV
examination NN I-INTV
, , I-INTV
initiating VBG I-INTV
anti-diabetic JJ I-INTV
medication NN I-INTV
or CC I-INTV
increasing VBG I-INTV
the DT I-INTV
dosage NN I-INTV
in IN I-INTV
cases NNS I-INTV
of IN I-INTV
uncontrolled JJ I-INTV
blood NN I-INTV
glucose NN I-INTV
, , I-INTV
and CC I-INTV
scheduling VBG I-INTV
a DT I-INTV
follow-up JJ I-INTV
appointment NN I-INTV
. . O

RESULTS VB O
The DT O
GPs NNP O
reported VBD O
on IN O
their PRP$ O
clinical JJ O
decision NN O
making NN O
in IN O
1410 CD B-POPU
consultations NNS I-POPU
with IN I-POPU
Type NNP I-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
at IN I-POPU
baseline NN I-POPU
and CC I-POPU
1449 CD I-POPU
consultations NNS I-POPU
after IN O
the DT O
intervention NN O
period NN O
. . O

The DT O
intervention NN O
resulted VBD O
in IN O
statistically RB O
significant JJ O
improvement NN O
for IN O
two CD O
of IN O
the DT O
seven CD O
outcome JJ O
measures NNS O
: : O
foot NN B-OC
examination NN I-OC
( ( O
odds NNS O
ratio VBP O
1.68 CD O
; : O
95 CD O
% NN O
confidence NN O
interval JJ O
1.19-2.39 JJ O
) ) O
and CC O
eye NN O
examination NN B-OC
( ( O
1.52 CD O
; : O
1.07-2.16 JJ O
) ) O
. . O

Discussion NN B-OC
of IN I-OC
problems NNS I-OC
with IN I-OC
medication NN I-OC
showed VBD O
a DT O
near JJ O
significant JJ O
trend NN O
towards NNS O
increased VBD O
benefit NN O
for IN O
the DT O
intervention NN O
group NN O
( ( O
1.52 CD O
; : O
0.99-2.32 JJ O
) ) O
. . O

Practice NNP B-OC
characteristics NNS I-OC
were VBD O
not RB O
found VBN O
to TO O
be VB O
related VBN O
to TO O
the DT O
success NN O
of IN O
the DT O
intervention NN O
. . O

CONCLUSIONS NNP O
Feedback NNP O
reports NNS O
with IN O
support NN O
from IN O
facilitators NNS O
appear VBP O
to TO O
increase VB O
rates NNS O
of IN O
foot NN B-OC
examination NN I-OC
and CC I-OC
eye NN I-OC
examination NN I-OC
in IN O
general JJ O
practice NN O
. . O

Alternative JJ O
interventions NNS O
should MD O
be VB O
explored VBN O
to TO O
improve VB O
the DT O
pursuit NN O
of IN O
metabolic JJ O
control NN O
by IN O
GPs NNP O
. . O

-DOCSTART- -X- O O

A DT O
randomized JJ O
trial NN O
of IN O
continuous JJ O
subcutaneous JJ O
insulin NN B-INTV
infusion NN O
and CC O
intensive JJ O
injection NN O
therapy NN O
in IN O
type NN B-POPU
1 CD I-POPU
diabetes NNS I-POPU
for IN I-POPU
patients NNS I-POPU
with IN I-POPU
long-standing JJ I-POPU
poor JJ I-POPU
glycemic JJ I-POPU
control NN I-POPU
. . O

OBJECTIVE NNP O
To TO O
assess VB O
in IN O
a DT O
randomized JJ O
crossover NN O
trial NN O
the DT O
efficacy NN O
of IN O
continuous JJ O
subcutaneous JJ O
insulin NN O
infusion NN O
in IN O
improving VBG O
glycemic JJ B-OC
control NN I-OC
and CC I-OC
health-related JJ I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN O
type JJ B-POPU
1 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
long-standing JJ I-POPU
poor JJ I-POPU
glycemic JJ I-POPU
control NN I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
79 CD I-POPU
patients NNS I-POPU
in IN I-POPU
11 CD I-POPU
Dutch NN I-POPU
centers NNS I-POPU
were VBD O
randomized VBN O
to TO O
16 CD O
weeks NNS O
of IN O
continuous JJ B-INTV
subcutaneous JJ I-INTV
insulin NN I-INTV
infusion NN I-INTV
followed VBN I-INTV
by IN I-INTV
16 CD I-INTV
weeks NNS I-INTV
intensive JJ I-INTV
injection NN I-INTV
therapy NN I-INTV
or CC I-INTV
the DT I-INTV
reverse JJ I-INTV
order NN I-INTV
. . O

Glycemic NNP O
control NN O
was VBD O
assessed VBN O
by IN O
HbA NNP O
( ( O
1c CD O
) ) O
, , O
self-reported JJ O
hypoglycemic JJ O
events NNS O
, , O
and CC O
blood NN O
glucose JJ O
memory NN O
meter NN O
read VBD O
outs NNS O
. . O

Changes NNS O
in IN O
quality NN B-OC
of IN I-OC
life NN I-OC
were VBD O
assessed VBN O
by IN O
self-report JJ O
questionnaires NNS O
administered VBN O
at IN O
baseline NN O
and CC O
16 CD O
weeks NNS O
. . O

RESULTS NNP O
As IN O
the DT O
drop-out NN O
rate NN O
after IN O
crossover NN O
was VBD O
high JJ O
( ( O
17 CD O
of IN O
79 CD O
patients NNS O
[ JJ O
22 CD O
% NN O
] NN O
) ) O
, , O
we PRP O
analyzed VBD O
the DT O
trial NN O
as IN O
a DT O
parallel JJ O
clinical JJ O
trial NN O
, , O
using VBG O
data NNS O
of IN O
the DT O
first JJ O
half NN O
of IN O
the DT O
crossover NN O
phase NN O
only RB O
. . O

At IN O
16 CD O
weeks NNS O
, , O
mean JJ B-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
was VBD O
0.84 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
-1.31 NNP O
to TO O
-0.36 VB O
) ) O
lower JJR O
in IN O
the DT O
continuous JJ O
subcutaneous JJ O
insulin NN O
infusion NN O
group NN O
compared VBN O
with IN O
the DT O
insulin NN B-INTV
injection NN O
group NN O
( ( O
P NNP O
= NNP O
0.002 CD O
) ) O
. . O

Stability NN B-OC
of IN I-OC
blood NN I-OC
glucose JJ I-OC
self-measurement JJ I-OC
values NNS I-OC
, , O
expressed VBD O
as IN O
SD NNP O
of IN O
the DT O
nine-point JJ O
blood NN O
glucose NN O
profiles NNS O
, , O
improved VBN O
in IN O
the DT O
insulin NN O
pump NN O
group NN O
by IN O
29.3 CD O
+/- JJ O
41.1 CD O
vs. FW O
8.2 CD O
+/- JJ O
36.5 CD O
% NN O
in IN O
the DT O
injection NN O
group NN O
( ( O
P NNP O
= NNP O
0.039 CD O
) ) O
. . O

The DT O
number NN B-OC
of IN I-OC
mild JJ I-OC
hypoglycemic JJ I-OC
episodes NNS I-OC
per IN O
patient-week NN O
was VBD O
0.99 CD O
( ( O
95 CD O
% NN O
CI NNP O
0.11-1.87 NN O
) ) O
higher JJR O
in IN O
the DT O
insulin NN O
pump NN O
group NN O
( ( O
P NNP O
= NNP O
0.028 CD O
) ) O
. . O

Weight NNP B-OC
gain NN I-OC
was VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O

Scores NNS B-OC
on IN I-OC
the DT I-OC
Short-Form JJ I-OC
36-Item JJ I-OC
subscales NNS I-OC
'general POS I-OC
health NN I-OC
' '' I-OC
and CC I-OC
'mental JJ I-OC
health NN I-OC
' '' I-OC
improved VBN O
in IN O
the DT O
continuous JJ O
subcutaneous JJ O
insulin NN O
infusion NN O
group NN O
, , O
compared VBN O
with IN O
stable JJ O
values NNS O
in IN O
the DT O
injection NN O
group NN O
( ( O
P NNP O
= NNP O
0.048 CD O
and CC O
0.050 CD O
, , O
respectively RB O
) ) O
. . O

CONCLUSIONS NNP O
Continuous NNP O
subcutaneous JJ O
insulin NN B-INTV
infusion NN O
improves VBZ O
glycemic JJ O
control NN O
and CC O
some DT O
aspects NNS O
of IN O
health-related JJ O
quality NN O
of IN O
life NN O
in IN O
patients NNS B-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
long-term JJ I-POPU
poor JJ I-POPU
glycemic JJ I-POPU
control NN I-POPU
. . O

-DOCSTART- -X- O O

[ VB O
The DT O
effect NN O
of IN O
losartan JJ B-INTV
versus NN I-INTV
atenolol NN I-INTV
on IN O
cardiovascular JJ B-OC
morbidity NN I-OC
and CC I-OC
mortality NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus NNS I-POPU
in IN I-POPU
the DT I-POPU
LIFE-study NNP I-POPU
] NNP I-POPU
. . O

INTRODUCTION NNP O
The DT O
most RBS O
suitable JJ O
antihypertensive JJ O
drug NN O
to TO O
reduce VB O
the DT O
risk NN O
of IN O
cardiovascular JJ O
disease NN O
in IN O
patients NNS B-POPU
with IN I-POPU
hypertension NN I-POPU
and CC I-POPU
diabetes VBZ I-POPU
is VBZ O
unclear JJ O
. . O

In IN O
a DT O
prespecified JJ O
analysis NN O
of IN O
the DT O
LIFE-study NNP O
we PRP O
compared VBN O
the DT O
effects NNS O
of IN O
losartan NN B-INTV
and CC I-INTV
atenolol NN I-INTV
on IN O
cardiovascular JJ B-OC
morbidity NN I-OC
and CC I-OC
mortality NN I-OC
in IN O
diabetic JJ B-POPU
patients NNS I-POPU
. . O

MATERIAL NNP O
AND NNP O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
1195 CD I-POPU
patients NNS I-POPU
in IN I-POPU
the DT I-POPU
LIFE-study NNP I-POPU
had VBD I-POPU
diabetes NNS I-POPU
at IN O
the DT O
time NN O
of IN O
the DT O
randomisation NN O
. . O

The DT O
patients NNS O
were VBD O
randomised VBN O
for IN O
double-blind JJ O
treatment NN O
with IN O
losartan JJ B-INTV
versus NN I-INTV
atenolol NN I-INTV
. . O

The DT O
patients NNS B-POPU
had VBD I-POPU
ECG-verified JJ I-POPU
left JJ I-POPU
ventricular NN I-POPU
hypertrophy NN I-POPU
, , I-POPU
mean JJ I-POPU
age NN I-POPU
67 CD I-POPU
years NNS I-POPU
, , I-POPU
blood NN I-POPU
pressure NN I-POPU
177/96 CD I-POPU
mmHg NN I-POPU
after IN I-POPU
two CD I-POPU
weeks NNS I-POPU
placebo JJ I-POPU
run-in JJ I-POPU
period NN I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
at IN I-POPU
least JJS I-POPU
four CD I-POPU
years NNS I-POPU
( ( I-POPU
mean JJ I-POPU
4.7 CD I-POPU
years NNS I-POPU
) ) I-POPU
. . O

The DT O
primary JJ O
composite JJ O
endpoint NN O
was VBD O
cardiovascular JJ B-OC
death NN I-OC
, , I-OC
stroke VBD I-OC
or CC I-OC
myocardial JJ I-OC
infarction NN I-OC
. . O

RESULTS NNP O
Blood NNP B-OC
pressure NN I-OC
was VBD O
reduced VBN O
to TO O
146/79 CD O
and CC O
148/79 CD O
in IN O
losartan-treated JJ B-INTV
patients NNS O
and CC O
atenolol-treated JJ B-INTV
patients NNS O
, , O
respectively RB O
. . O

The DT O
primary JJ O
endpoint NN O
occurred VBD O
in IN O
103 CD O
patients NNS O
assigned VBN O
losartan JJ B-INTV
( ( O
n JJ O
= NNP O
586 CD O
) ) O
and CC O
139 CD O
assigned VBN O
atenolol NN B-INTV
( ( O
n JJ O
= NNP O
609 CD O
) ) O
. . O

Relative JJ B-OC
risk NN I-OC
reduction NN I-OC
24 CD O
% NN O
( ( O
p JJ O
< NNP O
0.031 CD O
) ) O
. . O

Cardiovascular JJ B-OC
mortality NN I-OC
was VBD O
reduced VBN O
by IN O
37 CD O
% NN O
in IN O
favour NN O
of IN O
losartan NN B-INTV
( ( O
p JJ O
< NNP O
0.028 CD O
) ) O
, , O
and CC O
all DT O
cause NN O
mortality NN B-OC
by IN O
39 CD O
% NN O
( ( O
p JJ O
< NNP O
0.002 CD O
) ) O
. . O

DISCUSSION NNP O
Losartan NNP B-INTV
was VBD O
very RB O
effective JJ O
in IN O
reducing VBG O
cardiovascular JJ B-OC
morbidity NN I-OC
and CC I-OC
mortality NN I-OC
as RB O
compared VBN O
to TO O
atenolol VB B-INTV
. . O

These DT O
results NNS O
will MD O
have VB O
a DT O
major JJ O
impact NN O
on IN O
the DT O
choice NN O
of IN O
anti-hypertensive JJ O
treatment NN O
for IN O
patients NNS B-POPU
with IN I-POPU
hypertension NN I-POPU
and CC I-POPU
diabetes NNS I-POPU
. . O

-DOCSTART- -X- O O

Clonidine NNP B-INTV
premedication NN O
improves VBZ O
metabolic JJ B-OC
control NN I-OC
in IN I-OC
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
during IN I-POPU
ophthalmic JJ I-POPU
surgery NN I-POPU
. . O

BACKGROUND NNP O
In IN O
stressful JJ O
conditions NNS O
, , O
increasing VBG O
blood NN O
glucose NN O
concentrations NNS O
are VBP O
closely RB O
related VBN O
to TO O
an DT O
increase NN O
in IN O
catecholamines NNS O
and CC O
cortisol NN O
release NN O
. . O

Clonidine NNP O
, , O
a DT O
centrally RB O
acting VBG O
alpha NN O
( ( O
2 CD O
) ) O
-adrenoceptor NN O
agonist NN O
, , O
has VBZ O
neuroendocrine JJ O
effects NNS O
, , O
including VBG O
inhibition NN O
of IN O
sympathoadrenal JJ O
activity NN O
. . O

We PRP O
therefore RB O
evaluated VBD O
the DT O
effect NN O
of IN O
clonidine NN B-INTV
on IN O
blood NN B-OC
glucose NN I-OC
control NN I-OC
and CC O
insulin NN B-OC
requirements NNS I-OC
during IN O
ophthalmic JJ O
surgery NN O
when WRB O
given VBN O
as IN O
premedication NN O
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
. . O

METHODS NNP O
After IN O
randomization NN O
, , O
patients NNS O
were VBD O
premedicated VBN O
with IN O
clonidine NN B-INTV
or CC I-INTV
flunitrazepam NN I-INTV
( ( O
control NN O
) ) O
. . O

Patients NNPS O
were VBD O
given VBN O
insulin NN B-INTV
by IN O
continuous JJ O
i.v NN O
. . O

infusion NN O
to TO O
maintain VB O
blood NN O
glucose NN O
in IN O
the DT O
range NN O
5.5-11.1 JJ O
mmol NN O
litre NN O
( ( O
-1 NNP O
) ) O
. . O

Blood NNP B-OC
glucose JJ I-OC
concentrations NNS I-OC
were VBD O
measured VBN O
every DT O
15 CD O
min NN O
during IN O
surgery NN O
, , O
and CC O
hourly RB O
for IN O
6 CD O
h NN O
after IN O
surgery NN O
. . O

Plasma NNP B-OC
C-peptide JJ I-OC
and CC I-OC
counter-regulatory JJ I-OC
hormones NNS I-OC
were VBD O
also RB O
measured VBN O
. . O

RESULTS NNP O
Glycaemia NNP B-OC
was VBD O
significantly RB O
lower JJR O
in IN O
the DT O
clonidine NN O
group NN O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
and CC O
the DT O
median JJ B-OC
amount NN I-OC
of IN I-OC
insulin NN I-OC
administered VBN I-OC
was VBD O
significantly RB O
reduced VBN O
: : O
clonidine NN O
group NN O
9.0 CD O
( ( O
interquartile JJ O
range NN O
5.1 CD O
) ) O
units NNS O
; : O
control VB O
18.6 CD O
( ( O
10.2 CD O
) ) O
units NNS O
; : O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

Plasma NNP B-OC
catecholamine JJ I-OC
concentrations NNS I-OC
were VBD O
lower JJR O
in IN O
patients NNS O
given VBN O
clonidine NN B-INTV
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
but CC O
there EX O
was VBD O
no DT O
difference NN O
in IN O
cortisol JJ B-OC
concentrations NNS I-OC
. . O

CONCLUSION NNP O
Premedication NNP O
of IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN O
clonidine JJ B-INTV
90 CD O
min NN O
before IN O
surgery NN O
improves VBZ O
blood NN B-OC
glucose VB I-OC
control NN I-OC
and CC O
decreases VBZ O
insulin NN B-OC
requirements NNS I-OC
during IN O
ophthalmic JJ O
surgery NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
2 CD O
weeks NNS O
of IN O
theophylline NN O
on IN O
glucose JJ B-OC
counterregulation NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
and CC I-POPU
unawareness NN I-POPU
of IN I-POPU
hypoglycemia NN I-POPU
. . O

BACKGROUND NNP O
AND NNP O
OBJECTIVE NNP O
A NNP O
single JJ O
dose NN O
of IN O
theophylline JJ O
improves NNS O
hypoglycemia NN O
unawareness NN O
in IN O
type NN B-POPU
1 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
. . O

Prolonged NNP O
theophylline NN O
use NN O
is VBZ O
, , O
however RB O
, , O
associated VBN O
with IN O
emergence NN O
of IN O
tolerance NN O
. . O

This DT O
study NN O
investigated VBD O
whether IN O
prolonged JJ O
use NN O
of IN O
theophylline NN O
retains NNS O
efficacy VBP O
for IN O
counterregulatory NN B-OC
defects NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
and CC I-POPU
hypoglycemia NN I-POPU
unawareness NN I-POPU
. . O

METHODS JJ O
Experiments NNS O
were VBD O
performed VBN O
with IN O
12 CD B-POPU
subjects NNS I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
and CC I-POPU
hypoglycemia NN I-POPU
unawareness NN I-POPU
. . O

All DT O
subjects NNS B-POPU
participated VBN O
in IN O
a DT O
crossover NN O
study NN O
of IN O
2 CD O
randomly NNS O
scheduled VBN O
15-day JJ B-INTV
study NN I-INTV
periods NNS I-INTV
during IN I-INTV
which WDT I-INTV
250 CD I-INTV
mg NN I-INTV
theophylline NN I-INTV
twice RB I-INTV
daily RB I-INTV
or CC I-INTV
matching VBG I-INTV
placebo NN I-INTV
was VBD I-INTV
used VBN I-INTV
. . O

On IN B-INTV
the DT I-INTV
final JJ I-INTV
day NN I-INTV
of IN I-INTV
each DT I-INTV
period NN I-INTV
, , I-INTV
hyperinsulinemic JJ I-INTV
( ( I-INTV
360 CD I-INTV
pmol NN I-INTV
x NNP I-INTV
m NN I-INTV
( ( I-INTV
-2 NNP I-INTV
) ) I-INTV
x VBP I-INTV
min NN I-INTV
( ( I-INTV
-1 NNP I-INTV
) ) I-INTV
) ) I-INTV
hypoglycemic NN I-INTV
( ( I-INTV
5.0 CD I-INTV
, , I-INTV
3.5 CD I-INTV
, , I-INTV
2.5 CD I-INTV
mmol NN I-INTV
x NN I-INTV
L NNP I-INTV
( ( I-INTV
-1 NNP I-INTV
) ) I-INTV
) ) I-INTV
glucose VBP I-INTV
clamps NNS I-INTV
were VBD I-INTV
used VBN I-INTV
to TO I-INTV
assess VB I-INTV
counterregulatory NN I-INTV
and CC I-INTV
cardiovascular JJ I-INTV
responses NNS I-INTV
. . O

RESULTS NNP O
Under IN O
normoglycemic JJ O
conditions NNS O
, , O
there EX O
were VBD O
no DT O
differences NNS O
between IN O
theophylline NN O
and CC O
placebo NN O
. . O

Under IN O
hypoglycemic JJ O
conditions NNS O
, , O
theophylline NN O
enhanced VBD O
responses NNS O
of IN O
growth NN B-OC
hormone NN I-OC
, , I-OC
symptoms NNS I-OC
, , I-OC
heart NN I-OC
rate NN I-OC
, , I-OC
and CC I-OC
pulse JJ I-OC
pressure NN I-OC
( ( O
all DT O
P NNP O
< NNP O
.05 NNP O
) ) O
, , O
induced VBD B-OC
sweating VBG I-OC
at IN I-OC
higher JJR I-OC
plasma NN I-OC
glucose NN I-OC
levels NNS I-OC
( ( O
P NNP O
=.039 NNP O
) ) O
, , O
and CC O
reduced VBD B-OC
exogenous JJ I-OC
glucose NN I-OC
requirements NNS I-OC
( ( O
P NNP O
=.018 NNP O
) ) O
. . O

Hypoglycemia-induced JJ O
responses NNS O
of IN O
epinephrine NN O
, , O
norepinephrine NN O
, , O
and CC O
cortisol NNS O
were VBD O
not RB O
enhanced VBN O
by IN O
theophylline NN O
. . O

CONCLUSIONS NNP O
Prolonged NNP O
use NN O
of IN O
theophylline NN O
has VBZ O
a DT O
sustained VBN O
effect NN O
on IN O
cardiovascular NN B-OC
, , I-OC
metabolic NN I-OC
, , I-OC
and CC I-OC
symptom JJ I-OC
responses NNS I-OC
to TO O
hypoglycemia VB O
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
and CC I-POPU
hypoglycemia NN I-POPU
unawareness NN I-POPU
. . O

Whether IN O
these DT O
results NNS O
translate VBP O
into IN O
clinical JJ O
benefit NN O
remains VBZ O
to TO O
be VB O
determined VBN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
pentoxifylline JJ B-INTV
administration NN O
on IN O
urinary JJ O
N-acetyl-beta-glucosaminidase JJ O
excretion NN O
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
: : I-POPU
a DT O
short-term JJ O
, , O
prospective JJ O
, , O
randomized VBN O
study NN O
. . O

BACKGROUND NNP O
Tubulointerstitial NNP O
injury NN O
is VBZ O
a DT O
major JJ O
feature NN O
of IN O
diabetic JJ O
nephropathy NN O
and CC O
an DT O
important JJ O
predictor NN O
of IN O
renal JJ O
dysfunction NN O
. . O

In IN O
45 CD B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus FW I-POPU
( ( I-POPU
DM NNP I-POPU
) ) I-POPU
, , O
we PRP O
prospectively RB O
analyzed VBD O
urinary JJ O
excretion NN O
of IN O
N-acetyl-beta-glucosaminidase NNP O
( ( O
NAG NNP O
) ) O
, , O
a DT O
marker NN O
of IN O
tubular JJ O
renal JJ O
damage NN O
; : O
the DT O
potential JJ O
relationship NN O
with IN O
urinary JJ O
protein NN O
excretion NN O
; : O
and CC O
effects NNS O
of IN O
pentoxifylline NN B-INTV
( ( I-INTV
PTF NNP I-INTV
) ) I-INTV
administration NN O
. . O

METHODS NNP O
Forty-five JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
DM NNP I-POPU
initially RB I-POPU
were VBD I-POPU
compared VBN I-POPU
with IN I-POPU
15 CD I-POPU
healthy JJ I-POPU
controls NNS I-POPU
matched VBN I-POPU
for IN I-POPU
age NN I-POPU
and CC I-POPU
sex NN I-POPU
. . O

After IN O
randomization NN O
, , O
PTF NNP B-INTV
( ( O
1,200 CD O
mg/d NN O
) ) O
was VBD O
administered VBN O
for IN O
4 CD O
months NNS O
to TO O
30 CD O
patients NNS O
and CC O
results NNS O
were VBD O
compared VBN O
with IN O
data NNS O
from IN O
a DT O
control NN O
group NN O
( ( O
n JJ O
= NNP O
15 CD O
) ) O
. . O

RESULTS NNP O
Proteinuria NNP B-OC
and CC I-OC
urinary JJ I-OC
NAG NNP I-OC
excretion NN I-OC
were VBD O
significantly RB O
greater JJR O
in IN O
patients NNS O
with IN O
DM NNP O
with IN O
respect NN O
to TO O
healthy JJ O
controls NNS O
. . O

Before IN O
PTF NNP O
administration NN O
, , O
baseline JJ O
parameters NNS O
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
of IN O
patients NNS O
with IN O
DM NNP O
. . O

At IN O
the DT O
end NN O
of IN O
the DT O
study NN O
, , O
urinary JJ B-OC
protein NN I-OC
excretion NN I-OC
and CC I-OC
NAG-creatinine JJ I-OC
ratios NNS I-OC
decreased VBN O
in IN O
the DT O
active JJ O
group NN O
from IN O
920 CD O
+/- JJ O
522 CD O
mg/d NN O
and CC O
14.3 CD O
+/- JJ O
16.9 CD O
U/g NNP O
to TO O
803 CD O
+/- JJ O
523 CD O
mg/d NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
and CC O
10.5 CD O
+/- JJ O
9.3 CD O
U/g NNP O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
, , O
respectively RB O
. . O

Conversely RB O
, , O
proteinuria NNS B-OC
and CC I-OC
urinary JJ I-OC
NAG NNP I-OC
excretion NN I-OC
did VBD O
not RB O
change VB O
in IN O
the DT O
control NN B-INTV
group NN O
. . O

Regression NN O
analysis NN O
showed VBD O
that IN O
urinary JJ B-OC
NAG NNP I-OC
excretion NN I-OC
was VBD O
significantly RB O
associated VBN O
with IN O
duration NN B-OC
of IN I-OC
DM NNP I-OC
( ( O
r VB O
= RB O
0.61 CD O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
and CC O
proteinuria NN B-OC
( ( O
r JJ O
= VBZ O
0.51 CD O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

CONCLUSION NNP O
Urinary NNP B-OC
NAG NNP I-OC
excretion NN I-OC
is VBZ O
elevated VBN O
in IN O
patients NNS O
with IN O
type JJ B-POPU
2 CD I-POPU
DM NNP I-POPU
compared VBN O
with IN O
healthy JJ B-POPU
individuals NNS I-POPU
and CC O
increases NNS O
as IN O
nephropathy JJ O
progresses NNS O
. . O

PTF NNP B-INTV
administration NN O
is VBZ O
effective JJ O
in IN O
reducing VBG O
proteinuria NN B-OC
and CC I-OC
urinary JJ I-OC
NAG NNP I-OC
excretion NN I-OC
in IN O
these DT O
patients NNS O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
PTF NNP B-INTV
may MD O
have VB O
beneficial JJ O
effects NNS O
on IN O
tubulointerstitial JJ O
damage NN O
in IN O
diabetic JJ O
kidney NN O
disease NN O
. . O

-DOCSTART- -X- O O

Outcomes NNS B-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus VBP I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
in IN I-POPU
the DT I-POPU
current JJ I-POPU
era NN I-POPU
: : I-POPU
a DT O
report NN O
from IN O
the DT O
Prevention NNP O
of IN O
REStenosis NNP O
with IN O
Tranilast NNP O
and CC O
its PRP$ O
Outcomes NNP O
( ( O
PRESTO NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Diabetes NNP O
portends VBZ O
an DT O
adverse JJ O
prognosis NN O
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

Whether PRP$ O
improvements NNS O
in IN O
current JJ O
clinical JJ O
practice NN O
( ( O
stents NNS O
, , O
IIb/IIIa NNP O
antagonists VBZ O
) ) O
have VBP O
resulted VBN O
in IN O
substantial JJ O
improvement NN O
of IN O
these DT O
outcomes NNS O
remains VBZ O
an DT O
issue NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
the DT O
influence NN O
of IN O
diabetes NNS O
on IN O
9-month JJ O
outcomes NNS O
of IN O
patients NNS B-POPU
undergoing VBG I-POPU
PCI NNP I-POPU
in IN I-POPU
the DT I-POPU
current JJ I-POPU
era NN I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
The DT B-POPU
11 CD I-POPU
482 CD I-POPU
patients NNS I-POPU
enrolled VBN I-POPU
in IN I-POPU
the DT I-POPU
Prevention NNP I-POPU
of IN I-POPU
REStenosis NNP I-POPU
with IN I-POPU
Tranilast NNP I-POPU
and CC I-POPU
its PRP$ I-POPU
Outcomes NNP I-POPU
( ( I-POPU
PRESTO NNP I-POPU
) ) I-POPU
Trial NNP I-POPU
were VBD O
stratified VBN O
according VBG O
to TO O
the DT O
presence NN O
( ( O
n=2694 JJ O
) ) O
or CC O
absence NN O
( ( O
n=8798 JJ O
) ) O
of IN O
diabetes NNS O
. . O

Diabetic JJ O
patients NNS O
were VBD O
older JJR O
; : O
were VBD O
more RBR O
likely JJ O
to TO O
be VB O
female JJ O
; : O
had VBD O
a DT O
higher JJR O
proportion NN O
of IN O
congestive JJ B-OC
failure NN I-OC
, , I-OC
hypertension NN I-OC
, , I-OC
prior JJ I-OC
CABG NNP I-OC
, , I-OC
and CC I-OC
unstable JJ I-OC
angina NN I-OC
; : I-OC
and CC O
had VBD O
higher JJR O
body NN B-OC
mass NN I-OC
index NN I-OC
and CC O
lower JJR O
ejection NN B-OC
fraction NN I-OC
than IN O
nondiabetic JJ O
patients NNS O
( ( O
P NNP O
< VBZ O
0.01 CD O
for IN O
all DT O
comparisons NNS O
) ) O
. . O

The DT O
degree NN B-OC
of IN I-OC
multivessel NN I-OC
disease NN I-OC
was VBD O
similar JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

American JJ O
College NNP O
of IN O
Cardiology/American NNP O
Heart NNP O
Association NNP O
type VBD B-OC
C NNP I-OC
lesions NNS I-OC
were VBD O
more JJR O
common JJ O
in IN O
diabetic JJ O
patients NNS O
( ( O
17 CD O
% NN O
versus IN O
15 CD O
% NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

Angiographic NNP B-OC
and CC I-OC
procedural JJ I-OC
success NN I-OC
rates NNS I-OC
and CC O
in-hospital JJ B-OC
events NNS I-OC
were VBD O
similar JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

The DT O
primary JJ O
end NN O
point NN O
of IN O
death NN B-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
or CC I-OC
target VB I-OC
vessel JJ I-OC
revascularization NN I-OC
( ( I-OC
TVR NNP I-OC
) ) I-OC
was VBD O
analyzed VBN O
as IN O
time-to-first JJ O
event NN O
within IN O
9 CD O
months NNS O
of IN O
the DT O
index NN O
PCI NNP B-INTV
. . O

After IN O
adjusting VBG O
for IN O
certain JJ O
baseline NN O
characteristics NNS O
, , O
diabetes NNS O
was VBD O
independently RB O
associated VBN O
with IN O
death NN B-OC
at IN O
9 CD O
months NNS O
( ( O
relative JJ O
risk NN O
[ NNP O
RR NNP O
] NNP O
, , O
1.87 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.31 CD O
to TO O
2.68 CD O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
and CC O
with IN O
an DT O
increased VBN O
likelihood NN O
of IN O
TVR NNP B-OC
( ( O
RR NNP O
, , O
1.27 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.14 CD O
to TO O
1.42 CD O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
as RB O
well RB O
as IN O
the DT O
composite JJ O
end NN O
point NN O
of IN O
death/myocardial JJ B-OC
infarction/TVR NN I-OC
( ( O
RR NNP O
, , O
1.26 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.13 CD O
to TO O
1.40 CD O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

CONCLUSIONS NNP O
Despite IN O
advances NNS O
in IN O
interventional JJ O
techniques NNS O
, , O
diabetes VBZ O
remains VBZ O
a DT O
significant JJ O
independent JJ O
predictor NN O
of IN O
adverse JJ O
events NNS O
in IN O
the DT O
intermediate JJ O
term NN O
after IN O
PCI NNP B-INTV
. . O

-DOCSTART- -X- O O

Oscillatory NN B-POPU
potentials NNS I-POPU
, , I-POPU
retinopathy NN I-POPU
, , I-POPU
and CC I-POPU
long-term JJ I-POPU
glucose NN I-POPU
control NN I-POPU
in IN I-POPU
insulin-dependent JJ I-POPU
diabetes NNS I-POPU
. . O

The DT O
main JJ O
objective NN O
of IN O
the DT O
study NN O
was VBD O
to TO O
assess JJ O
effects NNS O
of IN O
long-term JJ B-INTV
lowering NN I-INTV
of IN I-INTV
glucosylated JJ I-INTV
hemoglobin NN I-INTV
( ( I-INTV
HbA1 NNP I-INTV
% NN I-INTV
) ) I-INTV
on IN O
neurosensory JJ O
function NN O
in IN O
insulin-dependent JJ B-POPU
diabetes NNS I-POPU
. . O

Individual NNP B-INTV
( ( I-INTV
OP-1 NNP I-INTV
, , I-INTV
OP-2 NNP I-INTV
, , I-INTV
OP-3 NNP I-INTV
) ) I-INTV
and CC I-INTV
summed VBN I-INTV
( ( I-INTV
OP-sum NNP I-INTV
) ) I-INTV
amplitudes NNS I-INTV
of IN I-INTV
oscillatory JJ I-INTV
potentials NNS I-INTV
( ( I-INTV
OPs NNP I-INTV
) ) I-INTV
of IN I-INTV
electroretinography NN I-INTV
were VBD I-INTV
recorded VBN I-INTV
at IN O
study JJ O
start NN O
and CC O
7-years NNS O
later RB O
in IN O
45 CD B-POPU
patients NNS I-POPU
( ( O
the DT O
Oslo NNP B-POPU
study NN O
) ) O
. . O

As IN O
an DT O
overall JJ O
7-year JJ O
change NN O
, , O
amplitudes NNS B-OC
of IN I-OC
OP-2 NNP I-OC
, , I-OC
OP-3 NNP I-OC
and CC I-OC
OP-sum NNP I-OC
were VBD I-OC
reduced VBN I-OC
( ( O
p JJ O
< NNP O
0.0001-0.01 NN O
) ) O
, , O
retinopathy JJ B-OC
worsened VBD I-OC
( ( O
p JJ O
= NNP O
0.005 CD O
) ) O
, , O
intraocular JJ B-OC
pressure NN I-OC
decreased VBN I-OC
( ( O
p JJ O
< NNP O
0.001 CD O
) ) O
, , O
systolic JJ B-OC
blood NN I-OC
pressure NN I-OC
increased VBD I-OC
( ( O
p JJ O
< NNP O
0.0002 CD O
) ) O
, , O
and CC O
glycemic JJ B-OC
control NN I-OC
improved VBN O
from IN O
HbA1 NNP O
of IN O
11.2 CD O
+/- JJ O
2.2 CD O
% NN O
at IN O
study JJ O
start NN O
to TO O
a DT O
7-year JJ O
cumulative JJ O
mean NN O
of IN O
9.5 CD O
+/- JJ O
1.5 CD O
% NN O
( ( O
p JJ O
< NNP O
0.0001 CD O
) ) O
. . O

Multiple JJ O
regression NN O
analysis NN O
did VBD O
not RB O
identify VB O
any DT O
independent JJ O
relations NNS O
between IN O
change NN O
in IN O
OP-1 NNP B-OC
, , I-OC
OP-2 NNP I-OC
, , I-OC
OP-3 NNP I-OC
, , I-OC
OP-sum NNP I-OC
and CC O
change NN B-OC
in IN I-OC
glycemic JJ I-OC
control NN I-OC
or CC I-OC
background NN I-OC
variables NNS I-OC
, , O
including VBG O
change NN O
in IN O
age NN O
and CC O
duration NN O
of IN O
diabetes NNS O
. . O

However RB O
, , O
cross-sectional JJ O
observations NNS O
at IN O
7 CD O
years NNS O
showed VBD O
negative JJ O
correlations NNS O
between IN O
all DT O
OPs NNP B-OC
and CC O
age NN O
( ( O
p JJ O
< NNP O
0.0001-0.003 NN O
) ) O
, , O
and CC O
between IN O
OP-3 NNP B-OC
and CC I-OC
duration NN I-OC
( ( O
p JJ O
= NNP O
0.003 CD O
) ) O
and CC O
counts NNS B-OC
of IN I-OC
microaneurysms NNS I-OC
( ( O
p JJ O
= NNP O
0.02 CD O
) ) O
. . O

The DT O
data NN O
suggest NN O
that IN O
various JJ O
clinical JJ O
background NN O
variables NNS O
may MD O
influence VB O
individual JJ O
and CC O
summed VBD O
amplitudes NNS O
of IN O
OPs NNP O
differently RB O
. . O

Reduced NNP B-OC
neurosensory JJ I-OC
retinal JJ I-OC
function NN I-OC
( ( I-OC
OPs NNP I-OC
) ) I-OC
seemed VBD O
to TO O
appear VB O
after IN O
7-years NNS O
, , O
independently RB O
of IN O
vascular JJ B-OC
defects NNS I-OC
of IN I-OC
retinopathy JJ I-OC
and CC O
long-term JJ B-OC
improvement NN I-OC
in IN I-OC
glucose JJ I-OC
control NN I-OC
. . O

-DOCSTART- -X- O O

ROMEO NN O
: : O
rethink NN O
organization NN O
to TO O
improve VB O
education NN O
and CC O
outcomes NNS O
. . O

AIMS NNP O
Scarcity NNP O
of IN O
resources NNS O
, , O
expertise NN O
and CC O
evidence-based JJ O
models NNS O
have VBP O
so RB O
far RB O
limited JJ O
delivery NN O
of IN O
patient-centred JJ O
diabetes NNS O
education NN O
. . O

We PRP O
have VBP O
developed VBN O
and CC O
validated VBD O
a DT O
group NN O
care NN O
approach NN O
that WDT O
is VBZ O
applicable JJ O
to TO O
everyday VB O
clinical JJ O
practice NN O
and CC O
cost-effective JJ O
in IN O
improving VBG O
metabolic JJ B-OC
control NN I-OC
, , I-OC
knowledge NN I-OC
of IN I-OC
diabetes NNS I-OC
, , I-OC
health NN I-OC
behaviours NNS I-OC
, , O
and CC O
quality NN B-OC
of IN I-OC
life NN I-OC
in IN O
Type NNP O
2 CD O
diabetes NNS O
. . O

A DT O
clinical JJ O
trial NN O
( ( O
ROMEO NNP O
) ) O
was VBD O
planned VBN O
to TO O
evaluate VB O
applicability NN O
and CC O
reproducibility NN O
of IN O
group NN O
care NN O
in IN O
other JJ O
outpatients NNS O
facilities NNS O
and CC O
assess VB O
its PRP$ O
impact NN O
on IN O
a DT O
larger JJR B-POPU
patient JJ I-POPU
population NN I-POPU
. . O

METHODS NNP O
Multicentre NNP O
, , O
randomized VBD O
, , O
controlled VBD O
clinical JJ O
trial NN O
of IN O
group NN B-INTV
vs. FW I-INTV
individual JJ I-INTV
care NN I-INTV
in IN O
the DT O
routine JJ O
management NN O
of IN O
Type NNP O
2 CD O
diabetes NNS O
. . O

Nine NNP B-POPU
hundred VBD I-POPU
patient JJ I-POPU
aged VBN I-POPU
< NN I-POPU
80 CD I-POPU
, , I-POPU
with IN I-POPU
diabetes NNS I-POPU
of IN I-POPU
> NN I-POPU
or CC I-POPU
=1 JJ I-POPU
year NN I-POPU
known VBN I-POPU
duration NN I-POPU
, , I-POPU
treated VBN I-POPU
by IN I-POPU
either DT I-POPU
diet JJ I-POPU
alone NN I-POPU
or CC I-POPU
diet JJ I-POPU
and CC I-POPU
oral JJ I-POPU
agents NNS I-POPU
, , I-POPU
will MD I-POPU
be VB I-POPU
recruited VBN I-POPU
in IN I-POPU
15 CD I-POPU
centres NNS I-POPU
and CC I-POPU
followed VBD I-POPU
for IN I-POPU
4 CD I-POPU
years NNS I-POPU
. . O

Training NN B-INTV
of IN I-INTV
physicians NNS I-INTV
, , I-INTV
nurses NNS I-INTV
and CC I-INTV
dietitians NNS I-INTV
included VBD I-INTV
preparation NN I-INTV
of IN I-INTV
operating VBG I-INTV
manual JJ I-INTV
and CC I-INTV
videos NNS I-INTV
, , I-INTV
interactive JJ I-INTV
sessions NNS I-INTV
, , I-INTV
and CC I-INTV
evaluation NN I-INTV
of IN I-INTV
local JJ I-INTV
facilities NNS I-INTV
and CC I-INTV
resources NNS I-INTV
. . O

RESULTS NNP O
PRIMARY NNP O
MEASUREMENTS NNP O
3-monthly JJ B-OC
HbA1c NNP I-OC
, , I-OC
fasting VBG I-OC
blood NN I-OC
glucose NN I-OC
, , I-OC
body NN I-OC
weight VBD I-OC
, , I-OC
waist-hip JJ I-OC
ratio NN I-OC
, , I-OC
yearly RB I-OC
blood NN I-OC
lipids NNS I-OC
, , I-OC
and CC I-OC
bi-yearly JJ I-OC
assessment NN I-OC
of IN I-OC
knowledge NN I-OC
of IN I-OC
diabetes NNS I-OC
, , I-OC
health NN I-OC
behaviours NNS I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
. . O

SECONDARY NNP O
OUTCOMES NNP O
systolic JJ B-OC
and CC I-OC
diastolic JJ I-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
evaluation NN I-OC
of IN I-OC
ECG NNP I-OC
for IN I-OC
ischaemia NN I-OC
and CC I-OC
QT NNP I-OC
interval NN I-OC
, , I-OC
hypoglycaemic JJ I-OC
and CC I-OC
anti-hypertensive JJ I-OC
medication NN I-OC
and CC I-OC
cardiovascular JJ I-OC
events NNS I-OC
. . O

Analysis NN O
will MD O
be VB O
by IN O
intention-to-treat JJ O
. . O

DISCUSSION NNP O
If IN O
ROMEO NNP O
confirms VBZ O
that IN O
group NN O
care NN O
can MD O
be VB O
successfully RB O
implemented VBN O
in IN O
different JJ O
clinics NNS O
, , O
a DT O
novel JJ O
clinico-pedagogic JJ O
tool NN O
will MD O
have VB O
been VBN O
acquired VBN O
to TO O
support VB O
patient-centred JJ O
education NN O
, , O
improve VB B-OC
lifestyle NN I-OC
and CC O
outcomes NNS B-OC
, , I-OC
support NN I-OC
team NN I-OC
work NN I-OC
, , I-OC
enhance NN I-OC
providers NNS I-OC
' POS I-OC
attitudes NNS I-OC
and CC O
competencies NNS B-OC
and CC O
ameliorate VB O
diabetes NNS O
care JJ O
organization NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
simvastatin NN B-INTV
and CC I-INTV
fenofibrate NN I-INTV
on IN O
endothelium NN O
in IN O
Type NNP B-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

Statins NNS O
and CC O
fibrates NNS O
influence VBP O
endothelial JJ O
activity NN O
and CC O
consequently RB O
atherogenesis NN O
but CC O
the DT O
mechanisms NNS O
are VBP O
not RB O
well RB O
understood RB O
. . O

Twenty NNP B-POPU
Type NNP I-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
dyslipidemia NN I-POPU
were VBD I-POPU
treated VBN I-POPU
3 CD O
months NNS O
with IN O
simvastatin NN B-INTV
( ( O
20 CD O
mg NNS O
daily RB O
) ) O
and CC O
then RB O
3 CD O
months NNS O
with IN O
fenofibrate NN B-INTV
( ( O
200 CD O
mg NNS O
daily RB O
) ) O
with IN O
2 CD O
months NNS O
of IN O
wash-out NN O
between IN O
the DT O
two CD O
treatments NNS O
. . O

Laboratory JJ O
parameters NNS O
of IN O
oxidative JJ O
stress NN O
, , O
fibrinolysis NN O
and CC O
endothelial JJ O
function NN O
were VBD O
evaluated VBN O
before RB O
and CC O
at IN O
the DT O
end NN O
of IN O
each DT O
treatment NN O
period NN O
. . O

The DT O
significant JJ O
decrease NN O
in IN O
serum JJ B-OC
total JJ I-OC
and CC I-OC
LDL-cholesterol JJ I-OC
concentrations NNS I-OC
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
caused VBN O
by IN O
simvastatin NN O
was VBD O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
serum JJ B-OC
N-acetyl-beta-glucosaminidase JJ I-OC
activity NN I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
ascorbic JJ B-OC
acid NN I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
plasminogen JJ B-OC
activator NN I-OC
inhibitor NN I-OC
( ( O
PAI-1 NNP O
) ) O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
vonWillebrand FW B-OC
factor NN I-OC
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
, , O
E-selectin NNP B-OC
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
and CC O
vascular JJ B-OC
endothelial JJ I-OC
growth NN I-OC
factor NN I-OC
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
concentrations NNS O
and CC O
with IN O
a DT O
decrease NN B-OC
in IN I-OC
plasma NN I-OC
glutathione NN I-OC
( ( I-OC
P NNP I-OC
< NNP I-OC
0.01 CD I-OC
) ) I-OC
levels NNS I-OC
. . O

Fenofibrate NNP O
caused VBD O
a DT O
significant JJ O
decrease NN O
in IN O
serum JJ B-OC
triglyceride JJ I-OC
concentration NN I-OC
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
associated VBN O
with IN O
a DT O
decrease NN O
in IN O
plasma NN B-OC
malondialdehyde NN I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
and CC O
an DT O
increase NN B-OC
in IN I-OC
plasma JJ I-OC
PAI-1 NNP I-OC
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
and CC O
P-selectin NNP B-OC
( ( I-OC
P NNP I-OC
< NNP I-OC
0.05 CD I-OC
) ) I-OC
concentrations NNS O
. . O

We PRP O
conclude VBP O
that IN O
simvastatin NN O
and CC O
fenofibrate NN O
interact NN O
, , O
by IN O
different JJ O
mechanisms NNS O
, , O
with IN O
oxidative JJ O
stress NN O
, , O
a DT O
key JJ O
factor NN O
in IN O
the DT O
modification NN O
of IN O
fibrinolysis NN O
and CC O
endothelial JJ O
function NN O
in IN O
Type NNP O
2 CD O
diabetes NNS O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
pioglitazone NN B-INTV
and CC I-INTV
glimepiride NN I-INTV
on IN O
glycemic JJ O
control NN O
and CC O
insulin NN O
sensitivity NN O
in IN O
Mexican JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus NN I-POPU
: : I-POPU
A DT O
multicenter NN O
, , O
randomized VBN O
, , O
double-blind JJ O
, , O
parallel-group JJ O
trial NN O
. . O

BACKGROUND NNP O
Pioglitazone NNP B-INTV
and CC O
glimepiride VB B-INTV
improve VB O
glycemic JJ O
control NN O
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus VBN I-POPU
by IN O
different JJ O
mechanisms NNS O
. . O

Pioglitazone NN B-INTV
is VBZ O
a DT O
thiazolidinedione NN O
that WDT O
reduces VBZ O
insulin NN O
resistance NN O
, , O
and CC O
glimepiride NN B-INTV
is VBZ O
a DT O
sulfonylurea JJ O
insulin NN O
secretagogue NN O
. . O

OBJECTIVE CC O
The DT O
goals NNS O
of IN O
this DT O
study NN O
were VBD O
to TO O
compare VB O
changes NNS O
in IN O
measures NNS O
of IN O
glycemic JJ O
control NN O
and CC O
insulin NN O
sensitivity NN O
in IN O
Mexican JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
received VBD I-POPU
pioglitazone NN I-POPU
or CC I-POPU
glimepiride NN I-POPU
for IN I-POPU
1 CD I-POPU
year NN I-POPU
. . O

METHODS NNP O
This DT O
was VBD O
a DT O
multicenter NN O
, , O
52-week JJ O
, , O
double-blind JJ O
, , O
parallel-group JJ O
trial NN O
. . O

Patients NNS O
were VBD O
randomized VBN O
to TO O
receive VB O
monotherapy NN O
with IN O
either DT O
glimepiride NN B-INTV
( ( O
2 CD O
mg NN O
QD NNP O
initially RB O
) ) O
or CC B-INTV
pioglitazone NN I-INTV
( ( O
15 CD O
mg NN O
QD NNP O
initially RB O
) ) O
. . O

Doses NNS O
were VBD O
titrated VBN O
( ( O
maximal JJ O
doses NNS O
: : O
pioglitazone NN B-INTV
45 CD O
mg NN O
, , O
glimepiride RB B-INTV
8 CD O
mg NN O
) ) O
to TO O
achieve VB O
glycemic JJ O
targets NNS O
( ( O
fasting VBG O
blood NN O
glucose JJ O
< NN O
or CC O
=7 VB O
mmol/L NNS O
and CC O
1-hour JJ O
postprandial JJ O
blood NN O
glucose JJ O
< NN O
or CC O
=10 VB O
mmol/L NN O
) ) O
. . O

Insulin NNP O
sensitivity NN O
( ( O
primary JJ O
end NN O
point NN O
) ) O
was VBD O
evaluated VBN O
in IN O
terms NNS O
of IN O
the DT O
Homeostasis NNP O
Model NNP O
Assessment NNP O
for IN O
Insulin NNP O
Sensitivity NNP O
( ( O
HOMA-S NNP O
) ) O
, , O
the DT O
Quantitative NNP O
Insulin NNP O
Sensitivity NNP O
Check NNP O
Index NNP O
( ( O
QUICKI NNP O
) ) O
, , O
and CC O
fasting VBG O
serum JJ O
insulin NN O
( ( O
FSI NNP O
) ) O
concentrations NNS O
. . O

Glycemic NNP O
control NN O
was VBD O
evaluated VBN O
in IN O
terms NNS O
of IN O
glycosylated VBN O
hemoglobin NN O
( ( O
HbA NNP O
( ( O
1c CD O
) ) O
) ) O
values NNS O
and CC O
fasting VBG O
plasma NN O
glucose NN O
( ( O
FPG NNP O
) ) O
concentrations NNS O
. . O

Patients NNS O
were VBD O
encouraged VBN O
to TO O
maintain VB O
their PRP$ O
individual JJ O
diet NN O
and CC O
exercise NN O
regimens NNS O
throughout IN O
the DT O
study NN O
. . O

RESULTS NNP O
Two CD B-POPU
hundred VBD I-POPU
forty-four JJ I-POPU
patients NNS I-POPU
( ( I-POPU
125 CD I-POPU
women NNS I-POPU
, , I-POPU
119 CD I-POPU
men NNS I-POPU
; : I-POPU
all DT I-POPU
but CC I-POPU
1 CD I-POPU
Hispanic NNP I-POPU
) ) I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO O
receive VB O
pioglitazone NN B-INTV
( ( O
n JJ O
= NNP O
121 CD O
) ) O
or CC O
glimepiride NN B-INTV
( ( O
n JJ O
= NNP O
123 CD O
) ) O
. . O

In IN O
the DT O
intent-to-treat JJ O
sample NN O
, , O
pioglitazone NN B-INTV
and CC O
glimepirede NN B-INTV
produced VBN O
comparable JJ O
reductions NNS B-OC
in IN I-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
from IN O
baseline NN O
to TO O
the DT O
end NN O
of IN O
the DT O
study NN O
( ( O
-0.78 CD O
% NN O
and CC O
-0.68 CD O
% NN O
, , O
respectively RB O
) ) O
. . O

The DT O
pioglitazone NN B-INTV
group NN O
had VBD O
significantly RB O
higher JJR O
HbA NNP B-OC
( ( I-OC
1c CD I-OC
) ) I-OC
values NNS O
compared VBN O
with IN O
the DT O
glimepiride NN B-INTV
group NN O
after IN O
12 CD O
weeks NNS O
of IN O
therapy NN O
( ( O
8.66 CD O
% NN O
vs JJ O
7.80 CD O
% NN O
; : O
P NNP O
= NNP O
0.007 CD O
) ) O
but CC O
had VBD O
significantly RB O
lower JJR O
values NNS O
after IN O
52 CD O
weeks NNS O
( ( O
7.46 CD O
% NN O
vs JJ O
7.77 CD O
% NN O
; : O
P NNP O
= NNP O
0.027 CD O
) ) O
. . O

Pioglitazone NN B-INTV
significantly RB O
reduced VBD O
FPG NNP B-OC
compared VBN O
with IN O
glimepiride NN B-INTV
( ( O
-0.6 JJ O
vs NN O
0.6 CD O
mmol/L NN O
; : O
P NNP O
= NNP O
0.01 CD O
) ) O
. . O

Pioglitazone NNP B-INTV
therapy NN O
was VBD O
associated VBN O
with IN O
significant JJ O
increases NNS O
in IN O
insulin NN B-OC
sensitivity NN I-OC
( ( I-OC
reduced JJ I-OC
insulin NN I-OC
resistance NN I-OC
) ) I-OC
, , O
whereas JJ O
glimepiride NN B-INTV
had VBD O
no DT O
effect NN O
. . O

HOMA-S JJ B-OC
values NNS I-OC
changed VBD O
18.0 CD O
% NN O
for IN O
pioglitazone NN B-INTV
and CC O
-7.9 CD O
% NN O
for IN O
glimepiride NN B-INTV
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
QUICKI NNP O
values VBZ O
changed VBD O
a DT O
respective JJ O
0.013 CD O
and CC O
-0.007 NNP O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
and CC O
FSI NNP O
values NNS O
were VBD O
-21.1 NNP O
and CC O
15.1 CD O
pmol/L NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

Both DT O
drugs NNS O
were VBD O
well RB O
tolerated VBN B-OC
, , O
with IN O
pioglitazone NN B-INTV
associated VBN O
with IN O
more RBR O
peripheral JJ B-OC
edema NN I-OC
( ( O
number NN O
of IN O
treatment-emergent JJ O
cases NNS O
: : O
35/121 CD O
[ $ O
28.9 CD O
% NN O
] NNP O
vs NN O
17/123 CD O
[ JJ O
13.8 CD O
% NN O
] NN O
; : O
P NNP O
= NNP O
0.005 CD O
) ) O
and CC O
fewer JJR O
hypoglycemic JJ B-OC
episodes NNS I-OC
( ( O
19 CD O
[ RB O
15.7 CD O
% NN O
] NNP O
vs NN O
38 CD O
[ JJ O
30.9 CD O
% NN O
] NN O
; : O
P NNP O
= NNP O
0.024 CD O
) ) O
. . O

The DT O
incidence NN O
of IN O
weight JJ B-OC
gain NN I-OC
was VBD O
not RB O
significantly RB O
different JJ O
between IN O
treatment NN O
groups NNS O
. . O

CONCLUSIONS NNP O
These DT O
data NNS O
suggest VBP O
that IN O
long-term JJ O
treatment NN O
with IN O
pioglitazone NN B-INTV
enhances NNS O
insulin VBP O
sensitivity NN O
relative VBP O
to TO O
glimepiride VB B-INTV
in IN O
Mexican JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
and CC O
that IN O
pioglitazone NN B-INTV
may MD O
have VB O
a DT O
more RBR O
sustained JJ O
antihyperglycemic JJ O
effect NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
the DT O
motilin NN O
agonist NN O
KC NNP B-INTV
11458 CD I-INTV
on IN O
gastric JJ O
emptying VBG O
in IN O
diabetic JJ O
gastroparesis NN O
. . O

BACKGROUND NNP O
KC NNP B-INTV
11458 CD I-INTV
, , O
a DT O
motilin JJ O
agonist NN O
without IN O
antibiotic JJ O
properties NNS O
, , O
accelerates VBZ O
gastric JJ O
emptying VBG O
in IN O
animals NNS B-POPU
and CC I-POPU
healthy JJ I-POPU
humans NNS I-POPU
. . O

AIM NNP O
To TO O
evaluate VB O
the DT O
acute JJ O
effects NNS O
of IN O
KC NNP B-INTV
11458 CD I-INTV
on IN O
gastric JJ O
emptying VBG O
in IN O
diabetic JJ O
gastroparesis NN O
. . O

METHODS NNP O
Twenty-nine JJ B-POPU
patients NNS I-POPU
( ( I-POPU
6 CD I-POPU
type NN I-POPU
1 CD I-POPU
and CC I-POPU
23 CD I-POPU
type NN I-POPU
2 CD I-POPU
) ) I-POPU
with IN I-POPU
gastroparesis NN I-POPU
underwent JJ O
assessments NNS O
of IN O
: : O
( ( O
i NN O
) ) O
gastric NN B-OC
emptying NN I-OC
of IN O
a DT O
solid/liquid JJ O
meal NN O
using VBG O
scintigraphy NN O
, , O
( ( O
ii NN O
) ) O
glycaemic FW O
control NN O
( ( O
blood NN O
glucose NN O
at IN O
0 CD O
, , O
30 CD O
, , O
60 CD O
, , O
90 CD O
and CC O
120 CD O
min NN O
during IN O
the DT O
gastric JJ O
emptying VBG O
measurement NN O
) ) O
and CC O
( ( O
iii NN O
) ) O
upper IN O
gastrointestinal JJ O
and CC O
'meal-related JJ O
' '' O
symptoms NNS O
( ( O
questionnaire NN O
) ) O
, , O
at IN B-POPU
baseline NN I-POPU
and CC I-POPU
after IN I-POPU
treatment NN I-POPU
with IN I-POPU
KC NNP I-POPU
11458 CD I-POPU
in IN I-POPU
a DT I-POPU
dose NN I-POPU
of IN I-POPU
8 CD I-POPU
mg NNS I-POPU
t.d.s. NN I-POPU
, , O
or CC B-POPU
placebo NN I-POPU
for IN I-POPU
8 CD I-POPU
days NNS I-POPU
. . O

RESULTS NNP O
KC NNP B-INTV
11458 CD I-INTV
had VBD O
no DT O
statistically RB O
significant JJ O
or CC O
clinically RB O
relevant JJ O
effect NN O
on IN O
gastric JJ B-OC
emptying NN I-OC
of IN O
either CC O
the DT O
solid JJ O
intragastric JJ O
retention NN O
at IN O
100 CD O
min NN O
( ( O
T100 NNP O
) ) O
( ( O
P NNP O
= NNP O
0.87 CD O
) ) O
or CC O
liquid $ O
50 CD O
% NN O
emptying JJ O
time NN O
( ( O
T50 NNP O
) ) O
( ( O
P NNP O
= NNP O
0.17 CD O
) ) O
components NNS O
of IN O
the DT O
meal NN O
. . O

KC NNP B-INTV
11458 CD I-INTV
slightly RB O
worsened VBN O
( ( O
P NNP O
= NNP O
0.04 CD O
) ) O
upper JJ B-OC
gastrointestinal NN I-OC
symptoms NNS I-OC
when WRB O
compared VBN O
with IN O
placebo NN B-INTV
. . O

The DT O
magnitude NN O
of IN O
the DT O
change NN O
in IN O
solid JJ B-OC
gastric JJ I-OC
emptying VBG I-OC
correlated VBN O
with IN O
the DT O
change NN O
in IN O
the DT O
blood NN B-OC
glucose JJ I-OC
concentration NN I-OC
( ( O
r JJ O
= VBZ O
0.49 CD O
; : O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

CONCLUSIONS NNP O
KC NNP B-INTV
11458 CD I-INTV
, , O
in IN O
a DT O
dose NN O
of IN O
8 CD O
mg NN O
t.d.s NN O
. . O

for IN O
8 CD O
days NNS O
, , O
does VBZ O
not RB O
accelerate VB O
gastric JJ B-OC
emptying VBG I-OC
in IN O
patients NNS O
with IN O
diabetic JJ O
gastroparesis NN O
. . O

The DT O
absence NN O
of IN O
efficacy NN O
may MD O
relate VB O
to TO O
an DT O
effect NN O
of IN O
hyperglycaemia NN O
. . O

-DOCSTART- -X- O O

Randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
trial NN O
of IN O
oral JJ O
sirolimus NN O
for IN O
restenosis NN B-OC
prevention NN O
in IN O
patients NNS B-POPU
with IN I-POPU
in-stent JJ I-POPU
restenosis NN I-POPU
: : I-POPU
the DT O
Oral NNP O
Sirolimus NNP B-INTV
to TO O
Inhibit NNP O
Recurrent NNP O
In-stent JJ O
Stenosis NNP O
( ( O
OSIRIS NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Despite IN O
recent JJ O
advances NNS O
in IN O
interventional JJ O
cardiology NN O
, , O
including VBG O
the DT O
introduction NN O
of IN O
drug-eluting JJ O
stents NNS O
for IN O
de FW O
novo FW O
coronary JJ O
lesions NNS O
, , O
the DT O
treatment NN O
of IN O
in-stent JJ O
restenosis NN O
( ( O
ISR NNP O
) ) O
remains VBZ O
a DT O
challenging JJ O
clinical JJ O
issue NN O
. . O

Given VBN O
the DT O
efficacy NN O
of IN O
systemic JJ O
sirolimus JJ O
administration NN O
to TO O
prevent VB O
neointimal JJ B-OC
hyperplasia NN I-OC
in IN O
animal JJ O
models NNS O
and CC O
to TO O
halt VB O
and CC O
even RB O
reverse VB O
the DT O
progression NN O
of IN O
allograft NN O
vasculopathy NN O
, , O
the DT O
aim NN O
of IN O
the DT O
present JJ O
double-blind NN O
, , O
placebo-controlled JJ O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
efficacy NN O
of IN O
a DT O
10-day JJ O
oral JJ O
sirolimus NN O
treatment NN O
with IN O
2 CD O
different JJ O
loading VBG O
regimens NNS O
for IN O
the DT O
prevention NN O
of IN O
recurrent JJ O
restenosis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
ISR NNP I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Three NNP B-POPU
hundred VBD I-POPU
symptomatic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
ISR NNP I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
1 CD O
of IN O
3 CD O
treatment NN O
arms NNS O
: : O
placebo NN B-INTV
or CC I-INTV
usual-dose JJ I-INTV
or CC I-INTV
high-dose JJ I-INTV
sirolimus NN I-INTV
. . O

Patients NNS O
received VBD O
a DT O
cumulative JJ O
loading NN O
dose NN O
of IN O
0 CD O
, , O
8 CD O
, , O
or CC O
24 CD O
mg NN O
of IN O
sirolimus JJ O
2 CD O
days NNS O
before IN O
and CC O
the DT O
day NN O
of IN O
repeat NN O
intervention NN O
followed VBN O
by IN O
maintenance NN O
therapy NN O
of IN O
2 CD O
mg/d NN O
for IN O
7 CD O
days NNS O
. . O

Angiographic JJ B-OC
restenosis NN I-OC
at IN I-OC
6-month JJ B-INTV
angiography NN I-INTV
was VBD O
the DT O
primary JJ O
end NN O
point NN O
of IN O
the DT O
study NN O
. . O

Restenosis NNP B-OC
was VBD O
significantly RB O
reduced VBN O
from IN O
42.2 CD O
% NN O
to TO O
38.6 CD O
% NN O
and CC O
to TO O
22.1 CD O
% NN O
in IN O
the DT O
placebo NN O
, , O
usual-dose JJ O
, , O
and CC O
high-dose JJ O
sirolimus NN O
groups NNS O
, , O
respectively RB O
( ( O
P=0.005 NNP O
) ) O
. . O

Similarly RB O
, , O
the DT O
need NN B-OC
for IN I-OC
target NN I-OC
vessel JJ I-OC
revascularization NN I-OC
was VBD O
reduced VBN O
from IN O
25.5 CD O
% NN O
to TO O
24.2 CD O
% NN O
and CC O
to TO O
15.2 CD O
% NN O
in IN O
the DT O
placebo NN O
, , O
usual-dose JJ O
, , O
and CC O
high-dose JJ O
groups NNS O
, , O
respectively RB O
( ( O
P=0.08 NNP O
) ) O
. . O

The DT B-OC
sirolimus JJ I-OC
blood NN I-OC
concentration NN I-OC
on IN O
the DT O
day NN O
of IN O
the DT O
procedure NN O
correlated VBD O
significantly RB O
with IN O
the DT O
late JJ O
lumen NNS O
loss NN O
at IN O
follow-up JJ O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

CONCLUSIONS NNP O
In IN O
patients NNS O
with IN O
ISR NNP O
, , O
an DT O
oral JJ O
adjunctive JJ O
sirolimus NN O
treatment NN O
with IN O
an DT O
intensified JJ O
loading NN O
regimen NNS O
before IN O
coronary JJ O
intervention NN O
resulted VBD O
in IN O
a DT O
significant JJ O
improvement NN O
in IN O
the DT O
angiographic JJ B-OC
parameters NNS I-OC
of IN I-OC
restenosis NN I-OC
. . O

-DOCSTART- -X- O O

Botulinum NNP B-INTV
toxin NN I-INTV
a DT O
has VBZ O
antinociceptive JJ B-OC
effects NNS I-OC
in IN O
treating VBG O
interstitial JJ O
cystitis NN O
. . O

OBJECTIVES NNP O
To TO O
present VB O
clinical JJ O
evidence NN O
with IN O
botulinum NN B-INTV
toxin NN I-INTV
A NNP I-INTV
( ( I-INTV
BTX-A NNP I-INTV
) ) I-INTV
suggesting VBG O
an DT O
antinociceptive JJ B-OC
role NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
interstitial JJ I-POPU
cystitis NN I-POPU
( ( I-POPU
IC NNP I-POPU
) ) I-POPU
. . O

Intriguing VBG O
evidence NN O
in IN O
a DT O
somatic JJ O
pain NN O
model NN O
has VBZ O
suggested VBN O
that IN O
BTX-A NNP B-INTV
injection NN I-INTV
may MD O
have VB O
an DT O
antinociceptive JJ B-OC
effect NN I-OC
on IN O
both DT O
acute NN O
and CC O
chronic NN O
( ( O
inflammatory NN O
) ) O
pain NN O
. . O

METHODS NNP O
Thirteen NNP B-POPU
female JJ I-POPU
patients NNS I-POPU
( ( I-POPU
6 CD I-POPU
in IN I-POPU
the DT I-POPU
United NNP I-POPU
States NNPS I-POPU
and CC I-POPU
7 CD I-POPU
in IN I-POPU
Poland NNP I-POPU
) ) I-POPU
with IN I-POPU
IC NNP I-POPU
according VBG I-POPU
to TO I-POPU
the DT I-POPU
criteria NNS I-POPU
of IN I-POPU
the DT I-POPU
National NNP I-POPU
Institute NNP I-POPU
of IN I-POPU
Diabetes NNP I-POPU
, , I-POPU
Digestive NNP I-POPU
and CC I-POPU
Kidney NNP I-POPU
Disease NNP I-POPU
were VBD I-POPU
included VBN I-POPU
. . O

Under IN O
short JJ O
general JJ O
anesthesia NN O
or CC O
sedation NN O
, , O
100 CD B-POPU
to TO I-POPU
200 CD I-POPU
U NNP I-POPU
of IN I-POPU
Dysport NNP I-POPU
( ( I-POPU
Polish JJ I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
Botox NNP I-POPU
( ( I-POPU
U.S. NNP I-POPU
patients NNS I-POPU
) ) I-POPU
was VBD O
injected VBN O
through IN O
a DT O
cystoscope NN O
into IN O
20 CD O
to TO O
30 CD O
sites NNS O
submucosally RB O
in IN O
the DT O
trigone NN O
and CC O
floor NN O
of IN O
the DT O
bladder NN O
. . O

Patients NNS O
were VBD O
evaluated VBN O
with IN O
the DT O
O'Leary-Sant NNP B-OC
validated VBD I-OC
IC NNP I-OC
questionnaire NN I-OC
or CC I-OC
with IN I-OC
voiding JJ I-OC
charts NNS I-OC
and CC I-OC
a DT I-OC
visual JJ I-OC
analog NN I-OC
pain VBP I-OC
scale JJ I-OC
1 CD O
month NN O
postoperatively RB O
and CC O
at IN O
subsequent JJ O
3-month JJ O
intervals NNS O
. . O

The DT O
Polish JJ B-POPU
patients NNS I-POPU
also RB O
underwent JJ O
pretreatment NN O
and CC O
post-treatment JJ O
urodynamic JJ B-OC
evaluations NNS I-OC
. . O

RESULTS NNP O
Overall NNP O
, , O
9 CD O
( ( O
69 CD O
% NN O
) ) O
of IN O
13 CD O
patients NNS O
noted JJ O
subjective JJ B-OC
improvement NN I-OC
after IN O
BTX-A NNP B-INTV
treatment NN O
. . O

The DT O
Interstitial NNP B-OC
Cystitis NNP I-OC
Symptom NNP I-OC
Index NNP I-OC
and CC I-OC
Interstitial NNP I-OC
Cystitis NNP I-OC
Problem NNP I-OC
Index NNP I-OC
mean NN I-OC
scores NNS I-OC
improved VBN O
by IN O
71 CD O
% NN O
and CC O
69 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

Daytime NNP B-OC
frequency NN I-OC
, , I-OC
nocturia NN I-OC
, , I-OC
and CC I-OC
pain NN I-OC
by IN I-OC
visual JJ I-OC
analog NN I-OC
scale NN I-OC
decreased VBN O
by IN O
44 CD O
% NN O
, , O
45 CD O
% NN O
, , O
and CC O
79 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

The DT O
first JJ B-OC
desire NN I-OC
to TO I-OC
void VB I-OC
and CC I-OC
maximal VB I-OC
cystometric JJ I-OC
capacity NN I-OC
increased VBN O
by IN O
58 CD O
% NN O
and CC O
57 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

CONCLUSIONS NNP O
Our PRP$ O
results NNS O
suggest VBP O
that IN O
BTX-A NNP B-INTV
has VBZ O
an DT O
antinociceptive JJ B-OC
effect NN I-OC
on IN O
bladder NN O
afferent NN O
pathways NNS O
in IN O
patients NNS O
with IN O
IC NNP O
, , O
producing VBG O
both DT O
symptomatic JJ O
and CC O
functional JJ O
( ( O
ie JJ O
, , O
urodynamic JJ O
) ) O
improvements NNS O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
long-term JJ B-INTV
vitamin NN I-INTV
E NNP I-INTV
supplementation NN I-INTV
on IN O
cardiovascular JJ B-POPU
events NNS I-POPU
and CC I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized NN O
controlled VBN O
trial NN O
. . O

CONTEXT NNP O
Experimental NNP O
and CC O
epidemiological JJ O
data NNS O
suggest VBP O
that IN O
vitamin NN B-INTV
E NNP I-INTV
supplementation NN I-INTV
may MD O
prevent VB O
cancer NN B-POPU
and CC I-POPU
cardiovascular JJ I-POPU
events NNS I-POPU
. . O

Clinical JJ O
trials NNS O
have VBP O
generally RB O
failed VBN O
to TO O
confirm VB O
benefits NNS O
, , O
possibly RB O
due JJ O
to TO O
their PRP$ O
relatively RB O
short JJ O
duration NN O
. . O

OBJECTIVE UH O
To TO O
evaluate VB O
whether IN O
long-term JJ B-INTV
supplementation NN I-INTV
with IN I-INTV
vitamin JJ I-INTV
E NN I-INTV
decreases VBZ O
the DT O
risk NN B-OC
of IN I-OC
cancer NN B-POPU
, , I-POPU
cancer NN I-POPU
death NN I-POPU
, , I-POPU
and CC I-POPU
major JJ I-POPU
cardiovascular JJ I-POPU
events NNS I-POPU
. . O

DESIGN NNP O
, , O
SETTING NNP O
, , O
AND NNP O
PATIENTS NNP O
A NNP O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
international JJ B-POPU
trial NN O
( ( O
the DT O
initial JJ O
Heart NNP O
Outcomes NNP O
Prevention NNP O
Evaluation NNP O
[ NNP O
HOPE NNP O
] NNP O
trial NN O
conducted VBD O
between IN O
December NNP O
21 CD O
, , O
1993 CD O
, , O
and CC O
April NNP O
15 CD O
, , O
1999 CD O
) ) O
of IN O
patients NNS B-POPU
at IN I-POPU
least JJS I-POPU
55 CD I-POPU
years NNS I-POPU
old JJ I-POPU
with IN I-POPU
vascular JJ I-POPU
disease NN I-POPU
or CC I-POPU
diabetes VBZ I-POPU
mellitus NN I-POPU
was VBD I-POPU
extended VBN I-POPU
( ( I-POPU
HOPE-The NNP I-POPU
Ongoing NNP I-POPU
Outcomes NNP I-POPU
[ NNP I-POPU
HOPE-TOO NNP I-POPU
] NNP I-POPU
) ) I-POPU
between IN I-POPU
April NNP I-POPU
16 CD I-POPU
, , I-POPU
1999 CD I-POPU
, , I-POPU
and CC I-POPU
May NNP I-POPU
26 CD I-POPU
, , I-POPU
2003 CD I-POPU
. . O

Of IN O
the DT O
initial JJ O
267 CD B-POPU
HOPE NNP I-POPU
centers NNS I-POPU
that WDT I-POPU
had VBD I-POPU
enrolled VBN I-POPU
9541 CD I-POPU
patients NNS I-POPU
, , I-POPU
174 CD I-POPU
centers NNS I-POPU
participated VBN I-POPU
in IN I-POPU
the DT I-POPU
HOPE-TOO NNP I-POPU
trial NN I-POPU
. . O

Of IN O
7030 CD B-POPU
patients NNS I-POPU
enrolled VBN I-POPU
at IN I-POPU
these DT I-POPU
centers NNS I-POPU
, , I-POPU
916 CD I-POPU
were VBD I-POPU
deceased VBN I-POPU
at IN I-POPU
the DT I-POPU
beginning NN I-POPU
of IN I-POPU
the DT I-POPU
extension NN I-POPU
, , I-POPU
1382 CD I-POPU
refused VBD I-POPU
participation NN I-POPU
, , I-POPU
3994 CD I-POPU
continued VBD I-POPU
to TO I-POPU
take VB I-POPU
the DT I-POPU
study NN I-POPU
intervention NN I-POPU
, , I-POPU
and CC I-POPU
738 CD I-POPU
agreed VBD I-POPU
to TO I-POPU
passive VB I-POPU
follow-up NN I-POPU
. . O

Median JJ O
duration NN O
of IN O
follow-up NN O
was VBD O
7.0 CD O
years NNS O
. . O

INTERVENTION NNP O
Daily NNP B-INTV
dose NN I-INTV
of IN I-INTV
natural JJ I-INTV
source NN I-INTV
vitamin NN I-INTV
E NNP I-INTV
( ( I-INTV
400 CD I-INTV
IU NNP I-INTV
) ) I-INTV
or CC I-INTV
matching VBG I-INTV
placebo NN I-INTV
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Primary NNP O
outcomes NNS O
included VBD O
cancer NN B-OC
incidence NN I-OC
, , I-OC
cancer NN I-OC
deaths NNS I-OC
, , I-OC
and CC I-OC
major JJ I-OC
cardiovascular JJ I-OC
events NNS I-OC
( ( I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
stroke NN I-OC
, , I-OC
and CC I-OC
cardiovascular JJ I-OC
death NN I-OC
) ) I-OC
. . O

Secondary JJ O
outcomes NNS O
included VBD O
heart NN B-OC
failure NN I-OC
, , I-OC
unstable JJ I-OC
angina NN I-OC
, , I-OC
and CC I-OC
revascularizations NNS I-OC
. . O

RESULTS NNP O
Among IN O
all DT O
HOPE NNP O
patients NNS O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
primary JJ O
analysis NN O
: : O
for IN O
cancer NN B-OC
incidence NN I-OC
, , O
there EX O
were VBD O
552 CD O
patients NNS O
( ( O
11.6 CD O
% NN O
) ) O
in IN O
the DT O
vitamin NN B-INTV
E NNP I-INTV
group NN O
vs VBD O
586 CD O
( ( O
12.3 CD O
% NN O
) ) O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
relative JJ O
risk NN O
[ NNP O
RR NNP O
] NNP O
, , O
0.94 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.84-1.06 NNP O
; : O
P NNP O
= NNP O
.30 NNP O
) ) O
; : O
for IN O
cancer NN B-OC
deaths NNS I-OC
, , O
156 CD O
( ( O
3.3 CD O
% NN O
) ) O
vs NN O
178 CD O
( ( O
3.7 CD O
% NN O
) ) O
, , O
respectively RB O
( ( O
RR NNP O
, , O
0.88 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.71-1.09 NNP O
; : O
P NNP O
= NNP O
.24 NNP O
) ) O
; : O
and CC O
for IN O
major JJ B-OC
cardiovascular JJ I-OC
events NNS I-OC
, , O
1022 CD O
( ( O
21.5 CD O
% NN O
) ) O
vs NN O
985 CD O
( ( O
20.6 CD O
% NN O
) ) O
, , O
respectively RB O
( ( O
RR NNP O
, , O
1.04 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.96-1.14 NNP O
; : O
P NNP O
= NNP O
.34 NNP O
) ) O
. . O

Patients NNS O
in IN O
the DT O
vitamin NN B-INTV
E NNP I-INTV
group NN O
had VBD O
a DT O
higher JJR O
risk NN B-OC
of IN I-OC
heart NN I-OC
failure NN I-OC
( ( O
RR NNP O
, , O
1.13 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.01-1.26 JJ O
; : O
P NNP O
= NNP O
.03 NNP O
) ) O
and CC O
hospitalization NN B-OC
for IN I-OC
heart NN I-OC
failure NN I-OC
( ( O
RR NNP O
, , O
1.21 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.00-1.47 JJ O
; : O
P NNP O
= NNP O
.045 NNP O
) ) O
. . O

Similarly RB O
, , O
among IN O
patients NNS O
enrolled VBN O
at IN O
the DT O
centers NNS O
participating VBG O
in IN O
the DT O
HOPE-TOO NNP O
trial NN O
, , O
there EX O
were VBD O
no DT O
differences NNS O
in IN O
cancer NN B-OC
incidence NN I-OC
, , I-OC
cancer NN I-OC
deaths NNS I-OC
, , I-OC
and CC I-OC
major JJ I-OC
cardiovascular JJ I-OC
events NNS I-OC
, , O
but CC O
higher JJR O
rates NNS B-OC
of IN I-OC
heart NN I-OC
failure NN I-OC
and CC I-OC
hospitalizations NNS I-OC
for IN I-OC
heart NN I-OC
failure NN I-OC
. . O

CONCLUSION NNP O
In IN O
patients NNS B-POPU
with IN I-POPU
vascular JJ I-POPU
disease NN I-POPU
or CC I-POPU
diabetes VBZ I-POPU
mellitus NNS I-POPU
, , O
long-term JJ B-INTV
vitamin NN I-INTV
E NNP I-INTV
supplementation NN I-INTV
does VBZ O
not RB O
prevent VB O
cancer NN B-OC
or CC I-OC
major JJ I-OC
cardiovascular JJ I-OC
events NNS I-OC
and CC O
may MD O
increase VB O
the DT O
risk NN B-OC
for IN I-OC
heart NN I-OC
failure NN I-OC
. . O

-DOCSTART- -X- O O

Automatic JJ B-POPU
detection NN I-POPU
of IN I-POPU
red JJ I-POPU
lesions NNS I-POPU
in IN I-POPU
digital JJ I-POPU
color NN I-POPU
fundus NN I-POPU
photographs NN I-POPU
. . O

The DT O
robust JJ O
detection NN B-INTV
of IN I-INTV
red JJ I-INTV
lesions NNS I-INTV
in IN I-INTV
digital JJ B-POPU
color NN I-POPU
fundus NN I-POPU
photographs NN I-POPU
is VBZ O
a DT O
critical JJ O
step NN O
in IN O
the DT O
development NN O
of IN O
automated JJ O
screening VBG O
systems NNS O
for IN O
diabetic JJ B-POPU
retinopathy NN I-POPU
. . O

In IN O
this DT O
paper NN O
, , O
a DT O
novel NN B-INTV
red JJ I-INTV
lesion NN I-INTV
detection NN I-INTV
method NN I-INTV
is VBZ O
presented VBN O
based VBN O
on IN O
a DT O
hybrid JJ O
approach NN O
, , O
combining VBG O
prior JJ O
works NNS O
by IN O
Spencer NNP O
et CC O
al NN O
. . O

( ( O
1996 CD O
) ) O
and CC O
Frame NNP O
et NNP O
al NN O
. . O

( ( O
1998 CD O
) ) O
with IN O
two CD O
important JJ O
new JJ O
contributions NNS O
. . O

The DT O
first JJ O
contribution NN O
is VBZ O
a DT O
new JJ O
red JJ B-INTV
lesion NN I-INTV
candidate NN I-INTV
detection NN I-INTV
system NN I-INTV
based VBN O
on IN O
pixel JJ O
classification NN O
. . O

Using VBG O
this DT O
technique NN O
, , O
vasculature NN B-OC
and CC I-OC
red JJ I-OC
lesions NNS I-OC
are VBP O
separated VBN O
from IN O
the DT O
background NN O
of IN O
the DT O
image NN O
. . O

After IN O
removal NN O
of IN O
the DT O
connected JJ O
vasculature NN O
the DT O
remaining VBG O
objects NNS O
are VBP O
considered VBN O
possible JJ O
red JJ O
lesions NNS O
. . O

Second NNP O
, , O
an DT O
extensive JJ O
number NN O
of IN O
new JJ O
features NNS O
are VBP O
added VBN O
to TO O
those DT O
proposed VBN O
by IN O
Spencer-Frame NNP O
. . O

The DT O
detected JJ O
candidate NN O
objects NNS O
are VBP O
classified VBN O
using VBG O
all DT O
features NNS O
and CC O
a DT O
k-nearest JJ O
neighbor NN O
classifier NN O
. . O

An DT O
extensive JJ O
evaluation NN O
was VBD O
performed VBN O
on IN O
a DT O
test NN O
set NN O
composed VBN O
of IN O
images NNS O
representative NN O
of IN O
those DT O
normally RB O
found VBN O
in IN O
a DT O
screening NN O
set NN O
. . O

When WRB O
determining VBG O
whether IN O
an DT O
image NN O
contains VBZ O
red JJ B-OC
lesions NNS I-OC
the DT O
system NN O
achieves VBZ O
a DT O
sensitivity NN B-OC
of IN O
100 CD O
% NN O
at IN O
a DT O
specificity NN O
of IN O
87 CD O
% NN O
. . O

The DT O
method NN O
is VBZ O
compared VBN O
with IN O
several JJ O
different JJ O
automatic JJ O
systems NNS O
and CC O
is VBZ O
shown VBN O
to TO O
outperform VB O
them PRP O
all DT O
. . O

Performance NNP B-OC
is VBZ O
close RB O
to TO O
that DT O
of IN O
a DT O
human JJ O
expert NN O
examining VBG O
the DT O
images NNS O
for IN O
the DT O
presence NN O
of IN O
red JJ O
lesions NNS O
. . O

-DOCSTART- -X- O O

Enhancement NN B-OC
of IN I-OC
blood NN I-OC
glucose NN I-OC
lowering VBG I-OC
effect NN I-OC
of IN O
a DT O
sulfonylurea NN B-INTV
when WRB O
coadministered VBN O
with IN O
an DT O
ACE NNP B-INTV
inhibitor NN I-INTV
: : I-INTV
results NNS O
of IN O
a DT O
glucose-clamp JJ O
study NN O
. . O

BACKGROUND NNP O
To TO O
investigate VB O
if IN O
coadministration NN O
of IN O
enalapril NN B-INTV
alters NNS O
the DT O
metabolic JJ O
effect NN O
of IN O
glibenclamide NN B-INTV
by IN O
employing VBG O
an DT O
euglycemic JJ O
glucose-clamp NN O
technique NN O
in IN O
healthy JJ B-POPU
volunteers NNS I-POPU
. . O

METHODS VB O
A DT O
double-blind JJ O
crossover NN O
study NN O
with IN O
nine CD B-POPU
healthy JJ I-POPU
normotensive JJ I-POPU
volunteers NNS I-POPU
( ( I-POPU
age NN I-POPU
27 CD I-POPU
+/- JJ I-POPU
3 CD I-POPU
y NN I-POPU
, , I-POPU
BMI NNP I-POPU
23.3 CD I-POPU
+/- JJ I-POPU
2.0 CD I-POPU
kg NN I-POPU
m NN I-POPU
( ( I-POPU
-2 NNP I-POPU
) ) I-POPU
; : I-POPU
mean JJ I-POPU
+/- JJ I-POPU
SD NNP I-POPU
) ) I-POPU
-randomly RB I-POPU
assigned VBN O
to TO O
a DT O
3-day JJ O
treatment NN O
of IN O
either CC O
5 CD B-INTV
mg NN I-INTV
enalapril NN I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

In IN O
the DT O
morning NN O
of IN O
the DT O
fourth JJ O
day NN O
, , O
volunteers NNS O
orally RB O
received VBD O
3.5 CD O
mg NNS O
glibenclamide RB B-INTV
together RB O
with IN O
either DT O
10 CD O
mg NN O
enalapril NN B-INTV
or CC I-INTV
placebo NN I-INTV
. . O

Blood NNP B-OC
glucose JJ I-OC
levels NNS I-OC
of IN O
volunteers NNS O
were VBD O
allowed VBN O
to TO O
fall VB O
by IN O
10 CD O
% NN O
from IN O
fasting NN O
levels NNS O
and CC O
were VBD O
kept VBN O
constant JJ O
thereafter NN O
by IN O
employing VBG O
a DT O
Biostator-based JJ B-INTV
euglycemic JJ I-INTV
glucose NN I-INTV
clamp NN I-INTV
. . O

RESULTS NNP O
Coadministration NNP O
of IN O
enalapril-compared JJ B-INTV
with IN O
placebo-resulted JJ B-INTV
in IN O
a DT O
temporarily RB O
higher JJR O
metabolic JJ B-OC
effect NN I-OC
of IN I-OC
glibenclamide NN B-INTV
( ( O
AUC NNP O
GIR NNP O
( ( O
0-120 NNP O
) ) O
229 CD O
+/- JJ O
173 CD O
vs JJ O
137 CD O
+/- JJ O
44 CD O
mg NN O
kg NN O
( ( O
-1 NNP O
) ) O
, , O
p JJ O
< VBP O
0.01 CD O
; : O
mean JJ O
+/- JJ O
SD NNP O
) ) O
, , O
which WDT O
lasted VBD O
from IN O
120 CD O
min NNS O
to TO O
240 CD O
min NNS O
after IN O
enalapril DT B-INTV
administration NN O
. . O

In IN O
parallel NN O
, , O
the DT O
maximal JJ B-OC
metabolic JJ I-OC
effect NN I-OC
of IN I-OC
glibenclamide NN B-INTV
tended VBD O
to TO O
be VB O
higher JJR O
with IN O
enalapril NN B-INTV
( ( O
GIR NNP O
( ( O
max NN O
) ) O
5.2 CD O
+/- JJ O
1.9 CD O
vs JJ O
4.1 CD O
+/- JJ O
1.3 CD O
mg NN O
kg NN O
( ( O
-1 NNP O
) ) O
min NN O
( ( O
-1 NNP O
) ) O
; : O
p CC O
= VB O
0.19 CD O
) ) O
. . O

However RB O
, , O
the DT O
total JJ B-OC
metabolic JJ I-OC
effect NN I-OC
of IN I-OC
glibenclamide NN B-INTV
was VBD O
almost RB O
identical JJ O
between IN O
volunteers NNS O
taking VBG O
enalapril NN B-INTV
or CC I-INTV
placebo NN I-INTV
( ( O
AUC NNP O
GIR NNP O
( ( O
0-600 CD O
) ) O
1267 CD O
+/- JJ O
334 CD O
vs JJ O
1286 CD O
+/- JJ O
249 CD O
mg NN O
kg NN O
( ( O
-1 NNP O
) ) O
, , O
ns RB O
) ) O
. . O

In IN O
contrast NN O
, , O
serum JJ B-OC
insulin NN I-OC
levels NNS I-OC
, , I-OC
C-peptide NNP I-OC
levels NNS I-OC
, , I-OC
and CC I-OC
serum JJ I-OC
glibenclamide NN B-INTV
profiles NNS B-OC
were VBD O
not RB O
significantly RB O
different JJ O
between IN O
enalapril NN B-INTV
and CC I-INTV
placebo NN I-INTV
. . O

CONCLUSIONS VB O
The DT O
results NNS O
of IN O
this DT O
study NN O
may MD O
explain VB O
the DT O
higher JJR O
incidence NN O
of IN O
hypoglycemic JJ B-OC
episodes NNS I-OC
observed VBN O
in IN O
patients NNS O
with IN O
type JJ O
2 CD O
diabetes NNS O
when WRB O
taking VBG O
ACE NNP B-INTV
inhibitors NNS I-INTV
together RB O
with IN O
sulfonylureas NNS B-INTV
or CC O
insulin NN B-INTV
. . O

ACE NNP B-INTV
inhibitors NNS I-INTV
may MD O
cause VB O
a DT O
temporary JJ O
increase NN O
of IN O
the DT O
insulin NN B-OC
sensitivity NN I-OC
, , O
which WDT O
leads VBZ O
to TO O
an DT O
increased VBN B-OC
risk NN I-OC
of IN I-OC
hypoglycemia NN I-OC
under IN O
these DT O
conditions NNS O
. . O

-DOCSTART- -X- O O

Combined VBN O
therapy NN O
for IN O
obese JJ B-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
: : I-POPU
suppertime NN B-INTV
mixed JJ I-INTV
insulin NN I-INTV
with IN I-INTV
daytime JJ I-INTV
sulfonylurea NN I-INTV
. . O

Combined VBN B-INTV
insulin NN I-INTV
and CC I-INTV
sulfonylurea JJ I-INTV
therapy NN I-INTV
for IN O
type NN B-OC
2 CD I-OC
diabetes NNS I-OC
may MD O
improve VB O
the DT O
effectiveness NN B-OC
of IN O
a DT O
single JJ O
injection NN B-INTV
of IN I-INTV
insulin NN I-INTV
, , O
thereby RB O
postponing VBG O
the DT O
need NN O
for IN O
multiple JJ O
injections NNS O
. . O

This DT O
concept NN O
was VBD O
tested VBN O
in IN O
21 CD B-POPU
obese JJ I-POPU
subjects NNS I-POPU
imperfectly RB I-POPU
controlled VBN I-POPU
by IN I-POPU
20 CD I-POPU
mg NNS I-POPU
of IN I-POPU
glyburide JJ I-POPU
daily JJ I-POPU
in IN B-INTV
a DT O
double JJ O
masked VBN O
, , O
placebo-controlled JJ B-INTV
, , O
parallel JJ O
design NN O
, , O
16-week JJ O
protocol NN O
. . O

Premixed CC B-INTV
70 CD I-INTV
% NN I-INTV
NPH/30 NNP I-INTV
% NN I-INTV
Regular NNP I-INTV
insulin NN I-INTV
was VBD I-INTV
taken VBN I-INTV
before RB I-INTV
supper JJ I-INTV
, , I-INTV
and CC I-INTV
the DT I-INTV
dosage NN I-INTV
was VBD I-INTV
adjusted VBN I-INTV
weekly RB I-INTV
by IN I-INTV
an DT I-INTV
algorithm NN I-INTV
seeking VBG I-INTV
nearly RB I-INTV
normal JJ I-INTV
fasting VBG I-INTV
glycemia NN I-INTV
. . O

Eleven JJ B-POPU
subjects NNS I-POPU
using VBG I-POPU
insulin NN I-POPU
plus CC I-POPU
10 CD I-POPU
mg NNS I-POPU
glyburide NN I-POPU
before IN O
breakfast NN O
had VBD O
lower JJR O
mean NN O
fasting VBG O
glucose NN O
at IN O
10-16 JJ O
weeks NNS O
than IN O
10 CD O
subjects NNS O
using VBG O
insulin NN O
with IN O
placebo NN B-INTV
( ( O
mean JJ O
+/- JJ O
SEM NNP O
; : O
5.9 CD O
+/- JJ O
0.3 CD O
versus NN O
7.5 CD O
+/- JJ O
0.7 CD O
mmol/L NN O
; : O
p CC O
less JJR O
than IN O
0.05 CD O
) ) O
, , O
and CC O
had VBD O
a DT O
greater JJR O
decrement NN O
of IN O
glycosylated JJ B-OC
hemoglobin NN I-OC
from IN O
baseline NN O
values NNS O
( ( O
1.3 CD O
+/- JJ O
0.1 CD O
versus NN O
0.8 CD O
+/- JJ O
0.2 CD O
% NN O
A1 NNP O
, , O
p NN O
less JJR O
than IN O
0.05 CD O
) ) O
. . O

After IN O
16 CD O
weeks NNS O
the DT O
combined JJ O
therapy NN O
group NN O
used VBD B-OC
half NN O
as IN O
much JJ O
insulin NN B-OC
as IN O
the DT O
insulin-only JJ O
group NN O
( ( O
50 CD O
+/- JJ O
5 CD O
versus NN O
101 CD O
+/- JJ O
13 CD O
units/d NN O
; : O
p CC O
less JJR O
than IN O
0.01 CD O
) ) O
. . O

Fasting VBG B-OC
serum JJ I-OC
free JJ I-OC
insulin NN I-OC
values NNS I-OC
increased VBD O
58 CD O
% NN O
from IN O
baseline NN O
after IN O
insulin NN O
therapy NN O
in IN O
the DT O
insulin-only JJ O
group NN O
( ( O
p VBZ O
less JJR O
than IN O
0.05 CD O
) ) O
but CC O
did VBD O
not RB O
increase VB O
with IN O
combined JJ O
therapy NN O
. . O

Weight NNP B-OC
gain NN I-OC
was VBD O
similar JJ O
in IN O
the DT O
two CD O
groups NNS O
. . O

These DT O
data NNS O
support NN O
this DT O
form NN O
of IN O
combined JJ O
therapy NN O
as IN O
one CD O
option NN O
for IN O
treating VBG O
obese JJ B-POPU
persons NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes VBZ I-POPU
no RB O
longer RBR O
responsive VB O
to TO O
oral JJ O
therapy NN O
alone RB O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
an DT O
Internet-based JJ B-INTV
intervention NN I-INTV
on IN O
plasma NNS B-OC
glucose JJ I-OC
levels NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

This DT O
study NN O
applied VBD O
a DT O
12-week JJ B-INTV
educational JJ I-INTV
intervention NN I-INTV
that WDT O
used VBD O
both DT B-INTV
the DT I-INTV
cellular JJ I-INTV
phone NN I-INTV
and CC I-INTV
the DT I-INTV
Internet NNP I-INTV
to TO I-INTV
send VB I-INTV
short JJ I-INTV
message NN I-INTV
service NN I-INTV
. . O

Forty-two NNP B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
were VBD O
asked VBN O
to TO O
access NN B-INTV
a DT I-INTV
Web NNP I-INTV
site NN I-INTV
by IN I-INTV
using VBG I-INTV
a DT I-INTV
cellular JJ I-INTV
phone NN I-INTV
or CC I-INTV
wire NN I-INTV
Internet NNP I-INTV
and CC I-INTV
input VB I-INTV
their PRP$ I-INTV
blood NN I-INTV
glucose NN I-INTV
levels NNS I-INTV
every DT I-INTV
day NN I-INTV
. . O

Patients NNS O
were VBD O
sent VBN O
the DT O
optimal JJ B-INTV
recommendations NNS I-INTV
by IN O
both DT O
the DT O
cellular JJ O
phone NN O
and CC O
the DT O
Internet NNP O
. . O

After IN O
12 CD O
weeks NNS O
, , O
the DT O
patients NNS O
had VBD O
a DT O
mean JJ O
decrease NN O
of IN O
28.6 CD O
mg/dL NNS O
in IN O
fasting VBG B-OC
plasma NN I-OC
glucose NN I-OC
and CC O
78.4 CD O
mg/dL NN O
in IN O
2-hour JJ B-OC
postprandial JJ I-OC
blood NN I-OC
sugar NN I-OC
levels NNS I-OC
and CC O
a DT O
mean JJ O
increase NN O
in IN O
the DT O
care NN B-OC
satisfaction NN I-OC
score NN I-OC
. . O

-DOCSTART- -X- O O

Secondary JJ O
prevention NN O
of IN O
macrovascular JJ B-OC
events NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
in IN I-POPU
the DT I-POPU
PROactive NNP I-POPU
Study NNP I-POPU
( ( O
PROspective NNP O
pioglitAzone RB O
Clinical JJ O
Trial NNP O
In IN O
macroVascular JJ O
Events NNS O
) ) O
: : O
a DT O
randomised JJ O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
are VBP O
at IN O
high JJ O
risk NN O
of IN O
fatal JJ O
and CC O
non-fatal JJ O
myocardial JJ B-OC
infarction NN I-OC
and CC O
stroke NN B-OC
. . O

There EX O
is VBZ O
indirect JJ O
evidence NN O
that IN O
agonists NNS O
of IN O
peroxisome JJ O
proliferator-activated JJ O
receptor NN O
gamma NN O
( ( O
PPAR NNP O
gamma NN O
) ) O
could MD O
reduce VB O
macrovascular JJ B-OC
complications NNS I-OC
. . O

Our PRP$ O
aim NN O
, , O
therefore RB O
, , O
was VBD O
to TO O
ascertain VB O
whether IN O
pioglitazone NN B-INTV
reduces NNS O
macrovascular JJ B-OC
morbidity NN I-OC
and CC O
mortality NN B-OC
in IN O
high-risk JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

METHODS NNP O
We PRP O
did VBD O
a DT O
prospective NN O
, , O
randomised VBD O
controlled VBN O
trial NN O
in IN O
5238 CD B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
had VBD I-POPU
evidence NN I-POPU
of IN I-POPU
macrovascular JJ I-POPU
disease NN I-POPU
. . O

We PRP O
recruited VBD O
patients NNS B-POPU
from IN I-POPU
primary-care JJ I-POPU
practices NNS I-POPU
and CC I-POPU
hospitals NNS I-POPU
. . O

We PRP O
assigned VBD O
patients NNS O
to TO O
oral JJ B-INTV
pioglitazone NN I-INTV
titrated VBD I-INTV
from IN I-INTV
15 CD I-INTV
mg NNS I-INTV
to TO I-INTV
45 CD I-INTV
mg NN I-INTV
( ( O
n=2605 JJ O
) ) O
or CC B-INTV
matching VBG I-INTV
placebo NN I-INTV
( ( O
n=2633 JJ O
) ) O
, , O
to TO O
be VB O
taken VBN O
in IN B-INTV
addition NN I-INTV
to TO I-INTV
their PRP$ I-INTV
glucose-lowering JJ I-INTV
drugs NNS I-INTV
and CC I-INTV
other JJ I-INTV
medications NNS I-INTV
. . O

Our PRP$ O
primary JJ O
endpoint NN O
was VBD O
the DT O
composite NN B-OC
of IN I-OC
all-cause JJ I-OC
mortality NN I-OC
, , I-OC
non JJ I-OC
fatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
including VBG I-OC
silent JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
) ) I-OC
, , I-OC
stroke VBD I-OC
, , I-OC
acute JJ I-OC
coronary JJ I-OC
syndrome NN I-OC
, , I-OC
endovascular JJ I-OC
or CC I-OC
surgical JJ I-OC
intervention NN I-OC
in IN I-OC
the DT I-OC
coronary NN I-OC
or CC I-OC
leg NN I-OC
arteries NNS I-OC
, , I-OC
and CC I-OC
amputation NN I-OC
above IN I-OC
the DT I-OC
ankle NN I-OC
. . O

Analysis NN O
was VBD O
by IN O
intention NN O
to TO O
treat VB O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
as IN O
an DT O
International NNP O
Standard NNP O
Randomised VBD O
Controlled NNP O
Trial NNP O
, , O
number NN O
ISRCTN NNP O
NCT00174993 NNP O
. . O

FINDINGS NNP O
Two CD O
patients NNS O
were VBD O
lost VBN O
to TO O
follow-up JJ O
, , O
but CC O
were VBD O
included VBN O
in IN O
analyses NNS O
. . O

The DT O
average JJ O
time NN O
of IN O
observation NN O
was VBD O
34.5 CD O
months NNS O
. . O

514 CD B-POPU
of IN I-POPU
2605 CD I-POPU
patients NNS I-POPU
in IN O
the DT O
pioglitazone NN O
group NN O
and CC O
572 CD O
of IN O
2633 CD O
patients NNS O
in IN O
the DT O
placebo NN O
group NN O
had VBD O
at IN O
least JJS O
one CD O
event NN O
in IN O
the DT O
primary JJ B-OC
composite JJ I-OC
endpoint NN I-OC
( ( O
HR NNP O
0.90 CD O
, , O
95 CD O
% NN O
CI NNP O
0.80-1.02 CD O
, , O
p=0.095 NN O
) ) O
. . O

The DT O
main JJ O
secondary JJ O
endpoint NN O
was VBD O
the DT O
composite NN B-OC
of IN I-OC
all-cause JJ I-OC
mortality NN I-OC
, , I-OC
non-fatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
and CC I-OC
stroke VBD I-OC
. . O

301 CD O
patients NNS O
in IN O
the DT O
pioglitazone NN O
group NN O
and CC O
358 CD O
in IN O
the DT O
placebo NN O
group NN O
reached VBD O
this DT O
endpoint NN B-OC
( ( O
0.84 CD O
, , O
0.72-0.98 CD O
, , O
p=0.027 NN O
) ) O
. . O

Overall JJ B-OC
safety NN I-OC
and CC I-OC
tolerability NN I-OC
was VBD O
good JJ O
with IN O
no DT O
change NN O
in IN O
the DT O
safety NN B-OC
profile NN I-OC
of IN O
pioglitazone NN O
identified VBN O
. . O

6 CD O
% NN O
( ( O
149 CD O
of IN O
2065 CD O
) ) O
and CC O
4 CD O
% NN O
( ( O
108 CD O
of IN O
2633 CD O
) ) O
of IN O
those DT O
in IN O
the DT O
pioglitazone NN O
and CC O
placebo NN O
groups NNS O
, , O
respectively RB O
, , O
were VBD O
admitted VBN O
to TO O
hospital VB O
with IN O
heart NN B-OC
failure NN I-OC
; : I-OC
mortality NN I-OC
rates NNS I-OC
from IN I-OC
heart NN I-OC
failure NN I-OC
did VBD O
not RB O
differ VB O
between IN O
groups NNS O
. . O

INTERPRETATION NNP O
Pioglitazone NNP O
reduces VBZ O
the DT O
composite NN O
of IN O
all-cause JJ O
mortality NN B-OC
, , I-OC
non-fatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
and CC O
stroke VBD B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
have VBP I-POPU
a DT I-POPU
high JJ I-POPU
risk NN I-POPU
of IN I-POPU
macrovascular JJ I-POPU
events NNS I-POPU
. . O

-DOCSTART- -X- O O

Ultrasound NNP B-INTV
therapy NN I-INTV
for IN O
recalcitrant JJ B-POPU
diabetic JJ I-POPU
foot NN I-POPU
ulcers NNS I-POPU
: : I-POPU
results NNS O
of IN O
a DT O
randomized JJ O
, , O
double-blind JJ O
, , O
controlled VBN O
, , O
multicenter NN B-POPU
study NN O
. . O

An DT O
estimated JJ O
15 CD O
% NN O
of IN O
patients NNS O
with IN O
diabetes NNS O
will MD O
develop VB O
a DT O
foot NN B-OC
ulcer NN I-OC
sometime RB O
in IN O
their PRP$ O
life NN O
, , O
making VBG O
them PRP O
30 CD O
to TO O
40 CD O
times NNS O
more RBR O
likely JJ O
to TO O
undergo VB O
amputation NN O
due JJ O
to TO O
a DT O
non-healing JJ O
foot NN O
ulcer NN O
than IN O
the DT O
non-diabetic JJ O
population NN O
. . O

To TO O
determine VB O
the DT O
safety NN O
and CC O
efficacy NN O
of IN O
a DT O
new JJ O
, , O
non-contact JJ B-INTV
, , I-INTV
kilohertz VB I-INTV
ultrasound JJ I-INTV
therapy NN I-INTV
for IN O
the DT O
healing NN O
of IN O
recalcitrant JJ B-POPU
diabetic JJ I-POPU
foot NN I-POPU
ulcers NNS I-POPU
- : O
as RB O
well RB O
as IN O
to TO O
evaluate VB O
the DT O
impact NN O
on IN O
total JJ O
closure NN O
and CC O
quantitative JJ O
bacterial JJ O
cultures NNS O
and CC O
the DT O
effect NN O
on IN O
healing NN O
of IN O
various JJ O
levels NNS O
of IN O
sharp/surgical JJ O
debridement NN O
- : O
a DT O
randomized JJ O
, , O
double-blinded JJ O
, , O
sham-controlled JJ O
, , O
multicenter NN B-POPU
study NN I-POPU
was VBD I-POPU
conducted VBN I-POPU
in IN I-POPU
hospital-based JJ I-POPU
and CC I-POPU
private JJ I-POPU
wound NN I-POPU
care NN I-POPU
clinics NNS I-POPU
. . O

Patients NNS B-POPU
( ( I-POPU
55 CD I-POPU
met VBD I-POPU
criteria NNS I-POPU
for IN I-POPU
efficacy NN I-POPU
analysis NN I-POPU
) ) I-POPU
received VBD I-POPU
standard NN I-POPU
of IN I-POPU
care NN I-POPU
, , I-POPU
which WDT I-POPU
included VBD I-POPU
products NNS I-POPU
that WDT I-POPU
provide VBP I-POPU
a DT I-POPU
moist NN I-POPU
environment NN I-POPU
, , I-POPU
offloading VBG I-POPU
diabetic JJ I-POPU
shoes NNS I-POPU
and CC I-POPU
socks NNS I-POPU
, , I-POPU
debridement NN I-POPU
, , I-POPU
wound JJ I-POPU
evaluation NN I-POPU
, , I-POPU
and CC I-POPU
measurement NN I-POPU
. . O

The DT O
" JJ O
therapy NN O
" NN O
was VBD O
either RB O
active JJ B-INTV
40 CD I-INTV
KHz NNP I-INTV
ultrasound NN I-INTV
delivered VBN I-INTV
by IN I-INTV
a DT I-INTV
saline JJ I-INTV
mist NN I-INTV
or CC I-INTV
a DT I-INTV
" JJ I-INTV
sham NN I-INTV
device NN I-INTV
" NNP I-INTV
which WDT I-INTV
delivered VBD I-INTV
a DT I-INTV
saline JJ I-INTV
mist NN I-INTV
without IN I-INTV
the DT I-INTV
use NN I-INTV
of IN I-INTV
ultrasound NN I-INTV
. . O

After IN O
12 CD O
weeks NNS O
of IN O
care NN O
, , O
the DT O
proportion NN B-OC
of IN I-OC
wounds NNS I-OC
healed VBN I-OC
( ( O
defined VBN O
as IN O
complete JJ O
epithelialization NN O
without IN O
drainage NN O
) ) O
in IN O
the DT O
active JJ O
ultrasound NN O
therapy NN O
device NN O
group NN O
was VBD O
significantly RB O
higher JJR O
than IN O
that DT O
in IN O
the DT O
sham NN O
control NN O
group NN O
( ( O
40.7 CD O
% NN O
versus IN O
14.3 CD O
% NN O
, , O
P NNP O
= NNP O
0.0366 CD O
, , O
Fisher NNP O
's POS O
exact JJ O
test NN O
) ) O
. . O

The DT O
ultrasound JJ B-INTV
treatment NN I-INTV
was VBD O
easy JJ O
to TO O
use VB O
and CC O
no DT O
difference NN O
in IN O
the DT O
number NN O
and CC O
type NN O
of IN O
adverse JJ B-OC
events NNS I-OC
between IN O
the DT O
two CD O
treatment NN O
groups NNS O
was VBD O
noted VBN O
. . O

Of IN O
interest NN O
, , O
wounds NNS O
were VBD O
debrided VBN O
at IN O
baseline NN O
followed VBN O
by IN O
a DT O
quantitative JJ O
culture NN O
biopsy NN O
. . O

The DT O
results NNS O
of IN O
these DT O
cultures NNS O
demonstrated VBD O
a DT O
significant JJ O
bioburden NN B-OC
( ( O
greater JJR O
than IN O
10 CD O
( ( O
5 CD O
) ) O
) ) O
in IN O
the DT O
majority NN O
of IN O
cases NNS O
, , O
despite IN O
a DT O
lack NN O
of IN O
clinical JJ O
signs NNS O
of IN O
infection NN O
. . O

Compared VBN O
to TO O
control VB O
, , O
this DT O
therapeutic JJ O
modality NN O
was VBD O
found VBN O
to TO O
increase VB O
the DT O
healing VBG B-OC
rate NN I-OC
of IN O
recalcitrant NN O
, , O
diabetic JJ O
foot NN O
ulcers NNS O
. . O

-DOCSTART- -X- O O

Nitroglycerin NNP B-INTV
, , I-INTV
nitroprusside RB I-INTV
, , O
or CC O
both DT O
, , O
in IN O
preventing VBG O
radial JJ B-OC
artery NN I-OC
spasm NN I-OC
during IN O
transradial JJ B-POPU
artery NN I-POPU
catheterization NN I-POPU
. . O

OBJECTIVE NNP O
Radial JJ O
artery NN O
spasm NN O
remains VBZ O
a DT O
major JJ O
complication NN O
of IN O
transradial JJ O
coronary JJ O
interventions NNS O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
the DT O
efficacy NN O
of IN O
three CD O
different JJ O
intra-arterial JJ O
vasodilating NN B-INTV
cocktails NNS I-INTV
in IN O
reducing VBG O
the DT O
incidence NN O
of IN O
radial JJ B-OC
artery NN I-OC
spasm NN I-OC
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
transradial JJ I-POPU
coronary JJ I-POPU
angiography NN I-POPU
. . O

The DT O
secondary JJ O
goal NN O
was VBD O
to TO O
assess VB O
the DT O
predictors NNS B-OC
of IN I-OC
arterial JJ I-OC
spasm NN I-OC
in IN O
this DT O
large JJ O
group NN O
of IN O
patients NNS O
. . O

METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
379 CD I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
the DT I-POPU
procedure NN I-POPU
were VBD I-POPU
randomly RB I-POPU
enrolled VBN I-POPU
in IN O
1 CD O
of IN O
3 CD O
groups NNS O
. . O

Every DT O
patient NN O
in IN O
each DT O
of IN O
the DT O
3 CD O
groups NNS O
received VBD O
intra-arterial JJ O
heparin NN B-INTV
, , I-INTV
lidocaine NN I-INTV
and CC O
diltiazem NN B-INTV
. . O

Along IN O
with IN O
that DT O
, , O
patients NNS O
in IN O
Group NNP O
A NNP O
received VBD O
nitroglycerin JJ B-INTV
; : I-INTV
patients NNS O
in IN O
Group NNP O
B NNP O
received VBD O
nitroprusside JJ B-INTV
instead RB O
of IN O
nitroglycerin NN B-INTV
; : I-INTV
and CC O
patients NNS O
in IN O
Group NNP O
C NNP O
received VBD O
both DT O
nitroglycerin NNS B-INTV
and CC I-INTV
nitroprusside RB I-INTV
. . O

A DT O
single JJ O
experienced NN O
operator NN O
, , O
blinded VBD O
to TO O
the DT O
study NN O
drug NN O
, , O
subjectively RB O
determined VBD O
the DT O
presence NN O
of IN O
spasm NN B-OC
. . O

RESULTS NNP O
Of IN O
379 CD O
patients NNS O
, , O
a DT O
total NN O
of IN O
44 CD O
patients NNS O
( ( O
11.6 CD O
% NN O
) ) O
experienced VBD O
spasm NN O
. . O

The DT O
occurrence NN O
of IN O
spasm NN B-OC
was VBD O
similar JJ O
, , O
independent JJ O
of IN O
the DT O
vasodilator NN O
cocktail NN O
used VBN O
( ( O
Group NNP O
A NNP O
: : O
12.2 CD O
% NN O
, , O
Group NNP O
B NNP O
: : O
13.4 CD O
% NN O
, , O
Group NNP O
C NNP O
: : O
9.5 CD O
% NN O
; : O
p CC O
= VB O
0.597 CD O
) ) O
. . O

After IN O
multivariate JJ O
analysis NN O
, , O
the DT O
following JJ O
variables NNS O
were VBD O
found VBN O
to TO O
be VB O
independent JJ O
predictors NNS O
of IN O
spasm NN O
: : O
radial JJ O
artery NN O
diameter NN O
( ( O
RD NNP O
) ) O
/height VBD O
index NN O
( ( O
p JJ O
= NNP O
0.005 CD O
) ) O
, , O
RD/BSA NNP O
index NN O
( ( O
p JJ O
= NNP O
0.012 CD O
) ) O
, , O
and CC O
sheath NN O
outer NN O
diameter NN O
( ( O
OD NNP O
) ) O
/RD NNP O
index NN O
( ( O
p JJ O
= NNP O
0.024 CD O
) ) O
. . O

CONCLUSION NN O
In IN O
this DT O
prospective JJ O
, , O
randomized JJ O
trial NN O
, , O
the DT O
addition NN O
of IN O
a DT O
direct JJ B-INTV
nitric JJ I-INTV
oxide NN I-INTV
donor NN I-INTV
to TO O
nitroglycerin VB B-INTV
in IN O
an DT O
antispastic JJ O
cocktail NN O
did VBD O
not RB O
reduce VB B-OC
the DT I-OC
risk NN I-OC
of IN I-OC
spasm NN I-OC
, , O
and CC O
the DT O
use NN O
of IN O
nitroglycerin NN B-INTV
was VBD O
found VBN O
to TO O
be VB O
as RB B-OC
effective JJ I-OC
as IN I-OC
nitroprusside NN B-INTV
. . O

Also RB O
, , O
morphometric JJ O
and CC O
mechanical JJ O
factors NNS O
play VBP O
a DT O
significant JJ O
role NN O
in IN O
predicting VBG B-OC
the DT I-OC
occurrence NN I-OC
of IN I-OC
radial JJ I-OC
spasm NN I-OC
. . O

The DT O
sex NN O
of IN O
the DT O
patient NN O
, , O
presence NN O
of IN O
diabetes NNS O
, , O
body NN O
surface JJ O
area NN O
and CC O
smoking VBG O
history NN O
appeared VBD O
to TO O
play VB O
no DT O
role NN O
in IN O
predicting VBG B-OC
the DT I-OC
occurrence NN I-OC
of IN I-OC
radial JJ I-OC
spasm NN I-OC
. . O

-DOCSTART- -X- O O

Intermittent NNP B-INTV
recombinant JJ I-INTV
growth NN I-INTV
hormone NN I-INTV
treatment NN I-INTV
in IN O
short JJ B-POPU
children NNS I-POPU
born VBP I-POPU
small JJ I-POPU
for IN I-POPU
gestational JJ I-POPU
age NN I-POPU
: : I-POPU
four-year JJ O
results NNS O
of IN O
a DT O
randomized JJ O
trial NN O
of IN O
two CD O
different JJ O
treatment NN O
regimens NNS O
. . O

BACKGROUND NNP O
Treatment NNP O
of IN O
short JJ B-POPU
children NNS I-POPU
born VBP I-POPU
small JJ I-POPU
for IN I-POPU
gestational JJ I-POPU
age NN I-POPU
SGA NNP I-POPU
with IN O
recombinant JJ B-INTV
human JJ I-INTV
growth NN I-INTV
hormone VBD I-INTV
r-hGH JJ I-INTV
increases NNS O
growth NN B-OC
velocity NN I-OC
during IN O
childhood NN O
. . O

As IN O
in IN O
other JJ O
indications NNS O
, , O
the DT O
growth NN B-OC
velocity NN I-OC
in IN O
these DT O
patients NNS O
is VBZ O
more JJR O
marked JJ O
during IN O
the DT O
first JJ O
year NN O
of IN O
treatment NN O
and CC O
then RB O
decreases VBZ O
. . O

This DT O
study NN O
was VBD O
undertaken VBN O
to TO O
evaluate VB O
the DT O
efficacy NN O
of IN O
different JJ O
r-hGH JJ B-INTV
treatment NN I-INTV
schedules NNS O
( ( O
67 CD O
microg/kg/day NN O
in IN O
a DT O
discontinuous JJ O
or CC O
continuous JJ O
regimen NNS O
) ) O
during IN O
the DT O
second JJ O
year NN O
of IN O
r-hGH JJ O
treatment NN O
by IN O
comparing VBG O
height JJ B-OC
velocity NN I-OC
changes NNS O
and CC O
total JJ B-OC
gain NN I-OC
of IN I-OC
height NN I-OC
over IN O
a DT O
4-year JJ O
period NN O
. . O

METHODS $ O
58 CD B-POPU
growth-retarded JJ I-POPU
SGA NNP I-POPU
children NNS I-POPU
aged VBN I-POPU
2-5 CD I-POPU
years NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO O
a DT O
TOTO NNP B-INTV
regimen NN I-INTV
( ( O
4 CD O
years NNS O
alternating VBG O
treatment NN O
( ( O
T NNP O
) ) O
and CC O
observation NN O
( ( O
O NNP O
) ) O
, , O
n JJ O
= NNP O
30 CD O
) ) O
or CC O
a DT O
TTOO JJ O
regimen NN O
( ( O
2 CD O
years NNS O
' POS O
treatment NN O
, , O
followed VBN O
by IN O
2 CD O
years NNS O
' POS O
observation NN O
, , O
n JJ O
= NNP O
28 CD O
) ) O
. . O

Height NNP B-OC
velocity NN I-OC
HV NNP I-OC
and CC I-OC
total JJ I-OC
height NN I-OC
gain NN I-OC
were VBD O
assessed VBN O
during IN O
the DT O
4-year JJ O
study NN O
. . O

RESULTS NNP O
In IN O
both DT O
groups NNS O
, , O
HV NNP B-OC
and CC I-OC
HV NNP I-OC
standard JJ I-OC
deviation NN I-OC
score VBD I-OC
HV-SDSCA NNP I-OC
increased VBD O
during IN O
treatment NN O
and CC O
decreased VBD O
during IN O
observation NN O
periods NNS O
. . O

Interruption NN O
of IN O
treatment NN O
in IN O
the DT O
TOTO NNP O
group NN O
did VBD O
not RB O
result VB O
in IN O
a DT O
better JJR O
gain NN B-OC
in IN I-OC
height JJ I-OC
standard NN I-OC
deviation NN I-OC
score VBD I-OC
H-SDSCA NNP I-OC
when WRB O
compared VBN O
with IN O
the DT O
TTOO NNP O
group NN O
. . O

After IN O
4 CD O
years NNS O
of IN O
study NN O
, , O
the DT O
gain NN B-OC
in IN I-OC
H-SDSCA NNP I-OC
was VBD O
1.4 CD O
+ NN O
or CC O
- : O
01 CD O
in IN O
the DT O
TOTO NNP O
group NN O
and CC O
1.6 CD O
+ NN O
or CC O
- : O
0.2 CD O
in IN O
the DT O
TTOO NNP O
group NN O
leading VBG O
to TO O
a DT O
mean JJ O
height NN B-OC
of IN O
-2.0 NNP O
+ NNP O
or CC O
- : O
1.0 CD O
SDS NNP O
and CC O
-2.0 NNP O
+ NNP O
or CC O
- : O
0.8 CD O
SDS NNP O
, , O
respectively RB O
. . O

The DT O
rate NN B-OC
of IN I-OC
bone NN I-OC
maturation NN I-OC
was VBD O
similar JJ O
in IN O
the DT O
two CD O
groups NNS O
. . O

CONCLUSIONS NNP O
In IN O
short JJ O
SGA NNP O
children NNS O
, , O
TOTO NNP B-INTV
and CC O
TTOO NNP B-INTV
regimens NNS O
produced VBD O
significant JJ O
improvements NNS O
in IN O
growth NN B-OC
during IN O
r-hGH JJ B-INTV
treatment NN I-INTV
. . O

However RB O
, , O
treatment NN O
interruption NN O
after IN O
1 CD O
year NN O
did VBD O
not RB O
influence VB O
the DT O
overall JJ B-OC
gain NN I-OC
in IN I-OC
height NN I-OC
SDS NNP I-OC
when WRB O
compared VBN O
with IN O
2 CD O
years NNS O
' POS O
continuous JJ O
treatment NN O
. . O

-DOCSTART- -X- O O

Dietary NNP B-INTV
sodium NN I-INTV
intake NN I-INTV
modulates VBZ O
myocardial JJ B-POPU
relaxation NN I-POPU
responsiveness NN B-OC
to TO O
angiotensin VB O
II NNP O
. . O

Dietary NNP B-INTV
sodium NN I-INTV
alters NNS O
renovascular JJ O
responsiveness NN O
to TO O
angiotensin VB O
II NNP O
( ( O
Ang NNP O
II NNP O
) ) O
in IN O
normal JJ B-POPU
subjects NNS I-POPU
. . O

Evidence NN O
supports VBZ O
a DT O
connection NN O
among IN O
dietary JJ B-INTV
sodium NN I-INTV
, , O
the DT O
rennin-angiotensin NN O
system NN O
, , O
and CC O
myocardial JJ O
function NN O
. . O

The DT O
authors NNS O
hypothesized VBD O
that IN O
a DT O
similar JJ O
relationship NN O
would MD O
exist VB O
in IN O
the DT O
heart NN O
, , O
and CC O
that IN O
the DT O
pattern NN O
of IN O
responses NNS O
would MD O
be VB O
qualitatively RB O
similar JJ O
to TO O
the DT O
renal JJ O
vasculature NN O
. . O

Thirteen NNP B-POPU
healthy JJ I-POPU
volunteers NNS I-POPU
( ( I-POPU
aged VBN I-POPU
38.6 CD I-POPU
+/- JJ I-POPU
4 CD I-POPU
years NNS I-POPU
) ) I-POPU
entered VBD O
a DT O
2 CD O
week NN O
crossover NN O
design NN O
study NN O
( ( O
week NN O
1 CD O
, , O
high JJ B-INTV
sodium NN I-INTV
diet JJ I-INTV
[ NNP I-INTV
HS NNP I-INTV
] NNP I-INTV
> VBD O
200 CD O
mmol NN O
Na/day NNP O
; : O
week NN O
2 CD O
, , O
low JJ B-INTV
sodium NN I-INTV
diet JJ I-INTV
[ NNP I-INTV
LS NNP I-INTV
] NNP I-INTV
, , O
< VBD O
10 CD O
mmol NNS O
Na/day NNP O
) ) O
to TO O
investigate VB O
the DT O
influence NN O
of IN O
dietary JJ O
sodium NN O
and CC O
Ang NNP O
II NNP O
on IN O
myocardial JJ O
relaxation NN O
and CC O
renal JJ B-OC
blood NN I-OC
flow NN I-OC
( ( I-OC
RBF NNP I-OC
) ) I-OC
. . O

At IN O
the DT O
end NN O
of IN O
each DT O
study NN O
week NN O
, , O
the DT O
authors NNS O
assessed VBD O
diastolic JJ B-OC
function NN I-OC
( ( I-OC
myocardial JJ I-OC
relaxation NN I-OC
velocities NNS I-OC
[ VBP I-OC
E NNP I-OC
' POS I-OC
] NN I-OC
using VBG O
tissue NN O
Doppler NNP O
imaging NN O
) ) O
and CC O
RBF NNP B-OC
( ( I-OC
para-aminohippurate JJ I-OC
clearance NN I-OC
) ) I-OC
at IN O
baseline NN O
and CC O
after IN O
infusion NN O
of IN O
Ang NNP O
II NNP O
( ( O
3 CD O
ng/kg/min RB O
x JJ O
45 CD O
min NN O
) ) O
. . O

On IN O
HS NNP O
diet NN O
, , O
E NNP O
' POS O
and CC O
RBF NNP B-OC
were VBD O
higher JJR O
than IN O
on IN O
LS NNP O
diet NN O
( ( O
E NNP O
' POS O
14.0 CD O
+/- JJ O
1.2 CD O
vs JJ O
12.6 CD O
+/- JJ O
1.0 CD O
cm/s NN O
, , O
P NNP O
= NNP O
0.02 CD O
; : O
RBF NNP O
596 CD O
+/- JJ O
24 CD O
vs JJ O
563 CD O
+/- JJ O
26 CD O
mL/min NN O
, , O
P NNP O
= NNP O
0.02 CD O
) ) O
. . O

Dietary JJ B-INTV
sodium NN I-INTV
significantly RB O
modulated VBD O
E NNP B-OC
' POS I-OC
and CC I-OC
RBF NNP I-OC
responsiveness NN I-OC
to TO O
Ang NNP O
II NNP O
infusion NN O
in IN O
like JJ O
manner NN O
. . O

HS NNP O
was VBD O
associated VBN O
with IN O
increased JJ O
responsiveness NN O
compared VBN O
with IN O
a DT O
blunted JJ O
LS NNP B-OC
response NN I-OC
( ( O
HS NNP O
DeltaE NNP O
' POS O
-1.4 JJ O
+/- JJ O
0.4 CD O
cm/s NN O
vs NN O
LS NNP O
DeltaE NNP O
' POS O
-0.1 JJ O
+/- JJ O
0.3 CD O
cm/s NN O
, , O
P NNP O
= NNP O
0.02 CD O
; : O
HS NNP O
DeltaRBF NNP O
-135.2 NNP O
+/- JJ O
13.2 CD O
vs NN O
LS NNP O
DeltaRBF NNP O
-62.5 NNP O
+/- JJ O
10.1 CD O
mL/min NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

The DT O
authors NNS O
describe VBP O
for IN O
the DT O
first JJ O
time NN O
that WDT O
dietary JJ B-INTV
sodium NN I-INTV
modulates VBZ O
myocardial JJ B-OC
relaxation NN I-OC
and CC I-OC
responsiveness NN I-OC
to TO O
Ang NNP O
II NNP O
. . O

It PRP O
is VBZ O
important JJ O
to TO O
consider VB O
dietary JJ B-INTV
sodium NN I-INTV
intake NN O
when WRB O
assessing VBG O
diastolic JJ B-OC
function NN I-OC
. . O

Ang NNP O
II NNP O
may MD O
play VB O
a DT O
role NN O
in IN O
the DT O
interaction NN O
between IN O
dietary JJ B-INTV
sodium NN I-INTV
and CC O
myocardial JJ B-OC
relaxation NN I-OC
. . O

Future NNP O
research NN O
will MD O
investigate VB O
whether IN O
abnormalities NNS O
in IN O
these DT O
mechanisms NNS O
play VBP O
a DT O
role NN O
in IN O
disorders NNS O
of IN O
diastolic JJ O
function NN O
. . O

-DOCSTART- -X- O O

Rationale NNP O
and CC O
design NN O
of IN O
the DT O
Folic NNP B-INTV
Acid NNP I-INTV
for IN O
Vascular NNP B-OC
Outcome NNP I-OC
Reduction NNP O
In IN O
Transplantation NNP O
( ( O
FAVORIT NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
chronic JJ I-POPU
kidney NN I-POPU
disease NN I-POPU
, , I-POPU
including VBG I-POPU
kidney NN I-POPU
transplant NN I-POPU
recipients NNS I-POPU
, , O
are VBP O
at IN O
high JJ O
risk NN O
for IN O
cardiovascular JJ B-OC
disease NN I-OC
( ( I-OC
CVD NNP I-OC
) ) I-OC
. . O

In IN O
addition NN O
to TO O
the DT O
constellation NN O
of IN O
traditional JJ O
CVD NNP O
risk NN O
factors NNS O
in IN O
chronic JJ O
kidney NN O
disease NN O
, , O
elevated VBD O
total JJ B-OC
homocysteine NN I-OC
( ( I-OC
tHcy NN I-OC
) ) I-OC
is VBZ O
notably RB O
more RBR O
prevalent JJ O
among IN O
the DT O
general JJ O
population NN O
. . O

The DT B-INTV
Folic NNP I-INTV
Acid NNP I-INTV
for IN O
Vascular NNP O
Outcome NNP O
Reduction NNP O
In IN O
Transplantation NNP O
( ( O
FAVORIT NNP O
) ) O
trial NN O
is VBZ O
designed VBN O
to TO O
evaluate VB O
whether IN O
lowering VBG O
tHcy NN B-OC
using VBG O
vitamin JJ B-INTV
supplementation NN I-INTV
reduces NNS O
CVD NNP B-OC
events NNS I-OC
in IN O
renal JJ B-POPU
transplant NN I-POPU
recipients NNS I-POPU
. . O

METHODS NNP O
FAVORIT NNP O
is VBZ O
a DT O
multicenter JJ O
double-blind NN O
randomized VBD O
controlled JJ O
clinical JJ O
trial NN O
. . O

Participants NNS B-POPU
are VBP I-POPU
clinically RB I-POPU
stable JJ I-POPU
renal JJ I-POPU
transplant NN I-POPU
recipients NNS I-POPU
who WP I-POPU
are VBP I-POPU
6 CD I-POPU
months NNS I-POPU
or CC I-POPU
longer JJR I-POPU
posttransplant NN I-POPU
with IN I-POPU
elevated JJ I-POPU
tHcy NN I-POPU
. . O

Patients NNS O
are VBP O
randomized VBN O
to TO O
a DT O
multivitamin NN B-INTV
that WDT I-INTV
includes VBZ I-INTV
either CC I-INTV
a DT I-INTV
high-dose JJ I-INTV
or CC I-INTV
low-dose JJ I-INTV
of IN I-INTV
folic JJ I-INTV
acid NN I-INTV
( ( O
5 CD O
or CC O
0 CD O
mg NN O
) ) O
, , O
vitamin FW B-INTV
B6 NNP I-INTV
( ( O
50 CD O
or CC O
1.4 CD O
mg NN O
) ) O
, , O
and CC B-INTV
vitamin NN I-INTV
B12 NNP I-INTV
( ( O
1000 CD O
or CC O
2 CD O
microg NN O
) ) O
. . O

The DT O
primary JJ O
end NN O
point NN O
is VBZ O
a DT O
composite NN B-OC
of IN I-OC
incident NN I-OC
or CC I-OC
recurrent NN I-OC
CVD NNP I-OC
outcomes RB I-OC
, , I-OC
that DT I-OC
is VBZ I-OC
, , I-OC
coronary JJ I-OC
heart NN I-OC
, , I-OC
cerebrovascular JJ I-OC
, , I-OC
or CC I-OC
abdominal JJ I-OC
aortic/lower NN I-OC
extremity NN I-OC
arterial JJ I-OC
events NNS I-OC
. . O

A DT O
sample JJ O
size NN O
of IN O
4000 CD O
is VBZ O
estimated VBN O
to TO O
provide VB O
87 CD O
% NN O
power NN O
to TO O
detect VB O
a DT O
20 CD O
% NN O
treatment NN O
effect NN O
. . O

Recruitment NN B-POPU
is VBZ I-POPU
expected VBN I-POPU
to TO I-POPU
continue VB I-POPU
until IN I-POPU
July NNP I-POPU
2006 CD I-POPU
, , O
with IN O
follow-up JJ O
through IN O
June NNP O
2010 CD O
. . O

RESULTS VB O
From IN B-POPU
August NNP I-POPU
2002 CD I-POPU
through IN I-POPU
December NNP I-POPU
2004 CD I-POPU
, , I-POPU
2234 CD I-POPU
of IN I-POPU
the DT I-POPU
target NN I-POPU
4000 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
enrolled VBN I-POPU
. . O

In IN O
accordance NN O
with IN O
trial NN O
design NN O
, , O
mean NN B-OC
( ( I-OC
SD NNP I-OC
) ) I-OC
screening VBG I-OC
tHcy NN I-OC
was VBD O
elevated VBN O
( ( O
17.4 CD O
+/- JJ O
6.2 CD O
micromol/L NN O
) ) O
, , O
and CC O
mean NN B-OC
( ( I-OC
SD NNP I-OC
) ) I-OC
estimated VBD I-OC
creatinine JJ I-OC
clearance NN I-OC
was VBD O
consistent JJ O
with IN O
stable JJ O
renal JJ O
function NN O
( ( O
58.0 CD O
+/- JJ O
18.6 CD O
mL/min NN O
) ) O
. . O

Evaluating VBG O
baseline JJ O
results NNS O
to TO O
date NN O
, , O
42 CD O
% NN O
of IN O
the DT O
randomized JJ O
participants NNS O
had VBD O
a DT O
history NN B-OC
of IN I-OC
diabetes NNS I-OC
mellitus NNS I-OC
, , O
and CC O
21 CD O
% NN O
had VBD O
prevalent JJ O
CVD NNP O
. . O

CONCLUSIONS NNP O
The DT O
FAVORIT NNP O
trial NN O
is VBZ O
designed VBN O
with IN O
sufficient JJ O
power NN O
and CC O
follow-up JJ O
time NN O
to TO O
detect VB O
a DT O
clinically RB O
relevant JJ O
change NN O
in IN O
CVD NNP O
risk NN O
between IN O
renal JJ B-POPU
transplant NN I-POPU
recipients NNS I-POPU
receiving VBG O
a DT O
high JJ O
or CC O
low JJ O
tHcy-lowering JJ O
folic JJ B-INTV
acid NN I-INTV
multivitamin NN I-INTV
. . O

Preliminary JJ O
screening NN O
and CC O
baseline NN O
data NNS O
support NN O
the DT O
trial NN O
's POS O
objectives NNS O
. . O

-DOCSTART- -X- O O

Polydioxanone NNP B-INTV
sternal JJ I-INTV
sutures NNS I-INTV
for IN O
prevention NN O
of IN O
sternal JJ O
dehiscence NN O
. . O

BACKGROUND NNP O
Sternal NNP B-OC
dehiscence NN I-OC
and CC I-OC
wound NN I-OC
instability NN I-OC
are VBP O
troublesome JJ O
complications NNS O
following VBG O
median JJ O
sternotomy NN O
. . O

Classic JJ O
sternal JJ O
approximation NN O
with IN O
stainless JJ O
steel NN O
wires NNS O
may MD O
not RB O
be VB O
the DT O
ideal JJ O
approach NN O
in IN O
patients NNS O
predisposed VBN O
to TO O
these DT O
complications NNS O
. . O

We PRP O
tested VBD O
the DT O
efficacy NN B-OC
of IN O
polydioxanone NN B-INTV
( ( I-INTV
PDS NNP I-INTV
) ) I-INTV
suture NN I-INTV
in IN O
sternal JJ B-OC
closure NN I-OC
and CC O
in IN O
prevention NN O
of IN O
complications NNS B-OC
in IN O
comparison NN O
to TO O
steel NN O
wires NNS O
in IN O
high-risk JJ B-POPU
individuals NNS I-POPU
. . O

METHODS NNP O
Three CD B-POPU
hundred VBD I-POPU
sixty-six JJ I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
elective JJ I-POPU
cardiac JJ I-POPU
surgery NN I-POPU
with IN I-POPU
full JJ I-POPU
median JJ I-POPU
sternotomy NN I-POPU
and CC I-POPU
having VBG I-POPU
body NN I-POPU
surface JJ I-POPU
area NN I-POPU
( ( I-POPU
BSA NNP I-POPU
) ) I-POPU
less JJR I-POPU
than IN I-POPU
1.5 CD I-POPU
m NN I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
PDS NNP B-INTV
( ( O
n JJ O
= NNP O
181 CD O
) ) O
or CC O
stainless JJ B-INTV
steel NN I-INTV
( ( O
SS NNP O
, , O
n JJ O
= NNP O
185 CD O
) ) O
sternal JJ O
approximation NN O
. . O

The DT O
study NN O
was VBD O
focused VBN O
on IN O
aseptic JJ O
sternal JJ O
complications NNS O
, , O
namely RB O
bone JJ B-OC
dehiscence NN I-OC
and CC I-OC
superficial JJ I-OC
wound NN I-OC
instability NN I-OC
. . O

RESULTS NNP O
Both NNP O
bone VBD B-OC
dehiscence NN I-OC
and CC I-OC
superficial JJ I-OC
wound NN I-OC
instability NN I-OC
were VBD O
less JJR O
frequent JJ O
in IN O
the DT O
PDS NNP B-INTV
Group NNP O
( ( O
4 CD O
and CC O
3 CD O
cases NNS O
in IN O
the DT O
SS NNP O
Group NNP O
, , O
respectively RB O
, , O
vs. IN O
no DT O
cases NNS O
in IN O
the DT O
PDS NNP O
Group NNP O
) ) O
. . O

Cox NNP B-OC
proportional JJ I-OC
hazards NNS I-OC
regression NN I-OC
model NN O
in IN O
the DT O
whole NN O
study NN O
population NN O
identified VBN O
female JJ B-OC
sex NN I-OC
, , I-OC
chronic JJ I-OC
renal JJ I-OC
insufficiency NN I-OC
, , I-OC
diabetes VBZ I-OC
, , I-OC
advanced JJ I-OC
age NN I-OC
, , I-OC
lower JJR I-OC
sternal JJ I-OC
thickness NN I-OC
, , I-OC
osteoporosis NN I-OC
, , I-OC
corticosteroid JJ I-OC
therapy NN I-OC
, , I-OC
and CC I-OC
prolonged VBD I-OC
CPB NNP I-OC
or CC I-OC
ventilation NN I-OC
times NNS I-OC
as IN O
predisposing VBG O
factors NNS O
to TO O
any DT O
of IN O
the DT O
two CD O
studied VBD O
sternal JJ O
complications NNS O
. . O

DISCUSSION NNP O
Data NNP O
suggest NN O
that IN O
PDS NNP B-INTV
suture NN O
can MD O
protect VB O
against IN O
development NN O
of IN O
aseptic JJ B-OC
sternal JJ I-OC
complications NNS I-OC
following VBG B-POPU
median JJ I-POPU
sternotomy NN I-POPU
in IN I-POPU
high-risk JJ I-POPU
patients NNS I-POPU
with IN I-POPU
little JJ I-POPU
body NN I-POPU
mass NN I-POPU
. . O

The DT O
adoption NN O
of IN O
PDS NNP B-INTV
in IN O
other JJ O
subsets NNS O
of IN O
patients NNS O
, , O
i.e. FW O
, , O
obese JJ O
individuals NNS O
, , O
is VBZ O
to TO O
be VB O
questioned VBN O
. . O

-DOCSTART- -X- O O

Efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
a DT O
very-low-protein JJ B-INTV
diet NN I-INTV
when WRB O
postponing VBG B-POPU
dialysis NN I-POPU
in IN I-POPU
the DT I-POPU
elderly JJ I-POPU
: : I-POPU
a DT O
prospective JJ O
randomized VBN O
multicenter NN O
controlled VBN O
study NN O
. . O

BACKGROUND NNP O
A NNP O
supplemented VBD B-INTV
very-low-protein JJ I-INTV
diet NN I-INTV
( ( I-INTV
sVLPD NN I-INTV
) ) I-INTV
seems VBZ O
to TO O
be VB O
safe JJ B-OC
when WRB O
postponing VBG O
dialysis NN O
therapy NN O
. . O

STUDY NNP O
DESIGN NNP O
Prospective NNP O
multicenter NN O
randomized VBD O
controlled VBN O
study NN O
designed VBN O
to TO O
assess VB O
the DT O
noninferiority NN O
of IN O
diet JJ B-INTV
versus JJ O
dialysis NN B-INTV
in IN O
1-year JJ O
mortality NN O
assessed VBN O
by IN O
using VBG O
intention-to-treat JJ B-INTV
and CC O
per-protocol JJ O
analysis NN O
. . O

SETTING NNP O
& CC O
PARTICIPANTS NNP O
Italian JJ B-POPU
uremic JJ I-POPU
patients NNS I-POPU
without IN I-POPU
diabetes NNS I-POPU
older JJR I-POPU
than IN I-POPU
70 CD I-POPU
years NNS I-POPU
with IN I-POPU
glomerular JJ I-POPU
filtration NN I-POPU
rate NN I-POPU
of IN I-POPU
5 CD I-POPU
to TO I-POPU
7 CD I-POPU
mL/min NN I-POPU
( ( I-POPU
0.08 CD I-POPU
to TO I-POPU
0.12 CD I-POPU
mL/s NN I-POPU
) ) I-POPU
. . O

INTERVENTION NNP O
Randomization NNP O
to TO O
an DT O
sVLPD NN B-INTV
( ( I-INTV
diet JJ I-INTV
group NN I-INTV
) ) I-INTV
or CC O
dialysis NN B-INTV
. . O

The DT O
sVLPD NN B-INTV
is VBZ O
a DT O
vegan JJ O
diet NN O
( ( O
35 CD O
kcal NN O
; : O
proteins NNS O
, , O
0.3 CD O
g/kg NN O
body NN O
weight VBD O
daily RB O
) ) O
supplemented VBD O
with IN O
keto-analogues NNS O
, , O
amino JJ O
acids NNS O
, , O
and CC O
vitamins NNS O
. . O

Patients NNS O
following VBG O
an DT O
sVLPD NN B-INTV
started VBD O
dialysis NN B-INTV
therapy NN I-INTV
in IN O
the DT O
case NN O
of IN O
malnutrition NN O
, , O
intractable JJ O
fluid NN O
overload NN O
, , O
hyperkalemia NN O
, , O
or CC O
appearance NN O
of IN O
uremic JJ O
symptoms NNS O
. . O

OUTCOMES NNP O
& CC O
MEASUREMENTS NNP O
Mortality NNP B-OC
, , I-OC
hospitalization NN I-OC
, , I-OC
and CC I-OC
metabolic JJ I-OC
markers NNS I-OC
. . O

RESULTS VB O
56 CD B-POPU
patients NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
each DT O
group NN O
, , O
median JJ O
follow-up NN O
was VBD O
26.5 CD O
months NNS O
( ( O
interquartile JJ O
range NN O
, , O
40 CD O
) ) O
, , O
and CC O
patients NNS O
in IN O
the DT O
diet JJ B-INTV
group NN I-INTV
spent VBD O
a DT O
median NN O
of IN O
10.7 CD O
months NNS O
( ( O
interquartile JJ O
range NN O
, , O
11 CD O
) ) O
following VBG O
an DT O
sVLPD NN B-INTV
. . O

Forty CD O
patients NNS O
in IN O
the DT O
diet JJ O
group NN O
started VBD O
dialysis NN B-INTV
treatment NN I-INTV
because IN O
of IN O
either DT O
fluid JJ B-OC
overload NN I-OC
or CC I-OC
hyperkalemia NN I-OC
. . O

There EX O
were VBD O
31 CD O
deaths NNS O
( ( O
55 CD O
% NN O
) ) O
in IN O
the DT O
dialysis NN B-INTV
group NN I-INTV
and CC O
28 CD O
deaths NNS B-OC
( ( O
50 CD O
% NN O
) ) O
in IN O
the DT O
diet JJ B-INTV
group NN I-INTV
. . O

One-year JJ B-OC
observed JJ I-OC
survival NN I-OC
rates NNS I-OC
at IN O
intention NN O
to TO O
treat VB O
were VBD O
83.7 CD O
% NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
74.5 CD O
to TO O
94.0 CD O
) ) O
in IN O
the DT O
dialysis NN B-INTV
group NN O
versus VBD O
87.3 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
, , O
78.9 CD O
to TO O
96.5 CD O
) ) O
in IN O
the DT O
diet JJ B-INTV
group NN O
( ( O
log-rank JJ O
test NN O
for IN O
noninferiority NN O
, , O
P NNP O
< NNP O
0.001 CD O
; : O
for IN O
superiority NN O
, , O
P NNP O
= NNP O
0.6 CD O
) ) O
: : O
the DT O
difference NN O
in IN O
survival NN B-OC
was VBD O
-3.6 JJ O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
, , O
-17 NNP O
to TO O
+10 VB O
; : O
P NNP O
= NNP O
0.002 CD O
) ) O
. . O

The DT B-OC
hazard NN I-OC
ratio NN I-OC
for IN I-OC
hospitalization NN I-OC
was VBD O
1.50 CD O
for IN O
the DT O
dialysis NN B-INTV
group NN I-INTV
( ( O
95 CD O
% NN O
CI NNP O
, , O
1.11 CD O
to TO O
2.01 CD O
; : O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

LIMITATIONS VB O
The DT O
unblinded JJ O
nature NN O
of IN O
the DT O
study NN O
, , O
exclusion NN O
of IN O
patients NNS O
with IN O
diabetes NNS O
, , O
and CC O
incomplete JJ O
enrollment NN O
. . O

CONCLUSION NNP O
An DT O
sVLPD NN B-INTV
was VBD O
effective JJ B-OC
and CC I-OC
safe JJ I-OC
when WRB O
postponing VBG O
dialysis NN O
treatment NN O
in IN O
elderly JJ B-POPU
patients NNS I-POPU
without IN I-POPU
diabetes NNS I-POPU
. . O

-DOCSTART- -X- O O

Tacrolimus NNP B-INTV
monotherapy NN O
without IN O
steroids NNS O
after IN B-POPU
liver JJ I-POPU
transplantation NN I-POPU
-- : I-POPU
a DT I-POPU
prospective JJ O
randomized VBN O
double-blinded JJ O
placebo-controlled JJ O
trial NN O
. . O

Early JJ O
steroid NN O
withdrawal NN O
after IN B-POPU
liver JJ I-POPU
transplantation NN I-POPU
( ( I-POPU
LT NNP I-POPU
) ) I-POPU
is VBZ O
desirable JJ O
in IN O
order NN O
to TO O
reduce VB O
steroid JJ O
side NN O
effects NNS O
. . O

Between NNP B-POPU
February NNP I-POPU
2000 CD I-POPU
and CC I-POPU
August NNP I-POPU
2004 CD I-POPU
, , I-POPU
110 CD I-POPU
patients NNS I-POPU
after IN I-POPU
LT NNP I-POPU
were VBD O
included VBN O
in IN O
this DT O
prospective JJ O
, , O
randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
trial NN O
. . O

Randomization NN O
was VBD O
performed VBN O
before IN O
LT NNP O
. . O

In IN O
all DT O
patients NNS O
, , O
tacrolimus NN B-INTV
was VBD I-INTV
used VBN I-INTV
without IN I-INTV
induction NN I-INTV
therapy NN I-INTV
. . O

All DT B-POPU
patients NNS I-POPU
received VBD I-POPU
methylprednisolon NN I-POPU
for IN I-POPU
14 CD I-POPU
days NNS I-POPU
, , O
thereafter RB O
a DT O
double-blinded JJ O
medication NN O
containing VBG O
either CC O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
56 CD O
) ) O
or CC O
methylprednisolon NN B-INTV
( ( O
n JJ O
= NNP O
54 CD O
) ) O
for IN O
6 CD O
months NNS O
, , O
which WDT O
was VBD O
completely RB O
stopped JJ O
thereafter RB O
. . O

End NN O
points NNS O
were VBD O
patient JJ B-OC
and CC I-OC
graft NN I-OC
survival NN I-OC
, , I-OC
acute NN I-OC
and CC I-OC
chronic JJ I-OC
rejection NN I-OC
, , I-OC
and CC I-OC
incidence NN I-OC
of IN I-OC
steroid JJ I-OC
side NN I-OC
effects NNS I-OC
during IN O
the DT O
first JJ O
year NN O
after IN B-POPU
LT NNP I-POPU
. . O

One-year JJ O
patient NN B-OC
survival NN I-OC
was VBD O
85.7 CD O
% NN O
( ( O
placebo NN O
) ) O
and CC O
88.8 CD O
% NN O
( ( O
steroid NN O
) ) O
( ( O
p JJ O
= NNP O
0.572 CD O
) ) O
. . O

Twenty-seven NNP O
( ( O
48.2 CD O
% NN O
) ) O
and CC O
19 CD O
( ( O
35.2 CD O
% NN O
) ) O
patients NNS O
experienced VBD O
acute JJ B-OC
rejection NN I-OC
( ( O
placebo JJ O
versus NN O
steroid NN O
, , O
respectively RB O
; : O
p VB O
= $ O
0.116 CD O
) ) O
. . O

Two CD O
patients NNS O
in IN O
the DT O
placebo NN O
group NN O
but CC O
none NN O
in IN O
the DT O
steroid NN O
group NN O
experienced VBD O
chronic JJ B-OC
rejection NN I-OC
( ( O
p JJ O
= NNP O
0.257 CD O
) ) O
. . O

The DT O
rates NNS B-OC
of IN I-OC
side JJ I-OC
effects NNS I-OC
were VBD O
( ( B-INTV
placebo JJ I-INTV
versus NN O
steroid NN B-INTV
, , O
respectively RB O
) ) O
: : O
CMV JJ B-OC
infection NN I-OC
25 CD O
% NN O
versus IN O
33 CD O
% NN O
( ( O
p JJ O
= NNP O
0.336 CD O
) ) O
, , O
post-transplant JJ B-OC
diabetes NNS I-OC
30 CD O
% NN O
versus IN O
53 CD O
% NN O
( ( O
p JJ O
= NNP O
0.024 CD O
) ) O
, , O
hypertension VBP B-OC
39 CD O
% NN O
versus IN O
52 CD O
% NN O
( ( O
p JJ O
= NNP O
0.248 CD O
) ) O
, , O
hypercholesterolemia $ B-OC
10 CD O
% NN O
versus IN O
41 CD O
% NN O
( ( O
p JJ O
= NNP O
0.002 CD O
) ) O
and CC O
hypertriglyceridemia $ B-OC
32 CD O
% NN O
versus IN O
54 CD O
% NN O
( ( O
p JJ O
= NNP O
0.046 CD O
) ) O
. . O

In IN O
conclusion NN O
, , O
early JJ O
steroid NN O
withdrawal NN O
after IN B-POPU
LT NNP I-POPU
is VBZ O
feasible JJ B-OC
under IN O
tacrolimus NN B-INTV
monotherapy NN O
without IN O
increased JJ O
rejection NN O
rates NNS O
and CC O
with IN O
a DT O
lower JJR B-OC
rate NN I-OC
of IN I-OC
side NN I-OC
effects NNS I-OC
. . O

-DOCSTART- -X- O O

The DT O
peroxisome JJ O
proliferator-activated JJ O
receptor-gamma JJ O
agonist NN O
pioglitazone NN B-INTV
increases VBZ O
number NN B-OC
and CC I-OC
function NN I-OC
of IN I-OC
endothelial JJ I-OC
progenitor NN I-OC
cells NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
and CC I-POPU
normal JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
. . O

OBJECTIVE CC O
Peroxisome JJ O
proliferator-activated JJ O
receptor-gamma NN O
( ( O
PPAR NNP O
gamma NN O
) ) O
agonists VBZ O
( ( B-INTV
thiazolidinediones NNS I-INTV
[ NNP I-INTV
TZDs NNP I-INTV
] NNP I-INTV
) ) I-INTV
are VBP O
used VBN O
for IN O
the DT O
treatment NN O
of IN O
diabetes NNS O
. . O

Bone CD O
marrow-derived JJ O
endothelial JJ O
progenitor NN O
cells NNS O
( ( O
EPCs NNP O
) ) O
improve VB O
vascular JJ B-OC
function NN I-OC
and CC O
predict NN O
cardiovascular NN B-OC
risk NN I-OC
. . O

The DT O
effect NN O
of IN O
pioglitazone NN B-INTV
therapy NN O
on IN O
EPCs NNP O
was VBD O
examined VBN O
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
AND NNP O
RESULTS NNP O
We PRP O
performed VBD O
a DT O
prospective JJ O
, , O
randomized VBN O
, , O
double-blind JJ O
study NN O
on IN O
patients NNS B-POPU
with IN I-POPU
documented JJ I-POPU
stable JJ I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
and CC I-POPU
normal JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
. . O

Of IN O
54 CD B-POPU
patients NNS I-POPU
with IN I-POPU
normal JJ I-POPU
fasting VBG I-POPU
glucose JJ I-POPU
levels NNS I-POPU
, , I-POPU
18 CD I-POPU
showed VBD I-POPU
impaired JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
and CC I-POPU
36 CD I-POPU
patients NNS I-POPU
with IN I-POPU
normal JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO O
30-day JJ O
treatment NN O
with IN O
pioglitazone NN B-INTV
( ( O
45 CD O
mg NN O
) ) O
or CC B-INTV
placebo NN I-INTV
in IN I-INTV
addition NN I-INTV
to TO I-INTV
optimal VB I-INTV
medical JJ I-INTV
therapy NN I-INTV
. . O

All DT O
patients NNS O
in IN O
the DT O
TZD NNP B-INTV
group NN O
showed VBD O
an DT O
increase NN O
of IN O
adiponectin JJ B-OC
levels NNS I-OC
as IN O
an DT O
indicator NN O
of IN O
compliance NN O
( ( O
11.4 CD O
+/- JJ O
1.1 CD O
to TO O
36.8 CD O
+/- JJ O
2.1 CD O
microg/ml NN O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

TZD NNP B-INTV
, , O
but CC O
not RB O
placebo VB B-INTV
, , O
decreased VBN O
mean JJ B-OC
high-sensitivity NN I-OC
C-reactive JJ I-OC
protein NN I-OC
to TO O
43 CD O
+/- JJ O
19 CD O
% NN O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

Pioglitazone NN O
increased VBD O
CD34 NNP B-OC
( ( I-OC
+ NNP I-OC
) ) I-OC
/kinase NN I-OC
insert JJ I-OC
domain NN I-OC
receptor NN I-OC
( ( I-OC
+ NNP I-OC
) ) I-OC
EPCs NNP I-OC
to TO O
142 CD O
+/- JJ O
9 CD O
% NN O
and CC O
cultured VBD B-OC
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled JJ I-OC
acetylated JJ I-OC
LDL NNP I-OC
( ( I-OC
+ NNP I-OC
) ) I-OC
/lectin NN I-OC
( ( I-OC
+ NNP I-OC
) ) I-OC
EPCs NNP I-OC
to TO O
180 CD O
+/- JJ O
3 CD O
% NN O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

EPC JJ B-OC
numbers NNS I-OC
were VBD O
not RB O
changed VBN O
in IN O
the DT O
placebo NN O
group NN O
. . O

TZD NNP O
increased VBD O
the DT O
SDF-1-induced NNP B-OC
migratory NN I-OC
capacity NN I-OC
to TO O
146 CD O
+/- JJ O
9 CD O
% NN O
per IN O
EPC NNP O
number NN O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
and CC O
upregulated VBD O
the DT O
clonogenic JJ B-OC
potential NN I-OC
of IN I-OC
EPCs NNP I-OC
, , O
increasing VBG O
the DT B-OC
colony-forming JJ I-OC
units NNS I-OC
to TO O
172 CD O
+/- JJ O
12 CD O
% NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

In IN O
cultured JJ O
human JJ O
EPCs NNP O
, , O
TZD NNP B-INTV
increased VBD O
EPC NNP B-OC
numbers NNS I-OC
and CC I-OC
migration NN I-OC
and CC I-OC
reduced JJ I-OC
NADPH-oxidase NNP I-OC
activity NN I-OC
. . O

The DT O
TZD NNP B-INTV
effect NN O
was VBD O
reversed VBN O
by IN O
the DT O
PPAR NNP O
gamma NN O
antagonist NN O
GW9662 NNP O
and CC O
mimicked VBN O
by IN O
treatment NN O
with IN O
adiponectin NN O
. . O

CONCLUSIONS VB O
The DT O
PPAR NNP O
gamma NN O
agonist NN O
pioglitazone NN B-INTV
increases VBZ O
the DT O
number NN B-OC
and CC I-OC
function NN I-OC
of IN I-OC
EPCs NNP I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
. . O

The DT O
effect NN O
represents VBZ O
a DT O
potential JJ O
regenerative NN O
mechanism NN O
in IN O
atherosclerosis NN O
and CC O
is VBZ O
observed VBN O
in IN O
normoglycemic JJ B-POPU
individuals NNS I-POPU
with IN I-POPU
stable JJ I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
. . O

-DOCSTART- -X- O O

Efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
sildenafil NN B-INTV
in IN O
Asian JJ B-POPU
males NNS I-POPU
with IN I-POPU
erectile JJ I-POPU
dysfunction NN I-POPU
and CC I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
. . O

OBJECTIVE NNP O
Assess NNP O
the DT O
effectiveness NN O
of IN O
sildenafil NN B-INTV
in IN O
Asian JJ B-POPU
males NNS I-POPU
with IN I-POPU
erectile JJ I-POPU
dysfunction NN I-POPU
( ( I-POPU
ED NNP I-POPU
) ) I-POPU
and CC I-POPU
one CD I-POPU
or CC I-POPU
more JJR I-POPU
of IN I-POPU
the DT I-POPU
co-morbidities NNS I-POPU
, , I-POPU
mild-to-moderate JJ I-POPU
hypertension NN I-POPU
, , I-POPU
dyslipidemia NN I-POPU
, , I-POPU
and CC I-POPU
diabetes NNS I-POPU
. . O

MATERIAL NNP O
AND NNP O
METHOD NNP O
A NNP O
six-week JJ O
, , O
double-blind JJ O
, , O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
, , O
multicenter NN O
study NN O
was VBD O
carried VBN O
out RP O
in IN O
Thailand NNP O
, , O
Malaysia NNP O
and CC O
Singapore NNP O
. . O

One CD B-POPU
hundred CD I-POPU
and CC I-POPU
fifty VB I-POPU
five CD I-POPU
male JJ I-POPU
subjects NNS I-POPU
were VBD O
randomized VBN O
( ( O
2:1 CD O
) ) O
to TO O
sildenafil VB B-INTV
( ( O
n JJ O
= NNP O
104 CD O
) ) O
or CC O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
51 CD O
) ) O
. . O

Sildenafil NNP B-INTV
was VBD O
started VBN O
at IN O
50 CD O
mg NN O
and CC O
increased VBD O
( ( O
100 CD O
mg NN O
) ) O
or CC O
decreased VBN O
( ( O
25 CD O
mg NN O
) ) O
at IN O
week NN O
2 CD O
if IN O
necessary JJ O
. . O

RESULTS VB O
On IN O
the DT O
primary JJ O
efficacy NN O
endpoint NN O
, , O
sildenafil-treated JJ B-INTV
subjects NNS O
had VBD O
significantly RB O
better JJR O
scores NNS B-OC
on IN O
the DT O
International NNP B-OC
Index NNP I-OC
of IN I-OC
Erectile NNP I-OC
Function NNP I-OC
( ( I-OC
IIEF NNP I-OC
) ) I-OC
questions NNS I-OC
3 CD I-OC
and CC I-OC
4 CD I-OC
than IN O
placebo NN O
( ( O
p JJ O
< NN O
0.001 CD O
, , O
both DT O
questions NNS O
) ) O
. . O

When WRB O
accumulated VBN O
into IN O
IIEF NNP O
domains NNS O
, , O
all DT O
five CD O
domains NNS O
were VBD O
significant JJ O
in IN O
favor NN O
of IN O
sildenafil NN O
. . O

In IN O
addition NN O
, , O
sildenafil-treated JJ B-INTV
subjects NNS O
were VBD O
more RBR O
satisfied JJ B-OC
with IN O
treatment NN O
and CC O
had VBD O
a DT O
higher JJR O
intercourse JJ B-OC
success NN I-OC
rate NN I-OC
. . O

The DT O
majority NN O
of IN O
adverse JJ O
events NNS O
were VBD O
mild VBN O
in IN O
severity NN B-OC
; : I-OC
the DT O
most RBS O
commonly RB O
reported VBD O
treatment-related JJ O
events NNS O
were VBD O
dizziness NN B-OC
( ( O
7.7 CD O
% NN O
) ) O
and CC O
tinnitus NN B-OC
( ( O
2.9 CD O
% NN O
) ) O
. . O

CONCLUSION NNP O
Sildenafil NNP O
( ( O
25 CD O
, , O
50 CD O
, , O
and CC O
100 CD O
mg NN O
) ) O
was VBD O
found VBN O
to TO O
be VB O
an DT O
effective JJ O
, , O
safe JJ O
, , O
and CC O
well-tolerated JJ O
treatment NN O
for IN O
ED NNP O
in IN O
the DT O
present JJ O
study NN O
population NN O
of IN O
Thai NNP O
, , O
Malaysian NNP O
, , O
and CC O
Singaporean NNP O
males NNS O
who WP O
also RB O
had VBD O
increased VBN O
cardiovascular JJ O
risk NN O
-DOCSTART- -X- O O

Prevention NN O
of IN O
type NN B-POPU
2 CD I-POPU
( ( I-POPU
non-insulin-dependent JJ I-POPU
) ) I-POPU
diabetes VBZ I-POPU
mellitus VBN I-POPU
by IN O
diet JJ O
and CC O
physical JJ O
exercise NN O
. . O

The DT O
6-year JJ O
Malmö NNP O
feasibility NN O
study NN O
. . O

From IN O
a DT O
previously RB O
reported VBN O
5-year JJ O
screening VBG O
programme NN O
of IN B-POPU
6,956 CD I-POPU
47-49-year-old JJ I-POPU
Malmö NNP I-POPU
males NNS I-POPU
, , I-POPU
a DT I-POPU
series NN I-POPU
of IN I-POPU
41 CD I-POPU
subjects NNS I-POPU
with IN I-POPU
early-stage JJ I-POPU
Type NNP I-POPU
2 CD I-POPU
( ( I-POPU
non-insulin-dependent JJ I-POPU
) ) I-POPU
diabetes VBZ I-POPU
mellitus JJ I-POPU
and CC I-POPU
181 CD I-POPU
subjects NNS I-POPU
with IN I-POPU
impaired JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
were VBD O
selected VBN O
for IN O
prospective JJ O
study NN O
and CC O
to TO O
test VB O
the DT O
feasibility NN O
aspect NN O
of IN O
long-term JJ O
intervention NN O
with IN O
an DT O
emphasis NN O
on IN B-INTV
life-style JJ I-INTV
changes NNS I-INTV
. . O

A DT O
5-year JJ O
protocol NN O
, , O
including VBG O
an DT O
initial JJ O
6-months JJ O
( ( O
randomised VBN O
) ) O
pilot NN O
study NN B-INTV
, , I-INTV
consisting VBG I-INTV
of IN I-INTV
dietary JJ I-INTV
treatment NN I-INTV
and/or JJ I-INTV
increase NN I-INTV
of IN I-INTV
physical JJ I-INTV
activity NN I-INTV
or CC I-INTV
training NN I-INTV
with IN I-INTV
annual JJ I-INTV
check-ups NNS I-INTV
, , O
was VBD O
completed VBN O
by IN O
90 CD O
% NN O
of IN O
subjects NNS B-OC
. . O

Body NNP B-OC
weight NN I-OC
was VBD O
reduced VBN O
by IN O
2.3-3.7 JJ O
% NN O
among IN O
participants NNS O
, , O
whereas JJ O
values NNS O
increased VBN O
by IN O
0.5-1.7 CD O
% NN O
in IN O
non-intervened JJ O
subjects NNS O
with IN O
impaired JJ O
glucose JJ O
tolerance NN O
and CC O
in IN O
normal JJ O
control NN O
subjects NNS O
( ( O
p NN O
less JJR O
than IN O
0.0001 CD B-OC
) ) I-OC
; : I-OC
maximal JJ I-OC
oxygen NN I-OC
uptake NN I-OC
( ( O
ml.min-1.kg-1 JJ O
) ) O
was VBD O
increased VBN O
by IN O
10-14 CD O
% NN O
vs NN O
decreased VBN O
by IN O
5-9 JJ O
% NN O
, , O
respectively RB O
( ( O
p NN O
less JJR O
than IN O
0.0001 CD B-OC
) ) I-OC
. . O

Glucose JJ B-OC
tolerance NN I-OC
was VBD O
normalized VBN O
in IN O
greater JJR O
than IN O
50 CD O
% NN O
of IN O
subjects NNS O
with IN O
impaired JJ O
glucose JJ O
tolerance NN O
, , O
the DT O
accumulated JJ B-OC
incidence NN I-OC
of IN I-OC
diabetes NNS I-OC
was VBD O
10.6 CD O
% NN O
, , O
and CC O
more JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
diabetic JJ O
patients NNS O
were VBD O
in IN B-OC
remission NN I-OC
after IN O
a DT O
mean JJ O
follow-up NN O
of IN O
6 CD O
years NNS B-OC
. . O

Blood NNP B-OC
pressure NN I-OC
, , I-OC
lipids NNS I-OC
, , I-OC
and CC I-OC
hyperinsulinaemia NN I-OC
were VBD O
reduced VBN O
and CC B-OC
early JJ I-OC
insulin NN I-OC
responsiveness NN I-OC
to TO I-OC
glucose VB I-OC
loading VBG O
preserved VBN O
. . O

Improvement NN O
in IN B-OC
glucose JJ I-OC
tolerance NN I-OC
was VBD O
correlated VBN O
to TO B-OC
weight VB I-OC
reduction NN I-OC
( ( O
r JJ O
= NN O
0.19 CD O
, , O
p NN O
less JJR O
than IN O
0.02 CD O
) ) O
and CC B-OC
increased JJ I-OC
fitness NN I-OC
( ( O
r JJ O
= NN O
0.22 CD O
, , O
p NN O
less JJR O
than IN O
0.02 CD O
) ) O
. . O

Treatment NN O
was VBD O
safe JJ O
, , O
and CC O
mortality NN O
was VBD O
low JJ O
( ( O
in IN O
fact NN O
33 CD O
% NN O
lower JJR O
than IN O
in IN O
the DT O
remainder NN O
of IN O
the DT O
cohort NN O
) ) O
. . O

( ( O
ABSTRACT NNP O
TRUNCATED NNP O
AT NNP O
250 CD O
WORDS NNP O
) ) O
-DOCSTART- -X- O O

Nateglinide NNP B-INTV
reduces VBZ O
carotid JJ B-OC
intima-media JJ I-OC
thickening NN I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
under IN I-POPU
good JJ I-POPU
glycemic JJ I-POPU
control NN I-POPU
. . O

OBJECTIVE NNP O
Postprandial NNP O
hyperglycemia NN O
observed VBD O
in IN O
type NN B-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus NN O
is VBZ O
a DT O
risk NN O
factor NN O
for IN O
atherosclerosis NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
investigate VB O
the DT O
effect NN O
of IN O
strict JJ B-INTV
glycemic NNS I-INTV
control NN I-INTV
by IN O
nateglinide NN O
on IN O
common JJ O
carotid NN B-OC
far RB I-OC
wall JJ I-OC
intima-media JJ I-OC
thickness NN I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
already RB I-POPU
under IN I-POPU
good JJ I-POPU
glycemic JJ I-POPU
control NN I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
We PRP O
performed VBD O
an DT O
open JJ O
labeled VBN O
randomized JJ O
prospective JJ O
trial NN O
on IN O
78 CD B-POPU
drug-naive JJ I-POPU
type NN I-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
whose WP$ I-POPU
HbA1c NNP I-POPU
was VBD I-POPU
less JJR I-POPU
than IN I-POPU
6.5 CD I-POPU
% NN I-POPU
. . O

Thirty-eight JJ B-POPU
patients NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
nateglinide NN B-INTV
( ( I-INTV
270 CD I-INTV
mg/dL NN I-INTV
) ) I-INTV
and CC I-INTV
40 CD I-INTV
to TO I-INTV
control VB I-INTV
group NN I-INTV
( ( I-INTV
no DT I-INTV
treatment NN I-INTV
) ) I-INTV
. . O

After IN O
12 CD O
months NNS O
, , O
a DT O
significant JJ O
reduction NN O
in IN O
HbA1c NNP B-OC
was VBD O
observed VBN O
in IN O
the DT O
nateglinide JJ O
group NN O
, , O
whereas IN O
a DT O
significant JJ O
increase NN O
of IN O
HbA1c NNP B-OC
was VBD O
observed VBN O
in IN O
the DT O
untreated JJ O
group NN O
. . O

The DT O
carotid JJ B-OC
intima-media JJ I-OC
thickness NN I-OC
at IN O
the DT O
end NN O
of IN O
1-year JJ O
follow-up NN O
was VBD O
significantly RB O
reduced VBN O
in IN O
the DT O
nateglinide JJ O
group NN O
compared VBN O
with IN O
the DT O
untreated JJ B-INTV
group NN I-INTV
( ( O
-0.017+/-0.054 JJ O
mm/year VBP O
versus IN O
0.024+/-0.066 JJ O
mm/year NN O
, , O
P=0.0064 NNP O
) ) O
. . O

Whereas NNP O
nateglinide JJ O
treatment NN O
also RB O
reduced VBD O
triglyceride JJ B-OC
, , I-OC
highly-sensitive JJ I-OC
C-reactive JJ I-OC
protein NN I-OC
, , I-OC
and CC I-OC
E-selectin NNP I-OC
, , O
multiple JJ O
regression NN O
analysis NN O
identified VBN O
HbA1c NNP B-OC
as IN O
the DT O
only JJ O
significant JJ O
independent JJ O
determinant NN O
of IN O
the DT O
change NN O
in IN O
carotid JJ B-OC
intima-media JJ I-OC
thickness NN I-OC
. . O

CONCLUSION NNP O
In IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
good JJ I-POPU
glycemic NNS I-POPU
control NN I-POPU
, , O
further JJ O
strict JJ B-INTV
glycemic NNS I-INTV
control NN I-INTV
by IN I-INTV
nateglinide JJ I-INTV
results NNS O
in IN O
regression NN O
of IN O
carotid JJ B-OC
intima-media JJ I-OC
thickness NN I-OC
. . O

-DOCSTART- -X- O O

A DT O
double-blind NN O
, , O
randomised VBD O
trial NN O
of IN O
tesaglitazar JJ B-INTV
versus NN O
pioglitazone NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus RB I-POPU
. . O

The DT O
efficacy NN O
and CC O
safety NN O
of IN O
tesaglitazar NN B-INTV
( ( O
0.5 CD O
and CC O
1 CD O
mg NN O
) ) O
and CC O
pioglitazone NN B-INTV
( ( O
15 CD O
, , O
30 CD O
and CC O
45 CD O
mg NN O
) ) O
were VBD O
compared VBN O
in IN O
a DT O
24-week JJ O
, , O
randomised JJ O
, , O
double-blind JJ O
study NN O
in IN O
1,707 CD B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus RB I-POPU
. . O

Tesaglitazar VB B-INTV
1 CD O
mg NN O
was VBD O
non-inferior JJ O
to TO O
pioglitazone VB B-INTV
45 CD O
mg NN O
for IN O
change NN O
from IN O
baseline NN O
in IN O
glycosylated JJ O
haemoglobin NN O
( ( O
HbA1C NNP O
) ) O
at IN O
24 CD O
weeks NNS O
( ( O
difference NN O
: : O
-0.056 JJ O
[ VBP O
95 CD O
% NN O
confidence NN O
intervals NNS O
-0.161 VBP O
, , O
0.049 CD O
] NN O
, , O
pNI NN O
< VBD O
0.001 CD O
for IN O
non-inferiority JJ O
hypothesis NN O
) ) O
. . O

Tesaglitazar $ B-INTV
1 CD O
mg NN O
improved VBN O
triglyceride NN B-OC
( ( I-OC
TG NNP I-OC
) ) I-OC
, , I-OC
high-density JJ I-OC
lipoprotein NN I-OC
cholesterol NN I-OC
( ( I-OC
HDL-C NNP I-OC
) ) I-OC
and CC I-OC
non-HDL-C JJ I-OC
levels NNS I-OC
compared VBN O
with IN O
all DT O
pioglitazone NN O
doses VBZ O
at IN O
24 CD O
weeks NNS O
( ( O
p JJ O
< NNP O
0.001 CD O
) ) O
. . O

Low-density JJ B-OC
lipoprotein NN I-OC
cholesterol NN I-OC
( ( I-OC
LDL-C NNP I-OC
) ) I-OC
was VBD O
lower JJR O
with IN O
tesaglitazar NN B-INTV
for IN O
all DT O
pioglitazone NN B-INTV
comparisons NNS O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
, , O
except IN O
for IN O
tesaglitazar NN B-INTV
0.5 CD O
mg NN O
versus NN O
pioglitazone NN B-INTV
15 CD O
mg. NN O
Tesaglitazar NNP B-INTV
1 CD O
mg NN O
decreased VBD O
LDL NNP B-OC
particle NN I-OC
number NN I-OC
, , O
when WRB O
compared VBN O
with IN O
all DT O
pioglitazone NN B-INTV
doses NNS O
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
. . O

Both DT O
agents NNS O
increased VBD O
body NN B-OC
weight NN I-OC
and CC I-OC
peripheral JJ I-OC
oedema NN I-OC
in IN O
a DT O
dose-dependent JJ O
manner NN O
, , O
but CC O
only RB O
tesaglitazar NN B-INTV
increased VBD O
serum JJ B-OC
creatinine NN I-OC
. . O

In IN O
summary JJ O
, , O
tesaglitazar NN B-INTV
provided VBD O
similar JJ O
glycaemic JJ B-OC
control NN I-OC
to TO O
pioglitazone VB B-INTV
, , O
was VBD O
associated VBN O
with IN O
significant JJ O
improvement NN O
in IN O
lipid JJ B-OC
and CC I-OC
lipoprotein JJ I-OC
variables NNS I-OC
, , O
and CC O
increased VBD O
serum NN O
creatinine NN O
in IN O
a DT O
dose-dependent JJ O
manner NN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
vacuum-compression NN B-INTV
therapy NN I-INTV
on IN O
healing NN O
of IN O
diabetic JJ B-POPU
foot NN I-POPU
ulcers NNS I-POPU
: : I-POPU
randomized VBN O
controlled JJ O
trial NN O
. . O

A DT O
single-blind JJ O
, , O
randomized VBN O
controlled VBD O
trial NN O
was VBD O
conducted VBN O
to TO O
evaluate VB O
vacuum-compression NN B-INTV
therapy NN I-INTV
( ( I-INTV
VCT NNP I-INTV
) ) I-INTV
for IN O
the DT O
healing NN O
of IN O
diabetic JJ B-POPU
foot NN I-POPU
ulcers NNS I-POPU
. . O

Eighteen NNP B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
foot JJ I-POPU
ulcers NNS I-POPU
were VBD I-POPU
recruited VBN I-POPU
through IN I-POPU
simple JJ I-POPU
nonprobability NN I-POPU
sampling VBG I-POPU
. . O

Subjects NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
either DT O
an DT O
experimental JJ O
or CC O
a DT O
control NN B-INTV
group NN O
. . O

Before IN O
and CC O
after IN O
intervention NN O
, , O
the DT O
foot NN B-OC
ulcer JJ I-OC
surface NN I-OC
area NN I-OC
was VBD O
estimated VBN O
stereologically RB O
, , O
based VBN O
on IN O
Cavalieri NNP O
's POS O
principle NN O
. . O

The DT O
experimental JJ O
group NN O
was VBD O
treated VBN O
with IN O
VCT NNP B-INTV
in IN I-INTV
addition NN I-INTV
to TO I-INTV
conventional JJ I-INTV
therapy NN I-INTV
for IN O
10 CD O
sessions NNS O
. . O

The DT O
control NN O
group NN O
received VBD O
only RB O
conventional JJ B-INTV
therapy NN I-INTV
, , I-INTV
including VBG I-INTV
debridement NN I-INTV
, , I-INTV
blood NN I-INTV
glucose NNS I-INTV
control NN I-INTV
agents NNS I-INTV
, , I-INTV
systemic JJ I-INTV
antibiotics NNS I-INTV
, , I-INTV
wound IN I-INTV
cleaning VBG I-INTV
with IN I-INTV
normal JJ I-INTV
saline NN I-INTV
, , I-INTV
offloading VBG I-INTV
( ( I-INTV
pressure NN I-INTV
relief NN I-INTV
) ) I-INTV
, , I-INTV
and CC I-INTV
daily RB I-INTV
wound JJ I-INTV
dressings NNS I-INTV
. . O

The DT O
mean JJ O
foot NN B-OC
ulcer JJ I-OC
surface NN I-OC
area NN I-OC
decreased VBD O
from IN O
46.88 CD O
+/- JJ O
9.28 CD O
mm NN O
( ( O
2 CD O
) ) O
to TO O
35.09 CD O
+/- JJ O
4.09 CD O
mm NN O
( ( O
2 CD O
) ) O
in IN O
the DT O
experimental JJ O
group NN O
( ( O
p JJ O
= NNP O
0.006 CD O
) ) O
and CC O
from IN O
46.62 CD O
+/- JJ O
10.03 CD O
mm NN O
( ( O
2 CD O
) ) O
to TO O
42.89 CD O
+/- JJ O
8.1 CD O
mm NN O
( ( O
2 CD O
) ) O
in IN O
the DT O
control NN O
group NN O
( ( O
p JJ O
= NNP O
0.01 CD O
) ) O
. . O

After IN O
treatment NN O
, , O
the DT O
experimental JJ O
group NN O
significantly RB O
improved VBN O
in IN O
measures NNS B-OC
of IN I-OC
foot NN I-OC
ulcer JJ I-OC
surface NN I-OC
area NN I-OC
compared VBN O
with IN O
the DT O
control NN O
group NN O
( ( O
p JJ O
= NNP O
0.024 CD O
) ) O
. . O

VCT NNP B-INTV
enhances VBZ O
diabetic JJ B-OC
foot NN I-OC
ulcer NN I-OC
healing VBG I-OC
when WRB O
combined VBN O
with IN O
appropriate JJ O
wound NN O
care NN O
. . O

-DOCSTART- -X- O O

Intensive JJ B-INTV
insulin NN I-INTV
therapy NN I-INTV
improves VBZ O
endothelial JJ B-OC
function NN I-OC
and CC O
microvascular JJ O
reactivity NN O
in IN O
young JJ B-POPU
people NNS I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
. . O

AIMS/HYPOTHESIS NNP O
Macrovascular NNP O
disease NN O
is VBZ O
an DT O
important JJ O
cause NN O
of IN O
the DT O
increased VBN O
morbidity NN O
and CC O
mortality NN O
rates NNS O
associated VBN O
with IN O
type NN O
1 CD O
diabetes NNS O
, , O
and CC O
this DT O
vascular JJ O
impairment NN O
begins VBZ O
in IN O
childhood NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
introducing VBG O
intensive JJ B-INTV
diabetes NNS I-INTV
management NN I-INTV
[ RB I-INTV
intensive JJ I-INTV
insulin NN O
therapy NN O
( ( O
IIT NNP O
) ) O
and CC O
'Sweet $ B-INTV
Talk NNP I-INTV
' POS I-INTV
text-messaging JJ I-INTV
support NN I-INTV
] NN I-INTV
produces VBZ O
measurable JJ O
improvements NNS O
in IN O
endothelial JJ B-OC
function NN I-OC
. . O

METHODS NNP O
One CD B-POPU
hundred CD I-POPU
and CC I-POPU
twenty-six JJ I-POPU
patients NNS I-POPU
fulfilled VBD I-POPU
the DT I-POPU
eligibility NN I-POPU
criteria NNS I-POPU
( ( I-POPU
type NN I-POPU
1 CD I-POPU
diabetes NNS I-POPU
for IN I-POPU
> NN I-POPU
1 CD I-POPU
year NN I-POPU
; : I-POPU
on IN I-POPU
conventional JJ I-POPU
insulin NN I-POPU
therapy NN I-POPU
( ( I-POPU
CIT NNP I-POPU
) ) I-POPU
; : I-POPU
aged VBN I-POPU
between IN I-POPU
8 CD I-POPU
and CC I-POPU
18 CD I-POPU
years NNS I-POPU
) ) I-POPU
, , I-POPU
of IN I-POPU
whom WP I-POPU
92 CD I-POPU
enrolled VBD I-POPU
. . O

Patients NNS O
were VBD O
randomised VBN O
to TO O
group NN O
1 CD O
, , O
CIT NNP B-INTV
only RB I-INTV
( ( I-INTV
n=28 JJ I-INTV
) ) I-INTV
; : I-INTV
group NN I-INTV
2 CD I-INTV
, , I-INTV
CIT NNP I-INTV
and CC I-INTV
Sweet NNP I-INTV
Talk NNP I-INTV
( ( I-INTV
n=33 NN I-INTV
) ) I-INTV
; : I-INTV
or CC I-INTV
group NN I-INTV
3 CD I-INTV
, , I-INTV
IIT NNP I-INTV
and CC I-INTV
Sweet NNP I-INTV
Talk NNP I-INTV
( ( I-INTV
n=31 NN I-INTV
) ) I-INTV
. . O

Vascular JJ B-INTV
assessments NNS I-INTV
( ( I-INTV
including VBG I-INTV
measures NNS I-INTV
of IN I-INTV
endothelial JJ I-INTV
damage NN I-INTV
, , I-INTV
activation NN I-INTV
, , I-INTV
dysfunction NN I-INTV
and CC I-INTV
oxidative JJ I-INTV
stress NN I-INTV
) ) I-INTV
and CC I-INTV
HbA1c NNP I-INTV
were VBD I-INTV
performed VBN I-INTV
at IN I-INTV
baseline NN I-INTV
and CC I-INTV
repeated VBD I-INTV
after IN I-INTV
12 CD I-INTV
months NNS I-INTV
of IN I-INTV
the DT I-INTV
study NN I-INTV
. . O

RESULTS NNP O
Glycaemic NNP B-OC
control NN I-OC
deteriorated VBD O
in IN O
patients NNS O
on IN O
CIT NNP O
, , O
but CC O
improved VBD O
significantly RB O
in IN O
patients NNS O
allocated VBN O
to TO O
IIT NNP O
( ( O
p=0.007 NN O
) ) O
. . O

IIT NNP O
was VBD O
associated VBN O
with IN O
significantly RB O
greater JJR O
improvements NNS O
in IN O
E-selectin NNP B-OC
( ( O
p JJ O
< NNP O
0.0001 CD O
) ) O
than IN O
CIT NNP O
( ( O
group NN O
1 CD O
, , O
p=0.026 NN O
and CC O
group NN O
2 CD O
, , O
p=0.053 NN O
) ) O
. . O

Vascular JJ B-OC
responses NNS I-OC
to TO O
acetylcholine VB O
improved VBN O
in IN O
patients NNS O
on IN O
IIT NNP O
( ( O
p=0.017 NN O
) ) O
, , O
but CC O
not RB O
in IN O
patients NNS O
receiving VBG O
CIT NNP O
. . O

These DT O
changes NNS O
were VBD O
all DT O
independent JJ O
of IN O
HbA1c NNP O
level NN O
. . O

CONCLUSIONS/INTERPRETATION NNP O
IIT NNP O
appears VBZ O
to TO O
be VB O
associated VBN O
with IN O
improvements NNS O
in IN O
vascular JJ B-OC
markers NNS I-OC
, , O
independently RB O
of IN O
changes NNS O
in IN O
HbA1c NNP O
, , O
suggesting VBG O
that IN O
IIT NNP O
may MD O
confer VB O
vascular JJ O
protection NN O
in IN O
addition NN O
to TO O
improving VBG O
glycaemic JJ B-OC
control NN I-OC
. . O

-DOCSTART- -X- O O

Short-term JJ B-INTV
aerobic JJ I-INTV
exercise NN I-INTV
training NN I-INTV
in IN O
obese JJ B-POPU
humans NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus JJ I-POPU
improves VBZ O
whole-body JJ O
insulin NN O
sensitivity NN O
through IN O
gains NNS O
in IN O
peripheral JJ O
, , O
not RB O
hepatic JJ O
insulin NN O
sensitivity NN O
. . O

CONTEXT NNP O
Short-term JJ B-INTV
aerobic JJ I-INTV
exercise NN I-INTV
training NN I-INTV
can MD O
improve VB O
whole-body JJ B-OC
insulin NN I-OC
sensitivity NN I-OC
in IN O
humans NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus VBP I-POPU
; : I-POPU
however RB O
, , O
the DT O
contributions NNS O
of IN O
peripheral JJ O
and CC O
hepatic JJ O
tissues NNS O
to TO O
these DT O
improvements NNS O
are VBP O
not RB O
known VBN O
. . O

OBJECTIVE VB O
Our PRP$ O
objective NN O
was VBD O
to TO O
determine VB O
the DT O
effect NN O
of IN O
7-d JJ O
aerobic JJ B-INTV
exercise NN I-INTV
training NN O
on IN O
peripheral JJ O
and CC O
hepatic JJ O
insulin NN O
sensitivity NN O
during IN O
isoglycemic/hyperinsulinemic JJ O
clamp NN O
conditions NNS O
. . O

DESIGN NNP O
Subjects NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
one CD O
of IN O
two CD O
groups NNS O
. . O

The DT O
energy NN B-INTV
balance NN I-INTV
group NN O
consumed VBD O
an DT B-INTV
isocaloric JJ I-INTV
diet JJ I-INTV
consisting NN I-INTV
of IN I-INTV
50 CD I-INTV
% NN I-INTV
carbohydrate NN I-INTV
, , I-INTV
30 CD I-INTV
% NN I-INTV
fat NN I-INTV
, , I-INTV
and CC I-INTV
20 CD I-INTV
% NN I-INTV
protein NN I-INTV
for IN I-INTV
15 CD I-INTV
d. NN I-INTV
The DT O
energy NN B-INTV
balance NN I-INTV
plus CC I-INTV
exercise NN I-INTV
group NN O
consumed VBD O
a DT O
similar JJ B-INTV
diet NN I-INTV
over IN I-INTV
the DT I-INTV
15 CD I-INTV
d NN I-INTV
and CC I-INTV
performed VBD I-INTV
50-min CD I-INTV
of IN I-INTV
treadmill NN I-INTV
walking VBG I-INTV
at IN I-INTV
70 CD I-INTV
% NN I-INTV
of IN I-INTV
maximum JJ I-INTV
oxygen NN I-INTV
consumption NN I-INTV
maximum NN I-INTV
during IN I-INTV
the DT I-INTV
second JJ I-INTV
7 CD I-INTV
d NN I-INTV
of IN I-INTV
the DT I-INTV
15-d JJ I-INTV
study NN I-INTV
period NN I-INTV
. . O

Each DT O
subject NN O
underwent VBD O
an DT O
initial JJ O
isoglycemic/hyperinsulinemic JJ B-INTV
clamp NN I-INTV
after IN O
1-wk JJ O
dietary JJ O
control NN O
and CC O
a DT O
second JJ O
clamp NN O
after IN O
completing VBG O
the DT O
study NN O
. . O

SETTING CC O
The DT B-POPU
study NN I-POPU
was VBD I-POPU
performed VBN I-POPU
at IN I-POPU
Ohio NNP I-POPU
State NNP I-POPU
University NNP I-POPU
's POS I-POPU
General NNP I-POPU
Clinical NNP I-POPU
Research NNP I-POPU
Center NNP I-POPU
. . O

PARTICIPANTS CC O
There EX B-POPU
were VBD I-POPU
18 CD I-POPU
obese JJ I-POPU
, , I-POPU
mildly RB I-POPU
diabetic JJ I-POPU
humans NNS I-POPU
included VBD I-POPU
in IN I-POPU
the DT I-POPU
study NN I-POPU
. . O

INTERVENTION NNP O
Aerobic NNP B-INTV
exercise NN I-INTV
training NN I-INTV
was VBD O
performed VBN O
for IN O
7 CD O
d. NN O
MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Whole-body NNP B-OC
, , I-OC
peripheral JJ I-OC
, , I-OC
and CC I-OC
hepatic JJ I-OC
insulin NN I-OC
sensitivity NN I-OC
were VBD O
measured VBN O
. . O

RESULTS NNP O
Exercise NNP B-INTV
training NN I-INTV
did VBD O
not RB O
have VB O
an DT O
impact NN O
on IN O
peripheral JJ B-OC
glucose JJ I-OC
uptake NN I-OC
or CC I-OC
endogenous JJ I-OC
glucose JJ I-OC
production NN I-OC
during IN O
the DT O
basal NN O
state NN O
or CC O
low-dose JJ O
insulin NN O
. . O

Likewise NNP O
, , O
it PRP O
did VBD O
not RB O
alter RB O
endogenous JJ B-OC
glucose JJ I-OC
production NN I-OC
during IN O
high-dose JJ O
insulin NN O
. . O

However RB O
, , O
1-wk CD O
of IN O
exercise NN B-INTV
training NN I-INTV
increased VBD O
both DT O
whole-body NN B-OC
( ( I-OC
P NNP I-OC
< NNP I-OC
0.05 CD I-OC
) ) I-OC
and CC I-OC
peripheral JJ I-OC
insulin NN I-OC
sensitivity NN I-OC
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
during IN O
high-dose JJ O
insulin NN O
. . O

CONCLUSION NNP O
Improvements NNPS O
to TO O
whole VB O
body NN O
insulin JJ O
sensitivity NN O
after IN O
short-term JJ B-INTV
aerobic JJ I-INTV
exercise NN I-INTV
training NN O
are VBP O
due JJ O
to TO O
gains NNS O
in IN O
peripheral JJ O
, , O
not RB O
heptic JJ O
insulin NN O
sensitivity NN O
. . O

-DOCSTART- -X- O O

The DT O
effect NN O
of IN O
coenzyme NN B-INTV
Q10 NNP I-INTV
on IN O
microcirculatory JJ B-OC
endothelial JJ I-OC
function NN I-OC
of IN O
subjects NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
mellitus NN I-POPU
. . O

-DOCSTART- -X- O O

Reduced VBN O
albuminuria NNS O
with IN O
sarpogrelate NN B-INTV
is VBZ O
accompanied VBN O
by IN O
a DT O
decrease NN O
in IN O
monocyte JJ O
chemoattractant JJ O
protein-1 NN O
levels NNS O
in IN O
type NN B-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

BACKGROUND NNP O
AND NNP O
OBJECTIVES NNP O
Sarpogrelate NNP B-INTV
has VBZ O
been VBN O
shown VBN O
to TO O
reduce VB O
albuminuria NNS O
in IN O
diabetic JJ O
nephropathy NN O
. . O

For IN O
examination NN O
of IN O
whether IN O
this DT O
is VBZ O
based VBN O
on IN O
the DT O
same JJ O
mechanisms NN O
as IN O
angiotensin NN O
II NNP O
receptor NN O
blockers NNS O
or CC O
thiazolidinedione NN B-INTV
, , O
effects NNS O
of IN O
sarpogrelate NN B-INTV
on IN O
atherosclerotic JJ O
inflammatory NN O
molecules NNS O
and CC O
their PRP$ O
relations NNS O
to TO O
albuminuria NNS O
in IN O
patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
diabetes NNS I-POPU
and CC I-POPU
had VBD I-POPU
already RB I-POPU
been VBN I-POPU
treated VBN I-POPU
with IN I-POPU
angiotensin NN I-POPU
II NNP I-POPU
receptor NN I-POPU
blockers NNS I-POPU
and CC I-POPU
with IN I-POPU
or CC I-POPU
without IN I-POPU
thiazolidinedione NN I-POPU
were VBD O
examined VBN O
. . O

DESIGN NNP O
, , O
SETTING NNP O
, , O
PARTICIPANTS NNP O
, , O
& CC O
MEASUREMENTS NNP O
Forty NNP B-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
diabetes NNS I-POPU
with IN I-POPU
nephropathy JJ I-POPU
and CC I-POPU
arteriosclerosis NN I-POPU
obliterans NNS I-POPU
and CC I-POPU
had VBD I-POPU
already RB I-POPU
been VBN I-POPU
treated VBN I-POPU
with IN I-POPU
angiotensin NN I-POPU
II NNP I-POPU
receptor NN I-POPU
blocker NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
40 CD I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
sarpogrelate VB B-INTV
( ( O
300 CD O
mg/d NN O
; : O
n CC O
= VB O
20 CD O
) ) O
or CC O
aspirin JJ B-INTV
group NN I-INTV
( ( O
100 CD O
mg/d NN O
; : O
n CC O
= VB O
20 CD O
) ) O
. . O

Plasma NNP B-OC
monocyte JJ I-OC
chemoattractant JJ I-OC
protein-1 NN I-OC
and CC I-OC
urinary JJ I-OC
albumin-to-creatinine JJ I-OC
ratio NN I-OC
and CC I-OC
monocyte NN I-OC
chemoattractant JJ I-OC
protein-1 NN I-OC
were VBD O
measured VBN O
at IN O
baseline NN O
and CC O
16 CD O
wk NN O
after IN O
administration NN O
. . O

RESULTS NNP O
Only RB O
the DT O
sarpogrelate NN B-INTV
group NN O
showed VBD O
increases NNS O
in IN O
plasma NN B-OC
adiponectin NN I-OC
and CC O
decreases NNS O
in IN O
both DT O
plasma NN B-OC
and CC I-OC
urinary JJ I-OC
monocyte NN I-OC
chemoattractant JJ I-OC
protein-1 JJ I-OC
and CC I-OC
albumin-to-creatinine JJ I-OC
ratio NN I-OC
levels NNS I-OC
. . O

Moreover RB O
, , O
percentage NN B-OC
change NN I-OC
of IN I-OC
monocyte NN I-OC
chemoattractant JJ I-OC
protein-1 JJ I-OC
level NN I-OC
correlated VBD O
positively RB O
to TO O
that DT O
of IN O
albumin-to-creatinine JJ O
ratio NN O
. . O

Even RB O
when WRB O
the DT O
sarpogrelate NN B-INTV
group NN O
was VBD O
further RB O
divided VBN O
into IN O
two CD O
groups NNS O
with IN O
( ( O
n JJ O
= NNP O
9 CD O
) ) O
or CC O
without IN O
thiazolidinedione NN B-INTV
( ( O
n JJ O
= NNP O
11 CD O
) ) O
, , O
changes NNS O
in IN O
monocyte NN B-OC
chemoattractant JJ I-OC
protein-1 JJ I-OC
or CC I-OC
albumin-to-creatinine JJ I-OC
ratio NN I-OC
did VBD O
not RB O
differ VB O
. . O

CONCLUSIONS NNP O
Sarpogrelate NNP B-INTV
can MD O
reduce VB O
albuminuria NNS O
and CC O
plasma NN O
and CC O
urinary JJ O
monocyte NN O
chemoattractant JJ O
protein-1 JJ O
levels NNS O
while IN O
increasing VBG O
plasma NN O
adiponectin NN O
in IN O
diabetic JJ O
nephropathy NN O
. . O

These DT O
effects NNS O
seem VBP O
to TO O
be VB O
mediated VBN O
via IN O
mechanisms NNS O
that WDT O
are VBP O
different JJ O
from IN O
those DT O
of IN O
angiotensin JJ B-INTV
II NNP I-INTV
receptor NN I-INTV
blocker NN I-INTV
or CC O
thiazolidinedione NN B-INTV
. . O

-DOCSTART- -X- O O

The DT O
effects NNS O
of IN O
candesartan NN B-INTV
on IN O
diabetes NNS B-OC
glomerulopathy NNS I-OC
: : I-OC
a DT O
double-blind NN O
, , O
placebo-controlled JJ B-INTV
trial NN O
. . O

Our PRP$ O
objective NN O
was VBD O
to TO O
study VB O
the DT O
effects NNS O
of IN O
candesartan NN B-INTV
on IN O
diabetic JJ B-OC
glomerulopathy NN I-OC
in IN O
young JJ B-POPU
normoalbuminuric JJ I-POPU
and CC I-POPU
normotensive JJ I-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
in IN O
a DT O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
trial NN O
. . O

In IN O
13 CD B-POPU
patients NNS I-POPU
aged VBN I-POPU
24 CD I-POPU
years NNS I-POPU
at IN I-POPU
baseline NN I-POPU
, , O
we PRP O
evaluated VBD O
blood NN O
pressure NN O
, , O
kidney NN O
biopsies NNS O
and CC O
kidney NN O
function NN O
tests NNS O
at IN O
baseline NN O
and CC O
after IN O
5 CD O
years NNS O
of IN O
treatment NN O
. . O

Kidney NNP O
biopsies NNS O
were VBD O
examined VBN O
with IN O
light JJ O
and CC O
electron JJ O
microscopy NN O
, , O
glomerular JJ O
filtration NN O
rate NN O
and CC O
effective JJ O
renal JJ O
plasma NN O
flow NN O
determined VBD O
with IN O
inulin NN O
and CC O
para-aminohippuric JJ O
acid NN O
clearances NNS O
. . O

Two CD O
patients NNS O
in IN O
the DT O
placebo NN B-INTV
group NN O
needed VBD O
antihypertensive JJ O
treatment NN O
because IN O
they PRP O
developed VBD O
microalbuminuria NNS B-OC
and/or JJ I-OC
hypertension NN I-OC
, , O
but CC O
no DT O
patient NN O
in IN O
the DT O
candesartan NN B-INTV
group NN O
did VBD O
. . O

A DT O
significant JJ O
reduction NN O
in IN O
mesangial JJ B-OC
matrix NN I-OC
volume NN I-OC
and CC I-OC
mesangial JJ I-OC
volume NN I-OC
occurred VBD O
in IN O
the DT O
candesartan NN O
group NN O
, , O
although IN O
changes NNS O
in IN O
morphological JJ B-OC
parameters NNS I-OC
were VBD O
similar JJ O
between IN O
groups NNS O
. . O

Office NNP B-OC
blood NN I-OC
pressure NN I-OC
was VBD O
significantly RB O
lower JJR O
in IN O
the DT O
candesartan NN B-INTV
group NN O
at IN O
follow-up NN O
than IN O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

Deterioration NN O
in IN O
morphological JJ B-OC
parameters NNS I-OC
observed VBD O
in IN O
earlier JJR O
studies NNS O
of IN O
our PRP$ O
patients NNS O
did VBD O
not RB O
become VB O
worse JJR O
during IN O
treatment NN O
with IN O
candesartan NN B-INTV
or CC O
placebo NN B-INTV
. . O

The DT O
effects NNS O
of IN O
candesartan NN B-INTV
, , O
with IN O
reduction NN O
in IN O
morphological JJ B-OC
parameters NNS I-OC
and CC I-OC
lowering NN I-OC
of IN I-OC
blood NN I-OC
pressure NN I-OC
, , O
might MD O
influence VB O
future JJ O
treatment NN O
of IN O
glomerulopathy NN O
in IN O
type NN B-POPU
1 CD I-POPU
diabetes VBZ I-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Sustained JJ O
benefit NN O
of IN O
continuous JJ O
glucose JJ O
monitoring NN O
on IN O
A1C NNP O
, , O
glucose JJ O
profiles NNS O
, , O
and CC O
hypoglycemia NN O
in IN O
adults NNS B-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
. . O

OBJECTIVE NNP O
To TO O
evaluate VB O
long-term JJ O
effects NNS O
of IN O
continuous JJ B-INTV
glucose JJ I-INTV
monitoring NN I-INTV
( ( I-INTV
CGM NNP I-INTV
) ) I-INTV
in IN O
intensively RB B-POPU
treated VBN I-POPU
adults NNS I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
We PRP O
studied VBD O
83 CD B-POPU
of IN I-POPU
86 CD I-POPU
individuals NNS I-POPU
> JJ I-POPU
or=25 CD I-POPU
years NNS I-POPU
of IN I-POPU
age NN I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
used VBD I-POPU
CGM NNP I-POPU
as IN I-POPU
part NN I-POPU
of IN I-POPU
a DT I-POPU
6-month JJ I-POPU
randomized JJ I-POPU
clinical JJ I-POPU
trial NN I-POPU
in IN I-POPU
a DT I-POPU
subsequent JJ I-POPU
6-month JJ I-POPU
extension NN I-POPU
study NN I-POPU
. . O

RESULTS NNP O
After IN O
12 CD O
months NNS O
, , O
median JJ O
CGM NNP O
use NN O
was VBD O
6.8 CD O
days NNS O
per IN O
week NN O
. . O

Mean JJ B-OC
change NN I-OC
in IN I-OC
A1C NNP I-OC
level NN I-OC
from IN O
baseline NN O
to TO O
12 CD O
months NNS O
was VBD O
-0.4 JJ O
+/- JJ O
0.6 CD O
% NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
in IN O
subjects NNS O
with IN O
baseline NN O
A1C NNP O
> NNP O
or=7.0 MD O
% NN O
. . O

A1C NNP B-OC
remained VBD O
stable JJ O
at IN O
6.4 CD O
% NN O
in IN O
those DT O
with IN O
baseline JJ O
A1C NNP O
< NNP O
7.0 CD O
% NN O
. . O

The DT O
incidence NN B-OC
rate NN I-OC
of IN I-OC
severe JJ I-OC
hypoglycemia NN I-OC
was VBD O
21.8 CD O
and CC O
7.1 CD O
events NNS O
per IN O
100 CD O
person-years NNS O
in IN O
the DT O
first JJ O
and CC O
last JJ O
6 CD O
months NNS O
, , O
respectively RB O
. . O

Time NNP B-OC
per IN I-OC
day NN I-OC
with IN I-OC
glucose JJ I-OC
levels NNS I-OC
in IN O
the DT O
range NN O
of IN O
71-180 JJ O
mg/dl NN O
increased VBN O
significantly RB O
( ( O
P NNP O
= NNP O
0.02 CD O
) ) O
from IN O
baseline NN O
to TO O
12 CD O
months NNS O
. . O

CONCLUSIONS NNP O
In IN O
intensively RB B-POPU
treated VBN I-POPU
adults NNS I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
, , O
CGM NNP O
use NN O
and CC O
benefit NN O
can MD O
be VB O
sustained VBN O
for IN O
12 CD O
months NNS O
. . O

-DOCSTART- -X- O O

Cost-effectiveness NN B-OC
of IN O
a DT O
telephone-delivered JJ B-INTV
intervention NN I-INTV
for IN I-INTV
physical JJ B-POPU
activity NN I-POPU
and CC I-POPU
diet NN I-POPU
. . O

BACKGROUND NNP O
Given NNP O
escalating VBG O
rates NNS O
of IN O
chronic JJ O
disease NN O
, , O
broad-reach NN O
and CC O
cost-effective JJ O
interventions NNS O
to TO O
increase VB O
physical JJ O
activity NN O
and CC O
improve VB O
dietary JJ O
intake NN O
are VBP O
needed VBN O
. . O

The DT O
cost-effectiveness NN B-OC
of IN O
a DT O
Telephone NNP B-INTV
Counselling NNP I-INTV
intervention NN I-INTV
to TO I-INTV
improve VB I-INTV
physical JJ I-INTV
activity NN I-INTV
and CC I-INTV
diet NN I-INTV
, , O
targeting VBG O
adults NNS B-POPU
with IN I-POPU
established VBN I-POPU
chronic JJ I-POPU
diseases NNS I-POPU
in IN I-POPU
a DT I-POPU
low JJ I-POPU
socio-economic JJ I-POPU
area NN I-POPU
of IN I-POPU
a DT I-POPU
major JJ I-POPU
Australian JJ I-POPU
city NN I-POPU
was VBD O
examined VBN O
. . O

METHODOLOGY/PRINCIPAL NNP O
FINDINGS NNP O
A NNP O
cost-effectiveness NN O
modelling NN O
study NN O
using VBG O
data NNS O
collected VBN O
between IN O
February NNP B-POPU
2005 CD I-POPU
and CC I-POPU
November NNP I-POPU
2007 CD I-POPU
from IN O
a DT O
cluster-randomised JJ O
trial NN O
that WDT O
compared VBN O
Telephone NNP B-INTV
Counselling NNP I-INTV
with IN I-INTV
a DT I-INTV
" JJ I-INTV
Usual NNP I-INTV
Care NNP I-INTV
" NNP I-INTV
( ( I-INTV
brief JJ I-INTV
intervention NN I-INTV
) ) I-INTV
alternative NN O
. . O

Economic JJ B-OC
outcomes NNS I-OC
were VBD O
assessed VBN O
using VBG O
a DT O
state-transition NN O
Markov NNP O
model NN O
, , O
which WDT O
predicted VBD O
the DT O
progress NN O
of IN O
participants NNS O
through IN O
five CD O
health NN O
states NNS O
relating VBG O
to TO O
physical JJ O
activity NN O
and CC O
dietary JJ O
improvement NN O
, , O
for IN O
ten CD O
years NNS O
after IN O
recruitment NN O
. . O

The DT O
costs NNS B-OC
and CC I-OC
health NN I-OC
benefits NNS I-OC
of IN O
Telephone NNP B-INTV
Counselling NNP I-INTV
, , I-INTV
Usual NNP I-INTV
Care NNP I-INTV
and CC I-INTV
an DT I-INTV
existing VBG I-INTV
practice NN I-INTV
( ( I-INTV
Real NNP I-INTV
Control NNP I-INTV
) ) I-INTV
group NN O
were VBD O
compared VBN O
. . O

Telephone CD B-INTV
Counselling VBG I-INTV
compared VBN O
to TO O
Usual NNP B-INTV
Care NNP I-INTV
was VBD O
not RB O
cost-effective JJ B-OC
( ( O
$ $ O
78,489 CD O
per IN O
quality NN O
adjusted VBN O
life NN O
year NN O
gained VBN O
) ) O
. . O

However RB O
, , O
the DT O
Usual NNP B-INTV
Care NNP I-INTV
group NN O
did VBD O
not RB O
represent VB O
existing VBG O
practice NN O
and CC O
is VBZ O
not RB O
a DT O
useful JJ O
comparator NN O
for IN O
decision NN O
making NN O
. . O

Comparing VBG O
Telephone CD B-INTV
Counselling VBG I-INTV
outcomes NNS O
to TO O
existing VBG B-INTV
practice NN I-INTV
( ( I-INTV
Real NNP I-INTV
Control NNP I-INTV
) ) I-INTV
, , O
the DT O
intervention NN O
was VBD O
found VBN O
to TO O
be VB O
cost-effective JJ B-OC
( ( O
$ $ O
29,375 CD O
per IN O
quality NN O
adjusted VBN O
life NN O
year NN O
gained VBN O
) ) O
. . O

Usual JJ B-INTV
Care NNP I-INTV
( ( I-INTV
brief JJ I-INTV
intervention NN I-INTV
) ) I-INTV
compared VBN O
to TO O
existing VBG B-INTV
practice NN I-INTV
( ( I-INTV
Real NNP I-INTV
Control NNP I-INTV
) ) I-INTV
was VBD O
also RB O
cost-effective JJ B-OC
( ( O
$ $ O
12,153 CD O
per IN O
quality NN O
adjusted VBN O
life NN O
year NN O
gained VBN O
) ) O
. . O

CONCLUSIONS/SIGNIFICANCE VB O
This DT O
modelling NN O
study NN O
shows VBZ O
that IN O
a DT O
decision NN O
to TO O
adopt VB O
a DT O
Telephone CD B-INTV
Counselling VBG I-INTV
program NN O
over IN O
existing VBG B-INTV
practice NN I-INTV
( ( I-INTV
Real NNP I-INTV
Control NNP I-INTV
) ) I-INTV
is VBZ O
likely JJ O
to TO O
be VB O
cost-effective JJ B-OC
. . O

Choosing VBG O
the DT O
'Usual JJ B-INTV
Care NNP I-INTV
' POS I-INTV
brief NN I-INTV
intervention NN I-INTV
over IN O
existing VBG B-INTV
practice NN I-INTV
( ( I-INTV
Real NNP I-INTV
Control NNP I-INTV
) ) I-INTV
shows VBZ O
a DT O
lower JJR O
cost NN O
per IN O
quality NN O
adjusted VBN O
life NN O
year NN O
, , O
but CC O
the DT O
lack NN O
of IN O
supporting VBG O
evidence NN O
for IN O
efficacy NN O
or CC O
sustainability NN O
is VBZ O
an DT O
important JJ O
consideration NN O
for IN O
decision NN O
makers NNS O
. . O

The DT O
economics NNS O
of IN O
behavioural JJ O
approaches NNS O
to TO O
improving VBG O
health NN O
must MD O
be VB O
made VBN O
explicit JJ O
if IN O
decision NN O
makers NNS O
are VBP O
to TO O
be VB O
convinced VBN O
that IN O
allocating VBG O
resources NNS O
toward IN O
such JJ O
programs NNS O
is VBZ O
worthwhile JJ O
. . O

TRIAL NNP O
REGISTRATION NNP O
This DT O
paper NN O
uses VBZ O
data NNS O
collected VBN O
in IN O
a DT O
previous JJ O
clinical JJ O
trial NN O
registered VBD O
at IN O
the DT O
Australian JJ O
Clinical NNP O
Trials NNP O
Registry NNP O
, , O
Australian JJ O
New NNP O
Zealand NNP O
Clinical NNP O
Trials NNP O
Registry NNP O
: : O
Anzcrt.org.au NNP O
ACTRN012607000195459 NNP O
. . O

-DOCSTART- -X- O O

Long-term JJ O
prospective JJ O
, , O
randomized VBN O
, , O
controlled VBN O
study NN O
using VBG O
repetitive JJ O
education NN O
at IN O
six-month JJ O
intervals NNS O
and CC O
monitoring NN O
for IN O
adherence NN O
in IN O
heart NN B-POPU
failure NN I-POPU
outpatients NNS I-POPU
: : I-POPU
the DT O
REMADHE NNP O
trial NN O
. . O

BACKGROUND VB O
The DT O
effectiveness NN O
of IN O
heart NN O
failure NN O
disease NN O
management NN O
programs NNS O
in IN O
patients NNS B-POPU
under IN I-POPU
cardiologists NNS I-POPU
' POS I-POPU
care NN I-POPU
over IN I-POPU
long-term JJ I-POPU
follow-up NN I-POPU
is VBZ O
not RB O
established VBN O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
We PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
a DT O
disease JJ B-INTV
management NN I-INTV
program NN I-INTV
with IN I-INTV
repetitive JJ I-INTV
education NN I-INTV
and CC I-INTV
telephone NN I-INTV
monitoring NN I-INTV
on IN O
primary JJ B-OC
( ( I-OC
combined VBN I-OC
death NN I-OC
or CC I-OC
unplanned JJ I-OC
first JJ I-OC
hospitalization NN I-OC
and CC I-OC
quality-of-life JJ I-OC
changes NNS I-OC
) ) I-OC
and CC I-OC
secondary JJ I-OC
end NN I-OC
points NNS I-OC
( ( I-OC
hospitalization NN I-OC
, , I-OC
death NN I-OC
, , I-OC
and CC I-OC
adherence NN I-OC
) ) I-OC
. . O

The DT O
REMADHE NNP O
[ NNP O
Repetitive NNP O
Education NNP B-INTV
and CC I-INTV
Monitoring NNP I-INTV
for IN O
ADherence NNP O
for IN O
Heart NNP O
Failure NNP O
] NNP O
trial NN O
is VBZ O
a DT O
long-term JJ O
randomized NN O
, , O
prospective JJ O
, , O
parallel JJ O
trial NN O
designed VBN O
to TO O
compare VB O
intervention NN O
with IN O
control NN B-INTV
. . O

One CD B-POPU
hundred VBD I-POPU
seventeen JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
usual JJ I-POPU
care NN I-POPU
, , I-POPU
and CC I-POPU
233 CD I-POPU
to TO I-POPU
additional JJ I-POPU
intervention NN I-POPU
. . O

The DT O
mean JJ O
follow-up NN O
was VBD O
2.47+/-1.75 CD O
years NNS O
, , O
with IN O
54 CD O
% NN O
adherence NN O
to TO O
the DT O
program NN O
. . O

In IN O
the DT O
intervention NN O
group NN O
, , O
the DT O
primary JJ O
end NN O
point NN O
composite NN B-OC
of IN I-OC
death NN I-OC
or CC I-OC
unplanned JJ I-OC
hospitalization NN I-OC
was VBD O
reduced VBN O
( ( O
hazard JJ O
ratio NN O
, , O
0.64 CD O
; : O
confidence NN O
interval NN O
, , O
0.43 CD O
to TO O
0.88 CD O
; : O
P=0.008 NNP O
) ) O
, , O
driven VBN O
by IN O
reduction NN O
in IN O
hospitalization NN B-OC
. . O

The DT O
quality-of-life JJ B-OC
questionnaire NN I-OC
score NN I-OC
improved VBD O
only RB O
in IN O
the DT O
intervention NN O
group NN O
( ( O
P NNP O
< NNP O
0.003 CD O
) ) O
. . O

Mortality NNP B-OC
was VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O

Number NNP B-OC
of IN I-OC
hospitalizations NNS I-OC
( ( O
1.3+/-1.7 JJ O
versus NN O
0.8+/-1.3 NN O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
, , O
total JJ B-OC
hospital NN I-OC
days NNS I-OC
during IN I-OC
the DT I-OC
follow-up JJ I-OC
( ( O
19.9+/-51 JJ O
versus NN O
11.1+/-24 JJ O
days NNS O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
, , O
and CC O
the DT O
need NN B-OC
for IN I-OC
emergency NN I-OC
visits NNS I-OC
( ( O
4.5+/-10.6 JJ O
versus NN O
1.6+/-2.4 CD O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
were VBD O
lower JJR O
in IN O
the DT O
intervention NN O
group NN O
. . O

Beneficial JJ B-OC
effects NNS I-OC
were VBD O
homogeneous JJ O
for IN O
sex NN O
, , O
race NN O
, , O
diabetes NNS O
and CC O
no DT O
diabetes NN O
, , O
age NN O
, , O
functional JJ O
class NN O
, , O
and CC O
etiology NN O
. . O

CONCLUSIONS NNP O
For IN O
a DT O
longer RBR O
follow-up JJ O
period NN O
than IN O
in IN O
previous JJ O
studies NNS O
, , O
this DT O
heart NN O
failure NN O
disease JJ O
management NN O
program NN O
model NN O
of IN O
patients NNS B-POPU
under IN I-POPU
the DT I-POPU
supervision NN I-POPU
of IN I-POPU
a DT I-POPU
cardiologist NN I-POPU
is VBZ O
associated VBN O
with IN O
a DT O
reduction NN O
in IN O
unplanned JJ B-OC
hospitalization NN I-OC
, , O
a DT O
reduction NN O
of IN O
total JJ B-OC
hospital NN I-OC
days NNS I-OC
, , O
and CC O
a DT O
reduced JJ O
need NN B-OC
for IN I-OC
emergency NN I-OC
care NN I-OC
, , O
as RB O
well RB O
as IN O
improved VBN B-OC
quality NN I-OC
of IN I-OC
life NN I-OC
, , O
despite IN O
modest JJ O
program NN B-OC
adherence NN I-OC
over IN O
time NN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
walnut NN B-INTV
consumption NN I-INTV
on IN O
endothelial JJ B-OC
function NN I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
: : I-POPU
a DT O
randomized VBN O
controlled VBN O
crossover RB O
trial NN O
. . O

OBJECTIVE NN O
To TO O
determine VB O
the DT O
effects NNS O
of IN O
daily JJ O
walnut NN B-INTV
consumption NN I-INTV
on IN O
endothelial JJ B-OC
function NN I-OC
, , I-OC
cardiovascular JJ I-OC
biomarkers NNS I-OC
, , I-OC
and CC I-OC
anthropometric JJ I-OC
measures NNS I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
individuals NNS I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
This DT O
study NN O
was VBD O
a DT O
randomized JJ O
, , O
controlled VBN O
, , O
single-blind NN O
, , O
crossover JJ O
trial NN O
. . O

Twenty-four JJ B-POPU
participants NNS I-POPU
with IN I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
( ( I-POPU
mean JJ I-POPU
age NN I-POPU
58 CD I-POPU
years NNS I-POPU
; : I-POPU
14 CD I-POPU
women NNS I-POPU
and CC I-POPU
10 CD I-POPU
men NNS I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
one CD O
of IN O
the DT O
two CD O
possible JJ O
sequence NN O
permutations NNS O
to TO O
receive VB O
an DT O
ad NN B-INTV
libitum NN I-INTV
diet JJ I-INTV
enriched VBD I-INTV
with IN I-INTV
56 CD I-INTV
g NNS I-INTV
( ( I-INTV
366 CD I-INTV
kcal NN I-INTV
) ) I-INTV
walnuts/day NN I-INTV
and CC I-INTV
an DT I-INTV
ad NN I-INTV
libitum NN I-INTV
diet NN I-INTV
without IN I-INTV
walnuts NNS I-INTV
for IN I-INTV
8 CD I-INTV
weeks NNS I-INTV
. . O

Subjects NNS O
underwent JJ O
endothelial JJ B-INTV
function NN I-INTV
testing VBG I-INTV
( ( O
measured VBN O
as IN O
flow-mediated JJ O
dilatation NN O
[ NNP O
FMD NNP O
] NNP O
) ) O
and CC O
assessment NN O
of IN O
cardiovascular JJ O
biomarkers NNS O
before IN O
and CC O
after IN O
each DT O
8-week JJ O
treatment NN O
phase NN O
. . O

The DT O
primary JJ O
outcome NN O
measure NN O
was VBD O
the DT O
change NN B-OC
in IN I-OC
FMD NNP I-OC
after IN O
8 CD O
weeks NNS O
. . O

Secondary JJ O
outcome NN O
measures NNS O
included VBD O
changes NNS B-OC
in IN I-OC
plasma NN I-OC
lipids NNS I-OC
, , I-OC
A1C NNP I-OC
, , I-OC
fasting VBG I-OC
glucose NN I-OC
, , I-OC
insulin NN I-OC
sensitivity NN I-OC
, , I-OC
and CC I-OC
anthropometric JJ I-OC
measures NNS I-OC
. . O

RESULTS NNP O
Endothelial NNP B-OC
function NN I-OC
significantly RB O
improved VBN O
after IN O
consumption NN O
of IN O
a DT O
walnut-enriched JJ O
ad NN O
libitum NN O
diet JJ O
compared VBN O
with IN O
that DT O
after IN O
consumption NN O
of IN O
an DT O
ad NN O
libitum NN O
diet NN O
without IN O
walnuts NNS O
( ( O
2.2 CD O
+/- JJ O
1.7 CD O
vs. FW O
1.2 CD O
+/- JJ O
1.6 CD O
% NN O
; : O
P NNP O
= NNP O
0.04 CD O
) ) O
. . O

The DT O
walnut-enriched JJ O
diet NN O
increased VBD O
fasting VBG B-OC
serum NN I-OC
glucose NN I-OC
and CC I-OC
lowered VBD I-OC
serum NN I-OC
total JJ I-OC
cholesterol NN I-OC
and CC I-OC
LDL NNP I-OC
cholesterol NN I-OC
from IN O
baseline NN O
( ( O
10.0 CD O
+/- JJ O
20.5 CD O
mg/dl NN O
, , O
P NNP O
= NNP O
0.04 CD O
; : O
-9.7 JJ O
+/- JJ O
14.5 CD O
mg/dl NN O
, , O
P NNP O
< NNP O
0.01 CD O
; : O
and CC O
-7.7 VB O
+/- JJ O
10 CD O
mg/dl NN O
, , O
P NNP O
< NNP O
0.01 CD O
, , O
respectively RB O
) ) O
, , O
although IN O
these DT O
changes NNS O
were VBD O
not RB O
significant JJ O
compared VBN O
with IN O
those DT O
for IN O
an DT O
ad NN O
libitum NN O
diet NN O
without IN O
walnuts NNS O
. . O

There EX O
were VBD O
no DT O
significant JJ O
changes NNS O
in IN O
anthropometric JJ B-OC
measures NNS I-OC
, , I-OC
plasma NN I-OC
A1C NNP I-OC
, , I-OC
and CC I-OC
insulin JJ I-OC
sensitivity NN I-OC
. . O

CONCLUSIONS VB O
A DT O
walnut-enriched JJ O
ad NN O
libitum NN O
diet JJ O
improves VBZ O
endothelium-dependent JJ O
vasodilatation NN O
in IN O
type NN O
2 CD O
diabetic JJ O
individuals NNS O
, , O
suggesting VBG O
a DT O
potential JJ O
reduction NN O
in IN O
overall JJ O
cardiac JJ B-OC
risk NN I-OC
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
device-guided JJ B-INTV
breathing NN I-INTV
exercises NNS I-INTV
on IN O
blood NN B-OC
pressure NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
hypertension NN I-POPU
: : I-POPU
a DT O
randomized NN O
controlled VBN O
trial NN O
. . O

OBJECTIVE NNP O
Hypertension NNP O
is VBZ O
a DT O
chronic JJ O
disorder NN O
with IN O
a DT O
high JJ O
prevalence NN O
worldwide NN O
. . O

Despite IN O
considerable JJ O
efforts NNS O
, , O
it PRP O
is VBZ O
sometimes RB O
hard JJ O
to TO O
reach VB O
treatment NN O
goals NNS O
for IN O
blood NN B-OC
pressure NN I-OC
( ( I-OC
BP NNP I-OC
) ) I-OC
with IN O
classical JJ O
treatment NN O
options NNS O
. . O

Reducing VBG O
breathing VBG O
frequency NN O
has VBZ O
been VBN O
advocated VBN O
as IN O
a DT O
method NN O
to TO O
reduce VB O
BP NNP B-OC
. . O

METHODS NNP O
A NNP O
randomized JJ O
, , O
single-blind JJ O
, , O
controlled VBD O
trial NN O
was VBD O
conducted VBN O
in IN O
30 CD B-POPU
non-diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
hypertension NN I-POPU
over IN O
a DT O
period NN O
of IN O
9 CD O
weeks NNS O
to TO O
evaluate VB O
the DT O
effect NN O
of IN O
a DT O
device NN B-INTV
that WDT I-INTV
helps VBZ I-INTV
to TO I-INTV
slow VB I-INTV
breathing NN I-INTV
( ( I-INTV
Resperate NNP I-INTV
) ) I-INTV
on IN O
BP NNP B-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( I-OC
QoL NNP I-OC
) ) I-OC
. . O

The DT O
control NN O
group NN O
listened VBD B-INTV
to TO I-INTV
music NN I-INTV
and CC I-INTV
used VBN I-INTV
no DT I-INTV
other JJ I-INTV
therapeutic JJ I-INTV
device NN I-INTV
. . O

RESULTS NNP O
There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
change NN O
in IN O
BP NNP B-OC
between IN O
intervention NN O
and CC O
control NN O
; : O
BP NNP B-OC
-4.2 NNP O
mmHg NN O
( ( O
95 CD O
% NN O
CI NNP O
-12.4 NNP O
to TO O
3.9 CD O
) ) O
/-2.6 NN O
mmHg NN O
( ( O
95 CD O
% NN O
CI NNP O
-8.4 NNP O
to TO O
3.3 CD O
) ) O
. . O

This DT O
result NN O
did VBD O
not RB O
alter VB O
in IN O
post NN O
hoc NN O
analyses NNS O
, , O
when WRB O
patients NNS O
not RB O
achieving VBG O
target NN B-OC
breathing NN I-OC
frequency NN I-OC
( ( O
< JJ O
10 CD O
breaths/min NN O
) ) O
or CC O
non-compliant JJ O
patients NNS O
were VBD O
excluded VBN O
. . O

QoL NNP B-OC
did VBD O
not RB O
change VB O
over IN O
time NN O
. . O

CONCLUSIONS NNP O
We PRP O
found VBD O
no DT O
effect NN O
of IN O
the DT O
Resperate NNP O
on IN O
BP NNP B-OC
or CC O
QoL NNP B-OC
compared VBN O
with IN O
the DT O
control NN O
group NN O
. . O

We PRP O
conclude VBP O
that IN O
, , O
at IN O
this DT O
moment NN O
, , O
this DT O
device NN O
has VBZ O
no DT O
added VBN O
value NN O
in IN O
the DT O
treatment NN O
of IN O
hypertension NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
between IN O
obtained VBN O
mydriasis NN B-POPU
in IN I-POPU
type NN I-POPU
2 CD I-POPU
diabetics NNS I-POPU
and CC I-POPU
non-diabetic JJ I-POPU
patients NNS I-POPU
. . O

BACKGROUND/AIMS NNP O
To TO O
evaluate VB O
and CC O
compare VB O
obtained VBN O
mydriasis NN O
with IN O
phenylephrine JJ B-INTV
10 CD O
% NN O
associated VBN O
with IN O
tropicamide JJ B-INTV
1 CD O
% NN O
in IN O
type NN B-POPU
2 CD I-POPU
diabetics NNS I-POPU
and CC I-POPU
non-diabetic JJ I-POPU
patients NNS I-POPU
. . O

METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
50 CD I-POPU
patients NNS I-POPU
( ( I-POPU
100 CD I-POPU
eyes NNS I-POPU
) ) I-POPU
scheduled VBD I-POPU
for IN I-POPU
fundoscopy NN I-POPU
were VBD I-POPU
dilated VBN I-POPU
with IN I-POPU
phenylephrine JJ I-POPU
10 CD I-POPU
% NN I-POPU
and CC I-POPU
yropicamide RB I-POPU
1 CD I-POPU
% NN I-POPU
( ( O
group NN O
0 CD O
: : O
n JJ O
= $ O
20 CD O
type NN O
2 CD O
diabetic JJ O
patients NNS O
, , O
40 CD O
eyes NNS O
, , O
and CC O
group NN O
1 CD O
: : O
n JJ O
= $ O
30 CD O
non-diabetic JJ O
patients NNS O
, , O
60 CD O
eyes NNS O
) ) O
. . O

Only RB O
one CD O
drop NN O
per IN O
eye NN O
of IN O
each DT O
drug NN O
was VBD O
administered VBN O
. . O

In IN O
both DT O
groups NNS O
, , O
pupil VBP B-OC
diameter NN I-OC
was VBD O
measured VBN O
after IN O
40 CD O
minutes NNS O
of IN O
eye NN O
drops NNS O
instillation NN O
. . O

RESULTS NNP O
Both DT O
groups NNS O
were VBD O
similar JJ O
regarding VBG O
age NN O
( ( O
p JJ O
= NN O
0.06 CD O
, , O
Mann-Whitney NNP O
test NN O
) ) O
. . O

Mean NNP B-OC
pupil NN I-OC
diameter NN I-OC
in IN O
group NN O
0 CD O
was VBD O
8.57 CD O
and CC O
8.73 CD O
in IN O
group NN O
1 CD O
. . O

There EX O
was VBD O
no DT O
statistic JJ B-OC
difference NN I-OC
between IN O
both DT O
groups NNS O
( ( O
p JJ O
= NNP O
0.44 CD O
) ) O
. . O

Pupil NNP B-OC
diameter NN I-OC
was VBD O
greater JJR O
than IN O
7 CD O
mm NNS O
in IN O
all DT O
patients NNS O
( ( O
100 CD O
% NN O
) ) O
. . O

CONCLUSION NN O
When WRB O
an DT O
appropriate JJ O
drug NN O
combination NN O
is VBZ O
used VBN O
, , O
diabetic JJ O
patients NNS O
can MD O
achieve VB O
mydriasis NN B-OC
as RB O
satisfactory JJ O
as IN O
non-diabetic JJ O
patients NNS O
, , O
allowing VBG O
adequate JJ O
fundus NN O
examination NN O
and/or IN O
retinopathy JJ O
treatment NN O
. . O

-DOCSTART- -X- O O

Lack NN O
of IN O
lipotoxicity NN O
effect NN O
on IN O
{ ( B-OC
beta NN I-OC
} ) I-OC
-cell NNP I-OC
dysfunction NN I-OC
in IN O
ketosis-prone NN B-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

OBJECTIVE NNP O
Over IN B-POPU
half NN I-POPU
of IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
obese JJ I-POPU
African JJ I-POPU
Americans NNPS I-POPU
with IN I-POPU
diabetic JJ I-POPU
ketoacidosis NN I-POPU
( ( I-POPU
DKA NNP I-POPU
) ) I-POPU
discontinue VBP O
insulin JJ O
therapy NN O
and CC O
go VB O
through IN O
a DT O
period NN O
of IN O
near-normoglycemia JJ O
remission NN O
. . O

This DT O
subtype NN O
of IN O
diabetes NNS O
is VBZ O
known VBN O
as IN O
ketosis-prone NN O
type NN O
2 CD O
diabetes NNS O
( ( O
KPDM NNP O
) ) O
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
To TO O
investigate VB O
the DT O
role NN O
of IN O
lipotoxicity NN O
on IN O
beta-cell NN B-OC
function NN I-OC
, , O
eight CD B-POPU
obese JJ I-POPU
African JJ I-POPU
Americans NNPS I-POPU
with IN I-POPU
KPDM NNP I-POPU
, , I-POPU
eight CD I-POPU
obese JJ I-POPU
subjects NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
with IN I-POPU
severe JJ I-POPU
hyperglycemia NN I-POPU
without IN I-POPU
ketosis NN I-POPU
( ( I-POPU
ketosis-resistant JJ I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
nine CD I-POPU
nondiabetic JJ I-POPU
obese NNS I-POPU
control NN I-POPU
subjects VBZ I-POPU
underwent JJ O
intravenous JJ B-INTV
infusion NN I-INTV
of IN I-INTV
20 CD I-INTV
% NN I-INTV
intralipid NN I-INTV
at IN I-INTV
40 CD I-INTV
ml/h NN I-INTV
for IN O
48 CD O
h. JJ O
beta-Cell NN B-OC
function NN I-OC
was VBD O
assessed VBN O
by IN O
changes NNS B-OC
in IN I-OC
insulin NN I-OC
and CC I-OC
C-peptide JJ I-OC
concentration NN I-OC
during IN O
infusions NNS O
and CC O
by IN O
changes NNS B-OC
in IN I-OC
acute JJ I-OC
insulin NN I-OC
response NN I-OC
to TO I-OC
arginine VB I-OC
stimulation NN I-OC
( ( I-OC
AIR NNP I-OC
( ( I-OC
arg NN I-OC
) ) I-OC
) ) I-OC
before IN O
and CC O
after IN O
lipid JJ B-INTV
infusion NN I-INTV
. . O

RESULTS VB O
The DT O
mean JJ B-OC
time NN I-OC
to TO I-OC
discontinue VB I-OC
insulin NN I-OC
therapy NN I-OC
was VBD O
11.0 CD O
+/- JJ O
8.0 CD O
weeks NNS O
in IN O
KPDM NNP O
and CC O
9.6 CD O
+/- JJ O
2.2 CD O
weeks NNS O
in IN O
ketosis-resistant JJ O
type NN O
2 CD O
diabetes NNS O
( ( O
P NNP O
= NNP O
NS NNP O
) ) O
. . O

At IN O
remission NN O
, , O
KPDM NNP O
and CC O
ketosis-resistant JJ O
type NN O
2 CD O
diabetes NNS O
had VBD O
similar JJ O
glucose NN B-OC
( ( O
94 CD O
+/- JJ O
14 CD O
vs. FW O
109 CD O
+/- JJ O
20 CD O
mg/dl NN O
) ) O
, , O
A1C NNP O
( ( O
5.7 CD O
+/- JJ O
0.4 CD O
vs. FW O
6.3 CD O
+/- JJ O
1.1 CD O
% NN O
) ) O
, , O
and CC O
baseline VB B-OC
AIR NNP I-OC
( ( I-OC
arg NN I-OC
) ) I-OC
response NN I-OC
( ( O
34.8 CD O
+/- JJ O
30 CD O
vs. FW O
64 CD O
+/- JJ O
69 CD O
microU/ml NN O
) ) O
. . O

P NNP O
= NNP O
NS NNP O
despite IN O
a DT O
fourfold JJ O
increase NN O
in IN O
free JJ B-OC
fatty JJ I-OC
acid NN I-OC
( ( I-OC
FFA NNP I-OC
) ) I-OC
levels NNS I-OC
( ( O
0.4 CD O
+/- JJ O
0.3 CD O
to TO O
1.8 CD O
+/- JJ O
1.1 CD O
mmol/l NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
during IN O
the DT O
48-h JJ O
intralipid JJ B-INTV
infusion NN I-INTV
; : I-INTV
the DT O
response NN B-OC
to TO I-OC
AIR NNP I-OC
( ( I-OC
arg NN I-OC
) ) I-OC
stimulation NN I-OC
, , O
as RB O
well RB O
as IN O
changes NNS O
in IN O
insulin NN B-OC
and CC I-OC
C-peptide JJ I-OC
levels NNS I-OC
, , O
were VBD O
similar JJ O
among IN O
obese JJ O
patients NNS O
with IN O
KPDM NNP O
, , O
patients NNS O
with IN O
ketosis-resistant JJ O
type NN O
2 CD O
diabetes NNS O
, , O
and CC O
nondiabetic JJ O
control NN O
subjects NNS O
. . O

CONCLUSIONS NNP O
Near-normoglycemia JJ O
remission NN O
in IN O
obese JJ B-POPU
African JJ I-POPU
American JJ I-POPU
patients NNS I-POPU
with IN I-POPU
KPDM NNP I-POPU
and CC I-POPU
ketosis-resistant JJ I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
is VBZ O
associated VBN O
with IN O
a DT O
remarkable JJ O
recovery NN O
in IN O
basal NN O
and CC O
stimulated VBD O
insulin NN O
secretion NN O
. . O

A DT O
high JJ O
FFA NNP O
level NN O
by IN O
intralipid JJ B-INTV
infusion NN I-INTV
for IN O
48 CD O
h NN O
was VBD O
not RB O
associated VBN O
with IN O
beta-cell JJ O
decompensation NN O
( ( O
lipotoxicity NN O
) ) O
in IN O
KPDM NNP B-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
laser NN B-INTV
photocoagulation NN I-INTV
for IN O
diabetic JJ O
retinopathy NN O
using VBG O
532-nm JJ O
standard NN O
laser NN O
versus NN O
multispot NN O
pattern JJ O
scan JJ O
laser NN O
. . O

PURPOSE VB O
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
the DT O
efficacy NN O
, , O
collateral JJ O
damage NN O
, , O
and CC O
convenience NN O
of IN O
panretinal JJ O
photocoagulation NN O
for IN O
proliferative JJ B-POPU
diabetic JJ I-POPU
retinopathy NN I-POPU
or CC I-POPU
severe JJ I-POPU
nonproliferative JJ I-POPU
diabetic JJ I-POPU
retinopathy NN I-POPU
using VBG O
a DT O
532-nm JJ O
solid-state NN B-INTV
green JJ I-INTV
laser NN I-INTV
( ( I-INTV
GLX NNP I-INTV
) ) I-INTV
versus VBP O
a DT O
multispot NN B-INTV
532-nm JJ I-INTV
pattern JJ I-INTV
scan JJ I-INTV
laser NN I-INTV
( ( O
PASCAL NNP O
) ) O
. . O

METHODS NNP O
This DT O
study NN O
was VBD O
a DT O
prospective JJ O
randomized VBN O
clinical JJ O
trial NN O
. . O

Sixty JJ B-POPU
patients NNS I-POPU
with IN I-POPU
bilaterally RB I-POPU
symmetrical JJ I-POPU
proliferative JJ I-POPU
diabetic JJ I-POPU
retinopathy NN I-POPU
or CC I-POPU
severe JJ I-POPU
nonproliferative JJ I-POPU
diabetic JJ I-POPU
retinopathy NN I-POPU
participated VBD O
. . O

Each DT O
patient JJ O
underwent JJ O
panretinal JJ O
photocoagulation NN O
: : O
one CD B-INTV
eye NN I-INTV
with IN I-INTV
GLX NNP I-INTV
and CC O
the DT O
other JJ O
with IN O
PASCAL NNP B-INTV
, , O
two CD O
sittings NNS O
per IN O
eye NN O
. . O

Grade $ O
3 CD O
burns NNS O
with IN O
a DT O
200-mum JJ O
spot NN O
size NN O
were VBD O
placed VBN O
with IN O
both DT O
modalities NNS O
. . O

The DT O
fluence NN B-OC
, , I-OC
pain NN I-OC
using VBG I-OC
the DT I-OC
visual JJ I-OC
analog NN I-OC
scale NN I-OC
, , I-OC
time NN I-OC
, , I-OC
laser NN I-OC
spot NN I-OC
spread NN I-OC
with IN O
infrared JJ O
images NNS O
, , O
and CC O
retinal JJ B-OC
sensitivity NN I-OC
were VBD O
compared VBN O
. . O

RESULTS NNP O
Pattern NNP O
scan JJ O
laser NN O
and CC O
GLX NNP O
required VBD O
an DT O
average JJ B-OC
fluence NN I-OC
of IN O
40.33 CD O
vs NNS O
191 CD O
J/cm NNP O
( ( O
2 CD O
) ) O
, , O
respectively RB O
. . O

Average JJ B-OC
time NN I-OC
required VBN I-OC
per IN I-OC
sitting VBG I-OC
was VBD O
1.43 CD O
minutes NNS O
with IN O
PASCAL NNP O
and CC O
4.53 CD O
minutes NNS O
with IN O
GLX NNP O
. . O

Average NNP B-OC
visual JJ I-OC
analog NN I-OC
scale NN I-OC
reading NN I-OC
for IN O
GLX NNP O
was VBD O
4.6 CD O
, , O
whereas NNS O
that IN O
for IN O
PASCAL NNP O
was VBD O
0.33 CD O
. . O

Heidelberg NNP O
retinal JJ O
angiography NN O
images NNS O
showed VBD O
the DT O
spot NN B-OC
spread NN I-OC
as IN O
being VBG O
430 CD O
versus NN O
310 CD O
microm NN O
at IN O
3 CD O
months NNS O
with IN O
GLX NNP O
and CC O
PASCAL NNP O
. . O

The DT O
eyes NNS O
treated VBN O
with IN O
PASCAL NNP O
showed VBD O
higher JJR O
average JJ B-OC
retinal JJ I-OC
sensitivity NN I-OC
in IN O
the DT O
central JJ O
15 CD O
degrees NNS O
and CC O
15 CD O
degrees NNS O
to TO O
30 CD O
degrees NNS O
zones NNS O
( ( O
25.08 CD O
and CC O
22.08 CD O
dB NN O
, , O
respectively RB O
) ) O
than IN O
the DT O
eyes NNS O
treated VBN O
with IN O
GLX NNP O
( ( O
23.16 CD O
and CC O
17.14 CD O
dB NN O
) ) O
, , O
respectively RB O
. . O

CONCLUSION NNP O
Pattern NNP O
scan JJ O
laser NN O
showed VBD O
lesser JJR O
collateral JJ O
damage NN O
and CC O
similar JJ O
regression NN B-OC
of IN I-OC
retinopathy JJ I-OC
compared VBN O
with IN O
GLX NNP O
. . O

Pattern NNP O
scan JJ O
laser NN O
treatment NN O
was VBD O
less JJR O
time NN O
consuming VBG O
and CC O
less RBR O
painful JJ O
for IN O
the DT O
patient NN O
compared VBN O
with IN O
GLX NNP O
. . O

-DOCSTART- -X- O O

The DT O
role NN O
of IN O
adjunctive JJ B-INTV
exenatide NN I-INTV
therapy NN I-INTV
in IN O
pediatric JJ B-POPU
type NN I-POPU
1 CD I-POPU
diabetes NNS I-POPU
. . O

OBJECTIVE NNP O
Exenatide NNP B-INTV
improves VBZ O
postprandial JJ O
glycemic JJ B-OC
excursions NNS I-OC
in IN O
type NN O
2 CD O
diabetes NNS O
. . O

Exenatide NNP B-INTV
could MD O
benefit VB O
type JJ O
1 CD O
diabetes NNS O
as RB O
well RB O
. . O

We PRP O
aimed VBD O
to TO O
determine VB O
an DT O
effective JJ O
and CC O
safe JJ O
glucose-lowering NN B-OC
adjuvant JJ O
exenatide NN O
dose NN O
in IN O
adolescents NNS B-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
Eight NNP B-POPU
subjects NNS I-POPU
completed VBD O
a DT O
three-part JJ O
double-blinded JJ O
randomized VBN O
controlled VBN O
study NN O
of IN O
premeal JJ O
exenatide NN B-INTV
. . O

Two CD B-INTV
doses NNS I-INTV
of IN I-INTV
exenatide NN I-INTV
( ( I-INTV
1.25 CD I-INTV
and CC I-INTV
2.5 CD I-INTV
microg NN I-INTV
) ) I-INTV
were VBD I-INTV
compared VBN I-INTV
with IN I-INTV
insulin NN I-INTV
monotherapy NN I-INTV
. . O

Prandial JJ O
insulin NN B-INTV
dose NN O
was VBD O
reduced VBN O
by IN O
20 CD O
% NN O
. . O

Gastric NNP O
emptying VBG O
and CC O
hormones NNS O
were VBD O
analyzed VBN O
for IN O
300 CD O
min JJ O
postmeal NN O
. . O

RESULTS NNP O
Treatment NNP O
with IN O
both DT O
doses NNS O
of IN O
exenatide JJ B-INTV
versus NN O
insulin NN B-INTV
monotherapy NN I-INTV
significantly RB O
reduced VBD B-OC
glucose JJ I-OC
excursions NNS I-OC
over IN O
300 CD O
min NNS O
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

Exenatide NNP B-INTV
administration NN O
failed VBD B-OC
to TO I-OC
suppress VB I-OC
glucagon NN I-OC
but CC I-OC
delayed VBD I-OC
gastric JJ I-OC
emptying NN I-OC
( ( O
P NNP O
< NNP O
0.004 CD O
) ) O
. . O

CONCLUSIONS NNP O
Adjunctive NNP O
exenatide NN B-INTV
therapy NN O
reduces VBZ B-OC
postprandial JJ I-OC
hyperglycemia NN I-OC
in IN O
adolescents NNS B-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
. . O

This DT O
reduction NN O
in IN O
glucose JJ B-OC
excursion NN I-OC
occurs VBZ O
despite IN O
reduction NN O
in IN O
insulin NN O
dose NN O
. . O

We PRP O
suggest VBP O
that DT O
exenatide NN B-INTV
has VBZ O
therapeutic JJ O
potential NN O
as IN O
adjunctive JJ O
therapy NN O
in IN O
type NN O
1 CD O
diabetes NNS O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
ranolazine NN B-INTV
on IN O
A1C NNP O
and CC O
glucose JJ O
levels NNS O
in IN O
hyperglycemic JJ B-POPU
patients NNS I-POPU
with IN I-POPU
non-ST JJ I-POPU
elevation NN I-POPU
acute NN I-POPU
coronary JJ I-POPU
syndrome NN I-POPU
. . O

OBJECTIVE IN O
We PRP O
determined VBD O
the DT O
relationships NNS O
between IN O
glycemia NN O
at IN O
randomization NN O
, , O
concurrent JJ B-INTV
antidiabetic JJ I-INTV
therapy NN I-INTV
, , O
and CC O
change NN O
in IN O
A1C NNP O
and CC O
fasting VBG O
plasma NN O
glucose NN O
( ( O
FPG NNP O
) ) O
in IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
receiving VBG I-POPU
standard JJ I-POPU
treatment NN I-POPU
for IN I-POPU
diabetes NNS I-POPU
and CC I-POPU
randomized VBN I-POPU
to TO I-POPU
ranolazine VB I-POPU
or CC I-POPU
placebo VB I-POPU
within IN I-POPU
the DT I-POPU
MERLIN-TIMI-36 NNP I-POPU
( ( I-POPU
MERLIN NNP I-POPU
) ) I-POPU
study NN I-POPU
. . O

Ranolazine NNP B-INTV
is VBZ O
a DT O
novel JJ O
first-in-class JJ O
drug NN O
approved VBD O
for IN O
treating VBG O
angina JJ O
pectoris NN O
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
Randomization NNP O
and CC O
4-month JJ O
glycemic NN B-INTV
and CC I-INTV
antidiabetes VBZ I-INTV
drug NN I-INTV
usage NN I-INTV
data NNS I-INTV
from IN O
MERLIN NNP O
were VBD O
analyzed VBN O
using VBG O
Spotfire NNP O
and CC O
SAS NNP O
version NN O
9.1 CD O
software NN O
. . O

RESULTS NNP O
In IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
and CC I-POPU
A1C NNP I-POPU
of IN I-POPU
> NNP I-POPU
or=8-10 JJ I-POPU
% NN I-POPU
at IN I-POPU
randomization NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
171 CD I-POPU
) ) I-POPU
, , O
there EX O
was VBD O
an DT O
absolute JJ O
A1C NNP B-OC
reduction NN I-OC
in IN O
the DT O
ranolazine NN B-INTV
group NN O
of IN O
1.2 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
-1.4 NNP O
to TO O
-1.0 VB O
) ) O
, , O
and CC O
the DT O
placebo-adjusted JJ B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
182 CD I-POPU
) ) I-POPU
decrease NN O
in IN O
A1C NNP B-OC
by IN O
ranolazine NN O
was VBD O
0.59 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
-0.99 NNP O
to TO O
-0.20 VB O
, , O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

In IN O
patients NNS B-POPU
with IN I-POPU
FPG NNP I-POPU
of IN I-POPU
150-400 JJ I-POPU
mg/dl NN I-POPU
at IN I-POPU
randomization NN I-POPU
, , I-POPU
ranolazine NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
131 CD I-POPU
) ) I-POPU
compared VBN O
with IN O
placebo NN B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
147 CD I-POPU
) ) I-POPU
reduced VBN O
FPG NNP O
by IN O
25.7 CD O
mg/dl NNS O
( ( O
95 CD O
% NN O
CI NNP O
-43.3 NNP O
to TO O
-8.1 VB O
, , O
P NNP O
= NNP O
0.001 CD O
) ) O
. . O

When WRB O
changes NNS O
in IN O
either DT O
A1C NNP B-OC
or CC I-OC
FPG NNP I-OC
were VBD O
correlated VBN O
to TO O
A1C NNP B-OC
or CC I-OC
FPG NNP I-OC
at IN O
randomization NN O
, , O
the DT O
slopes NNS O
were VBD O
significantly RB O
steeper JJR O
for IN O
ranolazine NN B-INTV
than IN O
placebo NN B-INTV
( ( O
A1C NNP O
, , O
P NNP O
= NNP O
0.046 CD O
; : O
FPG NNP O
, , O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
indicating VBG O
that IN O
lowering VBG O
of IN O
A1C NNP B-OC
and CC I-OC
FPG NNP I-OC
by IN O
ranolazine NN B-INTV
is VBZ O
related VBN O
to TO O
hyperglycemia VB O
at IN O
randomization NN O
. . O

Ranolazine NNP O
, , O
compared VBN O
with IN O
placebo NN O
, , O
was VBD O
not RB O
associated VBN O
with IN O
serious JJ B-OC
hypoglycemic JJ I-OC
events NNS I-OC
, , O
associated VBN O
with IN O
significant JJ O
changes NNS O
in IN O
concurrent JJ B-OC
antidiabetic JJ B-INTV
therapy NN I-INTV
, , O
or CC O
dependent NN O
on IN O
a DT O
history NN B-OC
of IN I-OC
angina NN I-OC
. . O

CONCLUSIONS NNP O
Ranolazine NNP B-INTV
, , O
when WRB O
added VBN O
to TO O
concurrent VB O
antidiabetes NNS O
treatment NN O
, , O
lowers NNS O
FPG NNP B-OC
and CC I-OC
A1C NNP I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
cardiovascular JJ I-POPU
disease NN I-POPU
and CC I-POPU
poorly RB I-POPU
controlled VBN I-POPU
diabetes NNS I-POPU
. . O

-DOCSTART- -X- O O

The DT O
11-beta-hydroxysteroid JJ O
dehydrogenase NN O
type NN O
1 CD O
inhibitor NN O
INCB13739 NNP B-INTV
improves VBZ O
hyperglycemia NN B-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
inadequately RB I-POPU
controlled VBN I-POPU
by IN I-POPU
metformin NN I-POPU
monotherapy NN I-POPU
. . O

OBJECTIVE CC O
11-Beta-hydroxysteroid JJ O
dehydrogenase NN O
type NN O
1 CD O
( ( O
11betaHSD1 CD O
) ) O
converts NNS O
inactive JJ O
cortisone NN O
into IN O
active JJ O
cortisol NN O
, , O
thereby RB O
amplifying VBG O
intracellular JJ O
glucocorticoid JJ O
action NN O
. . O

The DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
the DT O
11betaHSD1 CD O
inhibitor NN O
INCB13739 NNP O
were VBD O
assessed VBN O
when WRB O
added VBN O
to TO O
ongoing VBG O
metformin NN O
monotherapy NN O
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
exhibiting VBG I-POPU
inadequate JJ I-POPU
glycemic NNS I-POPU
control NN I-POPU
( ( I-POPU
A1C NNP I-POPU
7-11 CD I-POPU
% NN I-POPU
) ) I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
This DT O
double-blind JJ O
placebo-controlled JJ B-INTV
paralleled VBN O
study NN O
randomized VBD O
302 CD B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
( ( I-POPU
mean JJ I-POPU
A1C NNP I-POPU
8.3 CD I-POPU
% NN I-POPU
) ) I-POPU
on IN I-POPU
metformin NN I-POPU
monotherapy NN I-POPU
( ( I-POPU
mean JJ I-POPU
1.5 CD I-POPU
g/day NN I-POPU
) ) I-POPU
to TO O
receive VB O
one CD O
of IN O
five CD O
INCB13739 NNP B-INTV
doses NNS I-INTV
or CC I-INTV
placebo NN I-INTV
once RB O
daily JJ O
for IN O
12 CD O
weeks NNS O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
the DT O
change NN B-OC
in IN I-OC
A1C NNP I-OC
at IN I-OC
study JJ I-OC
end NN I-OC
. . O

Other JJ O
end NN O
points NNS O
included VBD O
changes NNS B-OC
in IN I-OC
fasting VBG I-OC
glucose NN I-OC
, , I-OC
lipids NNS I-OC
, , I-OC
weight NN I-OC
, , I-OC
adverse JJ I-OC
events NNS I-OC
, , I-OC
and CC I-OC
safety NN I-OC
. . O

RESULTS NNP O
After IN O
12 CD O
weeks NNS O
, , O
200 CD O
mg NN O
of IN O
INCB13739 NNP O
resulted VBD O
in IN O
significant JJ O
reductions NNS O
in IN O
A1C NNP B-OC
( ( O
-0.6 NNP O
% NN O
) ) O
, , O
fasting VBG B-OC
plasma NN I-OC
glucose NN I-OC
( ( O
-24 NNP O
mg/dl NN O
) ) O
, , O
and CC O
homeostasis NN B-OC
model NN I-OC
assessment-insulin JJ I-OC
resistance NN I-OC
( ( O
HOMA-IR NNP O
) ) O
( ( O
-24 CD O
% NN O
) ) O
compared VBN O
with IN O
placebo NN O
. . O

Total JJ B-OC
cholesterol NN I-OC
, , I-OC
LDL NNP I-OC
cholesterol NN I-OC
, , I-OC
and CC I-OC
triglycerides NNS I-OC
were VBD O
all DT O
significantly RB O
decreased VBN O
in IN O
hyperlipidemic JJ O
patients NNS O
. . O

Body NNP B-OC
weight VBD I-OC
decreased JJ O
relative NN O
to TO O
placebo VB O
after IN O
INCB13739 NNP O
therapy NN O
. . O

A DT O
reversible JJ O
dose-dependent JJ O
elevation NN O
in IN O
adrenocorticotrophic JJ B-OC
hormone NN I-OC
, , O
generally RB O
within IN O
the DT O
normal JJ O
reference NN O
range NN O
, , O
was VBD O
observed VBN O
. . O

Basal NNP B-OC
cortisol JJ I-OC
homeostasis NN I-OC
, , I-OC
testosterone NN I-OC
in IN I-OC
men NNS I-OC
, , I-OC
and CC I-OC
free JJ I-OC
androgen NN I-OC
index NN I-OC
in IN I-OC
women NNS I-OC
were VBD O
unchanged JJ O
by IN O
INCB13739 NNP O
. . O

Adverse JJ O
events NNS O
were VBD O
similar JJ O
across IN O
all DT O
treatment NN O
groups NNS O
. . O

CONCLUSIONS NNP O
INCB13739 NNP O
added VBD O
to TO O
ongoing VBG O
metformin NN O
therapy NN O
was VBD O
efficacious JJ B-OC
and CC O
well RB O
tolerated VBN B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
had VBD I-POPU
inadequate JJ I-POPU
glycemic NNS I-POPU
control NN I-POPU
with IN I-POPU
metformin NN I-POPU
alone RB I-POPU
. . O

11BetaHSD1 CD O
inhibition NN O
offers NNS O
a DT O
new JJ O
potential JJ O
approach NN O
to TO O
control VB O
glucose JJ B-OC
and CC I-OC
cardiovascular JJ I-OC
risk NN I-OC
factors NNS I-OC
in IN O
type NN B-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

-DOCSTART- -X- O O

Efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
routine JJ O
blood NN B-INTV
pressure NN I-INTV
lowering VBG I-INTV
in IN O
older JJR B-POPU
patients NNS I-POPU
with IN I-POPU
diabetes NNS I-POPU
: : I-POPU
results NNS O
from IN O
the DT O
ADVANCE NNP O
trial NN O
. . O

OBJECTIVE CC O
The DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
blood NN B-OC
pressure NN I-OC
lowering VBG I-OC
in IN O
elderly JJ B-POPU
patients NNS I-POPU
have VBP O
not RB O
been VBN O
sufficiently RB O
investigated VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
. . O

Using VBG O
data NNS O
from IN O
the DT O
Action NNP O
in IN O
Diabetes NNP O
and CC O
Vascular NNP O
disease NN O
: : O
preterAx NN O
and CC O
diamicroN-MR NN O
Controlled NNP O
Evaluation NNP O
study NN O
, , O
we PRP O
assessed VBD O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
routine JJ O
blood NN B-INTV
pressure NN I-INTV
lowering VBG I-INTV
to TO O
prevent VB O
major JJ O
clinical JJ O
outcomes NNS O
in IN O
elderly JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

METHODS NNP O
Eleven NNP B-POPU
thousand VBP I-POPU
one CD I-POPU
hundred CD I-POPU
and CC I-POPU
forty JJ I-POPU
patients NNS I-POPU
aged VBN I-POPU
at IN I-POPU
least JJS I-POPU
55 CD I-POPU
years NNS I-POPU
with IN I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
( ( I-POPU
mean JJ I-POPU
66+/-6 CD I-POPU
years NNS I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
perindopril-indapamide JJ B-INTV
or CC I-INTV
placebo NN I-INTV
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
a DT O
composite NN B-OC
of IN I-OC
major JJ I-OC
macrovascular NN I-OC
and CC I-OC
microvascular JJ I-OC
disease NN I-OC
. . O

The DT O
effects NNS O
of IN O
active JJ O
treatment NN O
on IN O
outcomes NNS O
were VBD O
estimated VBN O
in IN O
subgroups NNS B-POPU
according VBG I-POPU
to TO I-POPU
age NN I-POPU
: : I-POPU
below IN I-POPU
65 CD I-POPU
, , I-POPU
65-74 JJ I-POPU
and CC I-POPU
at IN I-POPU
least JJS I-POPU
75 CD I-POPU
years NNS I-POPU
. . O

RESULTS NNP O
During IN O
a DT O
mean JJ O
4.3-year JJ O
follow-up NN O
, , O
1799 CD O
( ( O
16.1 CD O
% NN O
) ) O
patients NNS O
experienced VBD O
a DT O
major JJ O
event NN O
. . O

Active JJ O
treatment NN O
produced VBD O
similar JJ O
relative JJ B-OC
risk NN I-OC
reductions NNS I-OC
for IN O
the DT O
primary JJ B-OC
outcome NN I-OC
, , I-OC
major JJ I-OC
macrovascular JJ I-OC
disease NN I-OC
, , I-OC
death NN I-OC
and CC I-OC
renal JJ I-OC
events NNS I-OC
across IN O
age NN O
groups NNS O
( ( O
all DT O
P NNP O
heterogeneity NN O
> NNP O
0.3 CD O
) ) O
. . O

Over IN O
5 CD O
years NNS O
, , O
active JJ O
treatment NN O
was VBD O
estimated VBN O
to TO O
prevent VB O
one CD O
primary JJ B-OC
outcome NN I-OC
in IN O
every DT O
21 CD O
, , O
71 CD O
and CC O
118 CD O
patients NNS O
of IN O
at IN O
least JJS O
75 CD O
, , O
65-74 JJ O
and CC O
below IN O
65 CD O
years NNS O
, , O
respectively RB O
. . O

Similar JJ O
patterns NNS O
of IN O
benefits NNS O
were VBD O
observed VBN O
for IN O
secondary JJ O
outcomes NNS O
. . O

There EX O
were VBD O
no DT O
differences NNS O
in IN O
the DT O
tolerability NN B-OC
between IN O
randomized VBN O
allocations NNS O
across IN O
age NN O
groups NNS O
( ( O
all DT O
P NNP O
heterogeneity NN O
> NNP O
0.6 CD O
) ) O
CONCLUSION NNP O
Routine NNP O
administration NN O
of IN O
perindopril-indapamide JJ B-INTV
lowers NNS O
blood NN B-OC
pressure NN I-OC
safely RB O
and CC O
reduces VBZ O
the DT O
risk NN B-OC
of IN O
major JJ O
clinical JJ O
outcomes NNS O
in IN O
patients NNS B-POPU
of IN I-POPU
at IN I-POPU
least JJS I-POPU
75 CD I-POPU
years NNS I-POPU
with IN I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

The DT O
greater JJR O
absolute JJ O
benefits NNS O
in IN O
older JJR B-POPU
patients NNS I-POPU
in IN I-POPU
this DT I-POPU
age NN I-POPU
group NN I-POPU
were VBD O
not RB O
offset VBN O
by IN O
an DT O
increased VBN O
risk NN O
of IN O
side NN B-OC
effects NNS I-OC
. . O

-DOCSTART- -X- O O

Rationale NNP O
and CC O
design NN O
of IN O
a DT O
randomized JJ O
trial NN O
to TO O
evaluate VB O
an DT O
evidence-based JJ B-POPU
prescription NN I-POPU
drug NN I-POPU
label NN I-POPU
on IN I-POPU
actual JJ I-POPU
medication NN I-POPU
use NN I-POPU
. . O

BACKGROUND NNP O
Medication NNP O
errors NNS O
are VBP O
an DT O
important JJ O
public JJ O
health NN O
concern NN O
, , O
and CC O
poor JJ O
understanding NN O
of IN O
medication NN O
labels NNS O
are VBP O
a DT O
root NN O
cause NN O
. . O

Research NN O
shows VBZ O
that IN O
labels NNS O
are VBP O
variable JJ O
, , O
of IN O
poor JJ O
quality NN O
, , O
and CC O
not RB O
patient-centered JJ O
. . O

No DT O
real-world JJ O
trials NNS O
have VBP O
evaluated VBN O
whether IN O
improved JJ O
medication NN O
labels NNS O
can MD O
affect VB O
appropriate JJ O
medication NN O
use NN O
, , O
adherence NN O
or CC O
health NN O
outcomes NNS O
. . O

TRIAL NNP O
DESIGN NNP O
We PRP O
developed VBD O
an DT O
evidence-based JJ B-INTV
prescription NN I-INTV
label NN I-INTV
that WDT O
addresses VBZ O
both DT O
content NN O
and CC O
format NN O
. . O

The DT O
enhanced JJ B-INTV
label NN I-INTV
includes VBZ O
a DT O
universal JJ O
medication NN O
schedule NN O
( ( O
UMS NNP O
) ) O
that WDT O
standardizes VBZ O
the DT O
directions NNS O
for IN O
use NN O
incorporating VBG O
1 CD O
) ) O
standard NN O
time NN O
periods NNS O
for IN O
administration NN O
( ( O
morning NN O
, , O
noon NN O
, , O
evening NN O
, , O
and CC O
bedtime NN O
) ) O
, , O
2 CD O
) ) O
numeric JJ O
vs. FW O
alpha NN O
characters NNS O
, , O
3 CD O
) ) O
'carriage NN O
returns NNS O
' POS O
to TO O
separate VB O
daily JJ O
dose NN O
and CC O
4 CD O
) ) O
a DT O
graphic JJ O
aid NN O
to TO O
visually RB O
depict VB O
dose NN O
and CC O
frequency NN O
. . O

We PRP O
will MD O
evaluate VB O
the DT O
effect NN O
of IN O
providing VBG O
this DT O
label NN B-INTV
to TO O
randomly VB B-POPU
sampled VBN I-POPU
patients NNS I-POPU
who WP I-POPU
receive VBP I-POPU
their PRP$ I-POPU
care NN I-POPU
from IN I-POPU
free JJ I-POPU
clinics NNS I-POPU
, , I-POPU
mobile JJ I-POPU
vans NNS I-POPU
and CC I-POPU
federally RB I-POPU
qualified JJ I-POPU
health NN I-POPU
centers NNS I-POPU
( ( I-POPU
FQHCs NNP I-POPU
) ) I-POPU
in IN I-POPU
Northern NNP I-POPU
Virginia NNP I-POPU
. . O

We PRP O
will MD O
recruit VB O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
or CC I-POPU
hypertension NN I-POPU
; : I-POPU
these DT O
patients NNS O
will MD O
be VB O
randomly RB O
assigned VBN O
to TO O
receive VB O
all DT O
of IN O
their PRP$ O
medications NNS O
with IN O
improved JJ O
labels NNS O
or CC O
to TO O
receive VB O
prescriptions NNS O
with IN O
standard JJ O
labels NNS O
. . O

The DT O
primary JJ O
outcome NN O
will MD O
be VB O
the DT O
patient NN B-OC
's POS I-OC
ability NN I-OC
to TO I-OC
correctly RB I-OC
demonstrate VB I-OC
dosing VBG I-OC
instructions NNS I-OC
. . O

Other JJ O
outcomes NNS O
include VBP O
adherence NN B-OC
, , I-OC
error NN I-OC
rates NNS I-OC
and CC I-OC
health NN I-OC
outcomes NNS I-OC
. . O

CONCLUSION NN O
To TO O
our PRP$ O
knowledge NN O
, , O
this DT O
trial NN O
is VBZ O
the DT O
first JJ O
to TO O
evaluate VB O
the DT O
effect NN O
of IN O
prescription NN O
label NN O
improvement NN O
on IN O
understanding NN B-OC
, , I-OC
medication NN I-OC
use NN I-OC
and CC O
outcomes NNS O
in IN O
a DT O
clinical JJ O
setting NN O
. . O

If IN O
successful JJ O
, , O
these DT O
findings NNS O
could MD O
be VB O
implemented VBN O
broadly RB O
to TO O
promote VB O
safe JJ O
and CC O
appropriate JJ O
medication NN O
use NN O
and CC O
to TO O
support VB O
evidence-based JJ O
standards NNS O
in IN O
the DT O
development NN O
of IN O
labels NNS O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
three-year JJ O
clinical JJ B-OC
outcomes NNS I-OC
between IN O
sirolimus-versus JJ B-INTV
paclitaxel-eluting JJ I-INTV
stents NNS I-INTV
in IN B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
: : I-POPU
prospective JJ O
randomized VBN O
multicenter NN O
trial NN O
. . O

BACKGROUND NNP O
Three-year JJ O
follow-up NN O
of IN O
major JJ B-OC
adverse JJ I-OC
cardiovascular JJ I-OC
event NN I-OC
( ( I-OC
MACE NNP I-OC
) ) I-OC
( ( I-OC
death NN I-OC
, , I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
target NN I-OC
lesion NN I-OC
revascularization NN I-OC
) ) I-OC
and CC O
the DT O
predictors NNS B-OC
of IN I-OC
MACEs NNP I-OC
in IN B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
after IN I-POPU
sirolimus-eluting JJ I-POPU
stent NN I-POPU
( ( I-POPU
SES NNP I-POPU
) ) I-POPU
or CC I-POPU
paclitaxel-eluting JJ I-POPU
stent NN I-POPU
( ( I-POPU
PES NNP I-POPU
) ) I-POPU
implantation NN I-POPU
have VBP O
not RB O
been VBN O
reported VBN O
. . O

METHODS NNP O
Diabetic NNP B-POPU
patients NNS I-POPU
with IN I-POPU
de FW I-POPU
novo FW I-POPU
coronary JJ I-POPU
lesions NNS I-POPU
( ( I-POPU
169 CD I-POPU
patients NNS I-POPU
with IN I-POPU
190 CD I-POPU
lesions NNS I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
prospectively RB O
to TO O
either DT O
SES NNP B-INTV
or CC I-INTV
PES NNP I-INTV
. . O

RESULTS NNP O
Baseline NNP O
characteristics NNS O
were VBD O
similar JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

The DT O
rates NNS B-OC
of IN I-OC
MACEs NNP I-OC
[ NNP O
5.9 CD O
% NN O
( ( O
n JJ O
= NNP O
5 CD O
) ) O
in IN O
the DT O
SES NNP B-INTV
vs. FW O
9.5 CD O
% NN O
( ( O
n JJ O
= NNP O
8 CD O
) ) O
in IN O
the DT O
PES NNP B-INTV
Group NNP O
, , O
P NNP O
= VBZ O
0.374 CD O
] NN O
and CC O
definite JJ B-OC
stent NN I-OC
thrombosis NN I-OC
[ VBD O
1.2 CD O
% NN O
( ( O
n JJ O
= NNP O
1 CD O
) ) O
in IN O
the DT O
SES NNP B-INTV
vs. FW O
3.6 CD O
% NN O
( ( O
n JJ O
= NNP O
3 CD O
) ) O
in IN O
the DT O
PES NNP B-INTV
Group NNP O
, , O
P NNP O
= VBZ O
0.368 CD O
] NN O
were VBD O
similar JJ O
in IN O
the DT O
two CD O
groups NNS O
during IN O
the DT O
three-year JJ O
follow-up NN O
. . O

Multivariate NNP O
logistic JJ O
analysis NN O
showed VBD O
that IN O
insulin NN O
treatment NN O
was VBD O
the DT O
only JJ O
independent JJ B-OC
predictor NN I-OC
of IN O
MACE NNP B-OC
[ NNP O
odds NNS O
ratio NN O
( ( O
OR NNP O
) ) O
8.60 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
( ( O
CI NNP O
) ) O
3.25-22.76 CD O
, , O
P NNP O
< VBZ O
0.001 CD O
] NN O
and CC O
target NN B-OC
vessel NN I-OC
revascularization NN I-OC
( ( I-OC
TVR NNP I-OC
) ) I-OC
( ( O
OR $ O
9.50 CD O
, , O
95 CD O
% NN O
CI NNP O
3.07-29.44 CD O
, , O
P NNP O
< NNP O
0.001 CD O
) ) O
during IN O
the DT O
three-year JJ O
follow-up NN O
. . O

CONCLUSIONS VB O
The DT O
rates NNS B-OC
of IN I-OC
MACEs NNP I-OC
, , I-OC
TVR NNP I-OC
, , I-OC
and CC I-OC
stent JJ I-OC
thrombosis NN I-OC
during IN O
the DT O
three-year JJ O
follow-up NN O
were VBD O
similar JJ O
in IN O
the DT O
SES NNP B-INTV
and CC I-INTV
PES NNP I-INTV
Groups NNP O
. . O

Insulin NNP O
treatment NN O
was VBD O
a DT O
main JJ O
predictor NN O
of IN O
MACEs NNP B-OC
and CC I-OC
TVR NNP I-OC
during IN O
the DT O
three-year JJ O
follow-up NN O
after IN O
either DT O
SES NNP B-INTV
or CC O
PES NNP B-INTV
implantation NN O
. . O

-DOCSTART- -X- O O

A DT O
web-based JJ B-INTV
patient NN I-INTV
activation NN I-INTV
intervention NN I-INTV
to TO O
improve VB O
hypertension NN O
care NN O
: : O
study NN O
design NN O
and CC O
baseline NN O
characteristics NNS O
in IN O
the DT O
web NN O
hypertension NN O
study NN O
. . O

BACKGROUND NNP O
Despite IN O
the DT O
known JJ O
health NN O
risks NNS O
of IN O
hypertension NN O
, , O
many JJ O
hypertensive JJ B-POPU
patients NNS I-POPU
still RB O
have VBP O
uncontrolled VBN O
blood NN O
pressure NN O
. . O

Clinical JJ O
inertia NN O
, , O
the DT O
tendency NN O
of IN O
physicians NNS O
not RB O
to TO O
intensify VB O
treatment NN O
, , O
is VBZ O
a DT O
common JJ O
barrier NN O
in IN O
controlling VBG O
chronic JJ O
diseases NNS O
. . O

This DT O
trial NN O
is VBZ O
aimed VBN O
at IN O
determining VBG O
the DT O
impact NN O
of IN O
activating VBG O
patients NNS O
to TO O
ask VB O
providers NNS O
to TO O
make VB O
changes NNS O
to TO O
their PRP$ O
care NN O
through IN O
tailored VBN O
feedback NN O
. . O

METHODS NNP O
Diagnosed VBD B-POPU
hypertensive JJ I-POPU
patients NNS I-POPU
were VBD O
enrolled VBN O
in IN O
this DT O
RCT NNP O
and CC O
randomized VBN O
to TO O
one CD O
of IN O
two CD O
study NN O
groups NNS O
: : O
( ( O
1 CD O
) ) O
the DT B-INTV
intervention NN I-INTV
condition NN I-INTV
-- : I-INTV
Web-based JJ I-INTV
hypertension NN I-INTV
feedback NN I-INTV
, , I-INTV
based VBN I-INTV
on IN I-INTV
the DT I-INTV
individual JJ I-INTV
patient NN I-INTV
's POS I-INTV
self-report NN I-INTV
of IN I-INTV
health NN I-INTV
variables NNS I-INTV
and CC I-INTV
previous JJ I-INTV
BP NNP I-INTV
measurements NNS I-INTV
, , I-INTV
to TO I-INTV
prompt VB I-INTV
them PRP I-INTV
to TO I-INTV
ask VB I-INTV
questions NNS I-INTV
during IN I-INTV
their PRP$ I-INTV
next JJ I-INTV
physician NN I-INTV
's POS I-INTV
visit NN I-INTV
about IN I-INTV
hypertension NN I-INTV
care NN I-INTV
( ( O
2 CD O
) ) O
the DT B-INTV
control NN I-INTV
condition NN I-INTV
-- : I-INTV
Web-based JJ I-INTV
preventive JJ I-INTV
health NN I-INTV
feedback NN I-INTV
, , I-INTV
based VBN I-INTV
on IN I-INTV
the DT I-INTV
individual NN I-INTV
's POS I-INTV
self-report NN I-INTV
of IN I-INTV
receiving VBG I-INTV
preventive JJ I-INTV
care NN I-INTV
( ( I-INTV
e.g. UH I-INTV
, , O
pap JJ B-INTV
testing VBG I-INTV
) ) I-INTV
, , I-INTV
to TO I-INTV
prompt VB I-INTV
them PRP I-INTV
to TO I-INTV
ask VB I-INTV
questions NNS I-INTV
during IN I-INTV
their PRP$ I-INTV
next JJ I-INTV
physician NN I-INTV
's POS I-INTV
visit NN I-INTV
about IN I-INTV
preventive JJ I-INTV
care NN I-INTV
. . O

The DT O
primary JJ O
outcome NN O
of IN O
the DT O
study NN O
is VBZ O
change VBN B-OC
in IN I-OC
blood NN I-OC
pressure NN I-OC
and CC I-OC
change NN I-OC
in IN I-OC
the DT I-OC
percentage NN I-OC
of IN I-OC
patients NNS I-OC
in IN I-OC
each DT I-OC
group NN I-OC
with IN I-OC
controlled VBN I-OC
blood NN I-OC
pressure NN I-OC
. . O

CONCLUSION NNP O
Five CD B-POPU
hundred VBD I-POPU
participants NNS I-POPU
were VBD I-POPU
enrolled VBN I-POPU
and CC I-POPU
baseline JJ I-POPU
characteristics NNS I-POPU
include VBP I-POPU
a DT I-POPU
mean JJ I-POPU
age NN I-POPU
of IN I-POPU
60.0 CD I-POPU
years NNS I-POPU
; : I-POPU
57.6 CD I-POPU
% NN I-POPU
female NN I-POPU
; : I-POPU
and CC I-POPU
77.6 CD I-POPU
% NN I-POPU
white JJ I-POPU
. . O

Overall JJ O
37.7 CD B-POPU
% NN I-POPU
participants NNS I-POPU
had VBD I-POPU
uncontrolled VBN I-POPU
blood NN I-POPU
pressure NN I-POPU
; : I-POPU
the DT I-POPU
mean NN I-POPU
body NN I-POPU
mass NN I-POPU
index NN I-POPU
( ( I-POPU
BMI NNP I-POPU
) ) I-POPU
was VBD I-POPU
in IN I-POPU
the DT I-POPU
obese JJ I-POPU
range NN I-POPU
( ( I-POPU
32.4 CD I-POPU
) ) I-POPU
and CC I-POPU
21.8 CD I-POPU
% NN I-POPU
had VBD I-POPU
diabetes NNS I-POPU
. . O

By IN O
activating VBG O
patients NNS O
to TO O
become VB O
involved VBN O
in IN O
their PRP$ O
own JJ O
care NN O
, , O
we PRP O
believe VBP O
the DT O
addition NN O
of IN O
the DT O
web-based JJ O
intervention NN O
will MD O
improve VB O
blood NN B-OC
pressure NN I-OC
control NN I-OC
compared VBN O
to TO O
a DT O
control NN O
group NN O
who WP O
receive VBP O
web-based JJ O
preventive JJ O
messages NNS O
unrelated VBN O
to TO O
hypertension NN O
. . O

-DOCSTART- -X- O O

High-calcium JJ B-INTV
milk NN I-INTV
prevents NNS O
overweight JJ O
and CC O
obesity NN O
among IN O
postmenopausal JJ B-POPU
women NNS I-POPU
. . O

BACKGROUND IN O
The DT O
Sixth NNP O
National NNP O
Nutrition NNP O
Survey NNP O
2003 CD O
revealed VBD O
that IN O
the DT O
highest JJS O
prevalence NN O
of IN O
overweight NN O
and CC O
obesity NN O
among IN O
Filipino NNP B-POPU
female JJ I-POPU
adults NNS I-POPU
( ( I-POPU
30.8 CD I-POPU
% NN I-POPU
) ) I-POPU
was VBD I-POPU
found VBN I-POPU
in IN I-POPU
the DT I-POPU
age NN I-POPU
group NN I-POPU
from IN I-POPU
40 CD I-POPU
to TO I-POPU
59 CD I-POPU
years NNS I-POPU
. . O

Obesity NN O
is VBZ O
associated VBN O
with IN O
a DT O
number NN O
of IN O
chronic JJ O
diseases NNS O
, , O
including VBG O
cardiovascular JJ O
disease NN O
, , O
hypertension NN O
, , O
and CC O
diabetes NNS O
. . O

Low JJ O
calcium NN O
intake NN O
has VBZ O
been VBN O
identified VBN O
as IN O
a DT O
potential JJ O
contributing NN O
factor NN O
to TO O
overweight NN O
and CC O
obesity NN O
. . O

OBJECTIVE UH O
To TO O
assess VB O
the DT O
effect NN O
of IN O
a DT O
high-calcium NN B-INTV
, , I-INTV
fortified VBN I-INTV
, , I-INTV
low-fat JJ I-INTV
milk NN I-INTV
drink NN I-INTV
with IN O
added JJ B-INTV
vitamin NN I-INTV
D NNP I-INTV
versus VBZ O
a DT O
low-calcium JJ B-INTV
placebo NN I-INTV
drink NN I-INTV
on IN O
anthropometric JJ O
measurements NNS O
of IN O
postmenopausal JJ B-POPU
women NNS I-POPU
. . O

METHODS NNP O
Women NNP B-POPU
who WP I-POPU
were VBD I-POPU
at IN I-POPU
least JJS I-POPU
5 CD I-POPU
years NNS I-POPU
postmenopausal NN I-POPU
were VBD I-POPU
invited VBN I-POPU
to TO I-POPU
participate VB I-POPU
in IN O
the DT O
study NN O
. . O

Potential JJ O
participants NNS O
underwent JJ O
three CD O
stages NNS O
of IN O
screening NN O
: : O
initial JJ O
interview NN O
, , O
dual-energy JJ O
x-ray JJ O
absorptiometry NN O
, , O
and CC O
blood NN O
testing NN O
for IN O
biochemical JJ O
screening NN O
. . O

Anthropometric JJ B-OC
indices NNS I-OC
were VBD O
measured VBN O
at IN O
baseline NN O
and CC O
the DT O
end NN O
of IN O
the DT O
study NN O
. . O

Sixty NNP B-POPU
women NNS I-POPU
were VBD I-POPU
qualified VBN I-POPU
to TO I-POPU
participate VB I-POPU
in IN O
the DT O
study NN O
. . O

The DT O
women NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
two CD O
groups NNS O
, , O
one CD O
of IN O
which WDT O
received VBD O
400 CD O
ml NN O
of IN O
the DT O
high-calcium JJ B-INTV
milk NN I-INTV
daily RB O
for IN O
16 CD O
weeks NNS O
while IN O
the DT O
other JJ O
received VBD O
the DT O
placebo NN B-INTV
drink NN I-INTV
. . O

RESULTS NNP O
No NNP O
significant JJ O
increases NNS O
were VBD O
observed VBN O
in IN O
the DT O
anthropometric JJ B-OC
indices NNS I-OC
of IN O
the DT O
subjects NNS O
receiving VBG O
the DT O
high-calcium NN B-INTV
fortified VBD I-INTV
milk NN I-INTV
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
. . O

However RB O
, , O
there EX O
were VBD O
significant JJ O
increases NNS O
in IN O
the DT O
weight NN B-OC
( ( O
p JJ O
= NNP O
.008 NNP O
) ) O
, , O
body JJ B-OC
mass NN I-OC
index NN I-OC
( ( O
p JJ O
= NNP O
.007 NNP O
) ) O
, , O
and CC O
waist NN B-OC
( ( O
p JJ O
= NNP O
.018 NNP O
) ) O
and CC O
hip NN B-OC
( ( O
p JJ O
= NNP O
.003 NNP O
) ) O
circumferences NNS B-OC
of IN O
the DT O
subjects NNS O
receiving VBG O
the DT O
placebo NN O
drink NN O
. . O

CONCLUSIONS VB O
A DT O
change NN O
in IN O
dietary JJ B-OC
calcium NN I-OC
intake NN I-OC
may MD O
be VB O
a DT O
useful JJ O
measure NN O
as IN O
part NN O
of IN O
an DT O
overall JJ O
approach NN O
to TO O
prevent VB O
the DT O
occurrence NN O
of IN O
overweight NN O
and CC O
obesity NN O
among IN O
postmenopausal JJ B-POPU
women NNS I-POPU
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
VX-770 NNP B-INTV
in IN O
persons NNS B-POPU
with IN I-POPU
cystic JJ I-POPU
fibrosis NN I-POPU
and CC I-POPU
the DT I-POPU
G551D-CFTR NNP I-POPU
mutation NN I-POPU
. . O

BACKGROUND VB O
A DT O
new JJ O
approach NN O
in IN O
the DT O
treatment NN O
of IN O
cystic JJ O
fibrosis NN O
involves VBZ O
improving VBG O
the DT O
function NN O
of IN O
mutant JJ O
cystic JJ O
fibrosis NN O
transmembrane NN O
conductance NN O
regulator NN O
( ( O
CFTR NNP O
) ) O
. . O

VX-770 NNP O
, , O
a DT O
CFTR NNP O
potentiator NN O
, , O
has VBZ O
been VBN O
shown VBN O
to TO O
increase VB O
the DT O
activity NN O
of IN O
wild-type NN O
and CC O
defective JJ O
cell-surface NN O
CFTR NNP O
in IN O
vitro NN O
. . O

METHODS NNP O
We PRP O
randomly VBP O
assigned VBD O
39 CD B-POPU
adults NNS I-POPU
with IN I-POPU
cystic JJ I-POPU
fibrosis NN I-POPU
and CC I-POPU
at IN I-POPU
least JJS I-POPU
one CD I-POPU
G551D-CFTR JJ I-POPU
allele NN I-POPU
to TO O
receive VB O
oral JJ B-INTV
VX-770 NNP I-INTV
every DT O
12 CD O
hours NNS O
at IN O
a DT O
dose NN O
of IN O
25 CD O
, , O
75 CD O
, , O
or CC O
150 CD O
mg NN O
or CC O
placebo NN B-INTV
for IN O
14 CD O
days NNS O
( ( O
in IN O
part NN O
1 CD O
of IN O
the DT O
study NN O
) ) O
or CC O
VX-770 JJ B-INTV
every DT O
12 CD O
hours NNS O
at IN O
a DT O
dose NN O
of IN O
150 CD O
or CC O
250 CD O
mg NN O
or CC O
placebo NN B-INTV
for IN O
28 CD O
days NNS O
( ( O
in IN O
part NN O
2 CD O
of IN O
the DT O
study NN O
) ) O
. . O

RESULTS VBN O
At IN O
day NN O
28 CD O
, , O
in IN O
the DT O
group NN O
of IN O
subjects NNS O
who WP O
received VBD O
150 CD O
mg NNS O
of IN O
VX-770 NNP O
, , O
the DT O
median JJ O
change NN O
in IN O
the DT O
nasal JJ B-OC
potential JJ I-OC
difference NN I-OC
( ( O
in IN O
response NN O
to TO O
the DT O
administration NN O
of IN O
a DT O
chloride-free JJ O
isoproterenol JJ O
solution NN O
) ) O
from IN O
baseline NN O
was VBD O
-3.5 JJ O
mV NN O
( ( O
range NN O
, , O
-8.3 NNP O
to TO O
0.5 CD O
; : O
P=0.02 NNP O
for IN O
the DT O
within-subject JJ O
comparison NN O
, , O
P=0.13 NNP O
vs. FW O
placebo NN O
) ) O
, , O
and CC O
the DT O
median JJ O
change NN O
in IN O
the DT O
level NN B-OC
of IN I-OC
sweat NN I-OC
chloride NN I-OC
was VBD O
-59.5 JJ O
mmol NN O
per IN O
liter NN O
( ( O
range NN O
, , O
-66.0 NN O
to TO O
-19.0 VB O
; : O
P=0.008 NNP O
within-subject NN O
, , O
P=0.02 NNP O
vs. FW O
placebo NN O
) ) O
. . O

The DT O
median JJ O
change NN O
from IN O
baseline NN O
in IN O
the DT O
percent NN O
of IN O
predicted VBN O
forced JJ B-OC
expiratory NN I-OC
volume NN I-OC
in IN O
1 CD O
second NN O
was VBD O
8.7 CD O
% NN O
( ( O
range NN O
, , O
2.3 CD O
to TO O
31.3 CD O
; : O
P=0.008 NNP O
for IN O
the DT O
within-subject JJ O
comparison NN O
, , O
P=0.56 NNP O
vs. FW O
placebo NN O
) ) O
. . O

None NN O
of IN O
the DT O
subjects NNS O
withdrew VBD O
from IN O
the DT O
study NN O
. . O

Six NNP O
severe JJ B-OC
adverse JJ I-OC
events NNS I-OC
occurred VBD O
in IN O
two CD O
subjects NNS O
( ( B-OC
diffuse IN I-OC
macular NN I-OC
rash NN I-OC
in IN O
one CD O
subject NN O
and CC O
five CD O
incidents NNS O
of IN O
elevated VBN B-OC
blood NN I-OC
and CC I-OC
urine JJ I-OC
glucose NN I-OC
levels NNS I-OC
in IN O
one CD O
subject NN O
with IN O
diabetes NNS B-OC
) ) I-OC
. . O

All DT O
severe JJ O
adverse JJ O
events NNS O
resolved VBN O
without IN O
the DT O
discontinuation NN O
of IN O
VX-770 NNP O
. . O

CONCLUSIONS NNP O
This DT O
study NN O
to TO O
evaluate VB O
the DT O
safety NN B-OC
and CC I-OC
adverse-event JJ I-OC
profile NN I-OC
of IN O
VX-770 NNP O
showed VBD O
that IN O
VX-770 NNP O
was VBD O
associated VBN O
with IN O
within-subject JJ O
improvements NNS O
in IN O
CFTR NNP B-OC
and CC I-OC
lung NN I-OC
function NN I-OC
. . O

These DT O
findings NNS O
provide VBP O
support NN O
for IN O
further JJ O
studies NNS O
of IN O
pharmacologic JJ O
potentiation NN O
of IN O
CFTR NNP O
as IN O
a DT O
means NN O
to TO O
treat VB B-POPU
cystic JJ I-POPU
fibrosis NN I-POPU
. . O

( ( O
Funded VBN O
by IN O
Vertex NNP O
Pharmaceuticals NNP O
and CC O
others NNS O
; : O
ClinicalTrials.gov NNP O
number NN O
, , O
NCT00457821 NNP O
. . O

) ) O
. . O

-DOCSTART- -X- O O

Pars NNS B-INTV
plana VBP I-INTV
vitrectomy NN I-INTV
for IN O
diabetic JJ O
macular JJ O
edema NN O
. . O

Internal NNP B-INTV
limiting VBG I-INTV
membrane NN I-INTV
delamination NN I-INTV
vs FW O
posterior JJ B-INTV
hyaloid NN I-INTV
removal NN I-INTV
. . O

A DT O
prospective JJ O
randomized VBN O
trial NN O
. . O

BACKGROUND NNP O
Diabetes VBZ O
mellitus RB O
, , O
as RB O
well RB O
as IN O
subsequent JJ O
ocular JJ O
complications NNS O
such JJ O
as IN O
cystoid JJ O
macular JJ O
edema NN O
( ( O
CME NNP O
) ) O
, , O
are VBP O
of IN O
fundametal JJ O
socio-economic JJ O
relevance NN O
. . O

Therefore RB O
, , O
we PRP O
evaluated VBD O
the DT O
influence NN O
of IN O
internal JJ B-INTV
limiting VBG I-INTV
membrane NN I-INTV
( ( I-INTV
ILM NNP I-INTV
) ) I-INTV
removal NN I-INTV
on IN O
longterm JJ O
morphological JJ O
and CC O
functional JJ O
outcome NN O
in IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus NNS I-POPU
( ( I-POPU
DM NNP I-POPU
) ) I-POPU
type NN I-POPU
2 CD I-POPU
and CC I-POPU
chronic JJ I-POPU
CME NNP I-POPU
without IN I-POPU
evident JJ I-POPU
vitreomacular JJ I-POPU
traction NN I-POPU
. . O

METHOD NNP O
Forty NNP B-POPU
eyes NNS I-POPU
with IN I-POPU
attached JJ I-POPU
posterior JJ I-POPU
hyaloid NN I-POPU
were VBD O
included VBN O
in IN O
this DT O
prospective JJ O
trial NN O
and CC O
randomized VBN O
intraoperatively RB O
. . O

Prior NNP O
focal JJ O
( ( O
n JJ O
= NNP O
31 CD O
) ) O
or CC O
panretinal JJ O
( ( B-INTV
n JJ I-INTV
= NNP I-INTV
25 CD I-INTV
) ) I-INTV
laser JJR I-INTV
coagulation NN I-INTV
was VBD O
permitted VBN O
. . O

Group NNP O
I PRP O
( ( O
n JJ O
= $ O
19 CD O
patients NNS B-INTV
) ) I-INTV
underwent JJ I-INTV
surgical JJ I-INTV
induction NN I-INTV
of IN I-INTV
posterior JJ I-INTV
vitreous JJ I-INTV
detachment NN I-INTV
( ( O
PVD NNP O
) ) O
, , O
group NN O
II NNP O
( ( B-INTV
n JJ I-INTV
= $ I-INTV
20 CD I-INTV
patients NNS I-INTV
) ) I-INTV
PVD NNP I-INTV
and CC I-INTV
removal NN I-INTV
of IN O
the DT O
ILM NNP O
. . O

Eleven NNP O
patients NNS O
with IN O
detached JJ O
posterior JJ O
hyaloid NN O
( ( O
group NN O
III NNP O
) ) O
were VBD O
not RB O
randomized VBN B-INTV
, , O
and CC O
ILM NNP O
removal NN O
was VBD O
performed VBN O
. . O

One CD O
eye NN O
had VBD O
to TO O
be VB O
excluded VBN O
from IN O
further JJ O
analysis NN O
. . O

Examinations NNS B-OC
included VBD I-OC
ETDRS NNP I-OC
best-corrected JJ I-OC
visual JJ I-OC
acuity NN I-OC
( ( I-OC
BCVA NNP I-OC
) ) I-OC
, , I-OC
fluorescein JJ I-OC
angiography NN I-OC
( ( O
FLA NNP O
) ) O
and CC O
OCT NNP O
at IN O
baseline NN O
, , O
3 CD O
and CC O
6 CD O
months NNS O
postoperatively RB O
. . O

Main NNP O
outcome JJ B-OC
measure NN O
was VBD O
BCVA NNP O
at IN O
6 CD B-OC
months NNS I-OC
, , I-OC
secondary JJ I-OC
was VBD I-OC
foveal JJ O
thickness NN B-OC
. . O

RESULTS NNP O
Mean NNP O
BCVA NNP O
over IN O
6 CD O
months NNS O
remained VBD O
unchanged JJ O
in IN O
85 CD O
% NN O
of IN O
patients NNS O
of IN O
group NN O
II NNP O
, , O
and CC O
decreased VBD O
in IN O
53 CD O
% NN O
of IN O
patients NNS O
of IN O
group NN O
I PRP O
. . O

Results NNS O
were VBD O
not RB O
statistically RB O
significant JJ O
different JJ O
[ NNP O
group NN O
I PRP O
: : O
mean JJ O
decrease NN O
log NN O
MAR NNP O
95 CD O
% NN O
CI NNP O
( ( O
0.06 CD O
; : O
0.32 CD O
) ) O
, , O
group NN O
II NNP O
: : O
( ( O
-0.02 VBP O
; : O
0.11 CD O
) ) O
] NN O
. . O

OCT NNP O
revealed VBD O
a DT O
significantly RB O
greater JJR B-OC
reduction NN I-OC
of IN I-OC
foveal JJ O
thickness NN O
following VBG O
PVD NNP O
with IN O
ILM NNP O
removal NN O
[ NNP O
group NN O
I PRP O
: : O
mean JJ O
change NN O
: : O
95 CD O
% NN O
CI NNP O
( ( O
-208.95 NNP O
μm NNP O
; : O
-78.05 NNP O
μm NNP O
) ) O
, , O
group NN O
II NNP O
: : O
( ( B-INTV
-80.90 JJ I-INTV
μm NN I-INTV
: : I-INTV
+59.17 JJ I-INTV
μm NN I-INTV
) ) I-INTV
] NN I-INTV
. . O

CONCLUSION NNP B-INTV
Vitrectomy NNP I-INTV
, , I-INTV
PVD NNP I-INTV
with IN I-INTV
or CC O
without IN O
ILM NNP O
removal NN O
does VBZ B-POPU
not RB I-POPU
improve VB I-POPU
vision NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
DM NNP I-POPU
type NN I-POPU
2 CD I-POPU
and CC I-POPU
cystoid JJ I-POPU
diabetic JJ I-POPU
macular NN I-POPU
edema NN I-POPU
without IN I-POPU
evident JJ I-POPU
vitreoretinal JJ O
traction NN O
. . O

ILM NNP O
delamination NN O
shows VBZ O
improved JJ O
morphological JJ O
results NNS O
, , O
and CC O
appears VBZ B-POPU
to TO I-POPU
be VB I-POPU
beneficial JJ I-POPU
in IN I-POPU
eyes NNS O
with IN O
preexisting VBG O
PVD NNP O
. . O

-DOCSTART- -X- O O

Factors NNS O
predictive VBP O
of IN O
severe JJ B-OC
hypoglycemia NN I-OC
in IN O
type NN B-POPU
1 CD I-POPU
diabetes NNS I-POPU
: : I-POPU
analysis NN O
from IN O
the DT O
Juvenile NNP O
Diabetes NNP O
Research NNP O
Foundation NNP O
continuous JJ O
glucose JJ O
monitoring VBG O
randomized VBN O
control NN O
trial NN O
dataset NN O
. . O

OBJECTIVE NNP O
Identify NNP O
factors NNS O
predictive VBP O
of IN O
severe JJ B-OC
hypoglycemia NN I-OC
( ( I-OC
SH NNP I-OC
) ) I-OC
and CC O
assess VB O
the DT O
clinical JJ B-OC
utility NN I-OC
of IN O
continuous JJ B-INTV
glucose JJ I-INTV
monitoring NN I-INTV
( ( I-INTV
CGM NNP I-INTV
) ) I-INTV
to TO O
warn VB O
of IN O
impending VBG O
SH NNP O
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
In IN O
a DT O
multicenter NN B-POPU
randomized VBN O
clinical JJ O
trial NN O
, , O
436 CD B-POPU
children NNS I-POPU
and CC I-POPU
adults NNS I-POPU
with IN I-POPU
type JJ I-POPU
1 CD I-POPU
diabetes NNS I-POPU
were VBD O
randomized VBN O
to TO O
a DT O
treatment NN O
group NN O
that WDT O
used VBD O
CGM NNP B-INTV
( ( O
N NNP O
= NNP O
224 CD O
) ) O
, , O
or CC O
a DT O
control NN B-INTV
group NN O
that WDT O
used VBD O
standard JJ B-INTV
home NN I-INTV
blood NN I-INTV
glucose JJ I-INTV
monitoring NN I-INTV
( ( O
N NNP O
= NNP O
212 CD O
) ) O
and CC O
completed VBD O
12 CD O
months NNS O
of IN O
follow-up NN O
. . O

After IN O
6 CD O
months NNS O
, , O
the DT O
original JJ O
control NN O
group NN O
initiated VBD O
CGM NNP B-INTV
while IN O
the DT O
treatment NN O
group NN O
continued VBD O
use NN O
of IN O
CGM NNP O
for IN O
6 CD O
months NNS O
. . O

Baseline NNP O
risk NN O
factors NNS O
for IN O
SH NNP O
were VBD O
evaluated VBN O
over IN O
12 CD O
months NNS O
of IN O
follow-up JJ O
using VBG O
proportional JJ O
hazards NNS O
regression NN O
. . O

CGM-derived JJ B-OC
indices NNS I-OC
of IN I-OC
hypoglycemia NN I-OC
were VBD O
used VBN O
to TO O
predict VB O
episodes NNS O
of IN O
SH NNP O
over IN O
a DT O
24-h JJ O
time NN O
horizon NN O
. . O

RESULTS VB O
The DT O
SH NNP B-OC
rate NN I-OC
was VBD O
17.9 CD O
per IN O
100 CD O
person-years NNS O
, , O
and CC O
a DT O
higher JJR O
rate NN B-OC
was VBD O
associated VBN O
with IN O
the DT O
occurrence NN O
of IN O
SH NNP B-OC
in IN O
the DT O
prior JJ O
6 CD O
months NNS O
and CC O
female JJ O
sex NN O
. . O

SH NNP B-OC
frequency NN I-OC
increased VBD O
eightfold RB O
when WRB O
30 CD O
% NN O
of IN O
CGM NNP B-INTV
values NNS B-OC
were VBD O
≤ JJ O
70 CD O
mg/dL NN O
on IN O
the DT O
prior JJ O
day NN O
( ( O
4.5 CD O
vs. FW O
0.5 CD O
% NN O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
but CC O
the DT B-OC
positive JJ I-OC
predictive JJ I-OC
value NN I-OC
( ( I-OC
PPV NNP I-OC
) ) I-OC
was VBD O
low JJ O
( ( O
< JJ O
5 CD O
% NN O
) ) O
. . O

Results NNS O
were VBD O
similar JJ O
for IN B-OC
hypoglycemic JJ I-OC
area NN I-OC
under IN I-OC
the DT I-OC
curve NN I-OC
and CC O
the DT B-OC
low JJ I-OC
blood NN I-OC
glucose NN I-OC
index NN I-OC
calculated VBN O
by IN B-INTV
CGM NNP I-INTV
. . O

CONCLUSIONS NNP B-OC
SH NNP I-OC
in IN O
the DT O
6 CD O
months NNS O
prior RB O
to TO O
the DT O
study NN O
was VBD O
the DT O
strongest JJS O
predictor NN O
of IN B-OC
SH NNP I-OC
during IN O
the DT O
study NN B-INTV
. . O

CGM-measured JJ B-INTV
hypoglycemia NN B-OC
over IN O
a DT O
24-h JJ O
span NN O
is VBZ O
highly RB O
associated VBN O
with IN B-OC
SH NNP I-OC
the DT O
following JJ O
day NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
but CC O
the DT B-OC
PPV NNP I-OC
is VBZ O
low JJ O
. . O

-DOCSTART- -X- O O

Prevalence NN B-OC
of IN I-OC
metabolic JJ I-OC
syndrome NN I-OC
in IN O
rural JJ B-POPU
and CC I-POPU
urban JJ I-POPU
Chinese JJ I-POPU
population NN I-POPU
in IN I-POPU
Qingdao NNP I-POPU
. . O

AIMS NNP O
To TO O
investigate VB O
the DT O
prevalence NN B-OC
of IN I-OC
metabolic JJ I-OC
syndrome NN I-OC
and CC O
its PRP$ O
components NNS O
in IN O
both DT O
rural JJ B-POPU
and CC I-POPU
urban JJ I-POPU
Chinese JJ I-POPU
population NN I-POPU
. . O

SUBJECTS NNP O
AND NNP O
METHODS NNP O
A NNP O
population-based JJ B-INTV
crosssectional JJ I-INTV
survey NN I-INTV
was VBD O
conducted VBN O
in IN O
Qingdao NNP B-POPU
, , I-POPU
China NNP I-POPU
in IN I-POPU
2006 CD I-POPU
with IN I-POPU
6100 CD I-POPU
Chinese JJ I-POPU
aged VBN I-POPU
35-74 JJ I-POPU
yr NN I-POPU
invited VBN I-POPU
and CC I-POPU
5355 CD I-POPU
who WP I-POPU
attended VBD I-POPU
; : I-POPU
3357 CD I-POPU
subjects NNS I-POPU
, , I-POPU
1562 CD I-POPU
urban NN I-POPU
( ( I-POPU
46.5 CD I-POPU
% NN I-POPU
) ) I-POPU
and CC I-POPU
1795 CD I-POPU
rural JJ I-POPU
residents NNS I-POPU
( ( I-POPU
53.5 CD I-POPU
% NN I-POPU
) ) I-POPU
met VBD I-POPU
the DT I-POPU
inclusion NN I-POPU
criteria NNS I-POPU
for IN I-POPU
the DT I-POPU
current JJ I-POPU
data NN I-POPU
analysis NN I-POPU
. . O

The DT O
metabolic JJ O
syndrome JJ O
definitions NNS O
of IN O
National NNP O
Cholesterol NNP O
Education NNP O
Program NNP O
Adult NNP O
Treatment NNP O
Expert NNP O
Panel NNP O
III NNP O
( ( O
NCEPATPIII NNP O
) ) O
2004 CD O
, , O
NCEP NNP O
2005 CD O
and CC O
International NNP O
Diabetes NNP O
Federation NNP O
( ( O
IDF NNP O
) ) O
were VBD O
used VBN O
. . O

RESULTS VB O
The DT O
age-standardized JJ B-OC
prevalences NNS I-OC
of IN I-OC
metabolic JJ I-OC
syndrome NN I-OC
were VBD O
16.2 CD O
% NN O
, , O
32.2 CD O
% NN O
, , O
and CC O
28.3 CD O
% NN O
in IN O
men NNS O
and CC O
26.8 CD O
% NN O
, , O
37.2 CD O
% NN O
, , O
and CC O
34.6 CD O
% NN O
in IN O
women NNS O
, , O
according VBG O
to TO O
the DT O
definitions NNS O
of IN O
the DT O
NCEP NNP O
2004 CD O
, , O
NCEP NNP O
2005 CD O
, , O
and CC O
IDF NNP O
, , O
respectively RB O
. . O

Urban JJ O
men NNS O
have VBP O
more JJR O
risk NN B-OC
factors NNS I-OC
and CC I-OC
higher JJR I-OC
prevalence NN I-OC
of IN I-OC
the DT I-OC
metabolic JJ I-OC
syndrome NN I-OC
than IN O
rural JJ O
men NNS O
, , O
but CC O
the DT O
differences NNS O
in IN O
women NNS O
were VBD O
not RB O
that IN O
striking VBG O
. . O

Elevated VBN B-OC
blood NN I-OC
pressure NN I-OC
( ( O
62.6 CD O
% NN O
) ) O
was VBD O
, , O
among IN O
risk NN O
factors NNS O
, , O
most JJS O
common JJ O
in IN O
the DT O
study NN O
population NN O
, , O
followed VBN O
by IN O
central JJ B-OC
obesity NN I-OC
( ( O
53.4 CD O
% NN O
) ) O
, , O
and CC O
hyperglycemia NN B-OC
( ( O
52.2 CD O
% NN O
) ) O
defined VBD O
using VBG O
the DT O
NCEP NNP O
2005 CD O
criteria NN O
. . O

CONCLUSIONS NNP O
Metabolic NNP O
disorders NNS O
were VBD O
common JJ O
among IN O
adult JJ B-POPU
Chinese NNPS I-POPU
in IN I-POPU
both DT I-POPU
rural JJ I-POPU
and CC I-POPU
urban JJ I-POPU
areas NNS I-POPU
in IN I-POPU
Qingdao NNP I-POPU
. . O

-DOCSTART- -X- O O

Efficacy NN O
of IN O
a DT O
family NN B-INTV
practice-based JJ I-INTV
lifestyle JJ I-INTV
intervention NN I-INTV
program NN I-INTV
to TO O
increase VB O
physical JJ B-OC
activity NN I-OC
and CC O
reduce VB O
clinical JJ O
and CC O
physiological JJ O
markers NNS O
of IN O
vascular JJ O
health NN O
in IN O
patients NNS B-POPU
with IN I-POPU
high JJ I-POPU
normal JJ I-POPU
blood NN I-POPU
pressure NN I-POPU
and/or RB I-POPU
high JJ I-POPU
normal JJ I-POPU
blood NN I-POPU
glucose NN I-POPU
( ( I-POPU
SNAC NNP I-POPU
) ) I-POPU
: : I-POPU
study NN O
protocol NN O
for IN O
a DT O
randomized VBN O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
Previous JJ O
interventions NNS O
to TO O
increase VB O
physical JJ B-OC
activity NN I-OC
and CC O
reduce VB O
cardiovascular JJ O
risk NN O
factors NNS O
have VBP O
been VBN O
targeted VBN O
at IN O
individuals NNS O
with IN O
established VBN O
disease NN O
; : O
less CC O
attention NN O
has VBZ O
been VBN O
given VBN O
to TO O
intervention VB O
among IN O
individuals NNS B-POPU
with IN I-POPU
high JJ I-POPU
risk NN I-POPU
for IN I-POPU
disease NN I-POPU
nor CC O
has VBZ O
there RB O
been VBN O
determination NN O
of IN O
the DT O
influence NN O
of IN O
setting VBG O
in IN O
which WDT O
the DT O
intervention NN O
is VBZ O
provided VBN O
. . O

In IN O
particular JJ O
, , O
family NN O
practice NN O
represents VBZ O
an DT O
ideal JJ O
setting NN O
for IN O
the DT O
provision NN O
and CC O
long-term JJ O
maintenance NN O
of IN O
lifestyle JJ O
interventions NNS O
for IN O
patients NNS B-POPU
at IN I-POPU
risk NN I-POPU
( ( I-POPU
ie JJ I-POPU
high-normal JJ I-POPU
blood NN I-POPU
pressure NN I-POPU
or CC I-POPU
impaired JJ I-POPU
glucose JJ I-POPU
tolerance NN I-POPU
) ) I-POPU
. . O

METHODS/DESIGN PDT O
The DT O
Staged NNP B-POPU
Nutrition NNP I-POPU
and CC I-POPU
Activity NNP I-POPU
Counseling NNP I-POPU
( ( I-POPU
SNAC NNP I-POPU
) ) I-POPU
study NN I-POPU
is VBZ O
a DT O
randomized JJ O
clustered JJ O
design NN O
clinical JJ O
trial NN O
that WDT O
will MD O
investigate VB O
the DT O
effectiveness NN O
and CC O
efficacy NN O
of IN O
a DT O
multi-component JJ B-INTV
lifestyle JJ I-INTV
intervention NN I-INTV
on IN O
cardiovascular JJ B-POPU
disease NN I-POPU
risk NN I-POPU
factors NNS I-POPU
and CC I-POPU
vascular JJ I-POPU
function NN I-POPU
in IN I-POPU
patients NNS I-POPU
at IN I-POPU
risk NN I-POPU
in IN I-POPU
primary JJ I-POPU
care NN I-POPU
. . O

Patients NNS O
will MD O
be VB O
randomized VBN O
by IN O
practice NN O
to TO O
either VB O
a DT O
standard NN B-INTV
of IN I-INTV
care NN I-INTV
lifestyle JJ I-INTV
intervention NN I-INTV
or CC O
a DT O
behaviourally-based JJ B-INTV
, , I-INTV
matched VBD I-INTV
prescriptive JJ I-INTV
physical JJ I-INTV
activity NN I-INTV
and CC I-INTV
diet JJ I-INTV
change NN I-INTV
program NN I-INTV
. . O

The DT O
primary JJ O
goal NN O
is VBZ O
to TO O
increase VB O
physical JJ B-OC
activity NN I-OC
and CC O
improve VB O
dietary JJ B-OC
intake NN I-OC
according VBG O
to TO O
Canada NNP B-OC
's POS I-OC
Guides NNP I-OC
to TO I-OC
Physical NNP I-OC
Activity NNP I-OC
Healthy NNP I-OC
Eating NNP I-OC
over IN O
24 CD O
months NNS O
. . O

The DT O
primary JJ O
intention NN O
to TO O
treat VB O
analysis NN O
will MD O
compare VB O
behavioral JJ O
, , O
physiological JJ O
and CC O
metabolic JJ O
outcomes NNS O
at IN O
6 CD O
, , O
12 CD O
and CC O
24 CD O
months NNS O
post-randomization JJ O
including VBG O
estimation NN O
of IN O
incident JJ O
hypertension NN B-OC
and/or NN O
diabetes VBZ B-OC
. . O

DISCUSSION VB O
The DT O
design NN O
features NNS O
of IN O
our PRP$ O
trial NN O
, , O
and CC O
the DT O
practical JJ O
problems NNS O
( ( O
and CC O
solutions NNS O
) ) O
associated VBN O
with IN O
implementing VBG O
these DT O
design NN O
features NNS O
, , O
particularly RB O
those DT O
that IN O
result NN O
in IN O
potential JJ O
delay NN O
between IN O
recruitment NN O
, , O
baseline NN O
data NNS O
collection NN O
, , O
randomization NN O
, , O
intervention NN O
, , O
and CC O
assessment NN O
will MD O
be VB O
discussed VBN O
. . O

Results NNS O
of IN O
the DT O
SNAC NNP O
trial NN O
will MD O
provide VB O
scientific JJ O
rationale NN O
for IN O
the DT O
implementation NN O
of IN O
this DT O
lifestyle JJ O
intervention NN O
in IN O
primary JJ O
care NN O
. . O

TRIAL NNP O
REGISTRATION NNP O
ISRCTN NNP O
: : O
ISRCTN:42921300 NNP O
. . O

-DOCSTART- -X- O O

A DT O
prospective JJ O
, , O
double-blind JJ O
, , O
randomized VBN O
, , O
controlled VBD O
clinical JJ O
trial NN O
comparing VBG O
standard NN B-INTV
wound NN I-INTV
care NN I-INTV
with IN O
adjunctive JJ B-INTV
hyperbaric JJ I-INTV
oxygen NN I-INTV
therapy NN I-INTV
( ( I-INTV
HBOT NNP I-INTV
) ) I-INTV
to TO O
standard VB O
wound NN O
care NN O
only RB O
for IN O
the DT O
treatment NN O
of IN O
chronic JJ B-POPU
, , I-POPU
non-healing JJ I-POPU
ulcers NNS I-POPU
of IN I-POPU
the DT I-POPU
lower JJR I-POPU
limb NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus NNS I-POPU
: : I-POPU
a DT O
study NN O
protocol NN O
. . O

BACKGROUND NNP O
It PRP O
has VBZ O
been VBN O
suggested VBN O
that IN O
the DT O
use NN O
of IN O
adjunctive JJ B-INTV
hyperbaric JJ I-INTV
oxygen NN I-INTV
therapy NN I-INTV
improves VBZ O
the DT O
healing NN O
of IN O
diabetic JJ B-OC
foot NN I-OC
ulcers NNS I-OC
, , O
and CC O
decreases VBZ O
the DT O
risk NN O
of IN O
lower JJR B-OC
extremity NN I-OC
amputations NNS I-OC
. . O

A DT O
limited JJ O
number NN O
of IN O
studies NNS O
have VBP O
used VBN O
a DT O
double JJ O
blind NN O
approach NN O
to TO O
evaluate VB O
the DT O
efficacy NN O
of IN O
hyperbaric JJ B-INTV
oxygen NN I-INTV
therapy NN I-INTV
in IN O
the DT O
treatment NN O
of IN O
diabetic JJ B-POPU
ulcers NNS I-POPU
. . O

The DT O
primary JJ O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
assess VB O
the DT O
efficacy NN O
of IN O
hyperbaric JJ B-INTV
oxygen NN I-INTV
therapy NN I-INTV
plus CC I-INTV
standard NN I-INTV
wound NN I-INTV
care NN I-INTV
compared VBN O
with IN O
standard NN B-INTV
wound NN I-INTV
care NN I-INTV
alone RB O
in IN O
preventing VBG O
the DT O
need NN O
for IN O
major JJ B-OC
amputation NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus NNS I-POPU
and CC I-POPU
chronic JJ I-POPU
ulcers NNS I-POPU
of IN I-POPU
the DT I-POPU
lower JJR I-POPU
limb NN I-POPU
. . O

METHODS/DESIGN NNP O
One CD B-POPU
hundred CD I-POPU
and CC I-POPU
eighteen JJ I-POPU
( ( I-POPU
59 CD I-POPU
patients NNS I-POPU
per IN I-POPU
arm NN I-POPU
) ) I-POPU
patients NNS I-POPU
with IN I-POPU
non-healing JJ I-POPU
diabetic JJ I-POPU
ulcers NNS I-POPU
of IN I-POPU
the DT I-POPU
lower JJR I-POPU
limb NN I-POPU
, , I-POPU
referred VBD I-POPU
to TO I-POPU
the DT I-POPU
Judy NNP I-POPU
Dan NNP I-POPU
Research NNP I-POPU
and CC I-POPU
Treatment NNP I-POPU
Centre NNP I-POPU
are VBP I-POPU
being VBG I-POPU
recruited VBN I-POPU
if IN I-POPU
they PRP I-POPU
are VBP I-POPU
at IN I-POPU
least JJS I-POPU
18 CD I-POPU
years NNS I-POPU
of IN I-POPU
age NN I-POPU
, , I-POPU
have VBP I-POPU
either DT I-POPU
Type NNP I-POPU
1 CD I-POPU
or CC I-POPU
2 CD I-POPU
diabetes NNS I-POPU
with IN I-POPU
a DT I-POPU
Wagner NNP I-POPU
grading NN I-POPU
of IN I-POPU
foot NN I-POPU
lesions NNS I-POPU
2 CD I-POPU
, , I-POPU
3 CD I-POPU
or CC I-POPU
4 CD I-POPU
on IN I-POPU
lower JJR I-POPU
limb NN I-POPU
not RB I-POPU
healing VBG I-POPU
for IN I-POPU
at IN I-POPU
least JJS I-POPU
4 CD I-POPU
weeks NNS I-POPU
. . O

Patients NNS O
receive JJ O
hyperbaric JJ B-INTV
oxygen NN I-INTV
therapy NN I-INTV
every DT O
day NN O
for IN O
6 CD O
weeks NNS O
during IN O
the DT O
treatment NN O
phase NN O
and CC O
are VBP O
provided VBN O
ongoing VBG B-INTV
wound NN I-INTV
care NN I-INTV
and CC O
weekly JJ O
assessments NNS O
. . O

Patients NNS O
are VBP O
required VBN O
to TO O
return VB O
to TO O
the DT O
study NN O
centre NN O
every DT O
week NN O
for IN O
an DT O
additional JJ O
6 CD O
weeks NNS O
of IN O
follow-up NN O
for IN O
wound JJ O
evaluation NN O
and CC O
management NN O
. . O

The DT O
primary JJ O
outcome NN O
is VBZ O
freedom RB B-OC
from IN I-OC
having VBG I-OC
, , I-OC
or CC I-OC
meeting VBG I-OC
the DT I-OC
criteria NN I-OC
for IN I-OC
, , I-OC
a DT I-OC
major JJ I-OC
amputation NN I-OC
( ( I-OC
below IN I-OC
knee NN I-OC
amputation NN I-OC
, , I-OC
or CC I-OC
metatarsal VB I-OC
level NN I-OC
) ) I-OC
up RB O
to TO O
12 CD O
weeks NNS O
after IN O
randomization NN O
. . O

The DT O
decision NN O
to TO O
amputate VB O
is VBZ O
made VBN O
by IN O
a DT O
vascular JJ O
surgeon NN O
. . O

Other JJ O
outcomes NNS O
include VBP O
wound IN B-OC
healing NN I-OC
, , I-OC
effectiveness NN I-OC
, , I-OC
safety NN I-OC
, , I-OC
healthcare JJ I-OC
resource NN I-OC
utilization NN I-OC
, , I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
, , I-OC
and CC I-OC
cost-effectiveness NN I-OC
. . O

The DT O
study NN O
will MD O
run VB O
for IN O
a DT O
total NN O
of IN O
about IN O
3 CD O
years NNS O
. . O

DISCUSSION VB O
The DT O
results NNS O
of IN O
this DT O
study NN O
will MD O
provide VB O
detailed JJ O
information NN O
on IN O
the DT O
efficacy NN O
of IN O
hyperbaric JJ B-INTV
oxygen NN I-INTV
therapy NN I-INTV
for IN O
the DT O
treatment NN O
of IN O
non-healing JJ B-POPU
ulcers NNS I-POPU
of IN I-POPU
the DT I-POPU
lower JJR I-POPU
limb NN I-POPU
. . O

This DT O
will MD O
be VB O
the DT O
first JJ O
double-blind JJ O
randomized VBN O
controlled JJ O
trial NN O
for IN O
this DT O
health NN O
technology NN O
which WDT O
evaluates VBZ O
the DT O
efficacy NN O
of IN O
hyperbaric JJ B-INTV
oxygen NN I-INTV
therapy NN I-INTV
in IN O
prevention NN O
of IN O
amputations NNS B-OC
in IN O
diabetic JJ B-POPU
patients NNS I-POPU
. . O

TRIAL NNP O
REGISTRATION NNP O
ClinicalTrials.gov NNP O
Identifier NNP O
: : O
NCT00621608 NN O
. . O

-DOCSTART- -X- O O

Nephrotoxicity NN O
of IN O
cyclosporin NN B-INTV
A NNP I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
type NN I-POPU
1 CD I-POPU
diabetes NNS I-POPU
mellitus RB I-POPU
. . O

Renal JJ O
function NN O
was VBD O
studied VBN O
in IN O
18 CD B-POPU
patients NNS I-POPU
with IN I-POPU
Type NNP I-POPU
1 CD I-POPU
diabetes NNS I-POPU
mellitus RB I-POPU
. . O

All DT B-POPU
were VBD I-POPU
participating VBG I-POPU
in IN I-POPU
the DT I-POPU
Canadian-European JJ I-POPU
randomized JJ I-POPU
placebo-controlled JJ I-POPU
cyclosporin NN I-POPU
trial NN I-POPU
in IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
Type NNP I-POPU
1 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
, , O
nine CD O
being VBG O
randomized VBN O
to TO O
placebo VB B-INTV
, , O
and CC O
nine CD O
to TO O
cyclosporin VB B-INTV
A NNP I-INTV
. . O

During IN O
treatment NN O
for IN O
12 CD O
to TO O
18 CD O
months NNS O
, , O
cyclosporin VBP B-INTV
A DT I-INTV
caused JJ O
significant JJ O
reductions NNS O
in IN O
the DT O
glomerular JJ B-OC
filtration NN I-OC
rate NN I-OC
( ( O
before IN O
drug NN O
withdrawal NN O
, , O
cyclosporin JJ B-INTV
97 CD O
+/- JJ O
18 CD O
vs NN O
placebo NN O
125 CD O
+/- JJ O
16 CD O
ml JJ O
min-1 JJ O
1.73-m-2 JJ O
, , O
p RB O
less JJR O
than IN O
0.05 CD O
) ) O
, , O
renal JJ B-OC
plasma NN I-OC
flow NN I-OC
( ( O
454 CD O
+/- JJ O
83 CD O
vs JJ O
536 CD O
+/- JJ O
70 CD O
ml JJ O
min-1 JJ O
1.73-m-2 JJ O
, , O
p RB O
less JJR O
than IN O
0.05 CD O
) ) O
, , O
and CC O
lithium JJ B-OC
clearance NN I-OC
( ( O
17 CD O
+/- JJ O
3 CD O
vs JJ O
28 CD O
+/- JJ O
5 CD O
ml JJ O
min-1 JJ O
1.73-m-2 JJ O
, , O
p RB O
less JJR O
than IN O
0.05 CD O
) ) O
. . O

The DT O
fractional JJ B-OC
proximal JJ I-OC
reabsorption NN I-OC
was VBD O
increased VBN O
( ( O
0.82 CD O
+/- JJ O
0.03 CD O
vs JJ O
0.78 CD O
+/- JJ O
0.03 CD O
, , O
p NN O
less JJR O
than IN O
0.05 CD O
) ) O
, , O
and CC O
the DT O
fractional JJ B-OC
distal JJ I-OC
sodium NN I-OC
reabsorption NN I-OC
reduced VBD O
( ( O
0.88 CD O
+/- JJ O
0.03 CD O
vs JJ O
0.94 CD O
+/- JJ O
0.02 CD O
, , O
p NN O
less JJR O
than IN O
0.05 CD O
) ) O
. . O

These DT O
results NNS O
are VBP O
in IN O
accordance NN O
with IN O
the DT O
hypothesis NN O
that IN O
the DT O
nephrotoxic JJ O
effect NN O
of IN O
cyclosporin NN B-INTV
A NNP I-INTV
results NNS O
from IN O
a DT O
preferential JJ O
constriction NN O
of IN O
afferent JJ O
glomerular JJ O
vessels NNS O
. . O

One CD O
year NN O
after IN O
withdrawal NN O
of IN O
the DT O
drug NN O
, , O
all DT O
variables NNS O
were VBD O
similar JJ O
in IN O
the DT O
two CD O
groups NNS O
, , O
except IN O
for IN O
blood NN B-OC
glucose NN I-OC
control NN I-OC
which WDT O
was VBD O
worse RBR O
in IN O
the DT O
cyclosporin NN B-INTV
A NNP I-INTV
treated VBD O
group NN O
. . O

When WRB O
corrected VBN O
for IN O
differences NNS O
in IN O
blood NN O
glucose NN O
control NN O
it PRP O
appeared VBD O
that IN O
in IN O
three CD O
out IN O
of IN O
nine CD O
patients NNS O
glomerular JJ B-OC
filtration NN I-OC
rate NN I-OC
had VBD O
not RB O
completely RB O
returned VBN O
to TO O
the DT O
reference NN O
range NN O
of IN O
the DT O
placebo NN B-INTV
group NN O
. . O

We PRP O
conclude VBP O
that IN O
the DT O
nephrotoxic JJ O
side-effects NNS O
of IN O
cyclosporin NN B-INTV
A NNP I-INTV
treatment NN O
for IN O
1 CD O
year NN O
are VBP O
reversible JJ O
. . O

There EX O
are VBP O
, , O
however RB O
, , O
signs NNS O
of IN O
minor JJ O
and CC O
perhaps RB O
chronic JJ O
renal JJ O
injury NN O
. . O

-DOCSTART- -X- O O

Poor NNP O
self-rated JJ O
health NN O
is VBZ O
not RB O
associated VBN O
with IN O
a DT O
high JJ O
total JJ O
allostatic JJ O
load NN O
in IN O
type NN B-POPU
2 CD I-POPU
diabetic JJ I-POPU
patients NNS I-POPU
-- : I-POPU
but CC I-POPU
high JJ O
blood NN O
pressure NN O
is VBZ O
. . O

OBJECTIVE NNP O
Allostatic NNP O
load NN O
has VBZ O
been VBN O
linked VBN O
to TO O
self-rated JJ O
health NN O
( ( O
SRH NNP O
) ) O
, , O
cardiovascular JJ O
disease NN O
and CC O
mortality NN O
in IN O
non-diabetic JJ B-POPU
individuals NNS I-POPU
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
construct VB O
an DT O
allostatic JJ O
load NN O
score NN O
and CC O
to TO O
find VB O
any DT O
correlations NNS O
with IN O
SRH NNP O
. . O

METHODS NNP O
The DT O
subjects NNS B-POPU
included VBN I-POPU
in IN I-POPU
the DT I-POPU
study NN I-POPU
came VBD I-POPU
from IN I-POPU
a DT I-POPU
randomized VBN I-POPU
, , I-POPU
controlled VBD I-POPU
trial NN I-POPU
of IN I-POPU
type NN I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

Blood NN O
samples NNS O
were VBD O
drawn VBN O
, , O
urine NN O
was VBD O
collected VBN O
for IN O
24h CD O
, , O
and CC O
questionnaires NNS O
, , O
including VBG O
SRH NNP O
, , O
were VBD O
filled VBN O
out RP O
on IN O
three CD O
occasions NNS O
: : O
at IN O
baseline NN O
; : O
after IN O
the DT O
10-week JJ O
intervention NN O
; : O
and CC O
at IN O
a DT O
follow-up JJ O
3 CD O
months NNS O
after IN O
the DT O
intervention NN O
. . O

Allostatic JJ O
load NN O
was VBD O
estimated VBN O
using VBG O
a DT O
wide JJ O
range NN O
of IN O
variables NNS O
, , O
including VBG O
systolic JJ B-OC
and CC I-OC
diastolic JJ I-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
pulse JJ I-OC
pressure NN I-OC
, , I-OC
cortisol NN I-OC
, , I-OC
catecholamines NNS I-OC
, , I-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
, , I-OC
insulin NN I-OC
, , I-OC
plasma VBP I-OC
glucose JJ I-OC
and CC I-OC
waist JJ I-OC
circumference NN I-OC
. . O

RESULTS NNP O
There EX O
was VBD O
no DT O
association NN O
between IN O
SRH NNP O
and CC O
allostatic JJ O
load NN O
. . O

However RB O
, , O
three CD O
other JJ O
components NNS O
were VBD O
significantly RB O
correlated VBN O
with IN O
allostatic JJ O
load NN O
at IN O
the DT O
baseline NN O
investigation NN O
and CC O
the DT O
two CD O
follow-up JJ O
investigations NNS O
- : O
namely RB O
, , O
systolic JJ B-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
diastolic JJ I-OC
blood NN I-OC
pressure NN I-OC
and CC I-OC
HbA NNP I-OC
( ( I-OC
1c CD I-OC
) ) I-OC
. . O

CONCLUSION VB O
The DT O
absence NN O
of IN O
an DT O
association NN O
between IN O
allostatic JJ O
load NN O
and CC O
SRH NNP B-OC
in IN O
diabetic JJ B-POPU
individuals NNS I-POPU
contrasts NNS O
with IN O
previous JJ O
findings NNS O
in IN O
non-diabetic JJ B-POPU
women NNS I-POPU
, , O
and CC O
shows VBZ O
that IN O
it PRP O
is VBZ O
hazardous JJ O
to TO O
apply VB O
findings NNS O
in IN O
one CD O
population NN O
to TO O
another DT O
, , O
especially RB O
diabetic JJ B-POPU
and CC I-POPU
non-diabetic JJ I-POPU
populations NNS I-POPU
. . O

-DOCSTART- -X- O O

Short-term JJ O
metabolic JJ O
effects NNS B-OC
of IN O
prednisone NN B-INTV
administration NN O
in IN O
healthy JJ B-POPU
subjects NNS I-POPU
. . O

AIMS NNP O
Supraphysiologic NNP O
glucocorticoid NN O
activity NN O
is VBZ O
well RB O
established VBN O
to TO O
cause VB O
impaired JJ O
glucose JJ B-OC
tolerance NN I-OC
and CC I-OC
insulin NN I-OC
resistance NN I-OC
, , O
yet RB O
no DT O
study NN O
has VBZ O
evaluated VBN O
dose-dependent JJ O
effects NNS O
of IN O
low-dose JJ O
prednisone NN B-INTV
during IN O
short-term JJ O
oral JJ O
administration NN O
. . O

METHODS NNP O
The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
quantify VB O
the DT O
effects NNS O
of IN O
daily JJ O
10 CD B-INTV
or CC I-INTV
25 CD I-INTV
mg NNS I-INTV
prednisone JJ I-INTV
administration NN O
for IN O
one CD O
week NN O
on IN O
insulin NN O
sensitivity NN O
by IN O
employing VBG O
a DT O
two-step JJ B-INTV
hyperinsulinemic JJ I-INTV
euglycemic JJ I-INTV
glucose NN I-INTV
clamp NN I-INTV
( ( O
Step JJ O
1 CD O
: : O
insulin NN O
infusion NN O
= VBD O
20 CD O
mU/m²/min NN O
; : O
Step CC O
2 CD B-INTV
: : I-INTV
insulin NN I-INTV
infusion NN I-INTV
= VBD I-INTV
80 CD I-INTV
mU/m²/min NN I-INTV
) ) I-INTV
in IN B-POPU
healthy JJ I-POPU
, , I-POPU
lean JJ I-POPU
males NNS I-POPU
. . O

The DT B-OC
amount NN I-OC
of IN I-OC
glucose NN I-OC
infused VBN I-OC
at IN I-OC
steady-state JJ I-OC
to TO O
maintain VB B-OC
stable JJ I-OC
blood NN I-OC
glucose JJ I-OC
[ $ O
90 CD O
mg/dl NN O
( ( O
4.95 CD O
mmol/l NN O
) ) O
] NN O
was VBD O
used VBN O
to TO O
calculate VB O
several JJ O
indices NNS O
of IN O
insulin NN O
sensitivity NN O
. . O

RESULTS NNP O
During IN O
Step NNP O
1 CD O
of IN O
the DT O
clamp NN B-OC
, , I-OC
whole JJ I-OC
body NN I-OC
glucose JJ I-OC
disposal NN I-OC
( ( I-OC
M NNP I-OC
) ) I-OC
was VBD O
reduced VBN O
by IN O
35 CD O
% NN O
( ( O
p JJ O
= NNP O
0.003 CD O
) ) O
and CC O
M/I NNP O
was VBD O
reduced VBN O
by IN O
29 CD O
% NN O
( ( O
p JJ O
= NNP O
0.025 CD O
) ) O
for IN O
25 CD O
mg NN B-INTV
prednisone NN I-INTV
compared VBN O
to TO B-INTV
placebo VB I-INTV
. . O

No DT O
appreciable JJ O
effect NN O
of IN O
10 CD O
mg NN O
prednisone NN O
was VBD O
observed VBN O
. . O

During IN O
Step NNP O
2 CD B-OC
, , O
M NNP O
was VBD O
reduced VBN O
by IN O
33 CD O
% NN O
( ( O
p JJ O
= NNP O
0.001 CD O
) ) O
and CC O
15 CD O
% NN O
( ( O
p JJ O
= NNP O
0.006 CD O
) ) O
for IN O
25 CD O
and CC O
10 CD O
mg NN B-INTV
prednisone NN I-INTV
compared VBN O
to TO B-INTV
placebo VB I-INTV
; : I-INTV
and CC B-OC
M/I NNP I-OC
ratio NN I-OC
was VBD O
reduced VBN O
by IN O
31 CD O
% NN O
( ( O
p JJ O
< NNP O
0.001 CD O
) ) O
and CC O
13 CD O
% NN O
( ( O
p JJ O
= NNP O
0.026 CD O
) ) O
, , O
respectively RB O
. . O

The DT B-OC
insulin NN I-OC
sensitivity NN I-OC
index NN I-OC
, , I-OC
Si NNP I-OC
, , O
calculated VBD O
as IN O
the DT O
quotient NN O
of IN O
augmentation NN O
of IN O
M/I NNP O
between IN O
Step NNP O
1 CD O
and CC O
2 CD O
, , O
was VBD O
reduced VBN O
by IN O
35.3 CD O
% NN O
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
and CC O
23.5 CD O
% NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
for IN O
25 CD O
and CC O
10 CD O
mg NN B-INTV
prednisone NN I-INTV
, , O
respectively RB O
. . O

CONCLUSION NNP O
Administration NNP O
of IN O
relatively RB O
low JJ O
pharmacological JJ O
doses NNS O
of IN O
prednisone NN O
for IN O
one CD O
week NN O
impaired JJ B-OC
insulin NN I-OC
sensitivity NN I-OC
in IN O
a DT O
dose-dependent JJ O
manner NN O
in IN B-POPU
healthy JJ I-POPU
males NNS I-POPU
. . O

These DT O
observed JJ O
changes NNS O
in IN O
insulin NN O
sensitivity NN O
are VBP O
likely JJ O
to TO O
be VB O
clinically RB O
relevant JJ O
, , O
especially RB O
in IN O
individuals NNS O
predisposed VBN O
to TO O
develop VB O
glucose JJ O
intolerance NN O
. . O

-DOCSTART- -X- O O

Long-term JJ B-OC
consequences NNS I-OC
of IN O
different JJ O
immunosuppressive JJ B-INTV
regimens NNS I-INTV
for IN O
renal JJ B-POPU
allografts NNS I-POPU
. . O

The DT O
long-term JJ B-OC
effects NNS I-OC
of IN O
four CD O
different JJ B-INTV
immunosuppressive JJ I-INTV
regimens NNS I-INTV
on IN O
renal JJ O
allografts NNS O
have VBP O
been VBN O
investigated VBN O
up RP O
to TO O
four CD O
years NNS O
. . O

A DT O
total NN O
of IN O
128 CD B-POPU
recipients NNS I-POPU
of IN I-POPU
first JJ I-POPU
cadaveric JJ I-POPU
renal NN I-POPU
allograft NN I-POPU
were VBD O
randomized VBN O
, , O
after IN O
an DT O
initial JJ O
induction NN O
period NN O
, , O
to TO O
receive VB O
either RB O
triple JJ O
drug NN O
therapy NN O
-- : O
i.e. NN O
, , O
( ( O
low-dose JJ O
) ) O
cyclosporine NN B-INTV
, , I-INTV
azathioprine NN I-INTV
, , I-INTV
and CC I-INTV
methylprednisolone NN I-INTV
, , I-INTV
or CC I-INTV
any DT I-INTV
possible JJ I-INTV
combination NN I-INTV
of IN I-INTV
two CD I-INTV
drugs NNS I-INTV
-- : I-INTV
i.e. NN I-INTV
, , O
Aza NNP B-INTV
plus CC I-INTV
CsA NNP I-INTV
, , I-INTV
Aza NNP I-INTV
plus CC I-INTV
MP NNP I-INTV
, , I-INTV
and CC I-INTV
CsA NNP I-INTV
plus CC I-INTV
MP NNP I-INTV
. . O

The DT O
actual JJ O
four-year JJ O
graft NN B-OC
survival NN I-OC
rates NNS I-OC
for IN O
the DT O
triple JJ O
therapy NN O
, , O
Aza NNP B-INTV
plus CC I-INTV
CsA NNP I-INTV
, , I-INTV
Aza NNP I-INTV
plus CC I-INTV
MP NNP I-INTV
, , I-INTV
and CC I-INTV
CsA NNP I-INTV
plus CC I-INTV
MP NNP I-INTV
groups NNS O
were VBD O
72 CD O
% NN O
, , O
69 CD O
% NN O
, , O
75 CD O
% NN O
, , O
and CC O
59 CD O
% NN O
, , O
and CC O
patient JJ O
survival NN O
rates NNS O
were VBD O
78 CD O
% NN O
, , O
81 CD O
% NN O
, , O
81 CD O
% NN O
, , O
and CC O
84 CD O
% NN O
, , O
respectively RB O
, , O
with IN O
no DT O
significant JJ O
differences NNS O
. . O

The DT O
cumulative JJ O
number NN O
of IN O
chronic JJ B-OC
rejections NNS I-OC
up IN O
to TO O
4 CD O
years NNS O
was VBD O
0.09 CD O
, , O
0.29 CD O
, , O
0.25 CD O
, , O
and CC O
0.34 CD O
per IN O
patient NN O
per IN O
group NN O
( ( O
P NNP O
= NNP O
ns NN O
) ) O
, , O
respectively RB O
. . O

At IN O
2 CD O
, , O
3 CD O
, , O
and CC O
4 CD O
years NNS O
posttransplantation NN O
, , O
the DT O
graft NN B-OC
function NN I-OC
was VBD O
significantly RB O
worse JJR O
in IN O
the DT O
Aza NNP B-INTV
plus CC I-INTV
MP NNP I-INTV
group NN O
compared VBN O
with IN O
the DT O
triple JJ O
therapy NN O
group NN O
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

Of IN O
the DT O
98 CD B-POPU
patients NNS I-POPU
who WP I-POPU
did VBD I-POPU
not RB I-POPU
have VB I-POPU
type NN I-POPU
I PRP I-POPU
or CC I-POPU
II NNP I-POPU
diabetes VBZ I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
transplantation NN I-POPU
, , O
17 CD O
developed VBD O
posttransplantation NN B-OC
diabetes NNS I-OC
mellitus VBP I-OC
or CC O
an DT O
abnormal JJ B-OC
glucose NN I-OC
tolerance NN I-OC
test NN I-OC
within IN O
2 CD O
years NNS O
posttransplantation NN O
. . O

All PDT O
these DT O
patients NNS O
had VBD O
received VBN O
steroids NNS B-INTV
and CC O
none NN O
of IN O
the DT O
patients NNS O
without IN O
steroids NNS O
had VBD O
these DT O
abnormalities NNS O
. . O

At IN O
two CD O
years NNS O
the DT O
mean NN O
cholesterol NN B-OC
level NN I-OC
was VBD O
highest JJS O
in IN O
the DT O
Aza NNP B-INTV
plus CC I-INTV
MP NNP I-INTV
group NN O
, , O
6.8 CD O
mmol/L NN O
and CC O
lowest JJS O
in IN O
the DT O
group NN O
receiving VBG O
triple JJ B-INTV
therapy NN I-INTV
, , O
5.8 CD O
mmol/L NN O
( ( O
P NNP O
= NNP O
ns NN O
) ) O
. . O

The DT O
use NN O
of IN O
( ( O
low-dose JJ O
) ) O
CsA NNP O
was VBD O
not RB O
associated VBN O
with IN O
lipid JJ B-OC
abnormalities NNS I-OC
or CC O
with IN O
disturbances NNS B-OC
in IN I-OC
glucose JJ I-OC
metabolism NN I-OC
. . O

A DT O
protocol NN O
graft NN O
biopsy NN O
was VBD O
performed VBN O
at IN O
two CD O
years NNS O
on IN O
all DT O
functioning VBG O
kidneys NNS O
, , O
and CC O
the DT O
histological JJ B-OC
changes NNS I-OC
were VBD O
scored VBN O
blindly RB O
. . O

No DT O
CsA-specific JJ B-OC
changes NNS I-OC
, , O
except IN O
isometric JJ B-OC
vacuolation NN I-OC
in IN I-OC
tubuli NN I-OC
, , O
were VBD O
found VBN O
. . O

Histological JJ B-OC
alterations NNS I-OC
characteristic NN I-OC
of IN I-OC
chronic JJ I-OC
rejection NN I-OC
were VBD O
expressed VBN O
as IN O
" NNP B-OC
chronic NN I-OC
allograft NN I-OC
damage NN I-OC
index NN I-OC
. . O

" CC B-OC
Chronic NNP I-OC
allograft NN I-OC
damage NN I-OC
index NN I-OC
was VBD O
lowest JJS O
in IN O
the DT O
triple JJ O
therapy NN O
group NN O
, , O
1.5 CD O
, , O
compared VBN O
with IN O
the DT O
other JJ O
groups NNS O
, , O
3.2-4.3 JJ O
( ( O
P NNP O
= NNP O
.01 NNP O
) ) O
, , O
indicating VBG O
the DT O
least JJS O
histopathological JJ B-OC
change NN I-OC
in IN O
the DT O
triple JJ O
therapy NN O
group NN O
. . O

In IN O
conclusion NN O
, , O
this DT O
long-term JJ O
study NN O
did VBD O
not RB O
show VB O
any DT O
serious JJ O
cyclosporine-related JJ B-INTV
side-effects NNS B-OC
when WRB O
used VBN O
in IN O
low JJ O
dose NN O
in IN O
combination NN O
with IN O
two CD O
other JJ O
drugs NNS O
. . O

Some DT O
side-effects NNS O
, , O
such JJ O
as IN O
posttransplant JJ B-OC
diabetes NNS I-OC
mellitus NNS I-OC
and CC O
probably RB O
some DT B-OC
lipid JJ I-OC
abnormalities NNS I-OC
, , O
could MD O
rather RB O
be VB O
traced VBN O
to TO O
a DT O
higher JJR O
dose NN O
of IN O
steroids NNS B-INTV
. . O

Moreover RB O
, , O
the DT O
triple JJ B-INTV
drug NN I-INTV
therapy NN I-INTV
was VBD O
more RBR O
efficacious JJ O
than IN O
any DT O
double JJ O
drug NN O
regimen NNS O
in IN O
the DT O
prevention NN O
of IN O
chronic JJ B-OC
histological JJ I-OC
changes NNS I-OC
in IN I-OC
renal JJ I-OC
allografts NNS I-OC
. . O

-DOCSTART- -X- O O

Treatment NN O
of IN O
vasculogenic JJ B-POPU
sexual JJ I-POPU
dysfunction NN I-POPU
with IN O
pentoxifylline NN B-INTV
. . O

OBJECTIVE UH O
To TO O
evaluate VB O
the DT O
use NN O
of IN O
pentoxifylline NN B-INTV
to TO O
treat VB O
impotence NN O
in IN O
men NNS B-POPU
with IN I-POPU
mild NN I-POPU
to TO I-POPU
moderate VB I-POPU
penile IN I-POPU
vascular JJ I-POPU
insufficiency NN I-POPU
. . O

DESIGN NNP O
Double-blind NNP O
randomized VBD O
clinical JJ O
trial NN O
. . O

SETTING NN O
Sexual JJ B-POPU
Dysfunction NNP I-POPU
Clinic NNP I-POPU
at IN I-POPU
VA NNP I-POPU
Medical NNP I-POPU
Center NNP I-POPU
, , I-POPU
Sepulveda NNP I-POPU
, , I-POPU
CA NNP I-POPU
. . O

PARTICIPANTS NNP O
Convenience NNP B-POPU
sample NN I-POPU
of IN I-POPU
couples NNS I-POPU
. . O

INTERVENTION NNP O
Twelve NNP O
weeks NNS O
of IN O
treatment NN O
with IN O
placebo NN B-INTV
or CC I-INTV
400 CD I-INTV
mg JJ I-INTV
tid NN I-INTV
of IN I-INTV
pentoxifylline NN I-INTV
. . O

MEASUREMENTS NNP O
( ( O
1 CD O
) ) O
Report NN B-OC
of IN I-OC
patient JJ B-POPU
verified VBN B-OC
by IN I-OC
partner NN B-POPU
as IN B-OC
to TO I-OC
number NN I-OC
of IN I-OC
coital JJ I-OC
episodes NNS I-OC
per IN I-OC
month NN I-OC
; : I-OC
( ( O
2 CD O
) ) O
penile-brachial JJ B-OC
pressure NN I-OC
index NN I-OC
determinations NNS I-OC
. . O

RESULTS NNP O
Pentoxifylline NNP B-INTV
therapy VBZ I-INTV
regularly RB O
increased VBN O
the DT O
PBPI NNP B-OC
in IN O
impotent JJ B-POPU
men NNS I-POPU
in IN O
comparison NN O
with IN O
the DT O
placebo NN O
, , O
frequently RB O
into IN O
the DT O
normal JJ O
range NN O
. . O

Pentoxifylline NNP O
therapy NN O
was VBD O
particularly RB O
useful JJ O
in IN O
restoring VBG B-OC
the DT I-OC
PBPI NNP I-OC
in IN O
men NNS B-POPU
with IN I-POPU
the DT I-POPU
pelvic JJ I-POPU
steal JJ I-POPU
syndrome NN I-POPU
; : I-POPU
six CD O
of IN O
seven CD O
such JJ O
subjects NNS O
improved VBN O
into IN O
the DT O
normal JJ O
range NN O
. . O

During IN O
the DT O
pentoxifylline JJ O
treatment NN O
period NN O
, , O
in IN O
contrast NN O
with IN O
the DT O
control NN O
period NN O
, , O
nine CD O
men NNS O
were VBD O
able JJ O
to TO O
reestablish VB B-OC
coital JJ I-OC
function NN I-OC
and CC O
three CD O
had VBD O
no DT O
improvement NN O
. . O

Six NNP O
couples NNS O
did VBD O
not RB O
attempt VB B-OC
intercourse JJ I-OC
despite IN O
a DT O
professed JJ O
interest NN O
in IN O
sexual JJ B-OC
activity NN I-OC
; : I-OC
however RB O
five CD O
out IN O
of IN O
the DT O
six CD O
men NNS O
experienced VBD O
erections NNS B-OC
during IN I-OC
episodes NNS I-OC
of IN I-OC
fantasy NN I-OC
or CC I-OC
attempts NNS I-OC
at IN I-OC
masturbation NN I-OC
during IN O
treatment NN O
. . O

There EX O
were VBD O
no DT O
complications NNS B-OC
of IN O
therapy NN O
. . O

CONCLUSIONS NNP O
These DT O
promising VBG O
preliminary JJ O
results NNS O
suggest VBP O
a DT O
well RB O
tolerated JJ O
alternative JJ O
therapy NN O
for IN O
erectile JJ B-POPU
dysfunction NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
mild JJ I-POPU
to TO I-POPU
moderate VB I-POPU
penile IN I-POPU
vascular JJ I-POPU
disease NN I-POPU
. . O

-DOCSTART- -X- O O

Hypertension NN B-POPU
and CC I-POPU
non-insulin-dependent JJ I-POPU
diabetes NNS I-POPU
. . O

A DT O
comparison NN O
between IN O
an DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
and CC O
a DT O
calcium NN B-INTV
antagonist NN I-INTV
. . O

The DT O
effects NNS O
of IN O
the DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
lisinopril NN I-INTV
were VBD O
compared VBN O
with IN O
those DT O
of IN O
the DT O
calcium NN B-INTV
antagonist NN I-INTV
nifedipine NN I-INTV
in IN O
162 CD B-POPU
non-insulin-dependent JJ I-POPU
diabetic JJ I-POPU
hypertensive NN I-POPU
patients NNS I-POPU
for IN O
a DT O
24-week JJ O
period NN O
. . O

In IN O
83 CD O
and CC O
79 CD O
patients NNS O
, , O
respectively RB O
, , O
lisinopril JJ B-INTV
and CC I-INTV
slow-release JJ I-INTV
nifedipine NN I-INTV
produced VBD O
similar JJ O
reductions NNS B-OC
in IN I-OC
blood NN I-OC
pressure NN I-OC
( ( O
systolic/diastolic JJ O
: : O
-16/-13 NN O
mmHg NN O
supine NN O
and CC O
-14/-11 NN O
mmHg NN O
standing NN O
after IN O
lisinopril NN O
; : O
-15/-12 CC O
mmHg VB O
supine NN O
and CC O
-14/-11 NN O
mmHg NN O
standing VBG O
nifedipine NN O
) ) O
. . O

Fasting VBG B-OC
and CC I-OC
post-prandial JJ I-OC
plasma NN I-OC
glucose NN I-OC
, , I-OC
glycosylated VBN I-OC
haemoglobin NN I-OC
and CC I-OC
plasma JJ I-OC
lipids NNS I-OC
appeared VBD O
to TO O
be VB O
unaffected VBN O
by IN O
either DT O
agent NN O
. . O

Also RB O
, , O
28 CD O
% NN O
of IN O
the DT O
patients NNS O
on IN O
lisinopril NN B-INTV
and CC O
30 CD O
% NN O
of IN O
those DT O
on IN O
nifedipine JJ B-INTV
presented VBN O
microalbuminuria NN O
. . O

Both DT O
drugs NNS O
induced VBD O
a DT O
reduction NN O
in IN O
the DT O
albumin JJ B-OC
excretion NN I-OC
rate NN I-OC
( ( I-OC
AER NNP I-OC
) ) I-OC
. . O

The DT O
geometric JJ O
mean NN O
x NN O
: : O
tolerance NN O
factor NN O
of IN O
the DT O
reduction NN B-OC
in IN I-OC
AER NNP I-OC
among IN O
the DT O
23 CD O
microalbuminuric JJ O
patients NNS O
on IN O
lisinopril NN B-INTV
( ( O
-10.0 JJ O
x:1.3 NNP O
micrograms/min NN O
) ) O
was VBD O
greater JJR O
, , O
though IN O
not RB O
significantly RB O
so RB O
, , O
than IN O
that DT O
observed VBD O
in IN O
the DT O
26 CD O
on IN O
nifedipine NN B-INTV
( ( O
-0.9 JJ O
x $ O
1.2 CD O
micrograms/min NN O
) ) O
. . O

Moreover RB O
, , O
lisinopril RB B-INTV
appeared VBD O
to TO O
be VB O
better RB O
tolerated VBN B-OC
than IN O
nifedipine NN B-INTV
in IN O
our PRP$ O
study NN O
population NN O
. . O

Microalbuminuria NNP O
is VBZ O
an DT O
important JJ O
risk NN O
factor NN O
for IN O
cardiovascular JJ O
mortality NN O
in IN O
non-insulin-dependent JJ B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
as RB O
well RB O
as IN O
in IN O
the DT O
general JJ O
population NN O
. . O

To TO O
what WP O
extent VB O
a DT O
reduction NN O
in IN O
the DT O
AER NNP B-OC
could MD O
ameliorate VB O
diabetic JJ O
patients NNS O
is VBZ O
, , O
at IN O
present JJ O
, , O
unknown JJ O
. . O

Finally RB O
, , O
both DT O
lisinopril FW B-INTV
and CC O
nifedipine NN B-INTV
showed VBD O
a DT O
similar JJ O
antihypertensive JJ B-OC
effect NN I-OC
in IN O
these DT O
patients NNS O
which WDT O
was VBD O
not RB O
associated VBN O
with IN O
significant JJ O
differences NNS O
in IN O
plasma NN O
glucose NN O
, , O
insulin NN O
or CC O
lipid JJ O
concentrations NNS O
. . O

The DT O
clinical JJ O
consequences NNS O
of IN O
the DT O
insignificant JJ O
differences NNS O
in IN O
AER NNP B-OC
remain VBP O
unclear JJ O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
coronary JJ B-INTV
bypass NN I-INTV
surgery NN I-INTV
with IN O
angioplasty NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
. . O

The DT O
Bypass NNP O
Angioplasty NNP O
Revascularization NNP O
Investigation NNP O
( ( O
BARI NNP O
) ) O
Investigators NNPS O
. . O

BACKGROUND NNP O
Coronary-artery JJ B-INTV
bypass NN I-INTV
grafting NN I-INTV
( ( I-INTV
CABG NNP I-INTV
) ) I-INTV
and CC O
percutaneous JJ B-INTV
transluminal JJ I-INTV
coronary NN I-INTV
angioplasty NN I-INTV
( ( I-INTV
PTCA NNP I-INTV
) ) I-INTV
are VBP O
alternative JJ O
methods NNS O
of IN O
revascularization NN O
in IN O
patients NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
. . O

We PRP O
tested VBD O
the DT O
hypothesis NN O
that IN O
in IN O
selected JJ O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
suitable JJ I-POPU
for IN I-POPU
treatment NN I-POPU
with IN I-POPU
either DT I-POPU
procedure NN I-POPU
, , O
an DT O
initial JJ O
strategy NN O
of IN O
PTCA NNP O
does VBZ O
not RB O
result VB O
in IN O
a DT O
poorer JJR O
five-year JJ O
clinical JJ B-OC
outcome NN I-OC
than IN O
CABG NNP O
. . O

METHODS NNP O
Patients NNPS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
an DT I-POPU
initial JJ I-POPU
treatment NN I-POPU
strategy NN I-POPU
of IN I-POPU
CABG NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
914 CD I-POPU
) ) I-POPU
or CC I-POPU
PTCA NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
915 CD I-POPU
) ) I-POPU
and CC O
were VBD O
followed VBN O
for IN O
an DT O
average NN O
of IN O
5.4 CD O
years NNS O
. . O

Analysis NN O
of IN O
outcome JJ O
events NNS O
was VBD O
performed VBN O
according VBG O
to TO O
the DT O
intention NN O
to TO O
treat VB O
. . O

RESULTS VB O
The DT O
respective JJ O
in-hospital JJ O
event NN O
rates NNS O
for IN O
CABG NNP O
and CC O
PTCA NNP O
were VBD O
1.3 CD O
percent NN O
and CC O
1.1 CD O
percent NN O
for IN O
mortality NN B-OC
, , O
4.6 CD O
percent NN O
and CC O
2.1 CD O
percent NN O
for IN O
Q-wave NNP B-OC
myocardial JJ I-OC
infarction NN I-OC
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
and CC O
0.8 CD O
percent NN O
and CC O
0.2 CD O
percent NN O
for IN O
stroke NN B-OC
. . O

The DT O
five-year JJ B-OC
survival NN I-OC
rate NN I-OC
was VBD O
89.3 CD O
percent NN O
for IN O
those DT O
assigned VBN O
to TO O
CABG NNP O
and CC O
86.3 CD O
percent NN O
for IN O
those DT O
assigned VBN O
to TO O
PTCA NNP O
( ( O
P NNP O
= NNP O
0.19 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
of IN O
the DT O
difference NN O
in IN O
survival NN O
, , O
-0.2 JJ O
percent NN O
to TO O
6.0 CD O
percent NN O
) ) O
. . O

The DT O
respective JJ B-OC
five-year JJ I-OC
survival NN I-OC
rates NNS I-OC
free VBP I-OC
from IN I-OC
Q-wave NNP I-OC
myocardial JJ I-OC
infarction NN I-OC
were VBD O
80.4 CD O
percent NN O
and CC O
78.7 CD O
percent NN O
. . O

By IN O
five CD O
years NNS O
after IN O
study NN O
entry NN O
, , O
8 CD O
percent NN O
of IN O
the DT O
patients NNS O
assigned VBD O
to TO O
CABG NNP O
had VBD O
undergone JJ O
additional JJ O
revascularization NN B-OC
procedures NNS I-OC
, , O
as IN O
compared VBN O
with IN O
54 CD O
percent NN O
of IN O
those DT O
assigned VBN O
to TO O
PTCA NNP O
; : O
69 CD O
percent NN O
of IN O
those DT O
assigned VBN O
to TO O
PTCA NNP O
did VBD O
not RB O
subsequently RB O
undergo JJ O
CABG NNP O
. . O

Among IN B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
being VBG I-POPU
treated VBN I-POPU
with IN I-POPU
insulin NN I-POPU
or CC I-POPU
oral JJ I-POPU
hypoglycemic JJ I-POPU
agents NNS I-POPU
at IN I-POPU
base NN I-POPU
line NN I-POPU
, , O
a DT O
subgroup NN O
not RB O
specified VBN O
by IN O
the DT O
protocol NN O
, , O
five-year JJ B-OC
survival NN I-OC
was VBD O
80.6 CD O
percent NN O
for IN O
the DT O
CABG NNP O
group NN O
as IN O
compared VBN O
with IN O
65.5 CD O
percent NN O
for IN O
the DT O
PTCA NNP O
group NN O
( ( O
P NNP O
= NNP O
0.003 CD O
) ) O
. . O

CONCLUSIONS NNP O
As IN O
compared VBN O
with IN O
CABG NNP B-INTV
, , O
an DT O
initial JJ O
strategy NN O
of IN O
PTCA NNP B-INTV
did VBD O
not RB O
significantly RB O
compromise VB O
five-year JJ B-OC
survival NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
, , O
although IN O
subsequent JJ B-OC
revascularization NN I-OC
was VBD O
required VBN O
more RBR O
often RB O
with IN O
this DT O
strategy NN O
. . O

For IN O
treated JJ B-POPU
diabetics NNS I-POPU
, , O
five-year JJ B-OC
survival NN I-OC
was VBD O
significantly RB O
better JJR O
after IN O
CABG NNP B-INTV
than IN O
after IN O
PTCA NNP B-INTV
. . O

-DOCSTART- -X- O O

Resource NNP O
utilization NN O
and CC O
costs NNS B-OC
of IN I-OC
care NN I-OC
in IN O
the DT O
diabetes NNS O
control NN O
and CC O
complications NNS O
trial NN O
. . O

OBJECTIVE UH O
To TO O
describe VB O
in IN O
detail NN O
the DT O
resources NNS B-OC
used VBN O
and CC O
costs NNS B-OC
incurred VBN I-OC
in IN O
the DT O
clinical JJ O
management NN O
of IN O
patients NNS B-POPU
with IN I-POPU
insulin-dependent JJ I-POPU
diabetes NNS I-POPU
mellitus FW I-POPU
( ( I-POPU
IDDM NNP I-POPU
) ) I-POPU
in IN I-POPU
the DT I-POPU
Diabetes NNP I-POPU
Control NNP I-POPU
and CC I-POPU
Complications NNP I-POPU
Trial NNP I-POPU
( ( I-POPU
DCCT NNP I-POPU
) ) I-POPU
. . O

RESEARCH NNP O
DESIGN NNP O
AND NNP O
METHODS NNP O
The DT O
resources NNS B-INTV
used VBN I-INTV
for IN I-INTV
intensive JJ I-INTV
and CC I-INTV
conventional JJ I-INTV
therapy NN I-INTV
and CC I-INTV
to TO I-INTV
deal VB I-INTV
with IN I-INTV
the DT I-INTV
side NN I-INTV
effects NNS I-INTV
of IN I-INTV
therapy NN I-INTV
were VBD I-INTV
assessed VBN I-INTV
at IN I-INTV
each DT I-INTV
of IN I-INTV
the DT I-INTV
29 CD B-POPU
DCCT NNP I-POPU
clinics NNS I-POPU
and CC B-INTV
summarized VBN I-INTV
. . O

Unit NN B-INTV
costs NNS I-INTV
were VBD I-INTV
derived VBN I-INTV
from IN I-INTV
the DT I-INTV
DCCT NNP I-INTV
, , I-INTV
manufacturers NNS I-INTV
, , I-INTV
and CC I-INTV
Medicare NNP I-INTV
and CC O
chosen VBN O
to TO O
reflect VB O
what WP O
an DT O
item NN O
would MD O
cost VB O
to TO O
a DT O
single-payer JJ O
national JJ O
health NN O
system NN O
. . O

Costs NNS B-OC
were VBD O
calculated VBN O
as IN O
the DT O
product NN O
of IN O
resources NNS O
used VBN O
and CC O
unit NN O
costs NNS O
. . O

The DT O
costs NNS B-OC
of IN O
the DT O
research NN O
component NN O
of IN O
the DT O
DCCT NNP B-INTV
were VBD O
not RB O
included VBN O
. . O

RESULTS NNP O
In IN O
the DT O
DCCT NNP B-INTV
, , O
the DT O
annual JJ B-OC
cost NN I-OC
of IN I-OC
intensive JJ I-OC
therapy NN I-OC
( ( O
$ $ O
4,000 CD O
and CC O
$ $ O
5,800/year CD O
for IN O
multiple JJ O
daily JJ O
injections NNS O
and CC O
continuous JJ O
subcutaneous JJ O
insulin NN O
infusion NN O
, , O
respectively RB O
) ) O
was VBD O
approximately RB O
three CD O
times NNS O
the DT O
cost NN B-OC
of IN I-OC
conventional JJ I-OC
therapy NN I-OC
( ( I-OC
$ $ I-OC
1,700/year CD I-OC
) ) O
. . O

A DT O
large JJ O
portion NN O
of IN O
the DT O
difference NN O
in IN O
cost NN B-OC
was VBD O
related VBN O
to TO O
the DT O
greater JJR O
frequency NN B-OC
of IN I-OC
outpatient JJ I-OC
visits NNS I-OC
and CC O
the DT O
greater JJR O
resources NNS B-OC
used VBN I-OC
in IN I-OC
self-care NN I-OC
. . O

CONCLUSIONS NNP O
DCCT NNP B-INTV
intensive JJ I-INTV
therapy NN I-INTV
is VBZ O
more RBR O
expensive JJ O
than IN O
conventional JJ O
therapy NN O
, , O
but CC O
it PRP O
offers VBZ O
the DT O
hope NN O
of IN O
cost NN O
savings NNS O
as IN O
a DT O
result NN O
of IN O
averted JJ O
complications NNS O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
glucocorticoids NNS B-INTV
on IN O
energy NN B-OC
metabolism NN I-OC
and CC O
food NN B-OC
intake NN I-OC
in IN O
humans NNS B-POPU
. . O

The DT O
effect NN O
of IN O
glucocorticoid JJ B-INTV
administration NN O
on IN O
energy NN B-OC
metabolism NN I-OC
and CC O
food NN B-OC
intake NN I-OC
was VBD O
studied VBN O
in IN O
20 CD B-POPU
healthy JJ I-POPU
, , I-POPU
nondiabetic JJ I-POPU
Caucasian NNP I-POPU
male NN I-POPU
volunteers NNS I-POPU
[ VBP I-POPU
27 CD I-POPU
+/- JJ I-POPU
5 CD I-POPU
( ( I-POPU
SD NNP I-POPU
) ) I-POPU
yr NN I-POPU
, , I-POPU
72 CD I-POPU
+/- JJ I-POPU
9 CD I-POPU
kg NN I-POPU
, , I-POPU
20 CD I-POPU
+/- JJ I-POPU
7 CD I-POPU
% NN I-POPU
body NN I-POPU
fat JJ I-POPU
] NNP I-POPU
randomly NN O
and CC O
blindly RB O
assigned VBD O
to TO O
glucocorticoid VB B-INTV
( ( I-INTV
methylprednisolone NN I-INTV
, , I-INTV
METH NNP I-INTV
; : I-INTV
n CC O
= VB O
10 CD O
) ) O
or CC O
placebo NN B-INTV
( ( I-INTV
PLAC NNP I-INTV
; : I-INTV
n CC O
= VB O
10 CD O
) ) O
treatment NN O
. . O

Each DT O
subject NN O
was VBD O
studied VBN O
twice RB O
: : O
during IN O
a DT O
weight JJ O
maintenance NN O
diet JJ O
and CC O
during IN O
ad NN O
libitum NN O
food NN O
intake NN O
. . O

Energy NNP B-OC
metabolism NN I-OC
was VBD O
measured VBN O
by IN O
indirect JJ O
calorimetry NN O
and CC O
food NN B-OC
intake NN I-OC
by IN O
an DT O
automated VBN O
food-selection NN O
system NN O
. . O

Twenty-four-hour JJ O
urinary JJ B-OC
norepinephrine NN I-OC
excretion NN I-OC
( ( O
24-h JJ O
NE NNP O
) ) O
was VBD O
used VBN O
as IN O
an DT O
estimate NN O
of IN O
sympathetic JJ B-OC
nervous JJ I-OC
system NN I-OC
activity NN I-OC
. . O

During IN O
weight JJ O
maintenance NN O
, , O
METH NNP O
intravenous JJ O
infusion NN O
( ( O
125 CD O
mg/30 NNS O
min NN O
) ) O
increased VBD O
energy NN B-OC
expenditure NN I-OC
compared VBN O
with IN O
PLAC NNP O
, , O
and CC O
after IN O
4 CD O
days NNS O
of IN O
oral JJ O
therapy NN O
, , O
METH NNP O
( ( O
40 CD O
mg/day NN O
) ) O
decreased VBD O
24-h JJ B-OC
NE NNP I-OC
and CC O
increased VBD O
energy NN B-OC
expenditure NN I-OC
compared VBN O
with IN O
PLAC NNP O
. . O

During IN O
ad NN O
libitum NN O
food NN O
intake NN O
, , O
after IN O
4 CD O
days NNS O
of IN O
METH NNP O
( ( O
40 CD O
mg/day NN O
) ) O
or CC O
PLAC NNP O
oral JJ O
therapy NN O
, , O
both DT O
groups NNS O
increased VBD O
their PRP$ O
energy NN B-OC
intake NN I-OC
over IN O
weight JJ O
maintenance NN O
, , O
but CC O
the DT O
increase NN O
was VBD O
significantly RB O
larger JJR O
in IN O
the DT O
METH NNP O
group NN O
compared VBN O
with IN O
the DT O
PLAC NNP O
group NN O
( ( O
4,554 CD O
+/- JJ O
1,857 CD O
vs. FW O
2,867 CD O
+/- JJ O
846 CD O
kcal/day NN O
; : O
P NNP O
= NNP O
0.04 CD O
) ) O
. . O

Our PRP$ O
data NNS O
suggest VBP O
that IN O
therapeutic JJ O
doses NNS O
of IN O
glucocorticoids NNS O
induce VBP O
obesity NN O
mostly RB O
by IN O
increasing VBG O
energy NN B-OC
intake NN I-OC
, , O
an DT O
effect NN O
which WDT O
may MD O
be VB O
related VBN O
to TO O
the DT O
ability NN O
of IN O
glucocorticoids NNS O
to TO O
act VB O
directly RB O
or CC O
indirectly RB O
on IN O
the DT O
central JJ O
regulation NN O
of IN O
appetite NN O
. . O

-DOCSTART- -X- O O

Baseline NNP O
characteristics NNS O
of IN O
participants NNS B-POPU
in IN I-POPU
the DT I-POPU
Appropriate NNP I-POPU
Blood NNP I-POPU
Pressure NNP I-POPU
Control NNP I-POPU
in IN I-POPU
Diabetes NNP I-POPU
trial NN I-POPU
. . O

The DT O
ABCD NNP O
( ( O
Appropriate NNP O
Blood NNP O
Pressure NNP O
Control NNP O
in IN O
Diabetes NNP O
) ) O
trial NN O
is VBZ O
a DT O
large JJ O
, , O
prospective JJ O
, , O
randomized JJ O
clinical JJ O
trial NN O
designed VBN O
to TO O
compare VB O
the DT O
effects NNS O
of IN O
intensive JJ B-INTV
with IN O
moderate JJ B-INTV
blood NN I-INTV
pressure NN I-INTV
control NN I-INTV
on IN O
the DT O
prevention NN O
and CC O
progression NN O
of IN O
diabetic JJ O
nephropathy NN O
, , O
retinopathy NN O
, , O
cardiovascular JJ O
disease NN O
, , O
and CC O
neuropathy JJ O
in IN O
non-insulin-dependent JJ O
diabetes NNS O
( ( O
NIDDM NNP O
) ) O
. . O

The DT O
secondary JJ O
objective NN O
is VBZ O
to TO O
determine VB O
equivalency NN O
of IN O
the DT O
effects NNS O
of IN O
a DT O
calcium NN B-INTV
channel NN I-INTV
blocker NN I-INTV
( ( I-INTV
nisoldipine JJ I-INTV
) ) I-INTV
and CC O
of IN O
an DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
( ( I-INTV
enalapril NN I-INTV
) ) I-INTV
as IN O
a DT O
first-line JJ O
antihypertensive JJ O
agent NN O
in IN O
the DT O
prevention NN O
and/or POS O
progression NN O
of IN O
these DT O
diabetic JJ O
vascular NN O
complications NNS O
. . O

The DT O
study NN O
consists VBZ O
of IN O
two CD B-POPU
study NN I-POPU
populations NNS I-POPU
: : I-POPU
a DT I-POPU
hypertensive JJ I-POPU
one NN I-POPU
( ( I-POPU
diastolic JJ I-POPU
blood NN I-POPU
pressure NN I-POPU
of IN I-POPU
> NN I-POPU
or CC I-POPU
= $ I-POPU
90.0 CD I-POPU
mm NN I-POPU
Hg NNP I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
randomization NN I-POPU
) ) I-POPU
and CC I-POPU
a DT I-POPU
normotensive JJ I-POPU
one NN I-POPU
( ( I-POPU
diastolic JJ I-POPU
blood NN I-POPU
pressure NN I-POPU
of IN I-POPU
80.0-89.0 JJ I-POPU
mm NN I-POPU
Hg NNP I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
randomization NN I-POPU
) ) I-POPU
. . O

A DT O
total NN O
of IN O
950 CD B-POPU
men NNS I-POPU
and CC I-POPU
women NNS I-POPU
aged VBN I-POPU
40-74 JJ I-POPU
years NNS I-POPU
were VBD O
randomized VBN O
and CC O
are VBP O
being VBG O
followed VBN O
for IN O
5 CD O
years NNS O
at IN O
a DT O
single JJ O
center NN O
. . O

There EX B-POPU
were VBD I-POPU
470 CD I-POPU
randomized JJ I-POPU
participants NNS I-POPU
in IN I-POPU
the DT I-POPU
hypertensive JJ I-POPU
population NN I-POPU
and CC I-POPU
480 CD I-POPU
randomized JJ I-POPU
participants NNS I-POPU
in IN I-POPU
the DT I-POPU
normotensive JJ I-POPU
population NN I-POPU
. . O

This DT O
report NN O
summarizes VBZ O
the DT O
demographic JJ B-OC
, , I-OC
biochemical JJ I-OC
, , O
and CC O
clinical JJ B-OC
characteristics NNS I-OC
of IN O
the DT O
randomized JJ B-POPU
patients NNS I-POPU
at IN O
the DT O
time NN O
of IN O
entry NN O
into IN O
the DT O
trial NN O
and CC O
evaluates VBZ O
the DT O
balance NN O
between IN O
the DT O
treatment NN O
groups NNS O
within IN O
each DT O
population NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
aldose JJ B-INTV
reductase NN I-INTV
inhibition NN O
on IN O
cardiovascular JJ B-OC
reflex NN I-OC
tests NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
definite JJ I-POPU
diabetic JJ I-POPU
autonomic JJ I-POPU
neuropathy NN I-POPU
over IN I-POPU
a DT I-POPU
period NN I-POPU
of IN I-POPU
2 CD I-POPU
years NNS I-POPU
. . O

The DT O
potential NN O
of IN O
the DT O
aldose JJ O
reductase NN O
inhibitor NN O
tolrestat NN B-INTV
to TO O
ameliorate VB O
definite JJ O
diabetic JJ O
autonomic NN O
neuropathy NN O
( ( O
DAN NNP O
) ) O
, , O
as IN O
defined VBN O
by IN O
standard JJ O
cardiovascular JJ O
autonomic JJ O
function NN O
tests NNS O
, , O
was VBD O
evaluated VBN O
in IN O
35 CD B-POPU
patients NNS I-POPU
over IN O
a DT O
period NN O
of IN O
2 CD O
years NNS O
, , O
with IN O
repeated VBN O
measurements NNS O
at IN O
3-month JJ O
intervals NNS O
. . O

The DT O
effect NN O
of IN O
tolrestat NN B-INTV
( ( O
200 CD O
mg NN O
a DT O
day NN O
) ) O
was VBD O
compared VBN O
with IN O
that DT O
of IN O
placebo NN B-INTV
on IN O
35 CD B-POPU
controls NNS I-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus NNS I-POPU
, , I-POPU
of IN I-POPU
similar JJ I-POPU
age NN I-POPU
, , I-POPU
gender NN I-POPU
, , I-POPU
and CC I-POPU
glycemic JJ I-POPU
control NN I-POPU
. . O

In IN O
the DT O
placebo NN B-INTV
group NN O
, , O
a DT O
significant JJ O
deterioration NN O
of IN O
the DT O
indices NNS O
, , O
with IN O
the DT O
exception NN O
of IN O
Valsalva NNP B-OC
ratio NN I-OC
, , O
was VBD O
recorded VBN O
, , O
while IN O
tolrestat NN B-INTV
induced VBD O
a DT O
significant JJ O
beneficial JJ O
change NN O
in IN O
the DT O
values NNS B-OC
of IN I-OC
most JJS I-OC
standard JJ I-OC
cardiovascular JJ I-OC
reflex NN I-OC
tests NNS I-OC
, , O
in IN O
comparison NN O
to TO O
baseline VB O
and CC O
placebo VB O
. . O

The DT O
deep JJ B-OC
breathing NN I-OC
tests NNS I-OC
( ( I-OC
expiration-inspiration NN I-OC
ratio NN I-OC
, , I-OC
standard JJ I-OC
deviation NN I-OC
, , I-OC
and CC I-OC
mean VB I-OC
circular JJ I-OC
resultant NN I-OC
of IN I-OC
R-R NNP I-OC
intervals NNS I-OC
) ) I-OC
, , I-OC
postural JJ I-OC
index NN I-OC
, , I-OC
and CC I-OC
postural JJ I-OC
hypotension NN I-OC
were VBD O
favorably RB O
affected VBN O
. . O

Three CD O
of IN O
35 CD O
patients NNS O
on IN O
tolrestat NN B-INTV
( ( O
8.6 CD O
% NN O
) ) O
developed VBD O
high JJ B-OC
transaminases NNS I-OC
levels NNS I-OC
( ( O
more JJR O
than IN O
threefold VB O
the DT O
upper JJ O
normal JJ O
limit NN O
) ) O
and CC O
were VBD O
withdrawn VBN O
from IN O
the DT O
study NN O
. . O

In IN O
conclusion NN O
, , O
tolrestat NN B-INTV
improved VBD O
autonomic RB B-OC
nervous JJ I-OC
system NN I-OC
function NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
definite JJ I-POPU
DAN NNP I-POPU
, , O
in IN O
comparison NN O
to TO O
baseline VB O
and CC O
placebo VB O
. . O

The DT O
clinical JJ O
importance NN O
of IN O
this DT O
finding NN O
needs VBZ O
further JJ O
investigation NN O
. . O

-DOCSTART- -X- O O

Why WRB O
were VBD O
the DT O
results NNS O
of IN O
the DT O
Heart NNP O
Outcomes NNP O
Prevention NNP O
Evaluation NNP O
( ( O
HOPE NNP O
) ) O
trial NN O
so IN O
astounding VBG O
? . O
The DT O
Heart NNP O
Outcomes NNP O
Prevention NNP O
Evaluation NNP O
( ( O
HOPE NNP O
) ) O
study NN O
was VBD O
important JJ O
because IN O
it PRP O
showed VBD O
the DT O
benefits NNS O
of IN O
ramipril NN B-INTV
- : O
an DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
( ( I-INTV
ACE NNP I-INTV
) ) I-INTV
inhibitor NN I-INTV
- : O
in IN O
patients NNS B-POPU
at IN I-POPU
high JJ I-POPU
risk NN I-POPU
for IN I-POPU
cardiovascular JJ I-POPU
events NNS I-POPU
. . O

Treatment NN O
with IN O
ramipril NN B-INTV
significantly RB O
reduced VBD O
the DT O
rates NNS B-OC
of IN I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
stroke NN I-OC
, , I-OC
coronary JJ I-OC
revascularization NN I-OC
, , I-OC
cardiac JJ I-OC
arrest NN I-OC
and CC I-OC
heart NN I-OC
failure NN I-OC
, , O
as RB O
well RB O
as IN O
the DT O
risk NN B-OC
of IN I-OC
diabetes-related JJ I-OC
complications NNS I-OC
and CC I-OC
of IN I-OC
diabetes NNS I-OC
itself PRP I-OC
. . O

The DT O
effects NNS O
of IN O
therapy NN O
with IN O
vitamin JJ B-INTV
E NN I-INTV
were VBD O
also RB O
evaluated VBN O
, , O
but CC O
no DT O
statistical JJ O
benefits NNS O
were VBD O
shown VBN O
. . O

The DT O
benefits NNS O
of IN O
ACE NNP B-INTV
inhibitor NN I-INTV
therapy NN O
that WDT O
were VBD O
observed VBN O
were VBD O
likely JJ O
due JJ O
to TO O
a DT O
variety NN O
of IN O
mechanisms NNS O
, , O
not RB O
just RB O
a DT O
reduction NN O
in IN O
blood NN O
pressure NN O
. . O

-DOCSTART- -X- O O

Development NNP B-OC
of IN I-OC
renal JJ I-OC
disease NN I-OC
in IN B-POPU
people NNS I-POPU
at IN I-POPU
high JJ I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
: : I-POPU
results NNS O
of IN O
the DT O
HOPE NNP O
randomized VBD O
study NN O
. . O

In IN O
people NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
, , O
renal JJ O
disease NN O
tends VBZ O
to TO O
progress VB B-OC
from IN I-OC
microalbuminuria NN I-OC
to TO O
clinical JJ B-OC
proteinuria NN I-OC
to TO O
renal JJ B-OC
insufficiency NN I-OC
. . O

Little JJ O
evidence NN O
has VBZ O
been VBN O
published VBN O
for IN O
the DT O
nondiabetic JJ O
population NN O
. . O

This DT O
study NN O
retrospectively RB O
analyzed VBD O
changes NNS B-OC
of IN I-OC
proteinuria NN I-OC
over IN O
4.5 CD O
yr NNS O
in IN O
the DT O
HOPE NNP O
( ( O
Heart NNP O
Outcomes NNP O
and CC O
Prevention NNP O
Evaluation NNP O
) ) O
study NN O
, , O
which WDT O
compared VBN O
ramipril NN B-INTV
's POS I-INTV
effects NNS O
to TO O
placebo VB B-INTV
in IN O
9297 CD O
participants NNS O
, , O
including VBG O
3577 CD O
with IN O
diabetes NNS O
and CC O
1956 CD O
with IN O
microalbuminuria NN O
. . O

This DT O
report NN O
is VBZ O
restricted VBN O
to TO O
7674 CD B-POPU
participants NNS I-POPU
with IN I-POPU
albuminuria NNS I-POPU
data NNS I-POPU
at IN I-POPU
baseline NN I-POPU
and CC I-POPU
at IN I-POPU
follow-up JJ I-POPU
. . O

Inclusion NN B-POPU
criteria NNS I-POPU
were VBD I-POPU
known VBN I-POPU
vascular JJ I-POPU
disease NN I-POPU
or CC I-POPU
diabetes VBZ I-POPU
plus CC I-POPU
one CD I-POPU
other JJ I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
factor NN I-POPU
, , I-POPU
exclusion NN I-POPU
criteria NNS I-POPU
included VBD I-POPU
heart NN I-POPU
failure NN I-POPU
or CC I-POPU
known VBN I-POPU
impaired JJ I-POPU
left VBD I-POPU
ventricular JJ I-POPU
function NN I-POPU
, , I-POPU
dipstick-positive JJ I-POPU
proteinuria NN I-POPU
( ( I-POPU
> JJ I-POPU
1+ CD I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
serum JJ I-POPU
creatinine NN I-POPU
> $ I-POPU
2.3 CD I-POPU
mg/dl NN I-POPU
( ( I-POPU
200 CD I-POPU
microM NN I-POPU
) ) I-POPU
. . O

Baseline NNP O
microalbuminuria NN O
predicted VBD O
subsequent JJ O
clinical JJ B-OC
proteinuria NN I-OC
for IN O
the DT O
study NN O
participants NNS O
overall JJ O
( ( O
adjusted VBN O
odds NNS O
ratio VBP O
[ CD O
OR NNP O
] NNP O
, , O
17.5 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
12.6 CD O
to TO O
24.4 CD O
) ) O
, , O
in IN O
participants NNS O
without IN O
diabetes NNS O
( ( O
OR NNP O
, , O
16.7 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
8.6 CD O
to TO O
32.4 CD O
) ) O
, , O
and CC O
in IN O
participants NNS O
with IN O
diabetes NNS O
( ( O
OR NNP O
, , O
18.2 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
12.4 CD O
to TO O
26.7 CD O
) ) O
. . O

Any DT O
progression NN B-OC
of IN I-OC
albuminuria NNS I-OC
( ( O
defined VBN O
as IN O
new JJ B-OC
microalbuminuria NNS I-OC
or CC I-OC
new JJ I-OC
clinical JJ I-OC
proteinuria NN I-OC
) ) I-OC
occurred VBD O
in IN O
1859 CD O
participants NNS O
; : O
1542 CD O
developed VBD O
new JJ B-OC
microalbuminuria NNS I-OC
, , O
and CC O
317 CD O
participants NNS O
developed VBD O
clinical JJ B-OC
proteinuria NN I-OC
. . O

Ramipril NNP B-INTV
reduced VBD O
the DT O
risk NN O
for IN O
any DT O
progression NN B-OC
( ( O
OR NNP O
, , O
0.87 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.78 CD O
to TO O
0.97 CD O
; : O
P NNP O
= NNP O
0.0146 CD O
) ) O
. . O

People NNS B-POPU
without IN I-POPU
and CC I-POPU
with IN I-POPU
diabetes NNS I-POPU
who WP I-POPU
are VBP I-POPU
at IN I-POPU
high JJ I-POPU
risk NN I-POPU
for IN I-POPU
cardiovascular JJ I-POPU
disease NN I-POPU
are VBP O
also RB O
at IN O
risk NN O
for IN O
a DT O
progressive JJ O
rise NN O
in IN O
albuminuria NN B-OC
. . O

Microalbuminuria NNP O
itself PRP O
predicts VBZ O
clinical JJ B-OC
proteinuria NNS I-OC
in IN O
nondiabetic JJ B-POPU
and CC I-POPU
in IN I-POPU
diabetic JJ I-POPU
people NNS I-POPU
. . O

Ramipril JJ B-INTV
prevents NNS O
or CC O
delays VBZ O
the DT O
progression NN B-OC
of IN I-OC
albuminuria NN I-OC
. . O

-DOCSTART- -X- O O

Reduced VBN O
platelet NN B-OC
thromboxane NN I-OC
formation NN I-OC
after IN O
long-term JJ O
administration NN O
of IN O
a DT O
dihydropyridine JJ B-INTV
calcium NN I-INTV
channel NN I-INTV
blocker NN I-INTV
: : I-INTV
a DT O
prospective JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
study NN O
with IN O
nitrendipine NN B-INTV
in IN O
borderline JJ B-POPU
hypertensive JJ I-POPU
patients NNS I-POPU
with IN I-POPU
IDDM-type NNP I-POPU
diabetes NNS I-POPU
mellitus NN I-POPU
. . O

Twenty-nine JJ B-POPU
IDDM NNP I-POPU
patients NNS I-POPU
with IN I-POPU
borderline JJ I-POPU
hypertension NN I-POPU
were VBD O
randomly RB O
allocated VBN O
to TO O
placebo VB B-INTV
or CC O
nitrendipine VB B-INTV
treatment NN O
. . O

Nitrendipine NNP B-INTV
was VBD O
given VBN O
orally RB O
at IN O
a DT O
dosage NN O
of IN O
20 CD O
mg NNS O
once RB O
daily RB O
over IN O
4 CD O
weeks NNS O
. . O

Stimulated VBN B-OC
platelet NN I-OC
thromboxane NN I-OC
formation NN I-OC
at IN O
rest NN O
and CC O
after IN O
standardized VBN O
, , O
non JJ B-OC
exhausting VBG I-OC
exercise NN I-OC
was VBD O
measured VBN O
by IN O
standard JJ O
methods NNS O
. . O

In IN O
addition NN O
, , O
plasma NN B-OC
levels NNS I-OC
of IN I-OC
platelet NN I-OC
factor NN I-OC
4 CD I-OC
and CC I-OC
aggregation NN I-OC
responses NNS I-OC
to TO I-OC
collagen VB I-OC
and CC I-OC
ADP NNP I-OC
were VBD O
determined VBN O
. . O

In IN O
the DT O
treatment NN O
group NN O
thromboxane NN B-OC
formation NN I-OC
after IN O
stimulation NN O
with IN O
collagen NN O
( ( O
0.3 CD O
and CC O
1.0 CD O
micrograms/ml NN O
) ) O
and CC O
1 CD O
mM NN O
arachidonic JJ O
acid NN O
( ( O
AA NNP O
) ) O
was VBD O
reduced VBN O
in IN O
the DT O
resting NN O
state NN O
. . O

Exercise NN B-OC
induced JJ I-OC
change NN I-OC
of IN I-OC
thromboxane NN I-OC
synthesis NN I-OC
in IN O
response NN O
to TO O
1.0 CD O
micrograms/ml NNS O
collagen NN O
was VBD O
significantly RB O
lower JJR O
as IN O
compared VBN O
to TO O
placebo VB B-INTV
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

In IN O
parallel JJ O
, , O
PF4 NNP B-OC
plasma NN I-OC
levels NNS I-OC
were VBD O
significantly RB O
lowered VBN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

Whole JJ B-OC
blood NN I-OC
aggregation NN I-OC
after IN I-OC
collagen NN I-OC
stimulation NN I-OC
( ( O
1.0 CD O
micrograms/ml NN O
) ) O
was VBD O
reduced VBN O
after IN O
4 CD O
weeks NNS O
of IN O
nitrendipine JJ B-INTV
treatment NN O
, , O
but CC O
ADP NNP O
( ( O
5 CD O
microM NN O
) ) O
induced VBD O
aggregation NN B-OC
was VBD O
not RB O
. . O

These DT O
effects NNS O
of IN O
nitrendipine NN B-INTV
were VBD O
not RB O
seen VBN O
in IN O
platelet NN O
rich JJ O
plasma NN O
. . O

In IN O
conclusion NN O
long-term JJ O
nitrendipine JJ B-INTV
treatment NN O
may MD O
inhibit VB O
collagen NN B-OC
dependent JJ I-OC
platelet NN I-OC
activation NN I-OC
in IN O
the DT O
blood NN O
of IN O
diabetic JJ B-POPU
patients NNS I-POPU
with IN I-POPU
borderline JJ I-POPU
hypertension NN I-POPU
. . O

-DOCSTART- -X- O O

Lowering VBG O
the DT O
triglyceride/high-density NN B-OC
lipoprotein NN I-OC
cholesterol NN I-OC
ratio NN I-OC
is VBZ O
associated VBN O
with IN O
the DT O
beneficial JJ O
impact NN O
of IN O
pioglitazone NN B-INTV
on IN O
progression NN B-OC
of IN I-OC
coronary JJ I-OC
atherosclerosis NN I-OC
in IN O
diabetic JJ B-POPU
patients NNS I-POPU
: : I-POPU
insights NNS O
from IN O
the DT O
PERISCOPE NNP O
( ( B-INTV
Pioglitazone NNP I-INTV
Effect NNP O
on IN O
Regression NNP O
of IN O
Intravascular NNP O
Sonographic NNP O
Coronary NNP O
Obstruction NNP O
Prospective NNP O
Evaluation NNP O
) ) O
study NN O
. . O

OBJECTIVES CC O
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
the DT O
factors NNS O
associated VBN O
with IN O
the DT O
favorable JJ O
effect NN B-OC
of IN O
pioglitazone NN B-INTV
on IN O
atheroma JJ B-OC
progression NN I-OC
. . O

BACKGROUND NNP O
Diabetes NNP O
mellitus NN O
is VBZ O
associated VBN O
with IN O
accelerated JJ O
coronary JJ B-OC
atheroma NN I-OC
progression NN I-OC
. . O

Pioglitazone NN B-INTV
slowed VBD O
progression NN B-OC
compared VBN O
with IN O
glimepiride NN B-INTV
in IN O
this DT O
population NN O
. . O

METHODS NNP O
In IN O
all DT O
, , O
360 CD B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
were VBD O
treated VBN O
with IN O
pioglitazone NN B-INTV
or CC O
glimepiride NN B-INTV
for IN O
18 CD O
months NNS O
in IN O
the DT O
PERISCOPE NNP O
( ( B-INTV
Pioglitazone NNP I-INTV
Effect NNP O
on IN O
Regression NNP O
of IN O
Intravascular NNP O
Sonographic NNP O
Coronary NNP O
Obstruction NNP O
Prospective NNP O
Evaluation NNP O
) ) O
study NN O
. . O

Coronary NNP B-OC
atheroma NN I-OC
progression NN I-OC
was VBD I-OC
evaluated VBN I-OC
by IN I-OC
serial JJ I-OC
intravascular JJ I-OC
ultrasound NN I-OC
. . O

The DT O
relationship NN O
between IN O
changes NNS B-OC
in IN I-OC
biochemical JJ I-OC
parameters NNS I-OC
, , I-OC
percent JJ I-OC
atheroma NN I-OC
volume NN I-OC
, , I-OC
and CC I-OC
total JJ I-OC
atheroma NN I-OC
volume NN I-OC
was VBD O
investigated VBN O
. . O

RESULTS JJ O
Pioglitazone-treated JJ B-INTV
patients NNS O
demonstrated VBD O
greater JJR O
increases NNS O
in IN O
high-density NN B-OC
lipoprotein NN I-OC
cholesterol NN I-OC
( ( I-OC
HDL-C NNP I-OC
) ) I-OC
and CC O
reductions NNS O
in IN O
glycated JJ B-OC
hemoglobin NN I-OC
, , I-OC
triglycerides NNS I-OC
, , I-OC
and CC I-OC
C-reactive JJ I-OC
protein NN I-OC
. . O

Significant JJ O
correlations NNS O
were VBD O
observed VBN O
between IN O
changes NNS O
in IN O
percent NN B-OC
atheroma NN I-OC
volume NN I-OC
and CC I-OC
triglycerides NNS I-OC
( ( O
r VB O
= RB O
0.15 CD O
, , O
p NN O
= NNP O
0.04 CD O
) ) O
, , O
triglyceride/HDL-C JJ B-OC
ratio NN I-OC
( ( O
r JJ O
= NN O
0.16 CD O
, , O
p NN O
= NNP O
0.03 CD O
) ) O
, , O
and CC O
glycated VBD B-OC
hemoglobin NN I-OC
( ( O
r JJ O
= NN O
0.16 CD O
, , O
p NN O
= NNP O
0.03 CD O
) ) O
with IN O
pioglitazone NN B-INTV
, , O
and CC O
changes NNS O
in IN O
low-density NN B-OC
lipoprotein NN I-OC
cholesterol NN I-OC
( ( O
r JJ O
= NNP O
-0.15 NNP O
, , O
p NN O
= NNP O
0.05 CD O
) ) O
, , O
apolipoprotein RB B-OC
B NNP I-OC
( ( O
r NN O
= NNP O
-0.16 NNP O
, , O
p NN O
= NNP O
0.04 CD O
) ) O
, , O
and CC O
apolipoprotein RB B-OC
A-I NNP I-OC
( ( O
r NN O
= NNP O
-0.20 NNP O
, , O
p NN O
= NNP O
0.01 CD O
) ) O
with IN O
glimepiride NN B-INTV
. . O

Substantial JJ B-OC
atheroma JJ I-OC
regression NN I-OC
, , O
compared VBN O
to TO O
progression NN B-OC
, , O
was VBD O
associated VBN O
with IN O
greater JJR O
relative JJ O
increases NNS O
in IN O
HDL-C NNP B-OC
( ( O
14.2 CD O
% NN O
vs. FW O
7.8 CD O
% NN O
, , O
p NN O
= NNP O
0.04 CD O
) ) O
, , O
relative JJ O
decreases NNS O
in IN O
triglycerides NNS B-OC
( ( O
-13.3 CD O
% NN O
vs. FW O
-1.9 CD O
% NN O
, , O
p NN O
= NNP O
0.045 CD O
) ) O
, , O
triglyceride/HDL-C JJ B-OC
ratio NN I-OC
( ( O
-22.5 NNP O
vs. FW O
-9.9 NNP O
% NN O
, , O
p NN O
= NNP O
0.05 CD O
) ) O
, , O
and CC O
decrease NN O
in IN O
glycated JJ B-OC
hemoglobin NN I-OC
( ( O
-0.6 CD O
% NN O
vs. FW O
-0.3 CD O
% NN O
, , O
p NN O
= NNP O
0.01 CD O
) ) O
. . O

Multivariable JJ O
analysis NN O
revealed VBD O
that IN O
pioglitazone-induced JJ B-INTV
effects NNS O
on IN O
triglyceride/HDL-C NN B-OC
were VBD O
associated VBN O
with IN O
changes NNS O
in IN O
percent NN B-OC
atheroma NN I-OC
volume NN I-OC
( ( O
p JJ O
= NNP O
0.03 CD O
) ) O
and CC O
total JJ B-OC
atheroma NN I-OC
volume NN I-OC
( ( O
p JJ O
= NNP O
0.02 CD O
) ) O
. . O

CONCLUSIONS NNP O
Favorable JJ O
effects NNS O
of IN O
pioglitazone NN B-INTV
on IN O
the DT O
triglyceride/HDL-C JJ B-OC
ratio NN I-OC
correlated VBN O
with IN O
delayed JJ O
atheroma NN B-OC
progression NN I-OC
in IN O
diabetic JJ B-POPU
patients NNS I-POPU
. . O

This DT O
finding NN O
highlights VBZ O
the DT O
potential JJ O
importance NN O
of IN O
targeting VBG O
atherogenic JJ O
dyslipidemia NN O
in IN O
diabetic JJ B-POPU
patients NNS I-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
. . O

